0001140361-14-031321.txt : 20140807 0001140361-14-031321.hdr.sgml : 20140807 20140807172642 ACCESSION NUMBER: 0001140361-14-031321 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140807 DATE AS OF CHANGE: 20140807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DISCOVERY LABORATORIES INC /DE/ CENTRAL INDEX KEY: 0000946486 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171943 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26422 FILM NUMBER: 141024948 BUSINESS ADDRESS: STREET 1: 2600 KELLY ROAD STREET 2: SUITE 100 CITY: WARRINGTON STATE: PA ZIP: 18976 BUSINESS PHONE: 2154889300 MAIL ADDRESS: STREET 1: 2600 KELLY ROAD STREET 2: SUITE 100 CITY: WARRINGTON STATE: PA ZIP: 18976 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 19961121 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN INC DATE OF NAME CHANGE: 19950609 10-Q 1 form10q.htm DISCOVERY LABORATORIES, INC 10-Q 6-30-2014

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2014

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000-26422

DISCOVERY LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Delaware		94-3171943
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification Number)

	2600 Kelly Road, Suite 100
	Warrington, Pennsylvania 18976-3622
	(Address of principal executive offices)

(215) 488-9300

(Registrant’s telephone number, including area code)

__________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o		Accelerated filer	x

Non-accelerated filer	o	(Do not check if a smaller reporting company)	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o NO x

As of July 31, 2014, 85,206,616 shares of the registrant’s common stock, par value $0.001 per share, were outstanding.

Table of Contents

PART I - FINANCIAL INFORMATION

		Page

Item 1.	Financial Statements	1

	CONSOLIDATED BALANCE SHEETS As of June 30, 2014 (unaudited) and December 31, 2013	1

	CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) For the Three and Six Months Ended June 30, 2014 and 2013	2

	CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) For the Three and Six Months Ended June 30, 2014 and 2013	3

	Notes to Consolidated Financial Statements (unaudited)	4

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative And Qualitative Disclosures About Market Risk	23

Item 4.	Controls and Procedures	23

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27

Item 6.	Exhibits	27

Signatures		28

Table of Contents

Unless the context otherwise requires, all references to “we,” “us,” “our,” and the “Company” include Discovery Laboratories, Inc., and its wholly owned, presently inactive subsidiary, Acute Therapeutics, Inc.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The forward-looking statements are only estimates and provide our current expectations or forecasts of future events and financial performance and may be identified by the use of forward-looking terminology, including such terms as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “will” or “should” or, in each case, their negative, or other variations or comparable terminology, though the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts and include, without limitation, statements concerning: our business strategy, outlook, objectives, future milestones, plans, intentions, goals, and future financial condition, including the period of time during which our existing resources are expected to fund our operations. Forward-looking statements also include our financial, clinical, manufacturing and distribution plans, and our expectations related to the commercialization of SURFAXIN® and our expectations, timing and anticipated outcomes of development activities, potential regulatory filings and plans to secure marketing authorization for our products under development, starting with AEROSURF®; our research and development programs, including planning for development activities, anticipated timing and design of clinical trials and potential development milestones, for our KL4 surfactant pipeline product candidates and our capillary aerosol generator (CAG) for delivery of aerosolized medications; plans for the manufacture of drug products, active pharmaceutical ingredients (APIs) and materials, and medical devices and related components; and plans regarding potential strategic alliances and other collaborative arrangements to develop, manufacture and market our products.

We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to many risks and uncertainties that could cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Examples of the risks and uncertainties include, but are not limited to:

•

the risk that we will require in the near term, but may be unable to secure, significant additional capital to continue our operations, fund our debt service and support our research and development activities, including expensive and time-consuming clinical trials, until such time, if ever, that our revenues from all sources are sufficient to offset our cash outflows. To the extent that we raise such capital through additional financings, such additional financings could result in equity dilution;

•

the risk that, if we fail to successfully commercialize SURFAXIN and if we are unable to achieve revenues over the next several years that are consistent with our expectations, it may be more difficult to secure the additional capital we will require when needed, if at all, whether from strategic alliances or other sources, to continue our commercial and medical affairs activities, as well as our research and development programs, and our operations would be impaired, which ultimately could have a material adverse effect on our business, financial condition and results of operations;

•

risks relating to the ability of our sales and marketing organization to effectively introduce SURFAXIN in the United States (U.S.) and, if approved, our other product candidates, in a timely manner, if at all; and that we may not succeed in developing sufficient market awareness of our products or that our product candidates may not gain market acceptance by physicians, patients, healthcare payers and others in the medical community;

•

risks relating to our ability to timely modify our business strategy to respond to changing circumstances, assumptions and forecasts, and otherwise as needed to manage growth effectively and respond to developments in our commercial operations and research and development activities, as well as our business, our industry and other factors;

Table of Contents

•

the risk that the initial and later phases of our AEROSURF clinical program may be interrupted, delayed, or fail, which will harm our business;

•

the risk that we and the U.S. Food and Drug Administration (FDA) or other regulatory authorities will not be able to agree on matters raised during the regulatory review process, or that we may be required to conduct significant additional activities to potentially gain approval of our product candidates, if ever;

•

the risk that we may not succeed in implementing our long-term manufacturing strategy to assure continuity of SURFAXIN commercial drug product supply, which may affect our ability to maintain sufficient supplies of SURFAXIN commercial drug product;

•

risks relating to the transfer of our manufacturing technology to contract manufacturing organizations (CMOs) and assemblers;

•

risks relating to our and our CMOs' ability to manufacture our KL4 surfactant, in liquid and lyophilized dosage forms, which require precise methods of manufacture in an aseptic manufacturing environment, as well as complex analytical and quality control release and stability methodologies, for both commercial and research and development activities;

•

risks relating to our and our CMOs’ ability to develop and manufacture combination drug/device products based on our CAG technology, for preclinical and clinical studies of our product candidates and, ultimately if approved, for commercialization;

•

the risk that we, our CMOs or any of our third-party suppliers, many of which are single-source providers, may encounter problems in manufacturing our KL4 surfactant drug products and the APIs used in the manufacture of our drug products, CAG devices and other materials on a timely basis or in an amount sufficient to support our needs;

•

risks relating to our plans to potentially secure marketing and distribution capabilities in certain markets through third-party strategic alliances and/or marketing alliances and/or distribution arrangements, that could require us to give up rights to our drug products, drug product candidates and drug delivery technologies;

•

the risk that we may be unable to enter into strategic alliances and/or collaboration agreements that would assist and support us in markets outside the U.S. with the development of our KL4 surfactant pipeline products, beginning with AEROSURF, including development of our lyophilized KL4 surfactant, and, if approved, commercialization of AEROSURF in markets outside the U.S.; support the commercialization of SURFAXIN in countries where regulatory approval is facilitated by the information contained in the SURFAXIN new drug application (NDA) approved by the FDA; and potentially support the development and, if approved, commercialization, of our other pipeline products;

•

risks relating to our pledge of substantially all of our assets to secure our obligations under our loan facility (Deerfield Loan) with affiliates of Deerfield Management Company, L.P., which could make it more difficult for us to secure additional capital to satisfy our obligations and require us to dedicate cash flow to payments for debt service, which would reduce the availability of our cash flow to fund working capital, capital expenditures and other investment; and

•

other risks and uncertainties as detailed in “Risk Factors” in our most recent Annual Report on Form 10‑K filed with the Securities and Exchange Commission (SEC) on March 17, 2014, and our other filings with the SEC and any amendments thereto, and in the documents incorporated by reference in this report.

Pharmaceutical, biotechnology and medical technology companies have suffered significant setbacks conducting clinical trials, even after obtaining promising earlier preclinical and clinical data. Moreover, data obtained from clinical trials are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. After gaining approval of a drug product, pharmaceutical and biotechnology companies face considerable challenges in marketing and distributing their products, and may never become profitable.

iii

Table of Contents

The forward-looking statements contained in this report or the documents incorporated by reference herein speak only as of their respective dates. Factors or events that could cause our actual results to differ may emerge from time to time and it is not possible for us to predict them all. Except to the extent required by applicable laws, rules or regulations, we do not undertake any obligation to publicly update any forward-looking statements or to publicly announce revisions to any of the forward-looking statements, whether because of new information, future events or otherwise.

Trademark Notice

AEROSURF®, AFECTAIR®, DISCOVERYLABS®, INSPIRED INNOVATION®, SURFAXIN®, and WARMING CRADLE® are registered trademarks of Discovery Laboratories, Inc. (Warrington, PA).

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1.

FINANCIAL STATEMENTS

DISCOVERY LABORATORIES, INC. AND SUBSIDIARY

Consolidated Balance Sheets

(in thousands, except per share data)

	June 30, 2014			December 31, 2013
	(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	65,557		$	86,283
Accounts receivable		41			67
Inventory, net		443			112
Prepaid expenses and other current assets		443			777
Total current assets		66,484			87,239

Property and equipment, net		2,178			1,656
Restricted cash		325			325
Other assets		487			97
Total assets	$	69,474		$	89,317
LIABILITIES & STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	1,507		$	1,433
Accrued expenses		5,951			4,785
Deferred revenue		105			139
Common stock warrant liability		3,224			5,425
Equipment loans, current portion		75			73
Total current liabilities		10,862			11,855

Long-term debt, $30,000 net of discount of $10,736 at June 30, 2014 and $11,646 at December 31, 2013		19,264			18,354
Equipment loans, non-current portion		28			69
Other liabilities		114			538
Total liabilities		30,268			30,816
Stockholders’ Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding		–			–
Common stock, $0.001 par value; 250,000,000 and 150,000,000 shares authorized; at June 30, 2014 and December 31, 2013, respectively; 85,227,508 and 84,659,111 shares issued at June 30, 2014 and December 31, 2013, respectively; 85,206,616 and 84,638,219 shares outstanding at June 30, 2014 and December 31, 2013, respectively		85			85
Additional paid-in capital		544,224			541,420
Accumulated deficit		(502,049	)		(479,950	)
Treasury stock (at cost); 20,892 shares		(3,054	)		(3,054	)
Total stockholders’ equity		39,206			58,501
Total liabilities & stockholders’ equity	$	69,474		$	89,317

See notes to consolidated financial statements.

Table of Contents

DISCOVERY LABORATORIES, INC. AND SUBSIDIARY

Consolidated Statements of Operations

(Unaudited)

(in thousands, except per share data)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2014			2013			2014			2013


Revenues:
Product sales	$	42		$	–		$	70		$	–
Grant revenue		1,051			182			1,054			254
		1,093			182			1,124			254
Expenses:
Cost of product sales		731			–			1,512			–
Research and development		6,858			6,863			12,448			15,335
Selling, general and administrative		4,446			4,129			8,869			8,349
		12,035			10,992			22,829			23,684
Operating loss		(10,942	)		(10,810	)		(21,705	)		(23,430	)

Change in fair value of common stock warrant liability		1,448			2,525			1,826			2,686

Other income / (expense):
Interest and other income		2			1			4			1
Interest and other expense		(1,131	)		(343	)		(2,224	)		(520	)
Other income / (expense), net		(1,129	)		(342	)		(2,220	)		(519	)
Net loss	$	(10,623	)	$	(8,627	)	$	(22,099	)	$	(21,263	)
Net loss per common share
Basic	$	(0.12	)	$	(0.18	)	$	(0.26	)	$	(0.46	)
Diluted	$	(0.14	)	$	(0.22	)	$	(0.28	)	$	(0.50	)
Weighted average number of common shares outstanding
Basic		85,061			49,135			84,766			46,411
Diluted		85,882			49,866			86,111			47,773

See notes to consolidated financial statements.

Table of Contents

DISCOVERY LABORATORIES, INC. AND SUBSIDIARY

Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

	Six Months Ended
	June 30,
	2014			2013

Cash flows from operating activities:
Net loss	$	(22,099	)	$	(21,263	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		371			364
Provision for excess inventory		1,465			–
Stock-based compensation and 401(k) Plan employer match		1,975			1,489
Fair value adjustment of common stock warrants		(1,826	)		(2,686	)
Amortization of discount on long-term debt		909			177
Changes in:					–
Inventory		(2,196	)		159
Accounts receivable		26			–
Prepaid expenses and other current assets		334			101
Accounts payable		74			753
Accrued expenses		1,166			580
Deferred revenue		(34	)		–
Other assets		–			(107	)
Other liabilities		(423	)		(10	)
Net cash used in operating activities		(20,258	)		(20,443	)
Cash flows from investing activities:
Purchase of property and equipment		(883	)		(120	)
Net cash used in investing activities		(883	)		(120	)
Cash flows from financing activities:
Proceeds from issuance of securities, net of expenses		–			15,110
Proceeds from issuance of long-term debt, net of expenses		–			9,850
Proceeds from exercise of common stock options		31			1
Proceeds from exercise of common stock warrants		423			–
Repayment of equipment loans		(39	)		(37	)
Net cash provided by financing activities		415			24,924
Net decrease in cash and cash equivalents		(20,726	)		4,361
Cash and cash equivalents – beginning of period		86,283			26,892
Cash and cash equivalents – end of period	$	65,557		$	31,253
Supplementary disclosure of cash flows information:
Interest paid	$	1,305		$	336

See notes to consolidated financial statements.

Table of Contents

Notes to Consolidated Financial Statements (unaudited)

Note 1 – Organization and Business

Discovery Laboratories, Inc. (referred to as “we,” “us,” or the “Company”) is a specialty biotechnology company focused on creating life-saving products for critical-care patients with respiratory disease and improving the standard of care in pulmonary medicine. Our proprietary drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. We are developing our KL4 surfactant in liquid, lyophilized and aerosolized dosage forms. We are also developing novel drug delivery technologies and devices potentially to enable efficient delivery of our aerosolized KL4 surfactant. We believe that our proprietary technologies may make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.

We are initially focused on improving the management of respiratory distress syndrome (RDS) in premature infants. RDS is a serious respiratory condition caused by insufficient surfactant production in underdeveloped lungs of premature infants. RDS is the most prevalent respiratory disease in the Neonatal Intensive Care Unit (NICU) and can result in long-term respiratory problems, developmental delay and death. Our first KL4 surfactant drug product, SURFAXIN® (lucinactant) Intratracheal Suspension for the prevention of RDS in premature infants at high risk for RDS, was approved by the United States Food and Drug Administration (FDA) in 2012. SURFAXIN is our KL4 surfactant in liquid form, and is the first synthetic, peptide-containing surfactant approved by the FDA and the only alternative to animal-derived surfactants currently used in the United States (U.S.). SURFAXIN has been commercially available in the U.S. since November 2013.

Premature infants with severe RDS currently are treated with surfactants that can only be administered by endotracheal intubation supported with mechanical ventilation, both invasive procedures that may result in serious respiratory conditions and other complications. To avoid such complications, many neonatologists initially treat infants with less severe RDS by less invasive means, typically nasal continuous positive airway pressure (nCPAP). Unfortunately, a significant number of premature infants on nCPAP will not respond well (an outcome referred to as nCPAP failure) and thereafter may require endotracheal intubation, mechanical ventilation, and delayed surfactant therapy. Since neonatologists currently cannot predict which infants will experience nCPAP failure, neonatologists are faced with difficult choices in treating infants with less severe RDS. This is because the medical outcomes for those infants who experience nCPAP failure and receive delayed surfactant therapy may be less favorable than the outcomes for infants who receive surfactant therapy in the first hours of life.

AEROSURF® is our investigational combination drug/device product that combines our KL4 surfactant with our proprietary capillary aerosol generator (CAG). AEROSURF potentially will enable administration of aerosolized KL4 surfactant to premature infants supported with nCPAP, without invasive intubation and mechanical ventilation. By enabling delivery of our KL4 surfactant using less invasive procedures, we believe that AEROSURF may address a serious unmet medical need and potentially enable the treatment of a significantly greater number of premature infants with RDS who could benefit from surfactant therapy but are currently not treated. We are currently conducting a phase 2a clinical trial for AEROSURF for the treatment of RDS in premature infants, for which results are expected in the fourth quarter of 2014, and are initiating activities to prepare for a phase 2b clinical trial, with results expected in the second half of 2015.

We are also developing a lyophilized (freeze-dried) dosage form of our KL4 surfactant that is stored as a powder and reconstituted to liquid form prior to use with the objective of improving ease of use for healthcare practitioners, as well as potentially to prolong shelf life and eliminate the need for cold-chain storage. We are initially developing this dosage form for use in our AEROSURF development program. We are also planning to seek regulatory advice to determine if we could gain marketing authorization for a lyophilized dosage form of our KL4 surfactant under a development plan that would be both capital efficient and capable of implementation within a reasonable time. If feasible, we would likely implement such a development plan and would plan to introduce it commercially as a life-cycle extension of SURFAXIN under the name SURFAXIN LS™, in the U.S. and potentially in other markets.

To support the commercial introduction of SURFAXIN in the U.S. and our other KL4 surfactant pipeline products, if approved, we have our own specialty respiratory critical care commercial and medical affairs team. This team includes medical professionals with experience in neonatal/pediatric respiratory critical care, and has focused on products that address neonatal indications, beginning with SURFAXIN. We believe that this team will be positioned to efficiently introduce our other KL4 surfactant products under development, if approved, including AEROSURF and potentially SURFAXIN LS and future applications of our aerosolized KL4 surfactant. In addition, we recognize that our commercial and medical affairs team could potentially support introductions of other synergistic pipeline products, including products owned or developed by third parties for the NICU/PICU. To that end, we would consider potential transactions focused on securing commercial rights to such synergistic products, including in the form of product acquisitions, in-licensing agreements or distribution, marketing or co-marketing arrangements.

Table of Contents

In the future, we expect that we may be able to leverage the information, data and know-how that we gain from our development efforts with SURFAXIN and AEROSURF to support development of a product pipeline to address serious critical care respiratory conditions in larger children and adults in pediatric and adult intensive care units (PICUs and ICUs), including potentially acute lung injury (ALI), chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). At the present time, however, we are focusing our resources primarily on the commercial introduction of SURFAXIN and development of AEROSURF through phase 2 clinical trials. Once we have advanced these objectives, we expect to be in a better position to assess the potential of other development programs to address the critical care needs of patients in the PICU and ICU.

Note 2 – Liquidity Risks and Management’s Plans

We have incurred substantial losses since inception, due to investments in research and development, manufacturing, and, more recently, commercialization and medical affairs activities, and we expect to continue to incur substantial losses over the next several years. Historically, we have funded our business operations through various sources, including public and private securities offerings, debt facilities, strategic alliances, the use of committed equity financing facilities (CEFFs) and at-the-market (ATM) equity programs, and capital equipment financings.

As of June 30, 2014, we had cash and cash equivalents of $65.6 million and long-term debt of $30 million ($19.3 million net of discount) under our Deerfield Loan with affiliates of Deerfield Management Company, L.P. (Deerfield) (see, Note 7 – “Deerfield Loan”) . Before any additional financings, including under our ATM Program (see, Note 11 - “At-the-Market Program (ATM Program),” to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2013 (2013 Form 10‑K)), we anticipate that we will have sufficient cash available to fund our operations and debt service obligations through the third quarter of 2015.

For the next several years, we expect that our cash outflows for marketing, commercial and medical activities, development programs, operations and debt service will outpace the rate at which we may generate revenues. To execute our business strategy, pay debt obligations and fund our operations over the next several years, we will require significant additional infusions of capital until such time as the net revenues from the sale of approved products and from other sources are sufficient to offset our cash flow requirements. While we currently intend to retain all rights and commercialize our approved products in the U.S. by ourselves, an important priority for us is to identify strategic transactions that could provide additional capital and strategic resources to support the continued development and commercial introduction of our RDS products in markets outside the U.S. For our AEROSURF development program, we seek a significant strategic alliance that potentially could provide development, regulatory and commercial market expertise, and, if approved, support the commercial introduction of AEROSURF in the EU and other selected markets outside the U.S. Such alliances typically also would provide financial resources, in the form of upfront payments, milestone payments, commercialization royalties and a sharing of research and development expenses. To advance SURFAXIN in markets outside the U.S. where regulatory marketing authorization is facilitated by the information contained in our new drug application (NDA) approved by the FDA, we would consider various financing or collaboration arrangements that could potentially provide regulatory expertise, support the commercial introduction of SURFAXIN in markets outside the U.S., and a sharing of revenues. Such countries could potentially include those in Latin America, North Africa and the Middle East. To secure the necessary capital, we also plan to consider other public and private equity offerings, including under our ATM Program, which currently may allow for the sale of up to approximately $23 million of our commons stock, as well as other financing transactions, such as secured equipment financing facilities or other similar transactions.

Our future capital requirements will depend upon many factors, primarily our efforts to (i) execute the commercial introduction of SURFAXIN in the U.S.; (ii) advance the AEROSURF development program to completion of the phase 2 clinical trials as planned in the second half of 2015; (iii) assure long-term continuity of supply for both our commercial and lyophilized KL4 surfactant drug product, potentially with CMOs and/or at our manufacturing facility in Totowa, NJ (Totowa Facility); and (iv) secure one or more strategic alliances or other collaboration arrangements to support our development programs and commercialization of our approved products, if any, in markets outside the U.S. We believe that we will be better positioned to enter into a significant strategic alliance if we are successful in advancing the commercial introduction of SURFAXIN and completing and obtaining encouraging results from the AEROSURF phase 2 clinical program within our anticipated time.

Table of Contents

Although we currently believe that we will be able to successfully execute our business strategy as planned, there can be no assurance that any of our approved products, including SURFAXIN, will be commercially viable or that we will be able to execute our long-term manufacturing plan, that our AEROSURF development program will be successful within our anticipated time frame, if at all, that we will be able to secure regulatory marketing authorization for AEROSURF and our other KL4 surfactant product candidates, in the U.S. and other markets, that the ATM Program will be available when needed, if at all, or that we will be able to obtain additional capital when needed and on acceptable terms. We will require significant additional capital to sustain operations, satisfy debt obligations, and complete product development and execute the commercial introduction of our KL4 surfactant product candidates, if approved. Failure to secure the necessary additional capital when needed would have a material adverse effect on our business, financial condition and results of operations. Even if we succeed in raising additional capital and developing and subsequently commercializing our product candidates, we may never achieve sufficient sales revenue to achieve or maintain profitability.

As of June 30, 2014, we had outstanding warrants to purchase approximately 14.0 million shares of our common stock at various prices, exercisable on different dates into 2019. Of these warrants, warrants to purchase 7 million shares were issued to Deerfield in connection with the Deerfield Loan at an exercise price of $2.81 per share. The Deerfield Warrants may be exercised for cash or on a cashless basis. In lieu of paying cash upon exercise, the holders also may elect to reduce the principal amount of the Deerfield Loan in an amount sufficient to satisfy the exercise price of the Deerfield Warrants. In addition to the Deerfield Warrants, we have outstanding warrants issued in February 2011 to purchase approximately 4.6 million shares of common stock that contain anti-dilution provisions that adjust the exercise price if we issue any common stock, securities convertible into common stock, or other securities (subject to certain exceptions) at a value below the then-existing exercise price of the warrants. These warrants currently have an exercise price of $1.50 per share and expire in February 2016. Although we believe that, in the future, we may receive additional capital from the exercise of at least a portion of our outstanding warrants, there can be no assurance that the market price of our common stock will equal or exceed price levels that would make exercise of outstanding warrants likely, that holders of the Deerfield Warrants would choose to exercise their warrants for cash, or that holders of any of our outstanding warrants would choose to exercise any or all of their warrants prior to the applicable warrant expiration dates. Moreover, if our outstanding warrants are exercised, such exercises likely will be at a discount to the then-market value of our common stock and have a dilutive effect on the value of our shares of common stock at the time of exercise.

As of June 30, 2014, 250 million shares of common stock were authorized under our Amended and Restated Certificate of Incorporation, as amended, and approximately 137.2 million shares of common stock were available for issuance and not otherwise reserved.

Note 3 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying interim unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information in accordance with the instructions to Form10‑Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. There have been no changes to our critical accounting policies since December 31, 2013. For a discussion of our accounting policies, see, Note 3, “Accounting Policies and Recent Accounting Pronouncements,” to the consolidated financial statements in our 2013 Form 10-K. Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.

Inventory

Inventories, which are recorded at the lower of cost or market, include materials, labor, and other direct and indirect costs and are valued at cost using the first-in, first-out method. We capitalize inventories produced in preparation for commercial launch when the related product candidates receive regulatory approval and the related costs will be recoverable through the commercial sale of the product. Costs incurred prior to FDA approval of drug products and registration of medical devices are recorded in our statement of operations as research and development expense. Inventories are evaluated for impairment through consideration of factors such as the net realizable value, lower of cost or market, obsolescence, and expiry. Inventories do not have carrying values that exceed either cost or net realizable value.

We evaluate our expiry risk by evaluating current and future product demand relative to product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and hospital ordering practices.

Table of Contents

Accrued Severance and Retention Costs

A liability for employee severance and retention benefits is recognized when (1) management has committed to a plan of termination; (2) the plan provides sufficient details, such as the employees affected, amounts to be paid, and expected dates of termination and payment; (3) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn; and (4) the plan has been communicated to employees. The cost of such benefits are accrued over the remaining service period.

In September 2013, we implemented an employee severance and retention plan for employees at our Totowa Facility to minimize employee turnover and encourage employees to remain with us through any potential plant closing. The plan provides for severance for non-union employees and retention bonuses for management. If we succeed in our efforts to secure longer-term utilization of the Totowa Facility, the severance plan and retention bonuses will remain in effect. The total cash amount expected to be paid for severance and retention under this plan through June 2016, assuming a June 2015 plant closing, is approximately $1.1 million. The plan-related expense for the three and six months ended June 30, 2014 was $0.1 million and $0.3 million, respectively, and is included in research and development expense. The related accrued liability is $0.4 million as of June 30, 2014.

In addition, at the Totowa Facility, there are 13 employees who are subject to a collective bargaining agreement under which they would be eligible to receive severance payments if the Totowa Facility were closed. The related accrued liability is $0.4 million as of June 30, 2014.

Product Sales

Revenues from product sales are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured.

Our products are distributed in the U.S. using a specialty distributor. Under this model, the specialty distributor purchases and takes physical delivery and title of product, and then sells to hospitals. We began the commercial introduction of SURFAXIN in the fourth quarter of 2013 and we currently cannot make a reasonable estimate of future product returns when product is delivered to the specialty distributor. Therefore, we currently do not recognize revenue upon product shipment to the specialty distributor, even though the distributor is invoiced upon product shipment. Instead, we recognize revenue once product has been sold through to the hospital and all revenue recognition criteria have been met. Once product has been delivered to a hospital, the risk of material returns is significantly mitigated. We will begin to recognize revenue at the time of shipment of product to our specialty distributor when we can reasonably estimate expected distributor sales deductions and returns. In developing estimates for sales returns, we consider the shelf life of the product, expected demand based on market data and return rates of other surfactant products.

Product sales are recorded net of accruals for estimated chargebacks, discounts, specialty distributor deductions and returns.

Chargebacks. Chargebacks are discounts that occur when contracted customers purchase directly from our specialty distributor. Contracted customers, which currently consist primarily of Group Purchasing Organizations member hospitals, generally purchase the product at a discounted price. Our specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for specialty distributor chargebacks is based on known sales to contracted customers.

Sales discounts. Sales discounts are offered to certain contracted customers based upon a customer’s historical volume of surfactant product purchases. Customers must enter into a Letter of Participation (LOP) with us to receive sales discounts. Sales discounts are periodically adjusted on a prospective basis based upon the customer’s purchases of SURFAXIN, as provided in the LOP. The allowance for sales discounts is based on known sales to contracted customers.

Specialty distributor deductions. Our specialty distributor is offered various forms of consideration including allowances, service fees and prompt payment discounts. Specialty distributor allowances and service fees are provided in our contractual agreement and are generally a percentage of the purchase price paid by the specialty distributor. The specialty distributor is offered a prompt pay discount for payment within a specified period.

Returns. Sales of our products are not subject to a general right of return; however, we will accept product that is damaged or defective when shipped or for expired product up to six months subsequent to its expiry date. Product that has been administered to patients is no longer subject to any right of return.

Table of Contents

Research and development expense

We track research and development expense by activity, as follows: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs. Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred.

Net loss per common share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the quarters ended June 30, 2014 and 2013, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants was 20.9 million and 15.8 million shares, respectively.

In accordance with Accounting Standards Codification (ASC) Topic 260, “Earnings per Share,” when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of certain warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of the warrants results in an adjustment to the weighted average common shares outstanding. We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of the warrants. For the three and six months ended June 30, 2014 and 2013, the effect of the adjustments for warrants issued in February 2011 was dilutive.

The table below provides information pertaining to the calculation of diluted net loss per common share for the periods presented:

(in thousands)	Three Months Ended June 30,						Six Months Ended June 30,
	2014			2013			2014			2013

Numerator:
Net loss as reported	$	(10,623	)	$	(8,627	)	$	(22,099	)	$	(21,263	)
Less: income from change in fair value of warrant liability		(1,447	)		(2,494	)		(1,820	)		(2,584	)
Numerator for diluted net loss per common share	$	(12,070	)	$	(11,121	)	$	(23,919	)	$	(23,847	)

Denominator:
Basic weighted average common shares outstanding		85,061			49,135			84,766			46,411
Dilutive common shares from assumed warrant exercises		821			731			1,345			1,362
Diluted weighted average common shares outstanding		85,882			49,866			86,111			47,773

As of June 30, 2014 and 2013, 16.4 million and 10.8 million shares of common stock potentially issuable upon the exercise of certain stock options and warrants were excluded from the computation of diluted net loss per common share because their impact would have been anti-dilutive.

We do not have any components of other comprehensive income (loss).

Recent accounting pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. generally accepted accounting principles (GAAP) when it becomes effective. The new standard is effective for us in our fiscal year 2017. Early application is not permitted. We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. The standard permits the use of either the retrospective or cumulative effect transition method. We have not yet selected a transition method nor determined the effect of the standard on our financial reporting.

Table of Contents

Note 4 – Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

Level 1 – Quoted prices in active markets for identical assets and liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value on a Recurring Basis

The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:

	Fair Value		Fair value measurement using
	June 30, 2014		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	65,557	$	65,557	$	–	$	–
Certificate of Deposit		325		325		–		–
Total Assets	$	65,882	$	65,882	$	–	$	–

Liabilities:
Common stock warrant liability	$	3,224	$	–	$	–	$	3,224

	Fair Value		Fair value measurement using
	December 31, 2013		Level 1		Level 2		Level 3

Assets:
Cash and cash equivalents	$	86,283	$	86,283	$	–	$	–
Certificate of Deposit		325		325		–		–
Total Assets	$	86,608	$	86,608	$	–	$	–

Liabilities:
Common stock warrant liability	$	5,425	$	–	$	–	$	5,425

Table of Contents

The table below summarizes the activity of Level 3 inputs measured on a recurring basis for the six months ended June 30, 2014 and 2013:


(in thousands)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at December 31, 2013	$	5,425
Exercise of warrants		(375	)
Change in fair value of common stock warrant liability		(1,826	)
Balance at June 30, 2014	$	3,224

(in thousands)	Fair Value Measurements of Common Stock Warrants Using Significant Unobservable Inputs (Level 3)

Balance at December 31, 2012	$	6,305
Change in fair value of common stock warrant liability		(2,686	)
Balance at June 30, 2013	$	3,619

The significant unobservable inputs used in the fair value measurement of the common stock warrants measured on a recurring basis are the historical volatility of our common stock market price, expected term of the applicable warrants, and the risk-free interest rate based on the U.S. Treasury yield curve in effect at the measurement date. In addition to the significant unobservable inputs noted above, certain fair value measurements also take into account an assumption of the likelihood and timing of the occurrence of an event that would result in an adjustment to the exercise price in accordance with the anti-dilutive pricing provisions in the warrant. Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, may result in significantly higher or lower fair value measurements.

Significant Unobservable Input Assumptions of Level 3 Valuations	June 30, 2014	December 31, 2013

Historical Volatility	52% – 61%	62% – 76%
Expected Term (in years)	0.7 – 1.6	0.4 – 2.1
Risk-free interest rate	0.08% – 0.34%	0.08% – 0.44%

Fair Value of Long-Term Debt

At June 30, 2014, the estimated fair value of the Deerfield Loan was $23.2 million compared to a carrying value, net of discounts, of $19.3 million. At December 31, 2013, the estimated fair value of the Deerfield Loan was $23.6 million compared to a carrying value, net of discounts, of $18.4 million. The estimated fair value of the Deerfield Loan was based on discounting the future contractual cash flows to the present value. This analysis utilizes certain Level 3 unobservable inputs, including current cost of capital. Considerable judgment is required to interpret market data and to develop estimates of fair value. The estimates presented are not necessarily indicative of amounts that could be realized in a current market exchange. The use of alternative market assumptions and estimation methodologies could have a material effect on these estimates of fair value.

Table of Contents

Note 5 – Inventory

Inventory is comprised of the following for the periods presented:

	June 30,		December 31,
(in thousands)	2014		2013

Inventories, current:
Raw materials	$	147	$	52
Finished goods, net of reserves		296		60
		443		112
Inventories, non-current:
Raw materials		400		–
Total inventories, net	$	843	$	112

Raw materials inventory that is not expected to be used in commercial production until more than 12 months from the balance sheet date is classified as a non-current other asset on the balance sheet. The shelf life of our raw materials is 2‑5 years.

In addition, as of June 30, 2014, we had $0.7 million of raw materials that were purchased prior to October 4, 2013, the date the FDA approved updated SURFAXIN product specifications, which enabled the commercial introduction of SURFAXIN. These raw materials have a carrying value of zero, as the costs to purchase this material were expensed in the period of purchase as research and development expense, and accordingly are not reflected in the inventory balances shown above. These raw materials are anticipated to be used in manufacturing development, research and development activities and in the manufacture of commercial product.

Inventory reserves as of June 30, 2014 and December 31, 2013 were $2.0 million and $0.5 million, respectively. Inventory reserves reflect costs of SURFAXIN finished goods inventories that are not anticipated to be recoverable through the commercial sale of the product during the initial launch period due to product expiration. These reserves ensure that the inventory carrying values do not exceed net realizable value.

Note 6 – Common Stock Warrant Liability

The form of warrant agreement for the registered warrants that we issued in our February 2010 public offering generally provide that, in the event a related registration statement or an exemption from registration is not available for the issuance or resale of the warrant shares upon exercise of the warrant, the holder may exercise the warrant on a cashless basis. Notwithstanding the availability of cashless exercise, under GAAP, these registered warrants are deemed to be subject to potential net cash settlement and must be classified as derivative liabilities because (i) under federal securities laws, issuing freely-tradable registered shares upon exercise of the warrants may not be within our control in all circumstances, and (ii) the warrant agreements do not expressly provide that there is no circumstance in which we may be required to effect a net cash settlement of the warrants. The accounting guidance expressly precludes an evaluation of the likelihood that cash settlement could occur. Accordingly, the February 2010 warrants have been classified as a derivative liability and reported, at each balance sheet date, at estimated fair value determined using the Black-Scholes option-pricing model.

The form of warrant agreement for the registered warrants that we issued in the February 2011 public offering (February 2011 warrants) contain anti-dilutive provisions that adjust the exercise price if we issue any common stock, securities convertible into common stock, or other securities (subject to certain exceptions) at a value below the then-existing exercise price of the February 2011 warrants. Although by their express terms, these warrants are not subject to potential cash settlement, due to the nature of the anti-dilution provisions, these warrants have been classified as derivative liabilities and reported, at each balance sheet date, at estimated fair value determined using a trinomial pricing model.

Table of Contents

Selected terms and estimated fair value of warrants accounted for as derivative are as follows:

						Fair Value of Warrants (in thousands)
Issuance Date	Number of Warrant Shares Issuable		Exercise Price		Warrant Expiration Date	Value at Issuance Date
Issuance Date	Number of Warrant Shares Issuable		Exercise Price		Warrant Expiration Date	Value at Issuance Date		June 30, 2014		December 31, 2013

5/13/2009		466,667	$	17.25	5/13/2014	$	3,360	$	–	$	–
2/23/2010		916,669		12.75	2/23/2015		5,701		–		6
2/22/2011		4,552,600		1.50	2/22/2016		8,004		3,224		5,419
								$	3,224	$	5,425

There were no warrants exercised during the three months ended June 30, 2014. During the six months ended June 30, 2014, holders of the February 2011 warrants exercised warrants to purchase 282,350 shares of common stock for total proceeds of $0.4 million. There were no warrants exercised during the three and six months ended June 30, 2013.

Changes in the estimated fair value of warrants classified as derivative liabilities are reported in the accompanying Consolidated Statement of Operations as the “Change in fair value of common stock warrants.”

Note 7 – Deerfield Loan

Long-term debt consists solely of amounts due under a $30 million loan (Deerfield Loan) with affiliates of Deerfield Management Company, L.P. (Deerfield) for the periods presented:

(in thousands)	June 30, 2014			December 31, 2013

Note Payable	$	30,000		$	30,000
Unamortized discount		(10,736	)		(11,646	)
Long-term debt, net of discount	$	19,264		$	18,354

The principal amount of the loan is payable in three equal annual installments on the fourth, fifth and sixth anniversaries of the Deerfield Loan agreement beginning in February 2017, provided that the amount payable on the fourth anniversary shall be deferred for one year if either (i) “Net Sales” for the immediately preceding 12-month period are at least $20 million, or (ii) “Equity Value” is at least $200 million; and provided further, that the amount payable on the fifth anniversary (together with any amount deferred on the fourth anniversary) shall be deferred until the sixth anniversary if either (i) “Net Sales” for the immediately preceding 12-month period are at least $30 million, or (ii) “Equity Value” is at least $250 million. Accordingly, if the milestones are achieved in each year, payment of the principal amount could be deferred until the sixth anniversary date of the loan, February 13, 2019.

The following amounts comprise the Deerfield Loan interest expense for the periods presented:

(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013

Cash interest expense	$	654	$	218	$	1,302	$	331
Non-cash amortization of debt discounts		470		118		909		177
Amortization of debt costs		5		5		10		8
Total interest expense	$	1,129	$	341	$	2,221	$	516

Cash interest expense represents interest at an annual rate of 8.75% on the outstanding principal amount for the period, payable quarterly in cash. Non-cash amortization of debt discount represents the amortization of transaction fees and the fair value of the warrants issued in connection with the Deerfield Loan. The amortization of debt costs represents legal costs incurred in connection with the Deerfield Loan.

Table of Contents

In connection with the loan, we issued to Deerfield warrants to purchase 7.0 million shares of our common stock at an exercise price of $2.81 per share that expire on February 13, 2019. The Deerfield warrants are derivatives that qualify for an exemption from liability accounting provided in ASC 815 and are classified as equity. See, Note 9, “Deerfield Loan,” to the consolidated financial statements in our 2013 Form 10-K.

Note 8 – Stock Options and Stock-Based Employee Compensation

We recognize in our consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model. Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically three years.

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions:

	June 30,
	2014	2013

Weighted average expected volatility	100%	110%
Weighted average expected term	5.4 years	4.7 years
Weighted average risk-free interest rate	1.6%	0.74%
Expected dividends	–	–

The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented:

(in thousands)	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2014		2013		2014		2013
Research & Development	$	299	$	200	$	547	$	341
Selling, General & Administrative		482		407		938		622
Total	$	781	$	607	$	1,485	$	963

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10‑Q, including information with respect to our plans and strategy for our business and related financing activities, includes forward-looking statements that involve risks and uncertainties. You should review the “Forward-Looking Statements” section, and the risk factors discussed in the “Risk Factors” section and elsewhere in this Quarterly Report on Form 10-Q, as well as in our Annual Report on Form 10-K for the year ended December 31, 2013 that we filed with the Securities and Exchange Commission (SEC) on March 17, 2014 (2013 Form 10-K ) and our other filings with the SEC, and any amendments thereto, for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis or elsewhere in this Quarterly Report on Form 10-Q.

Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is provided as a supplement to the accompanying interim unaudited consolidated financial statements and footnotes to help provide an understanding of our financial condition, the changes in our financial condition and our results of operations. This item should be read in connection with our accompanying interim unaudited consolidated financial statements (including the notes thereto).

Table of Contents

OVERVIEW

Table of Contents

Business and Pipeline Programs Update

The reader is referred to, and encouraged to read in its entirety “Item 1 – Business,” in our 2013 Form 10-K, which contains a discussion of our Business and Business Strategy, as well as information concerning our proprietary technologies and our current and planned KL4 pipeline programs.

Following are updates to our pipeline programs since the filing of our 2013 Form 10-K:

SURFAXIN is the first synthetic, peptide-containing alternative to the previously available animal-derived surfactants. We initiated the commercial introduction of SURFAXIN in late 2013. Our commercial and medical teams currently are primarily focused on securing formulary acceptance or allowance for restricted use with hospitals that we believe to be recognized centers of excellence with strong reputations and regional and national influence in the neonatal community, as well as affiliated and regional hospitals. We believe that gaining formulary acceptance at selected centers of excellence could enhance our ability to gain formulary acceptance at other regional and national medical centers. We also are focused on providing in-service training to hospitals to assure that SURFAXIN is administered in a safe and consistent manner. Although not an indicator or predictor of revenue, in most cases, formulary acceptance is a necessary prerequisite to be able to sell SURFAXIN drug product to a hospital.

Our experience to date indicates that the time required to have SURFAXIN reviewed by hospital committees, accepted on hospital formulary, purchased by the hospital pharmacy, and ultimately used in the NICU is longer than we had expected. As a result, while we continue to believe that we will achieve wide market acceptance for SURFAXIN, we anticipate that revenues from sales of SURFAXIN will be modest in the next several years. Our experience also suggests that, to better inform the formulary committee review process and properly explain the method of administration and the potential benefits of SURFAXIN, including both potential medical and pharmacoeconomic benefits, it is important to emphasize medical education and scientific discussions. Therefore, in the second quarter of 2014, we resized and realigned our commercial and medical affairs teams to emphasize medical education balanced with an appropriate sales effort. We expect that this realignment could result in a reduction in expense in the second half of 2014 of approximately $1.0 million per quarter compared to recent historical expense

As we continue to monitor and learn from our progress, we plan to routinely reassess and adjust our tactical plan and make appropriate additional investments, if needed, to increase formulary uptake and SURFAXIN sales revenue. There can be no assurance, however, that we will succeed in these efforts.

Our AEROSURF phase 2 clinical program is underway. This initial phase 2a clinical trial was designed to assess the safety and tolerability of aerosolized KL4 surfactant in premature infants 29 to 32 weeks gestational age receiving nCPAP for RDS. In the second quarter of 2014, we experienced slower early enrollment than anticipated. During this time, we conducted an analysis of potentially eligible patient populations at our clinical trial sites and noted that a sizeable number of premature infants 33 to 34 weeks gestational age would potentially meet study eligibility requirements and may benefit from aerosolized KL4 surfactant. After consulting our clinical sites, AEROSURF Clinical Trial (ACT) Steering Committee, and Safety Review Committee (SRC), we have implemented trial protocol changes increasing the gestational age range to 29 to 34 weeks and expanding the number of patients in the trial to 42 from 36. As a result of the early slow enrollment and expansion of the number of patients, we now expect that the results of this trial will be available in the fourth quarter of 2014. We also are initiating activities to prepare for a phase 2b clinical trial, with results expected in the second half of 2015.

We continue to focus on implementing a long-term manufacturing strategy to assure continuity of our KL4 surfactant drug supply and are pursuing several alternatives.

We are working to identify potential alternatives that would enable longer-term utilization of our manufacturing facility in Totowa, NJ (Totowa Facility), the lease for which currently is scheduled to expire on June 30, 2015. At the present time, our Totowa Facility is the only approved manufacturing facility for SURFAXIN commercial product. We are actively engaged in discussions with the landlord, which is pursuing strategic options for the entire facility. We are also pursuing potentially manufacturing SURFAXIN using third-party CMOs. At this time, however, it is unlikely that we could complete the technology transfer of our SURFAXIN liquid KL4 surfactant manufacturing process in time to secure FDA approval for a new manufacturer of SURFAXIN prior to the scheduled expiration date of our lease. Accordingly, our primary goal currently is to secure longer-term utilization of our Totowa Facility. We believe that we will be successful in achieving our goal; however, if we do not succeed, we most likely will experience an interruption in supply of SURFAXIN drug product. See, Item 1A “–Risk Factors.”

Table of Contents

With respect to our lyophilized KL4 surfactant, we have worked with Patheon Inc. (Patheon, formerly DSM Pharmaceuticals, Inc.) to complete a technology transfer of our lyophilized KL4 surfactant manufacturing process and complete early manufacturing development activities. Patheon successfully manufactured a sufficient supply of lyophilized KL4 surfactant drug product to support our preclinical activities, development activities for our clinic-ready CAG, as well as our ongoing phase 2a clinical trial. We are working with Patheon to manufacture additional clinical supply to support our phase 2b clinical trial and have entered into a development agreement for the potential further development and manufacture of lyophilized KL4 surfactant for our potential AEROSURF phase 3 clinical program, as well as other potential pipeline development programs.

In the second quarter 2014, we secured three additional patents in the U.S., including two patents containing composition of matter and method of making claims for our lyophilized KL4 surfactant, which extend to 2033, and one related to our novel AFECTAIR® aerosol-conducting airway connector for infants that extends to April 2029. This device is intended to simplify the delivery of aerosolized medications and other inhaled therapies to critical-care infants requiring ventilatory support. We believe that these patents are indicative of our efforts to protect the long-term commercial potential of our KL4 surfactant and aerosol delivery technologies. Our lyophilized KL4 surfactant is being developed initially for our AEROSURF development program. Our longer term goal is to develop our technologies to address other potential indications that could benefit from our proprietary KL4 surfactant.

CRITICAL ACCOUNTING POLICIES

There have been no changes to our critical accounting policies since December 31, 2013. For a discussion of our accounting policies, see, Note 3, “Accounting Policies and Recent Accounting Pronouncements,” to the consolidated financial statements in our 2013 Form 10-K. Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.

Recent accounting pronouncements

RESULTS OF OPERATIONS

Net Loss and Operating Loss

The net loss for the three months ended June 30, 2014 and 2013 was $10.6 million (or $0.12 basic net loss per share) and $8.6 million (or $0.18 basic net loss per share), respectively. Included in the net loss is (i) the change in fair value of certain common stock warrants classified as derivative liabilities, resulting in non-cash income of $1.4 million and $2.5 million for 2014 and 2013, respectively, and (ii) interest expense of $1.1 million and $0.3 million for 2014 and 2013, respectively, associated with the Deerfield Loan.

The net loss for the six months ended June 30, 2014 and 2013 was $22.1 million (or $0.26 basic net loss per share) and $21.3 million (or $0.46 basic net loss per share), respectively. Included in the net loss is (i) the change in fair value of certain common stock warrants classified as derivative liabilities, resulting in non-cash income of $1.8 million and $2.7 million for 2014 and 2013, respectively, and (ii) interest expense of $2.2 million and $0.5 million for 2014 and 2013, respectively, associated with the Deerfield Loan.

Table of Contents

The operating loss for the three months ended June 30, 2014 and 2013 was $10.9 million and $10.8 million, respectively. The increase in operating loss from 2013 to 2014 was due to a $1.0 million increase in operating expenses, partially offset by a $0.9 million increase in grant revenues.

The operating loss for the six months ended June 30, 2014 and 2013 was $21.7 million and $23.4 million, respectively. The decrease in operating loss from 2013 to 2014 was due to a $0.9 million decrease in operating expenses and a $0.8 million increase in grant revenues.

Product Sales

In accordance with our revenue recognition policy, we recognize revenue once product has been sold through to the hospital and all revenue recognition criteria have been met. For the three and six months ended June 30, 2014, we recognized revenue in the amount of $42,000 and $70,000, respectively.

Grant Revenue

We recognized grant revenue of $1.1 million for both the three and six months ended June 30, 2014. During the second quarter of 2014, we were awarded the final $1.9 million of a $2.4 million Fast Track Small Business Innovation Research (SBIR) Grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH). This award provides support for the ongoing phase 2a clinical trial for AEROSURF. Our eligibility to be considered under this grant program was originally confirmed in 2010, and we previously received $0.6 million to support development activities related to our capillary aerosol generator technology. We expect to utilize the entire $1.9 million during 2014.

For the three and six months ended June 30, 2013, we recognized grant revenue of $0.2 million and $0.3 million, respectively. The grant funds were received and expended under a $0.6 million SBIR Phase I award from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) Center for Medical Counter Measures Against Radiation and Nuclear Threats to assess the ability of KL4 surfactant to mitigate the effects of acute radiation exposure to the lung, including acute pneumonitis and delayed lung injury.

Cost of product sales

Cost of product sales for the three and six months ended June 30, 2014 was $0.7 million and $1.5 million, respectively, and represents reserves for SURFAXIN finished goods inventories that are not anticipated to be recoverable through the commercial sale of the product during the initial launch period due to product expiration.

Research and Development Expenses

Our research and development expenses are charged to operations as incurred and are tracked by category rather than by development project. As many of our research and development activities form a foundation for the development of our KL4 surfactant and drug delivery technologies, they are expected to benefit more than a single project. For that reason, we cannot reasonably estimate the costs of our research and development activities on a project-by-project basis. We believe that tracking our expenses by category is a more accurate method of accounting for these activities. Our research and development costs consist of expenses associated with (a) product development and manufacturing, (b) medical and regulatory operations, (c) direct preclinical and clinical programs, and (d) other related expenses.

The table below summarizes research and development expenses for the periods presented:

(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013

Product development and manufacturing	$	3,298	$	4,998	$	6,922	$	11,822
Medical and regulatory operations		2,214		1,459		3,847		2,910
Direct preclinical and clinical programs		1,346		406		1,679		603
Total Research & Development Expenses	$	6,858	$	6,863	$	12,448	$	15,335

Table of Contents

Research and development expenses for the three months ended June 30, 2014 and 2013 include non-cash charges associated with stock-based compensation and depreciation of $0.5 million and $0.4 million, respectively; and $0.9 million and $0.7 million for the six months ended June 30, 2014 and 2013, respectively.

Product Development and Manufacturing

Product development and manufacturing includes (i) manufacturing operations, both in-house and with CMOs, validation activities and quality assurance and analytical chemistry capabilities to support production of drug supply for our KL4 surfactant products used in research and development activities, and of medical devices, including CAG and AFECTAIR devices, (ii) design and development activities related to our CAG device for use in our AEROSURF phase 2 clinical program; and (iii) pharmaceutical and manufacturing development activities, including development of a lyophilized dosage form of our KL4 surfactant. These costs include employee expenses, facility-related costs, depreciation, costs of drug substances (including raw materials), supplies, quality control and assurance activities, analytical services, and expert consultants and outside services to support pharmaceutical and device development activities.

Product development and manufacturing expenses for the three months ended June 30, 2014 decreased $1.7 million compared to the same period in 2013, due to (i) investments of $1.4 million in 2013 to complete development activities for our clinic-ready CAG device for use in our AEROSURF phase 2 clinical trials, including work that began in June 2012 with Battelle Memorial Institute (Battelle), which assisted with the device design and testing, and manufactured a supply of clinic-ready CAG devices for use in the initial AEROSURF phase 2a clinical trial, and (ii) $1.1 million of costs capitalized to SURFAXIN inventory in 2014, partially offset by (iii) a $0.2 million increase in purchases of active pharmaceutical ingredients (APIs) used in the manufacture of SURFAXIN and our lyophilized KL4 surfactant for the AEROSURF development program .

Product development and manufacturing expenses for the six months ended June 30, 2014 decreased $4.9 million compared to the same period in 2013, due to (i) investments in 2013 of $2.6 million to complete development activities for our clinic-ready CAG device for use in our AEROSURF phase 2 clinical trials, (ii) $2.0 million of costs capitalized to SURFAXIN inventory in 2014, and (iii) a reduction of $1.0 million in purchases of APIs used in the manufacture of SURFAXIN commercial drug product and our lyophilized KL4 surfactant for use in preclinical and clinical development activities, including the technology transfer of our KL4 surfactant manufacturing process to Patheon, further drug development at Patheon, and activities to prepare for our AEROSURF phase 2 clinical program.

Medical and Regulatory Operations

Medical and regulatory operations includes (i) medical, scientific, clinical, regulatory, data management and biostatistics activities in support of our research and development programs, and (ii) medical affairs activities to provide scientific and medical education support related to SURFAXIN, as well as our other KL4 surfactant and aerosol delivery products under development. These costs include personnel, expert consultants, outside services to support regulatory and data management, symposiums at key medical meetings, facilities-related costs, and other costs for the management of clinical trials.

Medical and regulatory operations expenses for the three months ended June 30, 2014 increased $0.8 million compared to the same period in 2013 due to (i) a $0.4 million increase related to our medical affairs capabilities to support the commercial introduction of SURFAXIN, and (ii) a $0.2 million increase to strengthen our clinical leadership team and support our AEROSURF development program.

Medical and regulatory operations expenses for the six months ended June 30, 2014 increased $0.9 million compared to the same period in 2013 due to (i) a $0.4 million increase related to our medical and regulatory capabilities to support our AEROSURF development program, including to strengthen our clinical leadership team, and (ii) a $0.3 million increase related to our medical affairs capabilities to execute the commercial introduction of SURFAXIN.

Direct Preclinical and Clinical Programs

Direct preclinical and clinical programs include: (i) development activities, toxicology studies and other preclinical studies to obtain data to support our investigational new drug (IND) applications and, potentially, New Drug Application (NDA) filings; and (ii) activities associated with conducting clinical trials, including patient enrollment costs, external site costs, clinical device and drug supply, and related external costs, such as research consultant fees and expenses.

Table of Contents

Direct preclinical and clinical programs expenses for the three months ended June 30, 2014 increased $0.9 million compared to the same period in 2013 due to (i) a $0.7 million increase in AEROSURF clinical trial activities, including ongoing enrollment of the Phase 2a study and initiating the manufacture of clinic-ready CAG devices for the AEROSURF Phase 2b clinical study, and (ii) $0.4 million of preclinical activities in 2014 related to our lyophilized dosage form of our KL4 surfactant.

Direct preclinical and clinical programs expenses for the six months ended June 30, 2014 increased $1.1 million compared to the same period in 2013 due to (i) a $0.8 million increase in AEROSURF clinical trial activities, including ongoing enrollment of the Phase 2a study and initial manufacturing of clinic-ready CAG devices for the planned AEROSURF Phase 2b clinical study, and (ii) $0.5 million of preclinical activities in 2014 related to our lyophilized dosage form of our KL4 surfactant.

We anticipate that direct clinical program costs associated with conducting the AEROSURF phase 2 clinical program will be approximately $10 - 11 million for 2014 and through the anticipated completion of the AEROSURF phase 2 program as expected in 2015.

Research and Development Projects – Updates

Due to the significant risks and uncertainties inherent in the clinical development and regulatory approval processes, the nature, timing and costs of the efforts necessary to complete individual projects in development are not reasonably estimable. With every phase of a development project, there are unknowns that may significantly affect cost projections and timelines. In view of the number and nature of these factors, many of which are outside our control, the success, timing of completion and ultimate cost of development of any of our product candidates is highly uncertain and cannot be estimated with any degree of certainty. Certain of the risks and uncertainties affecting our ability to estimate projections and timelines are discussed in the Risk Factors Section and elsewhere in this Quarterly Report on Form 10-Q and in “Item 1 – Business – Government Regulation,” “Item 1A – Risk Factors,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Results of Operations – Research and Development Expenses” in our 2013 Form 10-K.

Our research and development projects have been focused initially on the management of RDS in premature infants, and include (i) SURFAXIN liquid instillate, which was approved by the FDA in 2012 and introduced commercially in 2013, (ii) our lyophilized KL4 surfactant, which we are developing initially for use in our AEROSURF development program and, if we are able to gain FDA agreement for a development program that would be both capital efficient and capable of implementation within a reasonable time, potentially, SURFAXIN LS; (iii) our aerosol delivery technology, in particular the development of a CAG device to support our AEROSURF phase 2 clinical program; and (iv) AEROSURF phase 2 clinical trial activities. These and our other development programs are described “Item 1 – Business – Proprietary Platform – Surfactant and Aerosol Technologies,” and “‑ Surfactant Replacement Therapy for Respiratory Medicine” in our 2013 Form 10-K, and in our other periodic filings with the SEC.

To prepare for initiation of the AEROSURF phase 2 clinical program, during 2012 through 2013, we invested approximately $7 million to develop a clinic-ready CAG device with Battelle and our lyophilized KL4 surfactant manufacturing process at Patheon. We anticipate that direct clinical program costs associated with conducting the AEROSURF phase 2 clinical program will be approximately $10 - 11 million for 2014 and through the completion of phase 2b as expected in 2015. We also plan to invest in appropriate capabilities to support the further advancement of AEROSURF, including for manufacturing development of our lyophilized KL4 surfactant, the conduct of a phase 3 clinical program, and further development of a CAG device suitable for use in a phase 3 clinical program and, if successful, commercial use.

At the present time, we are focusing our efforts primarily on the commercial introduction of SURFAXIN and development of AEROSURF through the phase 2 clinical trials. We also believe that, in the future, we may be able to leverage the information, data and know-how that we gain from our work with SURFAXIN and AEROSURF to support development of a robust product pipeline that could address serious critical care respiratory conditions in larger children and adults in PICUs and ICUs, including potentially ALI, COPD and CF.

The reader is referred to and encouraged to review updates to the Pipeline Programs in “– Overview,” and “–Business and Pipeline Programs Update” at the beginning of this MD&A, which contain important updates and information necessary and important to this discussion. See also, “– Liquidity and Capital Resources.”

Table of Contents

Selling, General and Administrative Expenses

(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013
Selling, General and Administrative Expenses	$	4,446	$	4,129	$	8,869	$	8,349

Selling, general and administrative expenses consist of the costs of sales and marketing activities, executive management, business development, intellectual property, finance and accounting, legal, human resources, information technology, facilities and other administrative costs.

Selling, general and administrative expenses for the three and six months ended June 30, 2014 increased $0.3 million and $0.5 million, respectively, compared to the same periods in 2013 due to (i) increased investments in our marketing and field-based sales force to execute the commercial introduction of SURFAXIN, and (ii) an increase in related stock-based compensation expense.

Change in Fair Value of Common Stock Warrant Liability

(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013
Change in fair value of common stock warrant liability	$	1,448	$	2,525	$	1,826	$	2,686

We account for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815 “Derivatives and Hedging – Contracts in Entity’s Own Equity” (ASC 815), either as derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement. Derivative warrant liabilities are valued at the date of initial issuance and as of each subsequent balance sheet date using the Black-Scholes or trinomial pricing models, depending on the terms of the applicable warrant agreement. Changes in the fair value of the warrants are reflected in the consolidated statement of operations as “Change in the fair value of common stock warrant liability.” See, Note 6 to our consolidated financial statements in this Quarterly Report on Form 10-Q, and “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Results of Operations – Change in Fair Value of Common Stock Warrant Liability” our 2013 Form 10-K.

Changes in the fair value of common stock warrant liability generally are due to changes in our common stock share price during the periods.

Other Income and (Expense)

(in thousands)	Three Months Ended June 30,						Six Months Ended June 30,
	2014			2013			2014			2013

Interest income	$	2		$	1		$	4		$	1
Interest expense		(1,131	)		(343	)		(2,224	)		(520	)
Other income / (expense), net	$	(1,129	)	$	(342	)	$	(2,220	)	$	(519	)

Interest income consists of interest earned on our cash and cash equivalents. To ensure preservation of capital, we invest our cash in an interest bearing operating cash account and a U.S. treasury-based money market fund.

Interest expense consists of interest expense associated with the Deerfield Loan (see, Note 7 to our consolidated financial statements in this Quarterly Report on Form 10-Q) and interest expense incurred under our equipment financing facilities.

Table of Contents

The following amounts comprise the Deerfield Loan interest expense for the periods presented:

(in thousands)	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013

Cash interest expense	$	654	$	218	$	1,302	$	331
Non-cash amortization of debt discounts		470		118		909		177
Amortization of debt costs		5		5		10		8
Total interest expense	$	1,129	$	341	$	2,221	$	516

Cash interest expense represents interest at an annual rate of 8.75% calculated on the outstanding principal amount for the period, paid in cash on a quarterly basis. Non-cash amortization of debt discount represents the amortization of transaction fees and the fair value of the Deerfield Warrants. The amortization of debt costs represents professional fees incurred in connection with the Deerfield Loan.

LIQUIDITY AND CAPITAL RESOURCES

Overview

As of June 30, 2014, we had cash and cash equivalents of $65.6 million and long-term debt of $30 million ($19.3 million net of discount) under our Deerfield Loan with affiliates of Deerfield Management Company, L.P. (Deerfield) (see, Note 7, “Deerfield Loan,” to our consolidated financial statements in this Quarterly Report on Form 10-Q). Before any additional financings, including under our ATM Program (see, “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – At-the-Market Program (ATM Program) – Stifel ATM Program,” in our 2013 Form 10-K), we anticipate that we will have sufficient cash available to fund our operations and debt service obligations through the third quarter of 2015.

For the next several years, we expect that our cash outflows for marketing, commercial and medical activities, development programs, operations and debt service will outpace the rate at which we may generate revenues. To execute our business strategy, pay debt obligations and fund our operations over the next several years, we will require significant additional infusions of capital until such time as the net revenues from the sale of approved products and from other sources are sufficient to offset our cash flow requirements. While we currently intend to retain all rights and commercialize our approved products in the U.S. by ourselves, an important priority for us is to identify strategic transactions that could provide additional capital and strategic resources to support the continued development and commercial introduction of our RDS products in markets outside the U.S. For our AEROSURF development program, we seek a significant strategic alliance that potentially could provide development, regulatory and commercial market expertise, and, if approved, support the commercial introduction of AEROSURF in the EU and other selected markets outside the U.S. Such alliances typically also would provide financial resources, in the form of upfront payments, milestone payments, commercialization royalties and a sharing of research and development expenses. To advance SURFAXIN in markets outside the U.S. where regulatory marketing authorization is facilitated by the information contained in our new drug application (NDA) approved by the FDA, we would consider various financing or collaboration arrangements that could provide regulatory expertise, support the commercial introduction of SURFAXIN in markets outside the U.S., and potentially provide a sharing of revenues. Such countries could potentially include those in Latin America, North Africa and the Middle East. To secure the necessary capital, we also plan to consider other public and private equity offerings, including under our ATM Program, which currently may allow for the sale of up to approximately $23 million of our commons stock, as well as other financing transactions, such as secured equipment financing facilities or other similar transactions.

Our future capital requirements will depend upon many factors, primarily our efforts to (i) execute the commercial introduction of SURFAXIN in the U.S.; (ii) advance the AEROSURF development program to completion of the phase 2 clinical trials as planned in the second half of 2015; (iii) assure long-term continuity of supply for both our commercial and lyophilized KL4 surfactant drug product, potentially with CMOs and/or at Totowa Facility; and (iv) secure one or more strategic alliances or other collaboration arrangements to support our development programs and commercialization of our approved products, if any, in markets outside the U.S. We believe that we will be better positioned to enter into a significant strategic alliance if we are successful in advancing the commercial introduction of SURFAXIN and completing and obtaining encouraging results from the AEROSURF phase 2 clinical program within our anticipated time.

Table of Contents

As of June 30, 2014, 250 million shares of common stock were authorized under our Amended and Restated Certificate of Incorporation and approximately 137.2 million shares of common stock were available for issuance and not otherwise reserved.

Cash Flows

As of June 30, 2014, we had cash and cash equivalents of $65.6 million compared to $86.3 million as of December 31, 2013. Cash outflows before financing activities for the six months ended June 30, 2014 consisted of $20.3 million used for ongoing operating activities and $0.9 million for purchases of property and equipment. Cash provided by financing activities were $0.4 million of proceeds from the exercise of warrants and stock options.

Operating Activities

Net cash used in operating activities for the six months ended June 30, 2014 and 2013 was $20.3 million and $20.4 million, respectively. Net cash used in operating activities is a result of our net losses for the period, adjusted for non-cash items and changes in working capital.

Investing Activities

Net cash used in investing activities for the six months ended June 30, 2014 and 2013 represents capital expenditures of $0.9 million and $0.1 million, respectively. The increase in capital expenditures is due to timing of routine equipment purchases.

Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2014 and 2013 was $0.4 million and $24.9 million, respectively. Net cash provided by financing activities for the six months ended June 30, 2014 represents proceeds from the exercise of warrants and stock options. Net cash provided by financing activities for the six months ended June 30, 2013 includes proceeds of $15.1 million pursuant to a common stock offering and the first advance in February 2013 of $10.0 million ($9.9 million, net) under the Deerfield Loan.

Table of Contents

The following sections provide a more detailed discussion of our available financing facilities.

Common Stock Offerings

Historically, we have funded, and expect that we will continue to fund, our business operations through various sources, including financings in the form of common stock offerings. In May 2014, we filed with the SEC a universal shelf registration statement on Form S-3 (No. 333-196420) (2014 Universal Shelf) that was declared effective on June 13, 2014 for the proposed offering from time to time of up to $250 million of our securities, including common stock, preferred stock, varying forms of debt and warrant securities, or any combination of the foregoing, on terms and conditions that will be determined at the time of an offering. The 2014 Universal Shelf replaces an expired 2011 Universal Shelf. As of June 30, 2014, after reserves for outstanding unexercised warrants and amounts remaining under our ATM Program, approximately $199.0 million remained available under the 2014 Universal Shelf. The 2014 Universal Shelf will expire in June 2017.

At-the-Market Program (ATM Program)

We have an ATM Program with Stifel, Nicolaus & Company, Incorporated (Stifel), under which Stifel, as our exclusive agent, at our discretion and at such times that we may determine from time to time, may sell up to a maximum of $25 million of our common stock over a three-year period ending February 11, 2016. We are not required to sell any shares at any time during the term of the ATM Program. We have agreed to pay Stifel a commission of 3% of gross proceeds of any sales of shares. See, “Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources – At-the-Market Program (ATM Program) – Stifel ATM Program,” in our 2013 Form 10-K. As of June 30, 2014, approximately $23 million shares of common stock remained available under the ATM Program.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of disclosure controls and procedures

Our management, including our President and Chief Executive Officer (principal executive officer) and our Chief Financial Officer (principal financial officer), does not expect that our disclosure controls or our internal control over financial reporting will prevent all error and all fraud. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our President and Chief Executive Officer and our Chief Financial Officer have evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our President and Chief Executive Officer and our Chief Financial Officer, to allow for timely decisions regarding required disclosures, and recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Table of Contents

Changes in internal controls

There were no changes in our internal control over financial reporting identified in connection with the evaluation described above that occurred during the quarter ended June 30, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

We are not aware of any pending or threatened legal actions that would, if determined adversely to us, have a material adverse effect on our business and operations.

We have from time to time been involved in disputes and proceedings arising in the ordinary course of business, including in connection with the conduct of our clinical trials. In addition, as a public company, we are also potentially susceptible to litigation, such as claims asserting violations of securities laws. Any such claims, with or without merit, if not resolved, could be time-consuming and result in costly litigation. There can be no assurance that an adverse result in any future proceeding would not have a potentially material adverse effect on our business, results of operations and financial condition.

ITEM 1A.

RISK FACTORS

Investing in our securities involves risks. In addition to the other information in this quarterly report on Form 10-Q, stockholders and potential investors should carefully consider the risks and uncertainties discussed in the section "Item 1A – Risk Factors" in our 2013 Form 10-K, as supplemented by the risks and uncertainties discussed below and elsewhere in this Quarterly Report on 10-Q. The risks and uncertainties discussed in this Quarterly Report on Form 10-Q and described in our 2013 Form 10-K are not the only ones that may materialize. Additional risks and uncertainties not presently known to us or that we currently consider to be immaterial may also impair our business operations. If any of the risks and uncertainties discussed in this Quarterly Report on Form 10-Q or in our 2013 Form 10-K actually materialize, our business, financial condition and/or results of operations could be materially adversely affected, the trading price of our common stock could decline and a stockholder could lose all or part of his or her investment.

The projections that we may make from time to time are subject to inherent risks.

The projections that our management may provide from time to time (including, but not limited to, those relating to product approval, production and supply dates, commercial launch dates, and other financial or operational matters) reflect numerous assumptions made by management, including assumptions with respect to our specific as well as general business, economic, market and financial conditions and other matters, all of which are difficult to predict and many of which are beyond our control. Accordingly, there is a risk that the assumptions we make in preparing the projections, or the projections themselves, will prove inaccurate. There will be differences between actual and projected results, and actual results may be materially different from those contained in the projections. The inclusion of projections in this Form 10-Q or in our periodic reports and current reports on Form 8-K should not be regarded as an indication that we or our management or representatives considered or consider the projections to be a reliable prediction of future events, and the projections should not be relied upon as such.

Our efforts to achieve formulary acceptance of SURFAXIN, and to educate the medical community and third-party payers regarding the benefits of SURFAXIN, will require significant, focused and competent resources and we may not be successful in achieving our objectives. If we are unable to achieve formulary acceptance in our target hospitals, the revenues we generate from sales likely will be limited, which could have a material adverse effect on our operations, and our commercial and development programs.

We initiated the commercial introduction of SURFAXIN in late 2013. SURFAXIN product sales are expected to constitute most, if not all, of our total revenue from product sales over the next several years. If we fail to successfully commercialize SURFAXIN for any reason, we will be exposed to the following risks, among others:

Our ability to achieve broad market acceptance of our other KL4 surfactant products by physicians, respiratory therapists, nurses and other personnel in the NICU and elsewhere in the hospital, as well as patients, healthcare payers and others in the medical community in general, may be negatively impacted, which could impair our ability to develop, and if approved, commercialize other KL4 surfactant products

The market price of our stock could be adversely affected, which may make it more difficult to conduct equity financing transactions, attract strategic partners or enter into collaboration or other agreements and maintain compliance with the listing requirements of The Nasdaq Capital Market.

We may be unable to pay our debt service. We have pledged substantially all of our assets to secure our obligations under a $30 million loan (Deerfield Loan) from affiliates of Deerfield Management Company, L.P. (Deerfield). If we were to fail in the future to make any required payment under the Deerfield Loan or fail to comply with the covenants contained in the facility agreement and other related agreements, we would be in default regarding that indebtedness, which would enable the lenders to foreclose on the assets securing such debt and could result in the acceleration of the payment obligations under all or a portion of our consolidated indebtedness.

Table of Contents

Our long-term manufacturing strategy includes potentially manufacturing our KL4 surfactant at our Totowa Facility, and relying on third parties to manufacture our approved products as well as our drug product and medical device candidates, all of which expose us to risks that may affect our ability to maintain supplies of our commercial products and/or delay our research and development activities, regulatory approval and commercialization of our drug product and medical device candidates.

We currently manufacture SURFAXIN at our manufacturing operations in Totowa, New Jersey (Totowa Facility), for which our lease is currently scheduled to expire in June 2015. We also expect to manufacture lyophilized KL4 surfactant, our CAG, WARMING CRADLE® and AFECTAIR® devices, with CMOs. Our manufacturing plans could expose us to the following risks:

We are currently in discussions with our landlord to potentially secure long-term utilization of that facility. We believe that our efforts will be successful; however, if we are unable to succeed, we most likely will experience an interruption in supply of SURFAXIN drug product.

In seeking to identify CMOs to manufacture products on our behalf, we may be unable to identify manufacturers with whom we might establish appropriate arrangements on acceptable terms, if at all, because the number of potential CMOs is limited and the FDA must approve any replacement CMO. This approval could require one or more pre-approval inspections as well as a potentially lengthy qualification process. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our approved products after receipt of FDA approval. This could take as long as 2 years to qualify and receive regulatory approval.

We may implement a plan to execute a technology transfer of our manufacturing process to a CMO and, after investing significant time and resources, learn that the CMO we chose is unable to successfully complete the technology transfer and manufacture our products in accordance with our plan.

CMOs might be unable to manufacture our products in the volume and to our specifications to meet our commercial, preclinical and clinical needs, or we may have difficulty scheduling the production of drug product and devices in a timely manner to meet our timing requirements.

CMOs may not perform as agreed, or may not remain in the CMO business for a lengthy time, or may refuse to renew an expiring agreement as expected, or may fail to produce a sufficient supply to meet our commercial and/or clinical needs.

CMOs are subject to ongoing periodic unannounced inspection by the FDA, international health authorities, registered Notified Bodies, the U. S. Drug Enforcement Administration, and corresponding state agencies to ensure strict compliance with current good manufacturing practices (cGMP) and/or quality system regulations (QSR) and other government regulations and corresponding foreign standards. We do not have control over a CMO’s compliance with these regulations and standards.

Should we desire to make our drug products and/or devices available outside the U.S. for commercial or clinical purposes, our CMOs would become subject to, and may not be able to comply with, corresponding cGMPs and QSRs of the various foreign regulators having jurisdiction over our activities abroad. Such failures could restrict our ability to execute our business strategies.

If any third-party manufacturer makes improvements in the manufacturing process for our products, we may not have rights to, or may have to share, the intellectual property rights to any such innovation. We may be required to pay fees or other costs for access to such improvements.

Each of the foregoing risks and others could create uncertainty concerning our ability to maintain continuous supply of our products and product candidates, delay our commercial manufacturing plans and our development programs, as well as the approval, if any, of our product candidates, by the FDA or foreign regulator, or result in higher costs or deprive us of potential product revenues. Failure to succeed in our efforts could result in interruptions in our manufacturing capabilities and result in potential shortages of drug product.

Table of Contents

Our clinical development program for AEROSURF involves significant risks and uncertainties that are inherent in the clinical development and regulatory approval processes. Our clinical trials may be delayed, or fail, which would harm our business prospects.

Our ongoing AEROSURF phase 2a clinical trial is the first of a series of clinical trials that will be needed to gain marketing authorization for AEROSURF. We could experience delays that could have a significant impact on our time line for completion of such trials. Generally, such programs take two to five years or more to complete and may be delayed by a number of factors. We may not reach agreement with the U.S. Food and Drug Administration (FDA) or a foreign regulator on the design of any one or more of the clinical trials necessary for approval, or we may be unable to reach agreement on a single design that would permit us to conduct a single clinical program in multiple jurisdictions. Conditions imposed by the FDA and foreign regulators on our clinical program could significantly increase the time required to complete and the costs of conducting clinical trials. For example, we may not be successful in achieving a study design that is acceptable to both the FDA and regulators in other countries, which would cause us to limit the scope of our activities or greatly increase our investment. Like many biotechnology companies, even after obtaining promising preliminary findings or results in earlier preclinical studies and clinical trials, we may suffer significant setbacks in any stage of our clinical trials. Clinical data is susceptible to varying interpretations that may delay, limit or prevent regulatory approval. In addition, we may be unable to enroll patients quickly enough to meet our expectations for completing any or all of these trials.

The timing and completion of current and planned clinical trials of our product candidates depend on many factors, including the rate at which patients are enrolled. Delays in patient enrollment in clinical trials may occur, which would be likely to result in increased costs, program delays, or both. Patient enrollment is a function of many factors, including:

the number of clinical sites;

the size of the patient population;

the eligibility and enrollment criteria for the study;

the willingness of patients’ parents or guardians to participate in the clinical trial;

the existence of competing clinical trials;

the existence of alternative available products; and

geographical and geopolitical considerations.

In addition, if in our clinical trials we succeed in achieving our patient enrollment targets, our patients could suffer adverse medical events or side effects that are known to be associated with surfactant administration, such as a decrease in the oxygen level of the blood, or currently unknown to us. It is also possible that we, our AEROSURF Clinical Trial (ACT) Steering Committee, the Safety Review Committee (SRC), or the FDA could interrupt, delay or halt any one or more of our clinical trials for AEROSURF or any of our product candidates. If our ACT Steering Committee, the SRC, any regulator or we believe that study participants face unacceptable health risks, any one or more of our clinical trials could be suspended or terminated. In addition, clinical trials may be interrupted, delayed or halted, in whole or in part, for reasons other than health and safety concerns, including, among other things, matters related to the design of the study, drug availability, ACT Steering Committee and/or SRC recommendation, or business reasons. Even if we timely complete a clinical trial, we may fail to achieve the desired endpoints.

In addition to our planned clinical program to support AEROSURF, in the future we also may initiate or support clinical trials evaluating other KL4 surfactant pipeline products. All of these clinical trials will be time-consuming and potentially costly. Should we fail to complete our clinical development programs or should such programs yield unacceptable results, such failures would have a material adverse effect on our business.

We will require, but may be unable to secure when needed, significant additional capital to support our operations, pay our debt service, commercialize our approved products, continue our other research and development programs, and advance our long-term business strategy.

Our operations have consumed substantial amounts of cash since inception. As of June 30, 2014, we had cash and cash equivalents of approximately $66 million and $30 million of long-term debt under a secured loan with affiliates of Deerfield Management Company, L.P. Before any additional financings, including under our ATM Program, we anticipate that we will have sufficient cash available to support our current operations and debt service obligations through the third quarter of 2015.

Table of Contents

We expect to continue to require significant additional infusions of capital to be able to execute key components of our long-term business strategy. For example, we expect to make potentially significant additional investments to secure our long-term manufacturing capabilities for our liquid and lyophilized KL4 surfactant drug product, further the development of our CAG for use in a potential phase 3 clinical program and, if approved, for commercial applications, and to prepare for, initiate and conduct a potential AEROSURF phase 3 clinical program.

If we are unable to secure the additional capital when needed, if at all, on terms that are acceptable, our long-term business strategy would be adversely affected.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended June 30, 2014, we issued 8,750 unregistered shares of common stock to a consultant as compensation for management consulting services rendered during the three month period ended May 31, 2014. The shares were issued in reliance upon the exemption from securities registration provided by Section 4(2) of the Act.

ITEM 6.

EXHIBITS

Exhibits are listed on the Index to Exhibits at the end of this Quarterly Report. The exhibits required by Item 601 of Regulation S-K, listed on such Index in response to this Item, are incorporated herein by reference.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Discovery Laboratories, Inc.
		(Registrant)

Date:	August 7, 2014	By:	/s/ John G. Cooper
			John G. Cooper
			President and Chief Executive Officer

Date:	August 7, 2014	By:	/s/ John Tattory
			John Tattory
			Senior Vice President and Chief Financial Officer

Table of Contents

INDEX TO EXHIBITS

The following exhibits are included with this Quarterly Report on Form 10-Q.

Exhibit No.	Description	Method of Filing

3.1	Amended and Restated Certificate of Incorporation filed as of August 1, 2013, as amended by a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Discovery Laboratories, Inc. (Discovery), filed on June 10, 2014	Filed herewith.

3.2	Amended and Restated By-Laws of Discovery, as amended effective September 3, 2009	Incorporated by reference to Exhibit 3.1 to Discovery’s Current Report on Form 8-K, as filed with the SEC on September 4, 2009.

4.1	Form of Warrant to Purchase Common Stock issued in February 2010	Incorporated by reference to Exhibit 4.1 to Discovery’s Current Report on Form 8-K, as filed with the SEC on February 18, 2010.

4.2	Warrant Agreement, dated as of April 30, 2010, by and between Discovery and PharmaBio	Incorporated by reference to Exhibit 4.1 to Discovery’s Current Report on Form 8-K, as filed with the SEC on April 28, 2010.

4.3	Warrant Agreement dated June 11, 2010 by and between Kingsbridge Capital Limited and Discovery	Incorporated by reference to Exhibit 4.1 to Discovery’s Current Report on Form 8-K, as filed with the SEC on June 14, 2010.

4.4	Form of Series I Warrant to Purchase Common Stock issued on June 22, 2010 (Five-Year Warrant)	Incorporated by reference to Exhibit 4.1 to Discovery’s Current Report on Form 8-K, as filed with the SEC on June 17, 2010.

4.5	Warrant Agreement, dated as of October 12, 2010, by and between Discovery and PharmaBio	Incorporated by reference to Exhibit 4.1 to Discovery’s Current Report on Form 8-K, as filed with the SEC on October 13, 2010.

4.6	Form of Series I Warrant to Purchase Common Stock issued on February 22, 2011 (Five-Year Warrant)	Incorporated by reference to Exhibit 4.1 to Discovery’s Current Report on Form 8-K, as filed with the SEC on February 16, 2011.

4.9+	Form of Warrant dated February 13, 2013, issued to affiliates of Deerfield Management Co., LLP (Deerfield) under a Facility Agreement dated as of February 13, 2012 between Discovery and Deerfield	Incorporated by reference to Exhibit 4.1 to Discovery’s Current Report on Form 8-K, as filed with the SEC on June 14, 2013.

4.10+	Form of Warrant dated December 3, 2013, issued to affiliates of Deerfield Management Co., LLP (Deerfield) on December 3, 2013 under a Facility Agreement dated as of February 13, 2012 between Discovery and Deerfield	Incorporated by reference to Exhibit 4.1 to Discovery’s Current Report on Form 8-K, as filed with the SEC on December 6, 2013.

Table of Contents

Exhibit No.	Description	Method of Filing

10.1	Discovery’s 2011 Long-Term Incentive Plan	Incorporated by reference to Appendix II to Discovery’s Definitive Proxy Statement on Form DEF 14A, as filed with the SEC on August 15, 2011 (Commission File Number 000-26422).

10.2	Amendment to Discovery’s 2011 Long-Term Incentive Compensation Plan effective June 10, 2014	Filed herewith

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act	Filed herewith.

31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act	Filed herewith.

32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith.

101.1	The following consolidated financial statements from the Discovery Laboratories, Inc. Annual Report on Form 10-Q for the quarter ended March 31, 2014, formatted in Extensive Business Reporting Language (“XBRL”): (i) Balance Sheets as of March 31, 2014 (unaudited) and December 31, 2013, (ii) Statements of Operations (unaudited) for the three months ended March 31, 2014 and March 31, 2013, (iii) Statements of Cash Flows (unaudited) for the three months ended March 31, 2014 and March 31, 2013, and (v) Notes to consolidated financial statements.

101.INS	Instance Document	Filed herewith.

101.SCH	XBRL Taxonomy Extension Schema Document	Filed herewith.

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith.

101.DEF	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith.

101.LAB	XBRL Taxonomy Extension Label Linkbase Document	Filed herewith.

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith.

+ Confidential treatment requested as to certain portions of these exhibits. Such portions have been redacted and filed separately with the Commission.

* A management contract or compensatory plan or arrangement required to be filed as an exhibit to this quarterly report pursuant to Item 6 of Form 10-Q.

EX-3.1 2 ex3_1.htm EXHIBIT 3.1

Exhibit 3.1

Amended and Restated Certificate of Incorporation

filed as of August 1, 2013,

as Amended by a Certificate of Amendment to the

Amended and Restated Certificate of Incorporation

of Discovery Laboratories, Inc.,

filed on June 10, 2014

(Pursuant to Sections 228, 242, and 245 of the

General Corporation Law of the State of Delaware)

The Corporation was originally incorporated on November 6, 1992, under the name “Ansan, Inc.”

ARTICLE ONE

The name of the corporation (hereinafter called the “Corporation”) is Discovery Laboratories, Inc.

ARTICLE TWO

The address, including street, number, city, and county, of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New Castle; and the name of the registered agent of the Corporation in the State of Delaware at such address is The Corporation Trust Company.

ARTICLE THREE

The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.

ARTICLE FOUR

The total number of shares of all classes of stock which the Corporation shall have the authority to issue is 255,000,000 consisting of 250,000,000 shares of common stock, par value $0.001 per share (the “Common Stock”), and 5,000,000 shares of preferred stock, par value $0.001 per share (the “Preferred Stock”).

The Board of Directors may divide the Preferred Stock into any number of series, fix the designation and number of shares of each such series, and determine or change the designation, relative rights, preferences, and limitations of any series of Preferred Stock. The Board of Directors (within the limits and restrictions of any resolutions adopted by it originally fixing the number of any shares of any series of Preferred Stock) may increase or decrease the number of shares initially fixed for any series, but no such decrease shall reduce the number below the number of shares then outstanding and shares duly reserved for issuance.

ARTICLE FIVE

In furtherance and not in limitation of the powers conferred by statute, the Board of Directors shall have the power, both before and after receipt of any payment for any of the Corporation's capital stock, to adopt, amend, repeal or otherwise alter the Bylaws of the Corporation without any action on the part of the stockholders; provided, however, that the grant of such power to the Board of Directors shall not divest the stockholders of nor limit their power to adopt, amend, repeal, or otherwise alter the Bylaws.

ARTICLE SIX

Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.

ARTICLE SEVEN

The Corporation reserves the rights to adopt, repeal, rescind or amend in any respect any provisions contained in this Certificate of Incorporation in the manner now or hereafter prescribed by applicable law, and all rights conferred on stockholders herein are granted subject to this reservation.

ARTICLE EIGHT

A director of the Corporation shall, to the fullest extent permitted by the General Corporation Law of the State of Delaware as it now exists or as it may hereafter be amended, not be liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. Neither any amendment nor repeal of this Article EIGHT, nor the adoption of any provision of this Amended and Restated Certificate of Incorporation inconsistent with this Article EIGHT, shall eliminate or reduce the effect of this Article EIGHT in respect of any matter occurring or any cause of action, suit or claim that, but for this Article EIGHT, would accrue or arise prior to such amendment, repeal or adoption of an inconsistent provision.

ARTICLE NINE

This Amended and Restated Certificate of Incorporation was duly adopted in accordance with the provisions of Section 245 of the General Corporation Law of the State of Delaware.

EX-10.2 3 ex10_2.htm EXHIBIT 10.2

Exhibit 10.2

AMENDMENT TO THE

DISCOVERY LABORATORIES, INC.

2011 LONG-TERM INCENTIVE COMPENSATION PLAN

The Discovery Laboratories, Inc. 2011 Long-Term Incentive Compensation Plan (the “Plan”) is hereby amended as set forth below, effective June 10, 2014:

Section 4(a)(i) of the Plan is hereby amended to read as follows:

“(i) Subject to adjustment as provided in Section 4(b) and to the terms of this Section 4, the total number of Shares reserved and available for delivery pursuant to Awards granted under the Plan shall be (A) twelve million, seven hundred-thousand (12,700,000), plus (B) the number of shares that, immediately prior to the Effective Date, remain available for issuance or delivery under the 2007 Plan; plus (C) the number of shares subject to awards under the 2007 Plan which become available for grant under the Plan in accordance with Section 4(c) after the Effective Date.”

II.

Except as set forth herein, the Plan shall remain in full force and effect.

EX-31.1 4 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATIONS

I, John G. Cooper, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Discovery Laboratories, Inc. (the “Company);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: August 7, 2014	/s/ John G. Cooper
	John G. Cooper
	President and Chief Executive

EX-31.2 5 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATIONS

I, John Tattory, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Discovery Laboratories, Inc. (the “Company);

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

Date: August 7, 2014	/s/ John Tattory
	John Tattory
	Senior Vice President and Chief Financial Officer

EX-32.1 6 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATIONS

Pursuant to 18 U.S.C. § 1350, each of the undersigned officers of Discovery Laboratories, Inc. (the “Company”) hereby certifies that, to his knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2014 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 7, 2014

/s/ John G. Cooper
John G. Cooper
President and Chief Executive Officer

/s/ John Tattory
John Tattory
Senior Vice President and Chief Financial Officer

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to us and will be retained by us and furnished to the SEC or its staff upon request.

This certification is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. This certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-101.INS 7 dsco-20140630.xml XBRL INSTANCE DOCUMENT 0000946486 2014-01-01 2014-06-30 0000946486 2014-07-31 0000946486 2013-12-31 0000946486 2014-06-30 0000946486 2013-04-01 2013-06-30 0000946486 2013-01-01 2013-06-30 0000946486 2014-04-01 2014-06-30 0000946486 2012-12-31 0000946486 2013-06-30 0000946486 dsco:AtMarketAtmProgramMember 2014-06-30 0000946486 dsco:DeerfieldManagementCompanyMember 2014-06-30 0000946486 dsco:FiveYearWarrant3Member 2014-06-30 0000946486 dsco:SeveranceAndRetentionPlanMember 2014-06-30 0000946486 dsco:SeveranceAndRetentionPlanMember 2014-01-01 2014-06-30 0000946486 dsco:SeveranceAndRetentionPlanMember 2014-04-01 2014-06-30 0000946486 us-gaap:EmployeeSeveranceMember dsco:SeveranceAndRetentionPlanMember 2014-06-30 0000946486 us-gaap:EmployeeSeveranceMember dsco:SeveranceAndRetentionPlanMember 2014-01-01 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0000946486 us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel1Member 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2014-06-30 0000946486 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2014-06-30 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2014-06-30 0000946486 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember 2013-12-31 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:CertificatesOfDepositMember 2014-06-30 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CertificatesOfDepositMember 2013-12-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CashEquivalentsMember 2013-12-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2013-12-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2013-12-31 0000946486 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2013-12-31 0000946486 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2013-12-31 0000946486 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0000946486 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000946486 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2013-12-31 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2013-12-31 0000946486 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000946486 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2014-06-30 0000946486 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2014-06-30 0000946486 us-gaap:FairValueMeasurementsRecurringMember us-gaap:WarrantMember 2013-12-31 0000946486 us-gaap:FairValueInputsLevel2Member us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2013-12-31 0000946486 us-gaap:FairValueInputsLevel3Member 2013-12-31 0000946486 us-gaap:FairValueInputsLevel3Member 2012-12-31 0000946486 us-gaap:FairValueInputsLevel3Member 2014-01-01 2014-06-30 0000946486 us-gaap:FairValueInputsLevel3Member 2013-01-01 2013-06-30 0000946486 us-gaap:FairValueInputsLevel3Member 2013-06-30 0000946486 us-gaap:FairValueInputsLevel3Member 2014-06-30 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:MaximumMember 2013-01-01 2013-12-31 0000946486 us-gaap:MinimumMember us-gaap:FairValueInputsLevel3Member 2014-01-01 2014-06-30 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:MaximumMember 2014-01-01 2014-06-30 0000946486 us-gaap:FairValueInputsLevel3Member us-gaap:MinimumMember 2013-01-01 2013-12-31 0000946486 us-gaap:MinimumMember 2014-01-01 2014-06-30 0000946486 us-gaap:MaximumMember 2014-01-01 2014-06-30 0000946486 2013-10-04 0000946486 dsco:FiveYearWarrant2Member 2010-02-22 2010-02-23 0000946486 dsco:FiveYearWarrant1Member 2009-05-12 2009-05-13 0000946486 dsco:FiveYearWarrant3Member 2011-02-21 2011-02-22 0000946486 dsco:FiveYearWarrant1Member 2009-05-13 0000946486 dsco:FiveYearWarrant3Member 2011-02-22 0000946486 dsco:FiveYearWarrant2Member 2010-02-23 0000946486 dsco:FiveYearWarrant1Member 2013-12-31 0000946486 dsco:FiveYearWarrant2Member 2013-12-31 0000946486 dsco:FiveYearWarrant2Member 2014-06-30 0000946486 dsco:FiveYearWarrant1Member 2014-06-30 0000946486 dsco:FiveYearWarrant3Member 2013-12-31 0000946486 dsco:FiveYearWarrant3Member 2013-01-01 2013-06-30 0000946486 dsco:FiveYearWarrant3Member 2014-04-01 2014-06-30 0000946486 dsco:FiveYearWarrant3Member 2014-01-01 2014-06-30 0000946486 dsco:FourthAnniversaryMember us-gaap:MinimumMember 2014-06-30 0000946486 dsco:SixthAnniversaryMember us-gaap:MinimumMember 2014-06-30 0000946486 us-gaap:ResearchAndDevelopmentExpenseMember 2014-04-01 2014-06-30 0000946486 us-gaap:GeneralAndAdministrativeExpenseMember 2014-04-01 2014-06-30 0000946486 us-gaap:GeneralAndAdministrativeExpenseMember 2013-04-01 2013-06-30 0000946486 us-gaap:ResearchAndDevelopmentExpenseMember 2013-04-01 2013-06-30 0000946486 us-gaap:GeneralAndAdministrativeExpenseMember 2013-01-01 2013-06-30 0000946486 us-gaap:ResearchAndDevelopmentExpenseMember 2014-01-01 2014-06-30 0000946486 us-gaap:GeneralAndAdministrativeExpenseMember 2014-01-01 2014-06-30 0000946486 us-gaap:ResearchAndDevelopmentExpenseMember 2013-01-01 2013-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares dsco:Employee xbrli:pure dsco:Installment false --12-31 2014-06-30 No No Yes Accelerated Filer DISCOVERY LABORATORIES INC /DE/ 0000946486 85206616 2014 Q2 10-Q

67000

41000

1507000

1433000

5951000

4785000

541420000

544224000

299000

482000

607000

781000

407000

200000

963000

622000

547000

938000

341000

1485000

5000

8000

10000

470000

118000

177000

909000

177000

16400000

10800000

89317000

69474000

86608000

65557000

325000

65557000

325000

65882000

86283000

86608000

65882000

86283000

325000

87239000

66484000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Basis of Presentation</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">The accompanying interim unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information in accordance with the instructions to Form10‑Q.  Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete consolidated financial statements.  In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included.  Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.  There have been no changes to our critical accounting policies since December 31, 2013.  For a discussion of our accounting policies, <font style="font-size: 10pt; font-style: italic;">see</font>, Note 3, “Accounting Policies and Recent Accounting Pronouncements,” to the consolidated financial statements in our 2013 Form 10-K.  Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.</div></div>

-20726000

4361000

86283000

65557000

26892000

31253000

7000000

14000000

1.50

2.81

17.25

1.50

12.75

0.001

85000

85227508

84659111

250000000

150000000

85206616

84638219

731000

1512000

30000000

The principal amount of the loan is payable in equal annual installments on the fourth, fifth and sixth anniversaries of the Deerfield Loan agreement, provided that the amount payable on the fourth anniversary shall be deferred for one year if either (i) our “Net Sales” for the immediately preceding 12-month period are at least $20 million, or (ii) our “Equity Value” is at least $200 million; and provided further, that the amount payable on the fifth anniversary (together with any amount deferred on the fourth anniversary) shall be deferred until the sixth anniversary if either (i) our “Net Sales” for the immediately preceding 12-month period are at least $30 million, or (ii) our “Equity Value” is at least $250 million.

10736000

11646000

0.0875

139000

105000

371000

364000

3224000

5425000

6305000

3619000

3224000

-2584000

-1820000

-1447000

-2494000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-weight: bold; text-align: left;">Note 8 – Stock Options and Stock-Based Employee Compensation</div><div><br /></div><div style="font-size: 10pt; text-align: left;">We recognize in our consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model.  Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically three years.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td style="vertical-align: top; width: 60%;"><div> </div></td><td style="vertical-align: top; width: 1%;"></td><td colspan="3" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td></tr><tr><td style="vertical-align: top; width: 60%;"><div> </div></td><td style="vertical-align: top; width: 1%;"></td><td style="border-top: medium none; border-right: medium none; vertical-align: bottom; border-bottom: 2px solid; border-left: medium none; width: 9%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td style="vertical-align: bottom; width: 1%;"></td><td style="border-top: medium none; border-right: medium none; vertical-align: bottom; border-bottom: 2px solid; border-left: medium none; width: 9%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td></tr><tr><td style="vertical-align: bottom; width: 60%;"><div> </div></td><td style="vertical-align: top; width: 1%;"></td><td style="vertical-align: top; width: 9%;"></td><td style="vertical-align: top; width: 1%;"></td><td style="vertical-align: top; width: 9%;"></td></tr><tr><td style="vertical-align: top; width: 60%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average expected volatility</div></td><td style="vertical-align: top; width: 1%; background-color: rgb(204,238,255);"></td><td style="vertical-align: top; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">100<font style="font-size: 10pt;">%</font></div></td><td style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"><div> </div></td><td style="vertical-align: top; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">110%</div></td></tr><tr><td style="vertical-align: top; width: 60%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average expected term</div></td><td style="vertical-align: top; width: 1%; background-color: rgb(255,255,255);"></td><td style="vertical-align: top; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;"><font style="font-size: 10pt;"> </font>5.4 <font style="font-size: 10pt;">years</font></div></td><td style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"><div> </div></td><td style="vertical-align: top; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">4.7 years</div></td></tr><tr><td style="vertical-align: top; width: 60%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average risk-free interest rate</div></td><td style="vertical-align: top; width: 1%; background-color: rgb(204,238,255);"></td><td style="vertical-align: top; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">1.6<font style="font-size: 10pt;">%</font></div></td><td style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"><div> </div></td><td style="vertical-align: top; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">0.74%</div></td></tr><tr><td style="vertical-align: middle; width: 60%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Expected dividends</div></td><td style="vertical-align: top; width: 1%; background-color: rgb(255,255,255);"></td><td style="vertical-align: bottom; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">–</div></td><td style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"><div> </div></td><td style="vertical-align: bottom; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">–</div></td></tr></table><div><br /></div><div style="font-size: 10pt; text-align: left;">The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 32%;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 32%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: middle;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; width: 32%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: middle; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: middle; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 32%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Research & Development</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">299</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">200</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">547</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">341</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; width: 32%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Selling, General & Administrative</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">482</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">407</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">938</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">622</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 32%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">781</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">607</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,485</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">963</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr></table></div>

-0.18

-0.46

-0.12

-0.26

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Net loss per common share</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period.  Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period.  For the quarters ended June 30, 2014 and 2013, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants was 20.9 million and 15.8 million shares, respectively.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">In accordance with Accounting Standards Codification (ASC) Topic 260, “<font style="font-size: 10pt; font-style: italic;">Earnings per Share,</font>” when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of certain warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of the warrants results in an adjustment to the weighted average common shares outstanding.  We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of the warrants.  For the three and six months ended June 30, 2014 and 2013, the effect of the adjustments for warrants issued in February 2011 was dilutive.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">The table below provides information pertaining to the calculation of diluted net loss per common share for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Six Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Numerator:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Net loss as reported</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(10,623</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(8,627</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(22,099</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(21,263</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Less: income from change in fair value of warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(1,447</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(2,494</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(1,820</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(2,584</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Numerator for diluted net loss per common share</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(12,070</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(11,121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(23,919</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(23,847</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Denominator:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basic weighted average common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">85,061</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">49,135</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">84,766</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">46,411</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Dilutive common shares from assumed warrant exercises</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">821</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">731</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,345</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,362</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Diluted weighted average common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">85,882</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">49,866</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">86,111</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">47,773</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div><br /></div><div style="font-size: 10pt; text-align: left;">As of June 30, 2014 and 2013, 16.4 million and 10.8 million shares of common stock potentially issuable upon the exercise of certain stock options and warrants were excluded from the computation of diluted net loss per common share because their impact would have been anti-dilutive.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">We do not have any components of other comprehensive income (loss).</div></div>

-0.28

-0.50

-0.14

-0.22

1489000

1975000

P3Y

0.76

0.52

0.61

0.62

0.0008

0.0044

0.0034

0.0008

-2686000

-2525000

-1826000

-1448000

P2Y1M6D

P1Y7M6D

P0Y8M12D

P0Y4M24D

<div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-weight: bold; text-align: left;">Note 4 – Fair Value of Financial Instruments</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.  The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:</div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;">Level 1 – Quoted prices in active markets for identical assets and liabilities.</td></tr></table></div><div style="text-align: left;"> </div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;">Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr></table></div><div style="text-align: left;"> </div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 18pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;">Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td></tr></table></div><div><br /></div><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Fair Value on a Recurring Basis</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div> </div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="border-top: rgb(0,0,0) 2px solid; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Fair Value</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="10" style="border-top: rgb(0,0,0) 2px solid; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; padding-bottom: 2px; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Fair value measurement using</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td></tr><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div> </div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">June 30, 2014</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 1</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 2</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 3</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div> </div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Assets:</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash and cash equivalents</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">65,557</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">65,557</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Certificate of Deposit</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">325</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">325</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">65,882</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">65,882</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Liabilities:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Common stock warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div> </div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="border-top: rgb(0,0,0) 2px solid; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Fair Value</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="10" style="border-top: rgb(0,0,0) 2px solid; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; font-weight: bold; padding-bottom: 2px; text-align: center;">Fair value measurement using</td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td></tr><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div> </div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">December 31, 2013</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 1</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 2</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 3</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div> </div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr style="height: 18px;"><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Assets:</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash and cash equivalents</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">86,283</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">86,283</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Certificate of Deposit</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">325</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">325</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">86,608</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">86,608</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Liabilities:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Common stock warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">5,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">5,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div> </div><div>The table below summarizes the activity of Level 3 inputs measured on a recurring basis for the six months ended June 30, 2014 and 2013:</div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 62%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 62%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" style="vertical-align: top; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Fair Value Measurements of</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Common Stock Warrants Using</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Significant Unobservable Inputs</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at December 31, 2013</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">5,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Exercise of warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(375</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 62%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Change in fair value of common stock warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(1,826</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 62%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at June 30, 2014</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 15%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 62%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" style="border-top: rgb(0,0,0) 2px solid; vertical-align: top; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Fair Value Measurements of</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Common Stock Warrants Using</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Significant Unobservable Inputs</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at December 31, 2012</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">6,305</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 62%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Change in fair value of common stock warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 15%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(2,686</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 62%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at June 30, 2013</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">3,619</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr></table><div><br /></div><div style="font-size: 10pt; text-align: left;">The significant unobservable inputs used in the fair value measurement of the common stock warrants measured on a recurring basis are the historical volatility of our common stock market price, expected term of the applicable warrants, and the risk-free interest rate based on the U.S. Treasury yield curve in effect at the measurement date.  In addition to the significant unobservable inputs noted above, certain fair value measurements also take into account an assumption of the likelihood and timing of the occurrence of an event that would result in an adjustment to the exercise price in accordance with the anti-dilutive pricing provisions in the warrant.  Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, may result in significantly higher or lower fair value measurements.</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; width: 50%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Significant Unobservable Input</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Assumptions of Level 3 Valuations</div></td><td style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; width: 24%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30, 2014</div></td><td style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; width: 2%;">  </td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid; width: 24%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">December 31, 2013</div></td></tr><tr><td style="vertical-align: bottom; width: 50%;"></td><td style="vertical-align: bottom; width: 24%;"><div> </div></td><td style="vertical-align: bottom; width: 2%;"></td><td style="vertical-align: bottom; width: 24%;"><div> </div></td></tr><tr><td style="vertical-align: bottom; width: 50%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Historical Volatility</div></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">52<font style="font-size: 10pt;">% –</font> 61%</div></td><td style="vertical-align: bottom; width: 2%; background-color: rgb(204,238,255);"></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">62% – 76%</div></td></tr><tr><td style="vertical-align: bottom; width: 50%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Expected Term (in years)</div></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;"><font style="font-size: 10pt;"> </font>0.7<font style="font-size: 10pt;"> – </font>1.6</div></td><td style="vertical-align: bottom; width: 2%; background-color: rgb(255,255,255);"></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;"> 0.4 – 2.1</div></td></tr><tr><td style="vertical-align: bottom; width: 50%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Risk-free interest rate</div></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">0.08% – 0.34%</div></td><td style="vertical-align: bottom; width: 2%; background-color: rgb(204,238,255);"></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">0.08% – 0.44%</div></td></tr></table><div><br /></div><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Fair Value of Long-Term Debt</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">At June 30, 2014, the estimated fair value of the Deerfield Loan was $</font>23.2 <font style="font-size: 10pt;">million compared to a carrying value, net of discounts, of $19.3</font> <font style="font-size: 10pt;">million.  At December 31, 2013, the estimated fair value of the Deerfield Loan was $23.6 million compared to a carrying value, net of discounts, of $18.4 million.  The estimated fair value of the Deerfield Loan was based on discounting the future contractual cash flows to the present value.  This analysis utilizes certain Level 3 unobservable inputs, including current cost of capital.  Considerable judgment is required to interpret market data and to develop estimates of fair value.  The estimates presented are not necessarily indicative of amounts that could be realized in a current market exchange.  The use of alternative market assumptions and estimation methodologies could have a material effect on these estimates of fair value.</font></div></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div>The table below summarizes the activity of Level 3 inputs measured on a recurring basis for the six months ended June 30, 2014 and 2013:</div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 62%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 62%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" style="vertical-align: top; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Fair Value Measurements of</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Common Stock Warrants Using</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Significant Unobservable Inputs</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at December 31, 2013</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">5,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Exercise of warrants</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(375</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 62%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Change in fair value of common stock warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(1,826</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 62%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at June 30, 2014</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 15%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div> </div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 62%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" style="border-top: rgb(0,0,0) 2px solid; vertical-align: top; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Fair Value Measurements of</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Common Stock Warrants Using</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Significant Unobservable Inputs</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">(Level 3)</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 62%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at December 31, 2012</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">6,305</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 62%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Change in fair value of common stock warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 15%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(2,686</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 62%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Balance at June 30, 2013</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">3,619</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr></table></div>

-26000

753000

74000

580000

1166000

-34000

-10000

-423000

-159000

2196000

107000

-334000

-101000

1345000

1362000

731000

821000

218000

654000

331000

1302000

336000

1305000

443000

112000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-style: italic; text-align: justify;"><u>Inventory</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">Inventories, which are recorded at the lower of cost or market, include materials, labor, and other direct and indirect costs and are valued at cost using the first-in, first-out method. We capitalize inventories produced in preparation for commercial launch when the related product candidates receive regulatory approval and the related costs will be recoverable through the commercial sale of the product.  Costs incurred prior to FDA approval of drug products and registration of medical devices are recorded in our statement of operations as research and development expense.  Inventories are evaluated for impairment through consideration of factors such as the net realizable value, lower of cost or market, obsolescence, and expiry. Inventories do not have carrying values that exceed either cost or net realizable value.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">We evaluate our expiry risk by evaluating current and future product demand relative to product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and hospital ordering practices.</div></div>

296000

60000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-weight: bold; text-align: left;">Note 5 – Inventory</div><div><br /></div><div style="font-size: 10pt; text-align: justify;">Inventory is comprised of the following for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td valign="bottom" style="vertical-align: top; width: 56%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 8.9pt;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 56%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr style="height: 16px;"><td valign="bottom" style="vertical-align: bottom; width: 56%;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Inventories, current:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr style="height: 14px;"><td valign="bottom" style="vertical-align: bottom; width: 56%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Raw materials</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">147</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 56%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Finished goods, net of reserves</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">60</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%; background-color: rgb(204,238,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">443</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">112</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Inventories, non-current:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 56%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Raw materials</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">400</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 56%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 25.2pt; text-indent: -7.2pt;">Total inventories, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">843</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">112</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div><br /></div><div style="font-size: 10pt; text-align: left;">Raw materials inventory that is not expected to be used in commercial production until more than 12 months from the balance sheet date is classified as a non-current other asset on the balance sheet.  The shelf life of our raw materials is 2‑5 years.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">In addition, as of June 30, 2014, we had $0.7 million of raw materials that were purchased prior to October 4, 2013, the date the FDA approved updated SURFAXIN product specifications, which enabled the commercial introduction of SURFAXIN.  These raw materials have a carrying value of zero, as the costs to purchase this material were expensed in the period of purchase as research and development expense, and accordingly are not reflected in the inventory balances shown above.  These raw materials are anticipated to be used in manufacturing development, research and development activities and in the manufacture of commercial product.</div><div><br /></div><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">Inventory reserves as of June 30, 2014 and December 31, 2013 were $2.0</font> <font style="font-size: 10pt;">million and $0.5 million, respectively.  Inventory reserves reflect costs of SURFAXIN finished goods inventories that are not anticipated to be recoverable through the commercial sale of the product during the initial launch period due to product expiration.  These reserves ensure that the inventory carrying values do not exceed net realizable value.</font></div></div>

500000

2000000

147000

52000

10862000

11855000

89317000

69474000

3224000

5425000

3224000

5425000

30816000

30268000

30000000

18354000

19264000

23600000

23200000

28000

69000

73000

75000

19264000

18354000

-8627000

-10623000

-22099000

-21263000

-23847000

-12070000

-11121000

-23919000

-883000

-120000

415000

24924000

-20443000

-20258000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Recent accounting pronouncements</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">In May 2014, the FASB issued ASU No. 2014-09, <font style="font-size: 10pt; font-style: italic;">Revenue from Contracts with Customers</font>, which requires an entity to recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to customers.  The ASU will replace most existing revenue recognition guidance in U.S. <font style="font-size: 10pt;">generally accepted accounting principles (GAAP)</font> when it becomes effective.  The new standard is effective for us in our fiscal year 2017.  Early application is not permitted.  We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures.  The standard permits the use of either the retrospective or cumulative effect transition method.  We have not yet selected a transition method nor determined the effect of the standard on our financial reporting.</div></div>

12035000

22829000

10992000

23684000

-21705000

-10942000

-23430000

-10810000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-weight: bold; text-align: left;">Note 1 – Organization and Business</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Discovery Laboratories, Inc. (referred to as “we,” “us,” or the “Company”) is a specialty biotechnology company focused on creating life-saving products for critical-care patients with respiratory disease and improving the standard of care in pulmonary medicine.  Our proprietary drug technology produces a synthetic, peptide-containing surfactant (KL<font style="font-size: 7pt;">4</font> surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival.  We are developing our KL<font style="font-size: 7pt;">4</font> surfactant in liquid, lyophilized and aerosolized dosage forms.  We are also developing novel drug delivery technologies and devices potentially to enable efficient delivery of our aerosolized KL<font style="font-size: 7pt;">4</font> surfactant.  We believe that our proprietary technologies may make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">We are initially focused on improving the management of respiratory distress syndrome (RDS) in premature infants.  RDS is a serious respiratory condition caused by insufficient surfactant production in underdeveloped lungs of premature infants.  RDS is the most prevalent respiratory disease in the Neonatal Intensive Care Unit (NICU) and can result in long-term respiratory problems, developmental delay and death.  Our first KL<font style="font-size: 7pt;">4</font> surfactant drug product, SURFAXIN<font style="font-size: 7pt;">®</font> (lucinactant) Intratracheal Suspension for the prevention of RDS in premature infants at high risk for RDS, was approved by the United States Food and Drug Administration (FDA) in 2012.  SURFAXIN is our KL<font style="font-size: 7pt;">4</font> surfactant in liquid form, and is the first synthetic, peptide-containing surfactant approved by the FDA and the only alternative to animal-derived surfactants currently used in the United States (U.S.).  SURFAXIN has been commercially available in the U.S. since November 2013.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Premature infants with severe RDS currently are treated with surfactants that can only be administered by endotracheal intubation supported with mechanical ventilation, both invasive procedures that may result in serious respiratory conditions and other complications.  To avoid such complications, many neonatologists initially treat infants with less severe RDS by less invasive means, typically nasal continuous positive airway pressure (nCPAP).  Unfortunately, a significant number of premature infants on nCPAP will not respond well (an outcome referred to as nCPAP failure) and thereafter may require endotracheal intubation, mechanical ventilation, and delayed surfactant therapy.  Since neonatologists currently cannot predict which infants will experience nCPAP failure, neonatologists are faced with difficult choices in treating infants with less severe RDS.  This is because the medical outcomes for those infants who experience nCPAP failure and receive delayed surfactant therapy may be less favorable than the outcomes for infants who receive surfactant therapy in the first hours of life.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">AEROSURF<font style="font-size: 7pt;">®</font> is our investigational combination drug/device product that combines our KL<font style="font-size: 7pt;">4</font> surfactant with our proprietary capillary aerosol generator (CAG).  AEROSURF potentially will enable administration of aerosolized KL<font style="font-size: 7pt;">4</font> surfactant to premature infants supported with nCPAP, without invasive intubation and mechanical ventilation.  By enabling delivery of our KL<font style="font-size: 7pt;">4</font> surfactant using less invasive procedures, we believe that AEROSURF may address a serious unmet medical need and potentially enable the treatment of a significantly greater number of premature infants with RDS who could benefit from surfactant therapy but are currently not treated.  We are currently conducting a phase 2a clinical trial for AEROSURF for the treatment of RDS in premature infants, for which results are expected in the fourth quarter of 2014, and are initiating activities to prepare for a phase 2b clinical trial, with results expected in the second half of 2015.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">We are also developing a lyophilized (freeze-dried) dosage form of our KL<font style="font-size: 7pt;">4</font> surfactant that is stored as a powder and reconstituted to liquid form prior to use with the objective of improving ease of use for healthcare practitioners, as well as potentially to prolong shelf life and eliminate the need for cold-chain storage.  We are initially developing this dosage form for use in our AEROSURF development program.  We are also planning to seek regulatory advice to determine if we could gain marketing authorization for a lyophilized dosage form of our KL<font style="font-size: 7pt;">4</font> surfactant under a development plan that would be both capital efficient and capable of implementation within a reasonable time.  If feasible, we would likely implement such a development plan and would plan to introduce it commercially as a life-cycle extension of SURFAXIN under the name SURFAXIN LS™, in the U.S. and potentially in other markets.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">To support the commercial introduction of SURFAXIN in the U.S. and our other KL<font style="font-size: 7pt;">4</font> surfactant pipeline products, if approved, we have our own specialty respiratory critical care commercial and medical affairs team.  This team includes medical professionals with experience in neonatal/pediatric respiratory critical care, and has focused on products that address neonatal indications, beginning with SURFAXIN.  We believe that this team will be positioned to efficiently introduce our other KL<font style="font-size: 7pt;">4</font> surfactant products under development, if approved, including AEROSURF and potentially SURFAXIN LS and future applications of our aerosolized KL<font style="font-size: 7pt;">4</font> surfactant.  In addition, we recognize that our commercial and medical affairs team could potentially support introductions of other synergistic pipeline products, including products owned or developed by third parties for the NICU/PICU.  To that end, we would consider potential transactions focused on securing commercial rights to such synergistic products, including in the form of product acquisitions, in-licensing agreements or distribution, marketing or co-marketing arrangements.</div><div style="font-size: 10pt; text-align: left;"> </div><div style="font-size: 10pt; text-align: left;">In the future, we expect that we may be able to leverage the information, data and know-how that we gain from our development efforts with SURFAXIN and AEROSURF to support development of a product pipeline to address serious critical care respiratory conditions in larger children and adults in pediatric and adult intensive care units (PICUs and ICUs), including potentially acute lung injury (ALI), chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF).  At the present time, however, we are focusing our resources primarily on the commercial introduction of SURFAXIN and development of AEROSURF through phase 2 clinical trials.  Once we have advanced these objectives, we expect to be in a better position to assess the potential of other development programs to address the critical care needs of patients in the PICU and ICU.</div></div>

97000

487000

2224000

1131000

520000

343000

1000

2000

4000

1000

-2220000

-342000

-519000

-1129000

538000

114000

120000

883000

0.001

5000000

443000

777000

423000

400000

15110000

9850000

31000

1000

1656000

2178000

37000

39000

6858000

15335000

6863000

12448000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-style: italic; text-align: left;"><u>Research and development expense</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">We track research and development expense by activity, as follows: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs.   Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs.  Research and development costs are charged to operations as incurred.</div></div>

325000

1100000

300000

100000

400000

-502049000

-479950000

1051000

1054000

182000

254000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Product Sales</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">Revenues from product sales are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Our products are distributed in the U.S. using a specialty distributor.  Under this model, the specialty distributor purchases and takes physical delivery and title of product, and then sells to hospitals.  We began the commercial introduction of SURFAXIN in the fourth quarter of 2013 and we currently cannot make a reasonable estimate of future product returns when product is delivered to the specialty distributor.  Therefore, we currently do not recognize revenue upon product shipment to the specialty distributor, even though the distributor is invoiced upon product shipment.  Instead, we recognize revenue once product has been sold through to the hospital and all revenue recognition criteria have been met.  Once product has been delivered to a hospital, the risk of material returns is significantly mitigated.  We will begin to recognize revenue at the time of shipment of product to our specialty distributor when we can reasonably estimate expected distributor sales deductions and returns.  In developing estimates for sales returns, we consider the shelf life of the product, expected demand based on market data and return rates of other surfactant products.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Product sales are recorded net of accruals for estimated chargebacks, discounts, specialty distributor deductions and returns.</div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 13.5pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;"><font style="font-size: 10pt; font-style: italic;">Chargebacks</font>.  Chargebacks are discounts that occur when contracted customers purchase directly from our specialty distributor.  Contracted customers, which currently consist primarily of Group Purchasing Organizations member hospitals, generally purchase the product at a discounted price.  Our specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer.  The allowance for specialty distributor chargebacks is based on known sales to contracted customers.</td></tr></table></div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 17.8pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 13.7pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-style: italic; text-align: justify;"><font style="font-size: 10pt; font-style: italic;">Sales discounts</font><font style="font-size: 10pt; font-style: italic;">.</font>  <font style="font-style: normal;">Sales discounts are offered to certain contracted customers based upon a customer’s historical volume of surfactant product purchases.  Customers must enter into a Letter of Participation (LOP) with us to receive sales discounts.  Sales discounts are periodically adjusted on a prospective basis based upon the customer’s purchases of SURFAXIN, as provided in the LOP.  The allowance for sales discounts is based on known sales to contracted customers.</font></div></td></tr></table></div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 13.5pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;"><font style="font-size: 10pt; font-style: italic;">Specialty distributor deductions</font>. Our specialty distributor is offered various forms of consideration including allowances, service fees and prompt payment discounts. Specialty distributor allowances and service fees are provided in our contractual agreement and are generally a percentage of the purchase price paid by the specialty distributor. The specialty distributor is offered a prompt pay discount for payment within a specified period.</td></tr></table></div><div style="text-align: justify; margin-left: 31.5pt;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 13.5pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;"><font style="font-size: 10pt; font-style: italic;">Returns</font>.  Sales of our products are not subject to a general right of return; however, we will accept product that is damaged or defective when shipped or for expired product up to six months subsequent to its expiry date.  Product that has been administered to patients is no longer subject to any right of return.</td></tr></table></div></div>

P4Y8M12D

P5Y4M24D

70000

42000

1124000

1093000

254000

182000

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; text-align: left;">The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:</div><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div> </div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="border-top: rgb(0,0,0) 2px solid; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Fair Value</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="10" style="border-top: rgb(0,0,0) 2px solid; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; padding-bottom: 2px; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Fair value measurement using</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td></tr><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div> </div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">June 30, 2014</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 1</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 2</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 3</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div> </div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Assets:</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash and cash equivalents</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">65,557</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">65,557</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Certificate of Deposit</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">325</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">325</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">65,882</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">65,882</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Liabilities:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Common stock warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div><br /></div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div> </div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="border-top: rgb(0,0,0) 2px solid; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Fair Value</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="10" style="border-top: rgb(0,0,0) 2px solid; vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; font-weight: bold; padding-bottom: 2px; text-align: center;">Fair value measurement using</td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td></tr><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"><div> </div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">December 31, 2013</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 1</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 2</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;">Level 3</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom;"><div> </div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr style="height: 18px;"><td valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Assets:</div></td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td><td valign="bottom" style="vertical-align: bottom;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash and cash equivalents</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">86,283</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">86,283</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 52%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Certificate of Deposit</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">325</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">325</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total Assets</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">86,608</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">86,608</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Liabilities:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 52%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Common stock warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">5,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">5,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; text-align: left;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td style="vertical-align: top; width: 60%;"><div> </div></td><td style="vertical-align: top; width: 1%;"></td><td colspan="3" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td></tr><tr><td style="vertical-align: top; width: 60%;"><div> </div></td><td style="vertical-align: top; width: 1%;"></td><td style="border-top: medium none; border-right: medium none; vertical-align: bottom; border-bottom: 2px solid; border-left: medium none; width: 9%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td style="vertical-align: bottom; width: 1%;"></td><td style="border-top: medium none; border-right: medium none; vertical-align: bottom; border-bottom: 2px solid; border-left: medium none; width: 9%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td></tr><tr><td style="vertical-align: bottom; width: 60%;"><div> </div></td><td style="vertical-align: top; width: 1%;"></td><td style="vertical-align: top; width: 9%;"></td><td style="vertical-align: top; width: 1%;"></td><td style="vertical-align: top; width: 9%;"></td></tr><tr><td style="vertical-align: top; width: 60%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average expected volatility</div></td><td style="vertical-align: top; width: 1%; background-color: rgb(204,238,255);"></td><td style="vertical-align: top; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">100<font style="font-size: 10pt;">%</font></div></td><td style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"><div> </div></td><td style="vertical-align: top; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">110%</div></td></tr><tr><td style="vertical-align: top; width: 60%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average expected term</div></td><td style="vertical-align: top; width: 1%; background-color: rgb(255,255,255);"></td><td style="vertical-align: top; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;"><font style="font-size: 10pt;"> </font>5.4 <font style="font-size: 10pt;">years</font></div></td><td style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"><div> </div></td><td style="vertical-align: top; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">4.7 years</div></td></tr><tr><td style="vertical-align: top; width: 60%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Weighted average risk-free interest rate</div></td><td style="vertical-align: top; width: 1%; background-color: rgb(204,238,255);"></td><td style="vertical-align: top; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">1.6<font style="font-size: 10pt;">%</font></div></td><td style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"><div> </div></td><td style="vertical-align: top; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">0.74%</div></td></tr><tr><td style="vertical-align: middle; width: 60%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Expected dividends</div></td><td style="vertical-align: top; width: 1%; background-color: rgb(255,255,255);"></td><td style="vertical-align: bottom; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">–</div></td><td style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"><div> </div></td><td style="vertical-align: bottom; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">–</div></td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div>Selected terms and estimated fair value of warrants accounted for as derivative are as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 8%;"></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; padding-bottom: 2px;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; padding-bottom: 2px;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 15%;"><div>   </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="11" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; text-align: center;">Fair Value of Warrants</div><div style="font-size: 10pt; font-style: italic; text-align: center;">(in thousands)</div></td></tr><tr><td rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; padding-bottom: 2px; text-align: left; width: 8%;"><div style="font-size: 10pt;">Issuance </div><div style="font-size: 10pt;">Date</div></td><td rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left;"><div style="font-size: 10pt;">Number of </div><div style="font-size: 10pt;">Warrant Shares </div><div style="font-size: 10pt;">Issuable</div></td><td nowrap="nowrap" rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left;"><div style="font-size: 10pt;">Exercise </div><div style="font-size: 10pt;">Price</div></td><td nowrap="nowrap" rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; padding-bottom: 2px; text-align: left; width: 15%;"><div style="font-size: 10pt;">Warrant </div><div style="font-size: 10pt;">Expiration</div><div style="font-size: 10pt;">Date</div></td><td rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left;"><div></div><div style="font-size: 10pt;">Value at</div><div style="font-size: 10pt;">Issuance </div><div style="font-size: 10pt;">Date</div></td><td nowrap="nowrap" rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="7" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"><div style="font-size: 10pt;"> </div></td></tr><tr style="height: 14px;"><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; text-align: center;">June 30,</div><div style="font-size: 10pt; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; text-align: center;">December 31,</div><div style="font-size: 10pt; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 8%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 15%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 8%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">5/13/2009</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 16%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">466,667</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">17.25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">5/13/2014</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">3,360</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr style="height: 12px;"><td valign="bottom" style="vertical-align: top; width: 8%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">2/23/2010</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 16%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">916,669</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">12.75</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">2/23/2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">5,701</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 8%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">2/22/2011</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 16%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">4,552,600</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1.50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">2/22/2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">8,004</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">5,419</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 8%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 16%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 15%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">5,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; text-align: left;">The table below provides information pertaining to the calculation of diluted net loss per common share for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Six Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Numerator:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Net loss as reported</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(10,623</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(8,627</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(22,099</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(21,263</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Less: income from change in fair value of warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(1,447</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(2,494</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(1,820</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(2,584</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Numerator for diluted net loss per common share</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(12,070</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(11,121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(23,919</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(23,847</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Denominator:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basic weighted average common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">85,061</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">49,135</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">84,766</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">46,411</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Dilutive common shares from assumed warrant exercises</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">821</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">731</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,345</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,362</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Diluted weighted average common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">85,882</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">49,866</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">86,111</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">47,773</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; text-align: left;">The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 32%;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Three Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Six Months Ended</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 32%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: middle;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; width: 32%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: middle; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: middle; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; width: 32%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Research & Development</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">299</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">200</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">547</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">341</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 2px; width: 32%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Selling, General & Administrative</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">482</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">407</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">938</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">622</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: middle; padding-bottom: 4px; width: 32%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">781</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">607</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,485</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">963</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr></table></div>

4446000

8869000

8349000

4129000

2686000

1826000

1.1

0.0074

0.016

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-weight: bold; text-align: left;">Note 3 – Summary of Significant Accounting Policies</div><div><br /></div><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Basis of Presentation</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">The accompanying interim unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information in accordance with the instructions to Form10‑Q.  Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete consolidated financial statements.  In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included.  Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.  There have been no changes to our critical accounting policies since December 31, 2013.  For a discussion of our accounting policies, <font style="font-size: 10pt; font-style: italic;">see</font>, Note 3, “Accounting Policies and Recent Accounting Pronouncements,” to the consolidated financial statements in our 2013 Form 10-K.  Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.</div><div><br /></div><div style="font-size: 10pt; font-style: italic; text-align: justify;"><u>Inventory</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">Inventories, which are recorded at the lower of cost or market, include materials, labor, and other direct and indirect costs and are valued at cost using the first-in, first-out method. We capitalize inventories produced in preparation for commercial launch when the related product candidates receive regulatory approval and the related costs will be recoverable through the commercial sale of the product.  Costs incurred prior to FDA approval of drug products and registration of medical devices are recorded in our statement of operations as research and development expense.  Inventories are evaluated for impairment through consideration of factors such as the net realizable value, lower of cost or market, obsolescence, and expiry. Inventories do not have carrying values that exceed either cost or net realizable value.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">We evaluate our expiry risk by evaluating current and future product demand relative to product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and hospital ordering practices.</div><div style="font-size: 10pt; font-style: italic; text-align: left;"> </div><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Accrued Severance and Retention Costs</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">A liability for employee severance and retention benefits is recognized when (1) management has committed to a plan of termination; (2) the plan provides sufficient details, such as the employees affected, amounts to be paid, and expected dates of termination and payment; (3) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn; and (4) the plan has been communicated to employees.  The cost of such benefits are accrued over the remaining service period.</div><div><br /></div><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">In September 2013, we implemented an employee severance and retention plan for employees at our Totowa Facility to minimize employee turnover and encourage employees to remain with us through any potential plant closing.  The plan provides for severance for non-union employees and retention bonuses for management.  If we succeed in our efforts to secure longer-term utilization of the Totowa Facility, the severance plan and retention bonuses will remain in effect.  The total cash amount expected to be paid for severance and retention under this plan through June 2016, assuming a June 2015 plant closing, is approximately $1.1 million.  The plan-related expense for the three and six months ended June 30, 2014 was $</font>0.1<font style="font-size: 10pt;"> million and $0.3 million, respectively, and is included in research and development expense.  The related accrued liability is $</font>0.4 <font style="font-size: 10pt;">million as of June 30, 2014.</font></div><div><br /></div><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">In addition, at the Totowa Facility, there are 13 employees who are subject to a collective bargaining agreement under which they would be eligible to receive severance payments if the Totowa Facility were closed.  The related accrued liability is $</font>0.4<font style="font-size: 10pt;"> million as of June 30, 2014.</font></div><div><br /></div><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Product Sales</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">Revenues from product sales are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Our products are distributed in the U.S. using a specialty distributor.  Under this model, the specialty distributor purchases and takes physical delivery and title of product, and then sells to hospitals.  We began the commercial introduction of SURFAXIN in the fourth quarter of 2013 and we currently cannot make a reasonable estimate of future product returns when product is delivered to the specialty distributor.  Therefore, we currently do not recognize revenue upon product shipment to the specialty distributor, even though the distributor is invoiced upon product shipment.  Instead, we recognize revenue once product has been sold through to the hospital and all revenue recognition criteria have been met.  Once product has been delivered to a hospital, the risk of material returns is significantly mitigated.  We will begin to recognize revenue at the time of shipment of product to our specialty distributor when we can reasonably estimate expected distributor sales deductions and returns.  In developing estimates for sales returns, we consider the shelf life of the product, expected demand based on market data and return rates of other surfactant products.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Product sales are recorded net of accruals for estimated chargebacks, discounts, specialty distributor deductions and returns.</div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 13.5pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;"><font style="font-size: 10pt; font-style: italic;">Chargebacks</font>.  Chargebacks are discounts that occur when contracted customers purchase directly from our specialty distributor.  Contracted customers, which currently consist primarily of Group Purchasing Organizations member hospitals, generally purchase the product at a discounted price.  Our specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer.  The allowance for specialty distributor chargebacks is based on known sales to contracted customers.</td></tr></table></div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 17.8pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 13.7pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;"><div style="font-size: 10pt; font-style: italic; text-align: justify;"><font style="font-size: 10pt; font-style: italic;">Sales discounts</font><font style="font-size: 10pt; font-style: italic;">.</font>  <font style="font-style: normal;">Sales discounts are offered to certain contracted customers based upon a customer’s historical volume of surfactant product purchases.  Customers must enter into a Letter of Participation (LOP) with us to receive sales discounts.  Sales discounts are periodically adjusted on a prospective basis based upon the customer’s purchases of SURFAXIN, as provided in the LOP.  The allowance for sales discounts is based on known sales to contracted customers.</font></div></td></tr></table></div><div><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 13.5pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;"><font style="font-size: 10pt; font-style: italic;">Specialty distributor deductions</font>. Our specialty distributor is offered various forms of consideration including allowances, service fees and prompt payment discounts. Specialty distributor allowances and service fees are provided in our contractual agreement and are generally a percentage of the purchase price paid by the specialty distributor. The specialty distributor is offered a prompt pay discount for payment within a specified period.</td></tr></table></div><div style="text-align: justify; margin-left: 31.5pt;"><br /></div><div style="text-align: left;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 100%;"><tr><td style="width: 18pt;"></td><td style="font-size: 10pt; font-family: Symbol, serif; vertical-align: top; width: 13.5pt; align: right;">·</td><td style="font-size: 10pt; vertical-align: top; text-align: left; width: auto;"><font style="font-size: 10pt; font-style: italic;">Returns</font>.  Sales of our products are not subject to a general right of return; however, we will accept product that is damaged or defective when shipped or for expired product up to six months subsequent to its expiry date.  Product that has been administered to patients is no longer subject to any right of return.</td></tr></table></div><div style="text-align: left;"> </div><div style="font-style: italic; text-align: left;"><u>Research and development expense</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">We track research and development expense by activity, as follows: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs.   Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs.  Research and development costs are charged to operations as incurred.</div><div><br /></div><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Net loss per common share</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period.  Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period.  For the quarters ended June 30, 2014 and 2013, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants was 20.9 million and 15.8 million shares, respectively.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">In accordance with Accounting Standards Codification (ASC) Topic 260, “<font style="font-size: 10pt; font-style: italic;">Earnings per Share,</font>” when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of certain warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of the warrants results in an adjustment to the weighted average common shares outstanding.  We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of the warrants.  For the three and six months ended June 30, 2014 and 2013, the effect of the adjustments for warrants issued in February 2011 was dilutive.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">The table below provides information pertaining to the calculation of diluted net loss per common share for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Six Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Numerator:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Net loss as reported</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(10,623</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(8,627</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(22,099</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(21,263</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Less: income from change in fair value of warrant liability</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(1,447</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(2,494</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(1,820</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(2,584</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Numerator for diluted net loss per common share</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(12,070</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(11,121</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(23,919</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">(23,847</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Denominator:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Basic weighted average common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">85,061</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">49,135</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">84,766</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">46,411</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Dilutive common shares from assumed warrant exercises</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">821</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">731</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,345</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,362</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Diluted weighted average common shares outstanding</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">85,882</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">49,866</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">86,111</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">47,773</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div><br /></div><div style="font-size: 10pt; text-align: left;">As of June 30, 2014 and 2013, 16.4 million and 10.8 million shares of common stock potentially issuable upon the exercise of certain stock options and warrants were excluded from the computation of diluted net loss per common share because their impact would have been anti-dilutive.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">We do not have any components of other comprehensive income (loss).</div><div><br /></div><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Recent accounting pronouncements</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">In May 2014, the FASB issued ASU No. 2014-09, <font style="font-size: 10pt; font-style: italic;">Revenue from Contracts with Customers</font>, which requires an entity to recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to customers.  The ASU will replace most existing revenue recognition guidance in U.S. <font style="font-size: 10pt;">generally accepted accounting principles (GAAP)</font> when it becomes effective.  The new standard is effective for us in our fiscal year 2017.  Early application is not permitted.  We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures.  The standard permits the use of either the retrospective or cumulative effect transition method.  We have not yet selected a transition method nor determined the effect of the standard on our financial reporting.</div></div>

39206000

58501000

20892

3054000

6000

8004000

5425000

3360000

3224000

5701000

5419000

3224000

84766000

85061000

49135000

46411000

86111000

47773000

49866000

85882000

13 15800000 20900000 30000000 30000000 <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-weight: bold; text-align: left;">Note 6 – Common Stock Warrant Liability</div><div><br /></div><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">We account for common stock warrants in accordance with applicable accounting guidance provided in </font>ASC Topic 815 <font style="font-size: 10pt; font-style: italic;">“Derivatives and Hedging – Contracts in Entity’s Own Equity”</font> (ASC 815)<font style="font-size: 10pt;">, either as derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement.</font></div><div><br /></div><div style="font-size: 10pt; text-align: left;">The form of warrant agreement for the registered warrants that we issued in our February 2010 public offering generally provide that, in the event a related registration statement or an exemption from registration is not available for the issuance or resale of the warrant shares upon exercise of the warrant, the holder may exercise the warrant on a cashless basis.  Notwithstanding the availability of cashless exercise, under GAAP, these registered warrants are deemed to be subject to potential net cash settlement and must be classified as derivative liabilities because (i) under federal securities laws, issuing freely-tradable registered shares upon exercise of the warrants may not be within our control in all circumstances, and (ii) the warrant agreements do not expressly provide that there is no circumstance in which we may be required to effect a net cash settlement of the warrants.  The accounting guidance expressly precludes an evaluation of the likelihood that cash settlement could occur.  Accordingly, the February 2010 warrants have been classified as a derivative liability and reported, at each balance sheet date, at estimated fair value determined using the Black-Scholes option-pricing model.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">The form of warrant agreement for the registered warrants that we issued in the February 2011 public offering (February 2011 warrants) contain anti-dilutive provisions that adjust the exercise price if we issue any common stock, securities convertible into common stock, or other securities (subject to certain exceptions) at a value below the then-existing exercise price of the February 2011 warrants.  Although by their express terms, these warrants are not subject to potential cash settlement, due to the nature of the anti-dilution provisions, these warrants have been classified as derivative liabilities and reported, at each balance sheet date, at estimated fair value determined using a trinomial pricing model.</div><div> </div><div>Selected terms and estimated fair value of warrants accounted for as derivative are as follows:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 8%;"></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; padding-bottom: 2px;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; padding-bottom: 2px;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 15%;"><div>   </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="11" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; text-align: center;">Fair Value of Warrants</div><div style="font-size: 10pt; font-style: italic; text-align: center;">(in thousands)</div></td></tr><tr><td rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; padding-bottom: 2px; text-align: left; width: 8%;"><div style="font-size: 10pt;">Issuance </div><div style="font-size: 10pt;">Date</div></td><td rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left;"><div style="font-size: 10pt;">Number of </div><div style="font-size: 10pt;">Warrant Shares </div><div style="font-size: 10pt;">Issuable</div></td><td nowrap="nowrap" rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left;"><div style="font-size: 10pt;">Exercise </div><div style="font-size: 10pt;">Price</div></td><td nowrap="nowrap" rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; padding-bottom: 2px; text-align: left; width: 15%;"><div style="font-size: 10pt;">Warrant </div><div style="font-size: 10pt;">Expiration</div><div style="font-size: 10pt;">Date</div></td><td rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left;"><div></div><div style="font-size: 10pt;">Value at</div><div style="font-size: 10pt;">Issuance </div><div style="font-size: 10pt;">Date</div></td><td nowrap="nowrap" rowspan="2" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td colspan="7" style="vertical-align: bottom; padding-bottom: 2px; text-align: left;"><div style="font-size: 10pt;"> </div></td></tr><tr style="height: 14px;"><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; text-align: center;">June 30,</div><div style="font-size: 10pt; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; text-align: center;">December 31,</div><div style="font-size: 10pt; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 8%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 15%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"><div></div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; width: 8%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">5/13/2009</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 16%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">466,667</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">17.25</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">5/13/2014</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">3,360</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr style="height: 12px;"><td valign="bottom" style="vertical-align: top; width: 8%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">2/23/2010</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 16%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">916,669</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">12.75</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: top; width: 15%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;">2/23/2015</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">5,701</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">6</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 8%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">2/22/2011</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 16%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">4,552,600</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1.50</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 15%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">2/22/2016</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">8,004</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">5,419</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 8%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 16%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: top; padding-bottom: 4px; width: 15%; background-color: rgb(255,255,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">3,224</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">5,425</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div><br /></div><div style="font-size: 10pt; text-align: left;">There were no warrants exercised during the three months ended June 30, 2014.  During the six months ended June 30, 2014, holders of the February 2011 warrants exercised warrants to purchase 282,350 shares of common stock for total proceeds of $0.4 million.  There were no warrants exercised during the three and six months ended June 30, 2013.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Changes in the estimated fair value of warrants classified as derivative liabilities are reported in the accompanying Consolidated Statement of Operations as the “Change in fair value of common stock warrants.”</div></div> P5Y P5Y P5Y 2011-02-22 2009-05-13 2010-02-23 4600000 466667 4552600 916669 2014-05-13 2016-02-22 2015-02-23 0 0 282350 0 1465000 375000 <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-weight: bold; text-align: left;">Note 2 – Liquidity Risks and Management’s Plans</div><div><br /></div><div style="font-size: 10pt; text-align: left;">We have incurred substantial losses since inception, due to investments in research and development, manufacturing, and, more recently, commercialization and medical affairs activities, and we expect to continue to incur substantial losses over the next several years.  Historically, we have funded our business operations through various sources, including public and private securities offerings, debt facilities, strategic alliances, the use of committed equity financing facilities (CEFFs) and at-the-market (ATM) equity programs, and capital equipment financings.</div><div><br /></div><div style="font-size: 10pt; text-align: left;"><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">As of June 30, 2014, we had cash and cash equivalents of $</font>65.6 <font style="font-size: 10pt;">million and long-term debt of $30 million ($</font>19.3 <font style="font-size: 10pt;">million net of discount) under our Deerfield Loan with affiliates of Deerfield Management  Company, L.P. (Deerfield) (</font><font style="font-size: 10pt; font-style: italic;">see,</font><font style="font-size: 10pt;"> Note 7 – “Deerfield Loan”) .  Before any additional financings, including under our ATM Program (</font><font style="font-size: 10pt; font-style: italic;">see</font><font style="font-size: 10pt;">, Note 11</font><font style="font-size: 10pt;"> -</font><font style="font-size: 10pt;"> “At-the-Market Program (ATM Program),” to the consolidated financial statements in our </font>Annual Report on Form 10-K for the year ended December 31, 2013 (2013 Form 10‑K))<font style="font-size: 10pt;">, we anticipate that we will have sufficient cash available to fund our operations and debt service obligations through the third quarter of 2015.</font></div><div style="font-size: 10pt; text-align: left;"> </div></div><div style="font-size: 10pt; text-align: left;">For the next several years, we expect that our cash outflows for marketing, commercial and medical activities, development programs, operations and debt service will outpace the rate at which we may generate revenues.  To execute our business strategy, pay debt obligations and fund our operations over the next several years, we will require significant additional infusions of capital until such time as the net revenues from the sale of approved products and from other sources are sufficient to offset our cash flow requirements.  While we currently intend to retain all rights and commercialize our approved products in the U.S. by ourselves, an important priority for us is to identify strategic transactions that could provide additional capital and strategic resources to support the continued development and commercial introduction of our RDS products in markets outside the U.S<font style="font-size: 10pt;">.  </font>For our AEROSURF development program, we seek a significant strategic alliance that potentially could provide development, regulatory and commercial market expertise, and, if approved, support the commercial introduction of AEROSURF in the EU and other selected markets outside the U.S.  Such alliances typically also would provide financial resources, in the form of upfront payments, milestone payments, commercialization royalties and a sharing of research and development expenses.  To advance SURFAXIN in markets outside the U.S. where regulatory marketing authorization is facilitated by the information contained in our new drug application (NDA) approved by the FDA, we would consider various financing or collaboration arrangements that could potentially provide regulatory expertise, support the commercial introduction of SURFAXIN in markets outside the U.S., and a sharing of revenues.  Such countries could potentially include those in Latin America, North Africa and the Middle East.  To secure the necessary capital, we also plan to consider other public and private equity offerings, including under our ATM Program, which currently may allow for the sale of up to approximately $23 million of our commons stock, as well as other financing transactions, such as secured equipment financing facilities or other similar transactions.</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Our future capital requirements will depend upon many factors, primarily our efforts to (i) execute the commercial introduction of SURFAXIN in the U.S.; (ii) advance the AEROSURF development program to completion of the phase 2 clinical trials as planned in the second half of 2015; (iii) assure long-term continuity of supply for both our commercial and lyophilized KL<font style="font-size: 7pt;">4</font> surfactant  drug product, potentially with CMOs and/or at our manufacturing facility in Totowa, NJ (Totowa Facility); and (iv) secure one or more strategic alliances or other collaboration arrangements to support our development programs and commercialization of our approved products, if any, in markets outside the U.S.  We believe that we will be better positioned to enter into a significant strategic alliance if we are successful in advancing the commercial introduction of SURFAXIN and completing and obtaining encouraging results from the AEROSURF phase 2 clinical program within our anticipated time.</div><div> </div><div>Although we currently believe that we will be able to successfully execute our business strategy as planned, there can be no assurance that any of our approved products, including SURFAXIN, will be commercially viable or that we will be able to execute our long-term manufacturing plan, that our AEROSURF development program will be successful within our anticipated time frame, if at all, that we will be able to secure regulatory marketing authorization for AEROSURF and our other KL<font style="font-size: 7pt;">4</font> surfactant product candidates, in the U.S. and other markets, that the ATM Program will be available when needed, if at all, or that we will be able to obtain additional capital when needed and on acceptable terms. We will require significant additional capital to sustain operations, satisfy debt obligations, and complete product development and execute the commercial introduction of our KL<font style="font-size: 7pt;">4</font> surfactant product candidates, if approved.  Failure to secure the necessary additional capital when needed would have a material adverse effect on our business, financial condition and results of operations.  Even if we succeed in raising additional capital and developing and subsequently commercializing our product candidates, we may never achieve sufficient sales revenue to achieve or maintain profitability.</div><div><br /></div><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">As of June 30, 2014, we had outstanding warrants to purchase approximately </font>14.0 <font style="font-size: 10pt;">million shares of our common stock at various prices, exercisable on different dates into 2019.  Of these warrants, warrants to purchase 7 million shares were issued to Deerfield in connection with the Deerfield Loan at an exercise price of $2.81 per share.  The Deerfield Warrants may be exercised for cash or on a cashless basis.  In lieu of paying cash upon exercise, the holders also may elect to reduce the principal amount of the Deerfield Loan in an amount sufficient to satisfy the exercise price of the Deerfield Warrants.  In addition to the Deerfield Warrants, we have outstanding warrants issued in February 2011 to purchase approximately </font>4.6 <font style="font-size: 10pt;">million shares of common stock that contain anti-dilution provisions that adjust the exercise price if we issue any common stock, securities convertible into common stock, or other securities (subject to certain exceptions) at a value below the then-existing exercise price of the warrants.  These warrants currently have an exercise price of $1.50 per share and expire in February 2016.  Although we believe that, in the future, we may receive additional capital from the exercise of at least a portion of our outstanding warrants, there can be no assurance that the market price of our common stock will equal or exceed price levels that would make exercise of outstanding warrants likely, that holders of the Deerfield Warrants would choose to exercise their warrants for cash, or that holders of any of our outstanding warrants would choose to exercise any or all of their warrants prior to the applicable warrant expiration dates.  Moreover, if our outstanding warrants are exercised, such exercises likely will be at a discount to the then-market value of our common stock and have a dilutive effect on the value of our shares of common stock at the time of exercise.</font></div><div><br /></div><div style="font-size: 10pt; text-align: left;"><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">As of June 30, 2014, 250 million shares of common stock were authorized under our Amended and Restated Certificate of Incorporation</font><font style="font-size: 10pt;">, as amended,</font><font style="font-size: 10pt;"> and approximately </font>137.2 <font style="font-size: 10pt;">million shares of common stock were available for issuance and not otherwise reserved.</font></div></div></div> 23000000 137200000 <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; font-style: italic; text-align: left;"><u>Accrued Severance and Retention Costs</u></div><div><br /></div><div style="font-size: 10pt; text-align: left;">A liability for employee severance and retention benefits is recognized when (1) management has committed to a plan of termination; (2) the plan provides sufficient details, such as the employees affected, amounts to be paid, and expected dates of termination and payment; (3) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn; and (4) the plan has been communicated to employees.  The cost of such benefits are accrued over the remaining service period.</div><div><br /></div><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">In September 2013, we implemented an employee severance and retention plan for employees at our Totowa Facility to minimize employee turnover and encourage employees to remain with us through any potential plant closing.  The plan provides for severance for non-union employees and retention bonuses for management.  If we succeed in our efforts to secure longer-term utilization of the Totowa Facility, the severance plan and retention bonuses will remain in effect.  The total cash amount expected to be paid for severance and retention under this plan through June 2016, assuming a June 2015 plant closing, is approximately $1.1 million.  The plan-related expense for the three and six months ended June 30, 2014 was $</font>0.1<font style="font-size: 10pt;"> million and $0.3 million, respectively, and is included in research and development expense.  The related accrued liability is $</font>0.4 <font style="font-size: 10pt;">million as of June 30, 2014.</font></div><div><br /></div><div style="font-size: 10pt; text-align: left;"><font style="font-size: 10pt;">In addition, at the Totowa Facility, there are 13 employees who are subject to a collective bargaining agreement under which they would be eligible to receive severance payments if the Totowa Facility were closed.  The related accrued liability is $</font>0.4<font style="font-size: 10pt;"> million as of June 30, 2014.</font></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; text-align: left;">The significant unobservable inputs used in the fair value measurement of the common stock warrants measured on a recurring basis are the historical volatility of our common stock market price, expected term of the applicable warrants, and the risk-free interest rate based on the U.S. Treasury yield curve in effect at the measurement date.  In addition to the significant unobservable inputs noted above, certain fair value measurements also take into account an assumption of the likelihood and timing of the occurrence of an event that would result in an adjustment to the exercise price in accordance with the anti-dilutive pricing provisions in the warrant.  Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, may result in significantly higher or lower fair value measurements.</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; width: 50%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Significant Unobservable Input</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">Assumptions of Level 3 Valuations</div></td><td style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; width: 24%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30, 2014</div></td><td style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; width: 2%;">  </td><td style="vertical-align: bottom; white-space: nowrap; border-bottom: rgb(0,0,0) 2px solid; width: 24%;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">December 31, 2013</div></td></tr><tr><td style="vertical-align: bottom; width: 50%;"></td><td style="vertical-align: bottom; width: 24%;"><div> </div></td><td style="vertical-align: bottom; width: 2%;"></td><td style="vertical-align: bottom; width: 24%;"><div> </div></td></tr><tr><td style="vertical-align: bottom; width: 50%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Historical Volatility</div></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">52<font style="font-size: 10pt;">% –</font> 61%</div></td><td style="vertical-align: bottom; width: 2%; background-color: rgb(204,238,255);"></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">62% – 76%</div></td></tr><tr><td style="vertical-align: bottom; width: 50%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Expected Term (in years)</div></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;"><font style="font-size: 10pt;"> </font>0.7<font style="font-size: 10pt;"> – </font>1.6</div></td><td style="vertical-align: bottom; width: 2%; background-color: rgb(255,255,255);"></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: center;"> 0.4 – 2.1</div></td></tr><tr><td style="vertical-align: bottom; width: 50%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Risk-free interest rate</div></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">0.08% – 0.34%</div></td><td style="vertical-align: bottom; width: 2%; background-color: rgb(204,238,255);"></td><td style="vertical-align: bottom; width: 24%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: center;">0.08% – 0.44%</div></td></tr></table></div> 400000 0 112000 843000 700000 P2Y P5Y <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; text-align: justify;">Inventory is comprised of the following for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td valign="bottom" style="vertical-align: top; width: 56%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 10pt; font-weight: bold; text-align: center; text-indent: 8.9pt;">December 31,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: top; padding-bottom: 2px; width: 56%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr style="height: 16px;"><td valign="bottom" style="vertical-align: bottom; width: 56%;"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Inventories, current:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr style="height: 14px;"><td valign="bottom" style="vertical-align: bottom; width: 56%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Raw materials</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">147</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">52</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 56%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Finished goods, net of reserves</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">296</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">60</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%; background-color: rgb(204,238,255);"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">443</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">112</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Inventories, non-current:</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"> </td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 56%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Raw materials</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">400</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">–</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 56%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 25.2pt; text-indent: -7.2pt;">Total inventories, net</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">843</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">112</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div><br /></div></div> <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><div style="font-size: 10pt; font-weight: bold; text-align: justify;">Note 7 – Deerfield Loan</div><div><br /></div><div style="font-size: 10pt; text-align: left;">Long-term debt consists solely of amounts due under a $30 million loan (Deerfield Loan) with affiliates of Deerfield Management Company, L.P. (Deerfield) for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 56%;"><div style="font-size: 10pt; font-style: italic; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div>2014</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, Serif; font-weight: bold; text-align: center;">December 31,</div>2013</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Note Payable</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">30,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">30,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 56%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Unamortized discount</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(10,736</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(11,646</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 56%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Long-term debt, net of discount</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">19,264</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">18,354</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr></table><div><br /></div><div style="font-size: 10pt; text-align: left;">The principal amount of the loan is payable in three equal annual installments on the fourth, fifth, and sixth anniversaries of the Deerfield Loan agreement beginning in February 2017, provided that the amount payable on the fourth anniversary shall be deferred for one year if either (i) “Net Sales” for the immediately preceding 12-month period are at least $20 million, or (ii) “Equity Value” is at least $200 million; and provided further, that the amount payable on the fifth anniversary (together with any amount deferred on the fourth anniversary) shall be deferred until the sixth anniversary if either (i) “Net Sales” for the immediately preceding 12-month period are at least $30 million, or (ii) “Equity Value” is at least $250 million.  Accordingly, if the milestones are achieved in each year, payment of the principal amount could be deferred until the sixth anniversary date of the loan, February 13, 2019.</div><div><br /></div><div style="font-size: 10pt; text-align: justify;">The following amounts comprise the Deerfield Loan interest expense for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Six Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash interest expense</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">654</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">218</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,302</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">331</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-cash amortization of debt discounts</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">470</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">118</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">909</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">177</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amortization of debt costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total interest expense</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">1,129</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">341</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">2,221</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">516</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table><div style="clear: both;"><br /></div><div style="font-size: 10pt; text-align: left;">Cash interest expense represents interest at an annual rate of 8.75% on the outstanding principal amount for the period, payable quarterly in cash.  Non-cash amortization of debt discount represents the amortization of transaction fees and the fair value of the warrants issued in connection with the Deerfield Loan.  The amortization of debt costs represents legal costs incurred in connection with the Deerfield Loan.</div><div> </div><div>In connection with the loan, we issued to Deerfield warrants to purchase 7.0 million shares of our common stock at an exercise price of $2.81 per share that expire on February 13, 2019.  The Deerfield warrants are derivatives that qualify for an exemption from liability accounting provided in ASC 815 and are classified as equity.  <font style="font-size: 10pt; font-style: italic;">See</font>, Note 9, “Deerfield Loan,” to the consolidated financial statements in our 2013 Form 10-K.</div></div> 516000 1129000 341000 2221000 20000000 30000000 250000000 200000000 7000000 3 <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; text-align: justify;">The following amounts comprise the Deerfield Loan interest expense for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 90%;"><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div style="font-size: 10pt; font-style: italic; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Three Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="6" valign="bottom" style="vertical-align: bottom;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">Six Months Ended</div><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2014</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: rgb(0,0,0) 2px solid;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">2013</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: bottom;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Cash interest expense</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">654</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">218</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">1,302</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">331</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Non-cash amortization of debt discounts</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">470</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">118</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">909</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">177</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 42%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Amortization of debt costs</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">5</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">10</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">8</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 42%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 16.2pt; text-indent: -7.2pt;">Total interest expense</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">1,129</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">341</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">2,221</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">516</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td></tr></table></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="font-size: 10pt; text-align: left;">Long-term debt consists solely of amounts due under a $30 million loan (Deerfield Loan) with affiliates of Deerfield Management Company, L.P. (Deerfield) for the periods presented:</div><div><br /></div><table align="center" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; width: 80%;"><tr><td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 56%;"><div style="font-size: 10pt; font-style: italic; margin-left: 7.2pt; text-indent: -7.2pt;">(in thousands)</div></td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;"><div style="font-size: 10pt; font-weight: bold; text-align: center;">June 30,</div>2014</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%;"> </td><td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%;"> </td><td colspan="2" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: center;"><div style="font-size: 10pt; font-weight: bold;"><div style="font-size: 10pt; font-family: 'Times New Roman', Times, Serif; font-weight: bold; text-align: center;">December 31,</div>2013</div></td><td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px; text-align: center; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%;"><div> </div></td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%;"> </td><td colspan="2" valign="bottom" style="vertical-align: top;"></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%;"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; width: 56%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Note Payable</div></td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">30,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">30,000</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 56%; background-color: rgb(255,255,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Unamortized discount</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(10,736</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: left; width: 1%; background-color: rgb(255,255,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 2px solid; text-align: right; width: 9%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">(11,646</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: rgb(255,255,255);"><div style="font-size: 10pt;">)</div></td></tr><tr><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 56%; background-color: rgb(204,238,255);"><div style="font-size: 10pt; text-align: left; margin-left: 7.2pt; text-indent: -7.2pt;">Long-term debt, net of discount</div></td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">19,264</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: rgb(204,238,255);"> </td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: left; width: 1%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">$</div></td><td valign="bottom" style="vertical-align: bottom; border-bottom: rgb(0,0,0) 4px double; text-align: right; width: 9%; background-color: rgb(204,238,255);"><div style="font-size: 10pt;">18,354</div></td><td nowrap="nowrap" valign="bottom" style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: rgb(204,238,255);"> </td></tr></table></div> EX-101.SCH 8 dsco-20140630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - Liquidity Risks and Management's Plans link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - Common Stock Warrant Liability link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - Deerfield Loan link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - Stock Options and Stock-Based Employee Compensation link:presentationLink link:calculationLink link:definitionLink 070300 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 080500 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - Common Stock Warrant Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 080700 - Disclosure - Deerfield Loan (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - Stock Options and Stock-Based Employee Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - Liquidity Risks and Management's Plans (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 090402 - Disclosure - Fair Value of Financial Instruments, Level 3 Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 090404 - Disclosure - Fair Value of Financial Instruments, Significant Unobsesrvable input assumptions of Level 3 valuations (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - Common Stock Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - Deerfield Loan (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - Stock Options and Stock-Based Employee Compensation (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 dsco-20140630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 10 dsco-20140630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 11 dsco-20140630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Amendment Flag Current Fiscal Year End Date Document Period End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Central Index Key Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Document Type Summary of Significant Accounting Policies [Abstract] Accounts receivable Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Additional paid-in capital Adjustments to reconcile net loss to net cash used in operating activities: Employee stock-based compensation Allocated Share-based Compensation Expense Amortization of debt costs Amortization of Financing Costs Non-cash amortization of debt discounts Amortization of discount on long-term debt Amortization of Financing Costs and Discounts Potential common stock issuable upon exercise of stock options and warrants (in shares) Assets [Abstract] Assets, Fair Value Disclosure [Abstract] Total assets Assets Fair Value Current Assets: ASSETS Assets [Abstract] Total current assets Assets, Current Basis of Presentation Cash and cash equivalents [Member] Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents Cash and cash equivalents - end of period Cash and cash equivalents - beginning of period Certificate of Deposit [Member] Number of warrant shares outstanding (in shares) Class of Warrant or Right, Outstanding Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Exercise Price (in dollars per share) Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Class of Warrant or Right [Line Items] Class of Warrant or Right [Table] Common stock, par value (in dollars per share) Common stock, $0.001 par value; 250,000,000 and 150,000,000 shares authorized at June 30, 2014 and December 31, 2013, respectively; 85,227,508 and 84,659,111 shares issued at June 30, 2014 and December 31, 2013, respectively; 85,206,616 and 84,638,219 shares outstanding at June 30, 2014 and December 31, 2013, respectively Common stock, shares issued (in shares) Common stock, shares authorized (in shares) Common stock, shares outstanding (in shares) Cost of product sales Credit Facility [Axis] Credit Facility [Domain] Note Payable Debt Instrument, Face Amount Long-Term Debt Long-term Debt, Gross Loan facility payment terms Debt Instrument, Payment Terms Long-term debt, discount Unamortized discount Cash interest rate under loan facility (in hundredths) Deferred revenue Depreciation and amortization Common Stock Warrant Liability [Abstract] Common stock warrant liability Balance at beginning of period Balance at end of period Derivative Liability, Current Less: income from change in fair value of warrant liability Stock Options and Stock-Based Employee Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Options and Stock-Based Employee Compensation [Abstract] Net loss per common share [Abstract] Basic (in dollars per share) Net loss per common share Diluted (in dollars per share) Net loss per common share Earnings Per Share [Abstract] Stock-based compensation and 401(k) Plan employer match Employee Benefits and Share-based Compensation Weighted-average vesting period of stock options Severance [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Historical Volatility (in hundredths) Fair Value Assumptions, Expected Volatility Rate Assets and liabilities measured at fair value on a recurring basis [Abstract] Fair Value, Measurements, Recurring [Member] Recurring [Member] Measurement Frequency [Axis] Fair Value, Hierarchy [Axis] Risk-free interest rate (in hundredths) Fair Value Measurements, Recurring and Nonrecurring [Table] Fair value adjustment of common stock warrants Change in fair value of common stock warrant liability Fair Value Adjustment of Warrants Expected Term (in years) Fair Value, Measurement Frequency [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value of Financial Instruments [Abstract] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Summary of activities of unobservable inputs measured on a recurring basis [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Level 2 [Member] Level 1 [Member] Level 3 [Member] Common stock warrants measured at Level 3 inputs on recurring basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Financial Instrument [Axis] Selling, General & Administrative [Member] Consolidated Statements of Operations (Unaudited) [Abstract] Income Statement Location [Axis] Income Statement Location [Domain] Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable Accrued expenses Deferred revenue Increase (Decrease) in Deferred Revenue Other liabilities Changes in: Inventory Increase (Decrease) in Inventories Other assets Increase (Decrease) in Other Operating Assets Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Dilutive common shares from assumed warrant exercises (in shares) Cash interest expense Interest expense [Abstract] Interest paid Inventory, net Inventory Inventories, current [Abstract] Inventory, Net [Abstract] Inventory Inventory, Policy [Policy Text Block] Finished goods, net of reserves Inventories, non-current [Abstract] Inventory, Noncurrent [Abstract] Inventory Inventory Disclosure [Text Block] Inventory reserves Inventory [Line Items] Inventory [Abstract] Raw materials Carrying value of Facility Agreement [Abstract] Total current liabilities Liabilities, Current Total liabilities & stockholders' equity Liabilities and Equity Fair Value Financial and Nonfinancial Liabilities, Fair Value Disclosure Current Liabilities: Total liabilities Liabilities LIABILITIES & STOCKHOLDERS' EQUITY LIABILITIES & STOCKHOLDERS' EQUITY Liabilities [Abstract] Loan facility, maximum amount Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility [Line Items] Line of Credit Facility [Table] Long-term debt, net of discount Long-term Debt Fair value of loan Equipment loans, non-current portion Equipment loans, current portion Long-term Debt and Capital Lease Obligations, Current Long-term debt, $30,000 net of discount of $10,736 at June 30, 2014 and $11,646 at December 31, 2013 Long-term debt, carrying amount Long-Term Debt Maximum [Member] Minimum [Member] Money Markets [Member] Net loss Net loss Net loss as reported Cash flows from financing activities: Numerator for diluted net loss per common share Net Income (Loss) Available to Common Stockholders, Diluted Cash flows from investing activities: Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flow from operating activities: Numerator [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Recent accounting pronouncements Other income / (expense): Expenses: Total expenses Operating Expenses Operating loss Operating Income (Loss) Organization and Business [Abstract] Organization and Business Other assets Interest and other expense Other Nonoperating Expense Interest and other income Other Nonoperating Income Other income / (expense), net Other Nonoperating Income (Expense) Other liabilities Other Liabilities, Noncurrent Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Preferred stock, par value (in dollars per share) EX-101.PRE 12 dsco-20140630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 13 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!F'MSGR0$``(03```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;\W6 MM2JB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"$((9)X;EA@[7D?>O%D>WN#15U% M<["NU"HC+$E)!"K7LE23C'R,7N(NB9P72HI**\C($AP9]"\O>J.E`1>%W/%#J\@)JX1)M0(4[8VUKX<-7.Z%&Y%,Q`.*TKBK@$'H MWH3FSN\!ZWUOX6AL*2$:"NM?11TPZ**B7]I./[6>)H>'[*'4XW&9@]3YK`XG MD#AC04A7`/BZ2MIK4HM2;;@/Y+>+'6TO[,P@S?]K!Y_(P9%P7"/AN$'"<8N$ MHX.$XPX)1Q<)QST2#I9B`<%B5(9%J0R+4QD6J3(L5F58M,JP>)5A$2O#8E:. MQ:PP"3N'[6- MHR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B M9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%H MT9,9J&74"T\U<%J"`=[!ZH^^CSYLK$SO+ M=N5#9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A M`%"KK)4XNI9!KFWZ`L!7;Q):,I#[R]Q4F.`V$[27LQ2`)K\:SZ]F1 MUMN?KDV^M/.--;F`22H2;0I;-J;*Q&PO=V]R:V)O;VLN>&ULE);;;]HP%,;?)^U_B/*^Y@+TID(U>M&0 MVG4:O3Q:;F+`PK$SVREE?_U.C`@G\1:M3\$Q_O*=\_WLY.+RO1#!&].&*SD. MDZ,X#)C,5,[EEU@$(2#,. M5]:6YU%DLA4KJ#E2)9,PLU"ZH!:&>AF94C.:FQ5CMA!1&L?'44&Y#'<*Y_I_ M--1BP3-VK;*J8-+N1#03U()]L^*E"2<7"R[8\ZZB@);E=UJ`[W<1!H(:>Y-S MR_)Q.(*AVK#6#5V5TXH+F#T;Q(,PFC1%_M!!SA:T$O81RMNK0[_289H>U_^L M6_',V<8<%M7#X/V%RUQMZK]":[?-:``&-F[JA>=V!?-Q'#?WOC&^7-G]39"/ MD+[K(#S'70/IRMMWA$!2Y$9:;K=D)G?=YPHBK+L^@\J2,-#G''[H69[4QK'* M%311"9Y3:!&94D%EQLB\7FK($P35J`R@ED8F_9@,.#CH8#NNX_^T,[?@J@[= M$+4@#R5#,D/D9MCKIJUR10U2@>XW-8VZ*@]Z227_[4!S39Y6ADMFL,`@10J. M"ES-'?]5<:!O2WYRLS9.Y)Y*NG15(1^#`9(YZ1J95T5!];9NPIPO)8?]0*4E M7[-,5=)B&=R5TZ[,+>6:/%-1L5KIEDO(FE,!T!BK*RR#VW+6E9G)-XA$Z2U> M<8S\)W%WR94J"B7)W*IL35ZHUK7].TY?N8#F8)T3K./!>LV87G`F*@VJ9)'^BK@Q$<6,)R)1V=_N"T+&,_$X[.=[E]\8"P3 MC\O^D%L^,*UP1G>.Q/Y=VQ+"N*8>KOTI0U>;E%,<#@PZCOI3QKBD."L8?$@( M.QKB'95Z`/<[@IP/I>'44@_@`W?7S%(N#%HZQ+MQ]\[%IVL_>+@K([P;4X_@ M#GB^D1&$WAPOJ0=N/WG82-JJR"$U7+8)%(B15$.UPS& M-EIC+&!V=M\^U11V4\4N9N9B9DQ]7?3?55W5[J'YYY^>WNKF3/2P M;9;XJ`^',B^2.G^MBDN'3IKBG'4P__947MN;MRI?XJ[*FL^OUU5>5U=P\5*> MR^Y;[]0TJGS[V_%2-]G+&71_%4Z6WWSW'R;NJS)OZK8^=&MP9^%$IYI#*[3` MT_/3O@0%:MF-ICCLS(]BFTK'M)Z?^@7ZMRS>VM'_1GNJWWYIROWOY:6`U88X MJ0B\U/5GA?ZV5X]@L#49_:F/P)^-L2\.V>NY^ZM^^[4HCZ<.PNV"(B5LN_^6 M%&T.*PINUM)5GO+Z#!.`WT95JM2`%I M5"Y-(W]MN[KZ#R$QN$(GF?C,@6>!5[353 MJ2>VX/`F"%]_E_@CA2!-.?FHO/2^8/(MA.7+L^\^65]@)?,!B1#Q34,C/D7B M&Z+63;E-;@_T&$&'I#="!0T4W67!@G!9&XCV]^-T4Z$&,14>?5\T120EXBGA M!Q1)I@ASDDZ)D1,B=$.%S@M4,*3<.`8AG5N$B#-"6"#CAT3RD$CG""(/)C*. MX[P\!>],6+M[B@4VDX=(T*>HPU8]'AO9P&1L\YDQ'1NUC0B!O;500IF@MB<(D1N@L(-G5., MYA\)(H.%U%/NZT@Z'OQ#05":ED=(P70G!6S&$2*0&O=LY#OI(9$\)-(Y@L1+ M'4%&A7Y^)RF8Q8NM:80(!L3?\/P;6_6.P*J.MB'2KF")D'Y_*-$2OD>+@ID6 M%H@($9R1%[BL7L?4[+%`)V,SY)[#AJ?$[FXV^NU$E(#^M#Q"/V!-,4&P+973(QL9$*,>EL->3EVJT=2 M,:J?+Q>#W9^(8?.-Q/@`L1)BTL\&`-6N8+?0XTE"'4@Y.8)0!Z[4.4.EJ7Z^ M7!IV?R*-S2P2R-S*R:3*QP-PE\;6)J$.0)J>^A"RVQE$?>];N4+O7Z M\%1`Z@@K<)%`9J9(Q(^1Y#&2SB)$I'S7(:6GZ2$EU%48B^7`A/U7E96]YN?! M>`*PAIEP8-((.#`Z"%%Q[SJHR.E!)63I%0V,%N?8Y$<7N'XQ8LY+OADG0$#\ MV6P#I)S7*4:5PSX;Y^ZR)B_5*/HM*&3!B09F+HV24H`QW.$?@45!RL]CN0#<8JF M&U38K+Y'<*&J#Z3P[8A?)\0$<,*`3SXA0.")T>2QR!+`\7U?YS&JPQM9O+FL MBN98Q,7YW!IY_:IN6R44C_M3O`F.Q!;N$^%:D#U/X(:X?V[=#7!!>\V.Q1]9 M&PO=V]R:W-H965TP/!/![\OA[#.+OO[UFJO=&2 M)RS?ZV1AZAK-(Q8G^76O__U7\&VC:[P*\SA,64[W^@?E^O?#SS_M'JQ\Y3=* M*PTBY'ROWZJJ<`V#1S>:A7S!"IK#G0LKL[""R_)J\**D85QWRE)C:9HK(PN3 M7!<1W').#':Y)!'U673/:%Z)("5-PPK&SV])P9_1LFA.N"PL7^_%MXAE!80X M)VE2?=1!=2V+W!_7G)7A.07=[\0.HV?L^F(0/DNBDG%VJ180SA`#'6K>&EL# M(AUV<0(*T':MI)>]_D+<@"QUX["K#?HGH0_>^:WQ&WO\4B;Q;TE.P6V8)YR! M,V.OB/Z(L0DZ&X/>03T#?Y1:3"_A/:W^9(]?:7*]53#=#BA"86[\X5,>@:,0 M9K%T,%+$4A@`'+4LP=0`1\+W^OQ(XNJVUZW5PEF;%@%<.U->!0F&U+7HSBN6 M_2L@TH02099-$#@W04#RW,Y6TQG.;>?%Z,-\B?J&&.0V;9)[PA89$^X@\1VS3[S$DP M<&P'(STHF"(,T-^:`,DTWP2$T03,=73E*#=X>/'V%8A1W?;%/R_R@8R/766Z=]3$7IMR^GE=P(&/DC1]OK@/Q_8ADH4G)1%,$3WYL/[G MRT=8EB^-[2@8IY:_W*X&\KPN@+=E^>+^E'PE$4P1/?GPXIHO'^&^?$*DT1\% M(^3;MC60YW4!0D:F7P!3^I5$,$7T],,;>;Y^A.7U+[TYCX*9&+VG)'PE<5(2 MP131_[SWO^O?2413!$]Z=NO M2$=8EKZ67GV"$=(W8\G?!4:37P`3Z7-2$L$4T=-/H*:=/_X$EIE`G!'";X@),T]J!#=^^)SQ*,('L;$3)7]&RROU:)IR+6)WW+3A MZZMM;3>4+_5^4FH_$AF)Q9!3O"^N<-_@&@4&R;"X`OC%7/"WQ`^Y_" MX3\```#__P,`4$L#!!0`!@`(````(0!XP9*E:@,``!T+```9````>&PO=V]R M:W-H965T[QH%@TC&:AR3`N8=SS[VV[_+VIYX>"UHJ0R)H3A3HEP=6R8:M2,?0%40\':N;E!<54&Q9SM1K38I1D2Z^[$LN MR#:'O%_\D*0-=WUQ15^P5'#)=\H!.M<(OVR%[OJ4S!4:!Q)E/-E/("$ MD^D\&L'B&D5U@O=$D?52\!."KH%WRHKH'O07P*PS"T&3T='F^J]4(4=-X\R#;:53<*^:P;3=2V(@UYMW\*$+<;2!\MM MO',:;.L+XEY?;0RF<2YR//L3/MQ]K)+AA"6MMC6-F[5Z*#_K1J#&=(XA+`T^G"&C3>P1O<=O'2]_R97B/FE"K8ZO9./+J]O]OWNKGB]=LZ@KGE!/+>;('D3=#F';(UZBQ^O MT1P(78W7ZP=&$-T$C8.!$\36)WJXZ2_W7DCHA/::"[HA1K^94LPA7E"QIPG- M,X>M49CQQEPH M7M4CPI8K&$OJOP<80RDH!J!]OU7P```/__`P!02P,$%``& M``@````A`-!\67\Z`P```0H``!D```!X;"]W;W)K&ULE%9MCZ(P$/Y^R?T'TN_R*HA$W:SBWFUREUPN]_*Y0I%F@9*VKKO__J94 M$=!3]XM`YYFG\\Q,.\X>WLK">"5<4%;-D6/:R"!5PE):;>?H]Z^G48@,(7&5 MXH)59([>B4`/B\^?9GO&7T1.B#2`H1)SE$M91Y8EDIR46)BL)A58,L9++.&3 M;RU1V`ZO$M$*:(>+W<+`LHPF)6;(K224U"2<%EA"_R&DMCFQE M<@]=B?G+KAXEK*R!8D,+*M\;4F242?2\K1C'FP)TOSECG!RYFX\S^I(FG`F6 M21/H+!WHN>:I-;6`:3%+*2A0:3;HT8G6$V0M9DU^_E"R%YUW0^1L_X73 M]!NM""0;RJ0*L&'L14&?4[4$SM:9]U-3@!_<2$F&=X7\R?9?"=WF$JKM@R"E M*TK?8R(22"C0F*ZOF!)60`#P:Y14=08D!+\USSU-93Y'7F#Z$]MS`&YLB)!/ M5%$B(]D)RR"!YX'$@=<[G;V#,SQ;9],-?<3"UE5/H_* MJ7$%M("&>%UXH3>S7J&*R0&SU)@),EJ,VT>LSA&>TX?$YQL-2-;GB$G8DE@@ MLE4*]?JX4N4T4&JW]$TREAK2'(!F835V4PPO]?@Q+C8$^:TLV0*QN(N*;B/4U1$\G!-+5>;TE%7B.((MM[%X8#/1I M3*@;UG4')5AUS?[8'6B/KYO777/@V2?OGB8X8O=K4N"^)M<]-;?N/HV!S5O= MIYUU.]Y$Q$>$.L@C;S(@6!_-E[;HB0OZXNZ[2Y137V0X'=1-0ZYIO(F(-<)O M:C]R0G?0&^N>W0TZO=.3"/?9_?53X+XT+YP,M&G,?WNR:[[0DUVS=];1,)55 M``?RP#GE56O2(U>/@Y+P+5F1HA!&PG9JG+J0JW953_JE$\%U!R-VL+YR(KCU MU!!O#3"!:[PEWS'?TDH8!KF?MTP";.W>LTG(&``#K(P`` M&0```'AL+W=O!]C M:,`DBC,:>Y3=D7:EU6HOSP3C&(TQ%I#;O]]JJNVA"E(-.P^3>/QU^5"'KH,9 M[CZ_E4?G):^;HCJM77^Q=)W\E%6[XO2T=O_^Z^%3XCI-FYYVZ;$ZY6OW/6_< MS_<__W3W6M7?FT.>MPY4.#5K]]"VYUO/:[)#7J;-HCKG)WAG7]5EVL++^LEK MSG6>[KI%Y=$+ELO8*]/BY&*%VWI*C6J_+[+\:Y4]E_FIQ2)U?DQ;T-\:':7:IW;T8 ME"^+K*Z::M\NH)R'0H?'?./=>%#I_FY7P!'HMCMUOE^[7_S;;12XWOU=UZ!_ MBORUZ?WN-(?J]9>ZV/U6G'+H-OBD'7BLJN\:_;;3_P2+O<'JA\Z!/VIGE^_3 MYV/[9_7Z:UX\'5JP.X(CT@=VNWO_FC<9=!3*+()(5\JJ(PB`OYVRT*<&="1] MZWZ^%KOVL'95O(A62^4#[CSF3?M0Z)*NDSTW;57^BY!O2F&1P!2!GZ:(#[]. M7*S,8OAY7;P(DLB/8KL$#P^GZ\[7M$WO[^KJU8%3#@0WYU2?P/XM5-9M4=#< M\;9`/_2:+WI1MQ3H!KQ\N5>QNO->H/^9839#)J#$=D@H_XIXH.\J$IK4%RF+ MTS`TQ$B:U$$&WP0=.U:7CM0NV>-O;)&V22KJV!@C$! M?Y@XBL04(>K@$*>KTS!3IU;THS?(1)TZ_R:(PZ$Z@B0J(@A1!SMGNCH-,W5Q MS-0A`P*N_67=W4H$T1;/T:9A?L[QSB$C:9,(HFTU1YN&:=\"GVW%#3+H:APE MB3[K:&NW?22)XV721X@Z'9FS1XI>1%6J.*$2-LA('90(HO&&:I0GBH9M[B(C M:9,(HLV'^=MOH"RNHVGGAOX:2#28,++#_O]+#1SX=/K=,(^[TFM7:J2(T$[J M*=X[%2V=Q)D/P_4Z/53,=[$.;#@91'T20O7I03Y='XY]J'[5-^(T0F$WH/D> M]L??I)K@T/J:)EX1Z%7T+%0K]O$;'R&Q=Q)"=\:"8Z*WPP11JQ]7:GA%Y2,D]DY"J$X6(99] MBU,?SNWKOAC9MU(T=(>P]26$ZIL5'SY.?LN^1>@RH2/X:C&(8%,(F20.$M5G MB,*`98AV.H1S5^YDMXJ>A6K%KQ4,)#DM(E0G2Q*+/DP0V>D`(5&?A%!]>I9/ MGM`!3G[9:0.)3A/&XK2>Z3V%$YW&).@K52O^%2Y`2.RDA-!.0IF^3HO3FK9= M`;\"5+?@Q- M_E4ID!"JD^6*Q5O,`3ASA'D=2&%A.B@A5-^L/`DP!_K]&_'V$A9C66PJ<..I M)I8AT[(X&&:)6C'C-@82]P76&4>(3GTW:/J^[6C;OC70^(>CMR)"]'&:)6 M_/NF0@B47(.MA!!]X:PHY_CD].AHJ[>ZY-J]3.>`_">"<;B/1"'-:=H_/VL@41_6 M&4>H/CW)>_//H@_GONPM/*NAAP;^-[4*QN8S0<;G,SZN@0\DG-.G_/>T?BI. MC7/,]S"BEXL5C*8:'];`%VUU[AX\>*Q:>,BB^_4`#]7D\%3"<@'POJK:RPO] M.,CU,9W[_P```/__`P!02P,$%``&``@````A`$B1XJM)!0``-A<``!D```!X M;"]W;W)K&ULG)A=;Z,X%(;O5]K_@+AOP'R%1$E& MY:.[(\U*J]7.[#4E3H(:<`2T:?_]'F-@.(8Q26\F#?/XQ>\YQ_:)-U_>\[/V M1LLJ8\56)PM3UVB1LGU6'+?Z]W^?'GQ=J^JDV"=G5M"M_D$K_WB*7)^7+Z^4A M9?D%))ZS"EQ0+T#.$!,= M>UX9*P.4=IM]!@YXV+62'K;Z(UG'%M&-W:8)T(^,7JO!WUIU8M<_RFS_+2LH M1!ORQ#/PS-@+1[_N^2,8;(Q&/S49^+O4]O20O)[K?]CU3YH=3S6DVP5'W-AZ M_Q'1*H6(@LS"&A"1Y+WYO&;[^K35;6_A+DV;`*X]TZI^ MRKBDKJ6O5`JY;M0]^*E+\)"X(WC]@*7>%Z1IZ&NZ5+KI M/Z! M8*"D>HOG3N12"@3C-[7X0$S/LDW3E!PB MQO>LY0B)$&)9YFHU8F+,$,M#KT(V884-;?+59L-VJ*Y./DBRZSO82B`8M[7K M.&,K(4(L9^6,G$0((3X<P5FA'RNOJ,5SY(]BKM^(%@6J\311D.@:6-9BB.Q"%`;&<NY/:3-*]FGW;VAF&;10EU2_V4LP$R+&6?D3*8L0XWL$YZQY5XP89[E< M_GK_);Q=D(K8@2U-O5B;4;)C>0=N(>$8#@J(^B#NS4Q#Q!#7GV"BEE$L^UB) MX`SS#N-^OZ(O&1ZPMBOM/0$1D&*>X3P2M8B(&O'X:2)'+<:,*44-^^4-A^1W M?I,BHDW!?CUN=58B6"W<)D/N&6CY+/'JD3#XB`E&YGD6A> M)58BV"UO/>[/K6A8<&ZE3CW@/R8A)&T5\DU7+L*P110!B>958J4*=LL[C_O= MBGX%NY7[)S)L:J;-"D)I=BC"-UPY8G'[FFD1[)7W(/=[%9T+\NK]/.G:*R[*\IOM3LTES=/;,:[BN;/T]P M/TWASLQ<`'Q@K.Z^\)NQ_L9[]S\```#__P,`4$L#!!0`!@`(````(0"*A(5O M9@4``+,:```9````>&PO=V]R:W-H965T(D:`*.@#F]?9F7V7`R)\_G' M_KV\L,WF^T=Q,=YH5>>LW)ID,C4-6F;LD)>GK?GW7^&WI6G435H>T@LKZ=;\ MI+7Y???K+YMW5KW49TH;`Q3*>FN>F^:ZMJPZ.],BK2?L2DOXYT6#'8YY1GV6O!2T;(5+12]I`^^MS?JUO M:D7VB%R15B^OUV\9*ZX@\9Q?\N:S%36-(ELGIY)5Z?,%^OU!9FEVTVZ_C.2+ M/*M8S8[-!.0LT=!QGU?6R@*EW>:00P^X[49%CUOSB:P3XIK6;M,:]$].W^O! M9Z,^L_>HR@^_Y24%MV&<^`@\,_;"T>3`BZ"R-:H=MB/P1V48 MYJ=S`\/M0H]XQ]:'3Y_6&3@*,A.[;4;&+M``^&\4.0\-<"3]:*_O^:$Y;TUG M/G$74X<`;CS3N@ES+FD:V6O=L.)?`1'>J%[$[D3@VHD0^/A@9:>K#->^\L1> MNL2=?Z$)LTX%KKW*PTV`GK8FP+6O_/4FS#L5N'8J/V'EHA.!^7D3L2<+,ETY MB\?'8]6)P+43L<%=_7A8(C#:.//3)MUM*O9NP.2%H:^O*4\%9`V"MP`3X="' MW/]%'$0)%WGB*EL3>@?!5,,T>=LY#ME8;Q#:6<=X8\:6B?V84$7\,;)8RBK! M&'$@>X\I,_`"3W&/FO8YD$$3XUPWB ME2#E#8:9.$JX>(*!Q-*'@M*3/4KX*!&@1(@2$4K$*)'H",EO,&3HMSX0.;PU M831[#]60\02R;'/#W'7A&32=]B/=1N]^B"SG]M(9(?X0X<^P,1(,$7N^7,&* M1;E1*!#XWS=7&?(()6*42'2$9#5D_L>MYK!J]4(VTA.,*_(P=)__R(!H+ M?)0(4")$B0@E8I1(=(1D-#RZ'S>:PZK1:NX0C#":K.SY;&RTA"P==XSX`M&, M18`2(4I$*!&C1*(C)*=A)?"XTQR6L[3CK.1X]02C\6B/$CY*!"@1HD2$$C%* M)#I"\IGO\Y35&[YLX)64R)XI^<$3C,YOE/!1(D")$"4BE(A1(A&$>#C9_)DR MG,>2X;!$'AJN?RQR6`GLF;HJ%HS.:)3P42)`B1`E(I2(42+1$9+/!!:_0Z/Y MO@2/[+:6&MK*FMSKH"YK\WP\'&VQ%.D8S;#X.!+@2"@UAJ^)1FV)<)481Q(M M(EO/-RU?3BI$;'6D->!,V3=X':2Q=8\C/HX$.!)VR*I=)=F3I3(Q(^EW,E%6 MB+'^YT3;`-ENO@D:V*U/*?SD992\E7VIUT%:FX6.!O%QE0!'0AR)[B#.;.0W MVN#DCLX/%=ESO@T:>/Y@=A&;)VA(OV]P9C^VJV(+3G0[K"ZYH(B/JP0X$N)( MU"$B&2G8>(^PGG>2TYKR^4^>H1P8B>V&[;3+4O M>PDB]R&_@S1S(\"1$$H>JLZ" M[[K'[NMV:NW<\#L=K?>H2HBK1#@2XP@_^^?=OM]&PO=V]R:W-H965TVMK#-<'8IL88%Y#)S-M/RP(/:C*TDXO$EC[]+5H_ M0DAY^OP]/TO?TK+*BLM"UD:J+*67I-AGE^-"_O,F*DMY,@^.EZ*,7\YPW=\U,TY:[=N7 MGGR>)651%8=Z!'(*[VC_FF?*3`&EYZ=]!E?`TBZ5Z6$A?]'F.\V0E>>G6X+^ MR]*WJO-9JD[%FU=F^S"[I)!M&"//3['BJ8;@MN")V8?/]#R>M$L@HR(QTBRDEQ1DZ`+^E/&/6@(S$WV]_ MW[)]?5K(QGAD351#`UQZ2:O:S9BD+"6O55WD_W-(:Z2XB-Z(&-#[IAZ*'FQL M-HWA[[WQ2)]:FC7^0!>@L_PZX$,CHT]'IFY-I@]7)N"?\=_F&1#.5+TSF)@:IK,`DWYY-=?*D?(.!31K& MYLQ$ENZ,)A++EF"CR&2=5K8M6+4%OS1,=2JJN"W3-O)P@=\6#*@$+=.JK''! MIBT84`G[S`2E)>+(0%JV+=%V9=>J0H$"XW@?3/!D;S`-N./>OU?:L6.MQ+$; MZV)*;8YT^XB(99^8H'%Q^HB!#+!JNJ+-;A8R9C-S+/;$;8B.B5!/O#Z!P_A] MQ-14,5#09U"@=9_`@3;O((8I!@K[#`H4D<2V3^#L[_I(I[>"BV"2$UPT[!Y& M,_>TYK1YP>1>L,0%#BY8M1K=.VDFILE]@/$>8/QW&`W9,'B`63_`;-YCT."& M#S#1`\SV`68WS`@F@(?5!TS`:'BP=NY*PT1)M3D#O^_3OR4.\9(D'))8D81+ M$AY)^"01D,2:)#8D$9)$1!);DM@-$8)I8/WP`=,P>B'#O'0WA&&BR='F#'3@ MSF#3D(1#$JL^89@HCMMG$.&1A-\G>G&"/H/BK$EBTR=Z<<(^@^)$)+$EB=T0 M(5AGC*S#UJ$FM!Y^^+!6XKQC:H8XJ]B<&;(023@DL2()ER0\DO!)(B")-4EL M2"(DB8@DMB2Q&R($\\#"]`/S#J/%>]4KJDA$<2?C?(3(,@:$$>D!)KDMAT@YB6I8]5 M]!H6"@14PX\XOTT&&O()C3@TLFH0_E`RM]WG$V$?OAO8?8_2\61M:QR:\J6&KJ/U MSK*I'["7(TA8L/$L3B$KH=XPQFB>=H5Z5.D-5?I")6S=HYV%0*A'RFNA$DV^ M&Z%RJJHH+:%0;_32%A'UVZ9^(*T[0<(RM5^/6=$4;/^N:PKV@D0O6C2^[=+FG$H9$5C;@TXM&(3R,!C:QI9$,CX1UAIR+(G5%3R==R^E0W M+$1LAYKO[I7O[8^(_F%[?UW_$),*WRH4??/+FK?3&1N._=CZAD\JIHY>O)=" M-;HLIZD<\-R*1EP:\6C$IY&`1M8TLJ&1D$:B!FG2CM?#6UJ!G=>R@7L_^=PV M_#R6'Q7F:7E,E^GY7$E)\"8]QH?TR@NC]FEDL[I`;JFPL)3EDI^4,R_ MU,7U=K[U4M1PP'O[>((#_11.&-41P(>BJ-LO+,#]7P2>?P(``/__`P!02P,$ M%``&``@````A`#9I_1>Z!@``H2(``!D```!X;"]W;W)K&ULG)I=;Z,X%(;O5]K_@+AO$AORJ::C`>S=E7:EU6H_KBDA#9HD1$"G M,_]^CSF0,3R..G;Z>C]S6OZJ(\;WTVF?E>?L[*77%^ MV?K__"T?5KY7-^EYEQ[+<[[UO^>U_^GIYY\>W\KJ2WW(\\8#A7.]]0]-<]E, MIW5VR$]I/2DO^1G.[,OJE#;PL7J9UISQ?24%F;T\9.7I`A+/Q;%HOK>B MOG?*-K^]G,LJ?3Y"W-]8F&:]=OO!D#\56576Y;Z9@-P4.VK&O)ZNIZ#T]+@K M(`)ENU?E^ZW_F6TD7_O3I\?6H'^+_*T>_._5A_+MEZK8_5Z<] MUDUY^@\AUDFA".]$X+T38?S#(D$G`N]7D=$]"+O&\/[C84#`K1?P_O$>++K& M\'YM/.&K.9LOW$Y.<53:04[2)GUZK,HW#U8.^%Y?4K4.V0:4^]'%L;B.][WA MAG%6(I^52JL%(UG#'/WZ%/+9X_0KS*NL8R)DEKYW999+BL0]HF:1TDWZ`^]M M&&TB>J)O(O%`.WVF$.,U4)@Z>J`!+(;;T[B/2S72X])Z$)D,IWV,D2"1KRB2 M.$6$6T2:2/#>66(&+(&A&783%*Q,Z"V.^@/OHQ)R/69DEM=&R8A&0F\D!P=( M_V$5CN^_@B'K#"9>R`/J?X0,_+U.SCDE8B>1.`GA)*2-(`Y`"AGO@(*W/DR/ M:W0A#VE\$3*K=O$&,WQ1)$8$NGB5T4Q*W"+"*2)M!/$`\M5X#Q2L>Z!U/T(F M1`^TX/MS]X/O"97^M/DE^G-W6TL;0:*&/#*,6F7LX/Z&W&Z%EI`C9!C#!;&:+,/U\!6* M!SWC80N+>\F'-8534]H(XM3Z1YQ2C?34N=9F#3*6N&,GD3@)X22DC2!.,-CV MAY/&OONU-)TM?*6OG`Z:V[)GQUB,2D;("+>,M,M0+U2Y-%A`#B^PN!IN)'RE MK>Z((81>/+#9,EC`;D(G3=Q!5C-&Z`BWCM3ZPQ8AZ0^U0Y50X^W`@HO8L=8B MC1A":`=;\T5XPPUDK&ZX941W*8N,I+U9!7/2&^J%*K[&>X&E&JFR`L,+A"P= MC)D32=R(<"/2BE`CH+\?,$+16KY8:^5`Q!#"2;&@@]!^\XD)P=G*F#0)(5@P M@_LBFM^"($'`#$)VQ.T1H2ZHLFPP'=JZP_D%2A4FAAMZZ=E!Z$:XA%YJ@<2$ M@$W9(!)"K&=K@Q"$8$MU&9J49$>,,4-5:P,S'&D3:SN:)[22)V((H0ESHW.Q MXWQ"SJN1UJ(3!#`=E-WY,=&K\FQ\]%C,T>B-#12A+DLR;HY?S(9($)J3.2$$ MY]Q$!$'FC.P$[<*3'3'&!E5[#6P8N2*P8AO:$0Z^IK>=B*#L5,OF=B>Z!.%$ M$K>*<"/2BM`4H4JP@2&.58$%&]DQC._ES%;5=48XD<2M(MR(M"+$"*Y5F&IF MA)`)[8:TK>C.$0;:MXRH@W"AJ)2O7C2/Q1UCF3W)"!GAEI%6A%KRH4*3FX5F M&.B;:`=1*PPO4,GJQ;#0["W5=$1W,8N.M"+4#%7,#1;*N,S!52M]?NA[:0=9 M^AF[D<2-"#XNO0VPRPBTCK0BU1"L\'7/#+#AO9`Z$\-X. M5\66>NE9%"&K%R-TA'HX8]_+I16A9FB%Y\C,81:@@9E.$;+$&W,GDK@1X4:D M%:&&?*@6Y5A#.C('0E8CG$C27%]O1_$7 M!!';P)-7>+JG'4_8!AZOFL=COHF#&\<%W\`3/).7?`,/\N#X]'H!^('`)7W) M_TBKE^)<>\=\#UV;39:0*BO\B0%^:,I+^_CUN6S@IP'MOP?X*4@.SX9G$X#W M9=GT']0%KC\N>?H?``#__P,`4$L#!!0`!@`(````(0"PD^Z;BP0``/L2```9 M````>&PO=V]R:W-H965T:%C MSPM_X8/29I7EX$!,NU/3P]K]BI8QBEQ_LVHGZ&=.KWSPW>$G=OVCSK/O>45A MMB%/(@-[QEX$^BT3IR#8'T4_MQGXNW8R>D@N1?,/N_Y)\^.I@71/P9$PMLS> M">4IS"C(>).I4$I9`1<`GTZ9B]*`&4G>VO_7/&M.:S><>=,H"!'@SI[RYCD7 MDJZ37GC#RO\DA#HI*3+I1$*X^FX<3CT8C+M@^+DN>!)Z>#*-Y@]<@B_MM+-# MDB;9K&IV=:#DX(+Y.1$%C):@?)L6::*?J,_F"29(B'P5*JT63`&'Y+YN<#A; M^:^0D+1CMI*)7*=GHDA%=C=$3+_0);<3]QBDAL0W0N0>+/6^8%YU7R$4S5())`:-ZN9OJJHXUZ*%#^[KAB&-:^86+-"16P;O2NVRZ/6\F8C%H) M,B8PUE>CCYBP+R[%H^B7M.>)/:DB2/>*>WWI53(FKU:"2*)/JC>+GW2K*A)Y M6$EL$,9/GQA?J,;-R16P;OB^&DC#DC$9MA)$$C?#VGT2?S:J)!3!4U//J'TY M:J.T]0B/.@(AO79-%CL=`T+L2&Q$5+>BGQC4KSF-2'8?P^=+..H8.D@N)-"L MJ76]4X9G@?9T(LHPPG.M2F)E?#'[I#B1Z"<>MR6[CZ$MC+4+V[:2EN1)'6/R MK$AL_"$U>:*9&+@4S>P#I2I;$/B\-PGC4C7U*>W]ND-6A-B1V(BH;F%>AVXM MI2IH=YPUAKP+8=!";Z1&MWT\Z.$#L2&Q'5K6@D-+6BI5=QW`5^J!B)2075SS7GN8[V%$0==$-CQ?7X?!BU+$KT;/) M75RZDGL-\FVZI/61[FA1<"=E%[&/,(&;J#\K]SBV:`FON/"FJITG8N^CW;WH M!V#KX9P'D. M/(`/C#6W`_&*W&];;?X'``#__P,`4$L#!!0`!@`(````(0#\\7@D=`4``$,6 M```8````>&PO=V]R:W-H965T&ULE%C;CJ,X$'U?:?\!\=X! M&\PE2C(::/7N2#O2:K679YHX">H01T#?_G[+E#O&II.&ER10Q\5Q74X1K[Z] MU4?GA3=M)4YKERQ\U^&G4FRKTW[M_O/WPUWB.FU7G+;%49SXVGWGK?MM\^LO MJU?1/+4'SCL'/)S:M7OHNO/2\]KRP.NB78@S/X%E)YJZZ."RV7OMN>'%ME]4 M'SWJ^Y%7%]7)10_+9HH/L=M5);\7Y7/-3QTZ:?BQZ(!_>ZC.[8>WNISBKBZ: MI^?S72GJ,[AXK(Y5]]X[=9VZ7/[8GT13/!YAWV\D+,H/W_W%R'U=E8UHQ:Y; M@#L/B8[WG'JI!YXVJVT%.Y!A=QJ^6[O?R3(/B.MM5GV`_JWX:SOX[;0'\?I; M4VW_J$XU&T0+%OL! M`;CSR-ONH9(N7:=\;CM1_X>@?D<7)U0Y@6_EA,#/B8L#M1B^+XL7-&&$15]3 M\'`[?73NBZ[8K!KQZD#)`>'V7,@")DOP+,,20'`_#PO$0Z[Y+A?U2P'=0BY? M-C1=>2\0_E)!,H3$KJ,A)B(?(P)R@7A`[\(18C2?HUQD<@S\B_M^&QE"XC[; MKU!"WIB.BT)MFB%YF,SA(0]K5"729_'?&B, M-'D`1;A*P$90A1A$(=!60TM!*BTV]0@N88QFA:Z\E%%K7(BA5"KE$; M6N/X2K3DU!NHPNV"EV"+DG:+G880AE45A8F5WGQH3V(::#4Q(I;.H27!%JW$ MBA1"D!8EL67.AV82,1UG@Q0!N9P>K!YMT=*[Q6@I#&8PH%;IY5?-)BU+V6_G MD*`:#Z4AM.52851A)5:.<\.<:JO)2DKLY,J2T]'*H=W\F<*HVDK#V*XM`Y"D M`;E&36KN=&JHT/!YT=)0][G*XRT51Z$@MR!FY&8I/1E+O2U2F<)@Y`CS=5P4 M-_2A[.%@5)C$9FF]?.>R4VIE+%,8?#!+F:WWACV,$]T@)K%9FD_&HA]JQRJA MAJ[[ECE7+K!!R#41(Y;N?]&88\$/M1`I6HC!>`646O',^R>N717/<"`H9KQF MJ3X9RWYH55"F,!B0>!0N]*"L>H2:I&9I/AF+?FBI>J8PJJQ]>(DQIT)N`DC" M-'&#&K6$7P[P$,K[=D+[5>8`".T!H#"*8DHC.Z,F(`F8!I@49PT!.AX"S!X" M"H-)HU9L<\,:Z6V9I&;-`#J>`;8@9`JC&H_H8*"0&686:-(F+2G%D_6?HG`# MN8O^,ZN0,H51?>G32#]9$4,G'X"$Z,XVJ!@,5$!Q M&PZ#P0Q2J;UB-=G-&@5T/`H&[Z2*U'`4L#`<#P/E!6N.A22D.JXFN5GC@([' M@?W?,5,8?/0=\ZEO*U]N0L(X30<*9-*;-1CH>#`PJQLSA5'T`M^NQOP&P*`F M#U"F*TF/-@<"T\J):548)10I];508+D9`)8P7[\SF=1F#00XD+-?UB)=+8H: M8M2)P2?OW\H)`CY[_\8S.SR5JGFSYSD_'ENG%,_R/(["G\;+73PKS,@RH_+4 MQKJ?PQEB?]^[&.`([USL^<^BV5>GUCGR';CT%S%(1X.'@'C1B7-_6/0H.CB\ MZW\>X+"6PZF0OP#P3HCNXT(>,UZ.?S?_`P``__\#`%!+`P04``8`"````"$` M?RT@[JT#``#M#```&````'AL+W=O\;D[^W+,/SPVM?=`N*"L7?AH%/H>:4M6T7:S\'__NKN9^)Z0N*UPS5JR M\)^(\#\LW[^;[QF_%UM"I`<>6K'PMU)VLR`0Y98T6(Q81UI863/>8`FW?!.( MCA-<::.F#J(P3(,&T]8W'F;\$A]LO:8EN67EKB&M-$XXJ;$$?K&EG7CVUI27 MN&LPO]]U-R5K.G"QHC653]JI[S7E[.NF91RO:HC[$8UQ^>Q;WYRX;VC)F6!K M.0)W@0$]C7D:3`/PM)Q7%")0:?V;/^9 MT^H;;0ED&^JD*K!B[%Y)OU;J$1@')]9WN@(_N%>1-=[5\B?;?R%TLY50[@0B M4H'-JJ=;(DK(*+@911JC9#4`P'^OH6IK0$;PH_[&S\%X%$T2E*3_1PA,.#H[ MMUCBY9RSO0=;#H!%A]4&1C/PK-(20W)?3@N$HFP^*B-M"FH!M7Q8IF@>/$#Z MRUZ2&TGF>X,DLA7%J2(^.`D`;V"$'%W/J(P<1H<@-Y),ETC%51P]L``@,<<` MKR='B2&)1Y&GL1UZ;B3C(TEB*XK7%!8:.+D<38D7/D0Y%"4=VU^<&\E$%S4. MX<]>+\ZO6UAP)B['4F('R\E';B0&"X59G#I8UCI*QX=U"RN]!DN)[4(F;B&- M!'(R)-0!+UY36&AP5(XS=ME!5$9.Y@Z1Z[.:&\E4%Q1]NG$B*,XN6W#J+7AU MEU!&#EQFERTWDD3#)6JWG>RWUQ06XO0MB,K(09PXB$8RUHCN87AYS<)"T$RO M3YVV9GLS**-]K;>;_KV<1/)G+SDR&C.;KKSZS:@ZL=7;SOU2G6* MFAU>+.90]!JS\:)^YSE1%)8(G8AL5-6PKTTQ<]G$R=5*OY4SEY26#0S'1IYJ>&\`TI2%T+KV0[-3E&T".& MIV:JS=$,I@P8`9WG!4R[^GDP+,"PV>$-^8[YAK;"J\D:7(:C#)BX&5?-C62= M'FM63,*8J2^W\+."P/P2CD"\9DP^WZB!>/BALOP'``#__P,`4$L#!!0`!@`( M````(0"6&5M%%D@``'/V```4````>&PO6Y^\7V'=(")XU"9`424F4U'9K0%-2-\>R)(M4>QN+O2A6)[GT_2C_)_O[G1$1&?A1)>Z?MN="@IUO,BHPX<;Z_ M(O++?_[A:E)\*!?5>#;][;V]G=U[13D=SD;CZ<5O[[T_?;G]Y%Y1+0?3T6`R MFY:_O7==5O?^^=E__`]?5M6RX-UI]=M[E\OE_#?W[U?#R_)J4.W,YN647\YG MBZO!DC\7%_>K^:(3>[O[^X>W+\:C*?WBN%L-5VR[N/]_7O%:CK^ M\ZH\\DP^Z/$W[/?'XM7A5V_> M'9Z^>7?\XJ0X?GU4W'_^XGY[?)CU"%0M!A-0-"I_*+XNK]OC/M_E_YX^/'CX MY*#]T]%JL>#UXN6X&C+%'\O!0F@LG@^67?"VM_?VMQ_LM><(8'Q73B;;WT]G M'Z?%23FH8)]1<5Q5JW+1?N'SU[/VHS#''V:3U70Y6%P#T`0N73,L0OVNG,\6 M2WBW.%D.EJO.\,__6':>A95L_N*(;5[,%EV,'0Z')0#P\\A!60?)[.IJQH:7 ML^'W6\7)Y6!15L6;U=)D",#:KR6>RA'^$G[OP/EY'[^V7W];+L8S(.R=X-O] MM:N?7L^[Y-W;W?ZV_<8A3D2LPZH"C-]T?AY4EZ:5AOI' M^>?5^,-@4DZ7'>K!/])K5;$HAR6#SB8=-!U//_`FS+=53,ME>Z6WBW(^&(^* M\@?4:P5321?:[HIAD-F!P=A^\72V1)!O'O-V@=)>H%4UJ78Q%XE[X7A7HK#& M0\F!]MQ>[8WP7=P$2?]O$<^OQH.S\62\')==9"<!(`Z*N%%1%,QF0VF<%Q$L:F@KE5J MTB%.RS[;8+Z:32^VE^7BJAB59Q#A,XP5^EI,4UL'#^U'6+R\.H,PP;1UV+RSF>ELNGW+AIS4-VS$=WS# M`-.2E[/)",W^>2$8EM<=$8/Q`]F,,.!C=V=W=Z^88YD0ME7Y1?%(^#$<5:YP M!ZOEY6PQ_K$VDJTF:=G+_NZLWD^8 M#C6VX$BII^7X0SFY_J)X\FAK?__QUJ/=)T;()P^W#AX]W=K;VVOMI)?L=YI] M]V#K8`_68`.:_<&3K?V]IW'V##L_:P-MACXUATM6OG#L)PO,8B\ M6V`D!S_%R+TZ/OSJ^-7QJ=Q'W\_)Z9NCKW__YM7S%^].$+YOWQ^?_K&--:FB M(E-%%XM9=:N^B@JJ/5E'D),$%QNPQ&@VF0P658$AN>W M@U;X&6_FT#W9$;!/9N8`MB7XA(B. M&&:KN"BG$&9B]F,PNAI/+8J5^6J_XF"O\\@"?5$RDQ[%+>V*_>L_:WVGGH&ADG;(]>M MW>M9O\:_ZT-#?&Z:,>Y=1J"]VE>#:CR\HRY]/IZLY,/?3?-^5XXO+AF^/2!5 M-(`FTY6YDQDQW/'*U,1ZZ-;H@1RD-4-N4!5'"L!>3F8?[Z0J;/0YHXOSQ>RJ M4/2#GH$/R=Z,/ZP)/T9_6E5+UTW+&2[;<#8=DI4PQUR$*W@J)]UBP54%=F'= M.TW]O)PSW=A4G0O5E?(8/]J#-B+1(1_&RM<59,`(=H:*<\&R/-A][^VP@ M<&`>!8_U,@]W]S:^WRS>$FH7Y=5\,KM&6Y*U&W;BNI>U!`X2'M8)8T<]'6;; MT4O112C8!'G%+-QI@^\Z0/OKD=<0+[??D<#<2H/V2XDC*F<)(;2ZC27>KM": MH#9H6+BH'4.WE^G`UK=.^Z4V;.?C*;F16]@5-AF6Y2ANA]C'\BE@ORJ)[(S' M30\)^'4*>OTD3;+]Q(G*'\K%4$F93(%8U#V;F[5O(Z`)QMJW0\S>83_2@H-K M2UIIJ\VXO;U4(M!<8C9":LZNBSZ$][TX*H<*3\QF&0(8#"9BNO:@+U97`RF08>94OMJ58VG**L[#[PAH_YZMBR+O>+O?_G7 MXH[K+*R2H.0)-NRZ>#4XFZ'SR1*4Y&Z.I^0`-U*F`44^J)C\?WXLM_[^E_^E M?ZTJ^Q<:E[!-#XY0IH/I-3]O%F/2<9Y@'$S0`&=CH!M>3F>3V<6U:5T&HJW) MZL)/Z#QQB>F6R?B\W*X&'T1A&$Z^(0++(D,)*+'A]E#1WIS1YA-_'"\OL3S5 M?&RP&]F,X<0_XROC6:82B%ZU61@#V"08H_EJ0G9:Y+XJ1T37TW+G;W\E/;W0 MXG-08:GVT6*EJ"]MP`%3RK&HKD/4N@4W(JNC<84)4S-KY^ MY60&[?K/6_ZK^E$)F]_>>WSO_K,OAR#'<'E%56E/3Q8OF"VFC`U#K>$[Q4E)=/;@0BC M8DIAP]^'H"(T%1+\%NB/:,$D8_QR<1"8N>*?.;.$9 M>*6<*OE=E.?*C_$#\X894-PSZ);#\XF&-0T#/GV`*L3(+^@!04G*#SD&""0(_!C,I+V:E0EAMQ;`AGB+& M\3`;>7;-N]4JL7A-Q(A%J3'66E'C7@34LW7I0LLEO`B#W"=K`!,P MK]DU\G6)Q50)36'_M$)6J1*SM_=@K]AX?7ST?M.D%7)KFM4$19]'-?D^(1`L M=(7#$4`69ID:"8;5I)5'.`:7T2@[AWT2X8SZIC*#(%%??__NY>%_/GZ=^/P7 M=#7^]G_6KOK+^QH;DQ7>G/M>F^)4W$,Z42Y+F.MD16T)QD5@Y!>(I\7X,BD\ M0NV8:/:(K8H_ER1^BL6X^M[>9>06E5'4UCSH&@15$TH8$#_+WE:T']"#(&Y^ M+D_R,$L0LN#&R^>'IB;H9]@7ITJDX62AIF/\QVW4*P_,70R^?14KW;P3LUQ= M'MAXOW.RL]F@+YD2`MJ2\(<$KA(`9GL&'P9XP?)H@L+5B]A0-7^\QIY9HA%> M>=!CS9;/WK9M36$A4@5_HZ/%V4/OC@CF$IMEU44?E>(585251'2XX>(,ASBP M+?-8#H!8>I9D:CQ=KLX\CU811I.L8Y#->47H;E"!,9%I:G41L/(HCU)M)]0\]/*Z$W82U+F@C7I]#MPXPVD6J% MP]#X>0M7ABAT:N9,D2DY>T7WT0:>;7I5BB2MEF`=C+!!5H*AW-\B>(CE8IB0]1<+<%"R0_GWOLA MSJ[":Y05)L#B]AL6AC?.D0$0)6K@[`/G&K*#S36$=BN./6\(C206I^S:!,)X MNT6(FDUA0FV%[1*B+POW_6JZL#%EZW`:)2&^_[`19>'DK"3JFH-(7!IX_G-6FI-F.LC2"%`\H-F]57HO+`46 M..F2D&4-P*:`O".*DK:ML&Z<>I,H08Z M1&7C2I2V,2K/F$+E8X*>B?VDYC$?OGCW1G9JK MD_BK,_P/\RCDHMWWV%5ZSNJ=KEUG&H3*^V3EF_DAU[;M4%0],FJ)P#)[@B&4 M7;B.C6F9=].W^,#D M8=$ZM4'/'`(9@'[C("WZU;4G<)0%:B=N/GF^F:)6L8"^`"5)DK]1NTV0H,02 M99F<)`FRWG5Z)?I2J^D59<%HKZ94QLSXY+FU(#'R95^?L0,T:\YP8>D:>*>@-R`X+"* M=4+:IOY=:1/2R<+3H)A;(7)_4`S)-YG_29\NJEDQ7\*-_NCL;UW\YZDN]S_< M.<7WE$N$-;<&X."PGZ.Y6Y'*SQ6T7CW,5NUU"!MK"QDQQDE(#F**/1(W1MZ-YBP,[UFR"[YT%LS@'8['C M3%&DFT"QYNSL3W"70@;P76>8P9G#:JI9<:8_V-0[A[AA\;FK#HC=X"G%K$X1X>BN_ECLA,0:P!Y M=43*XQI*"F*'XW.R^^0+K.H`<7VER?A[PF1)AL_CH7X/=%K87Q$OB5MP4LP? MAUL(`1M)&,FM%:.'UT,5EWZP7+?G!U."SI+M+B2<5JL3=Z]._O[?_O>6N%P" M;/D;+9Y+GR1`ABZPY=K2Q"G<[@D5FZL&,@$?W=@$57M929JO]*2F?V[+R4M3,HJ1+[#6)?`BPM5R7QD"G2Z%T-SDE( M$%`O2]=KI]*+^@,B#B>K$2%@'`HPY[AXZ&ZTGAN!+%D`:3VC,9C-SE4)HQ*VC%[;JT1L)-R%>5\,F&KF&R11MBTF=?V34DBUM:YI(M.+5 MB3'E^A4+ZW')OKK.I9Y0+Y:81]#Z590I$#)!X!F6%YXE7$]B&/TA4(Y_T M/A%>Z"BA>8RR32K7WG_+?VF+V!K;"RE>VZ(;2\*)BKXFV@)BVP4Q&&EN^9B" M-%,MWD@)+!DF%NJ41MO)CI&";VPGU/]E*:4&M8M@O'#*Z$).+0*T(9-]5N:< M%35\&]Y5#8\W!H2?\80$>U;G_9C0D9'*\$>?S_S7[?IO.\WHE?P^V[M\=NS& MVZ7%T.%AGJ,([T-A-5K./10<>558U.HBM))S5;>1`Z&C229Y.ON]?4F/M?M) M96%^J3=0_7>/HG'6S;.'QUS/#AY6)&'$\\Y$UC5C9* M_7NQ26'CZ,W;YYNVS/#:A.:M;I\@;U35@./-&"'74_F9-+012*3A$*A@2670FSH0Z`_YWJ1Q$M,620QTX M5G.^<)!$&IAV557-U<\8YJNC/&-ZF[YO/*FO`[K;%W>^NV/ME]ZY.]>:Z__^5_K('ANT`* ME)9*J:HM6E.B=1KJW`-\XN5:1J@I5)IHM++XU.L$2J29;(D%^PX:66URI?KR M:@$3FA_',U(*\"**CV8G!"(YFWE3<70DH\\I->T'.-P;;'`)NIV(.(+&=OKV MHOY@H^>4*(C86WIN4EP#N+'G[]&X=`U;O=.8T/B4UDKUBDMZSD*;^SBGYT=RDUJ$SDH@#CIY@']2\ MC'Y@](5>YGR6Q(6'8DBE'F!T(6Z,6/C1?CBP;F>OIT%=O'CYLG)5,EAN\WXP M'RBDTV\VK6^>=Z.,.'93N(NYFEN^-,T=S4RSCF:"TSBK'G"H()F><^E+^T?6 M,*\]?';P:.>@H%]V`GO9J.8!!!OS8#>-V/AL[^G.@_2GCN4P"UJ3#,ETN1EB M>I'K>5DNN!:"!.TKSO%["`(S@5V0:N#6(VJ!Q7TX\@;PK>+5SEN:Q],HCO-V MRH1C-2Z']N=_8'?0,S)%6YW%?X&%U[1`OT;?%H]-^]`QGS!DF+;&>;EA7Y78 M?F7BE-A*)\5K/LJ%Q.,#D0V>+-ZZOOYU\?UKH/O9%JTQH)8;`;9U%N'0Y?4; M<_]JM&0XVK33"UA#LV>HI'312D`T*HY.\WCV%HMF2)Y.5_S@U^K(!7@I/Y5[ M8;Y.'K7THIHDT"[/V[=,%!OJVXDO_?TO__WK31P;-#)-H?0N8S]#-,$CBZ)- ME69MGZX2/L0&(<"7GC70PKDZ*5?I#%.*BBR5&*7)$S3K%'W5 M@N4S]FF8ZIJ`AM^1(B&I+NJ!?F(&=JX]\=QN&:3)8&6&JL\)V+ABY6 MU*D#@U0F0`U[7JX!H?+7_9PN/\1SPR'LX025N9T-82\.501J[:?+6Z$S8B1\PFJ*ES)7?#8&*IGO*HRCYK,KKBXA2Y7$[7DO3 M4]J.S-;%?%8,"9P[/.9@'`:?/Y*B;R(<5BN!%*JY'6'>$AC<]U)49T!!H1JX5?V#U,'-9;A]IR M11O1+5#K">H0@`5BR"Y$1Q=*(I<.BAMCU_Z9(B*/R&2L(:DV_>[Y24T4]NNQ M*13G+A:!I,FU?Y`LZ=,K*6K(EPH.B/&6%48:Y=EL"]$98F;D(KG^Q#)-7&23 MZR*6NLH"0K(].;P6R:#'$\KP(A.`5N0:2=9>AU]0V!NL`JJ*(0X-71XPVL M@7*C1R^GD>-(2S:+7`A&<&U1BR$?U$A3&!\CK/S(@F*V*0C)FEL5&06,=7IME[_D47L?$VMTJV%9&+7`T!"@1WMRVIN M*84Y1/J!U(@Z5HO/]NM`(R@[B8K,&2*D>P"SDK2#7;-(KJD)Y4RP>4]'M$/` MUHJK(F.+)M*30(=5BT<)LTQE*P5A+1!O8/20$(]Z/[=P[H6-2LX+C(H5G;1H M:9U<):B>J;2>I8.8*";MH,K&F``Q.!5"5ZTJ.LHOYTP-E<[_@@F8(>H"/4XZ M,E//$@TE:)P/5``UH0+G>F--2DG(MV*ZB[I&@MUVSXA!(!"\.[D.+H.];AG=PB6[GMZ)LWYJ[=![NAQ`#[ MU6FAR/DJJ)&\7\X^2LG\2['A_RY>>D[DFKO`1(B-\8?-($B$+GA>>.4*-&LG MI[:@29!N4M>U(R2R]_"E.YLU/T0S&91",B.PL9WT=N]ABL=]@Y:6T]EJ=8OA MTIF>-_*=\#C2B#M8+B1X)#\;IQ&[6P]](^X-<\=I59VO)@+'95&651)3[TG3 M-GR[),_".>-,*F60^7-V%H^&ZU+A%?4"38@?8NET\\H;LMX1X2CPH4U">*]C M1_:J3HD4@#P`2I&A1QB472B0;FJA$//!^XBU)ACDR2 M0KT0-3,L@I]#7.NPIA1)&0KB(&(W*MH(1HT62Y#!'WVD(!RC+\2YFE[&R20L MTP-H,/J9C[/.E9.N33`:4T$-MWK_[M2KW6.`"C$*4:3[M[O98$V"K5:OLHW6 M:@\3CNP.7>PU=))\I8X<1UL(+`)Q3`"S9%HD>7TN"Z];?1@E.9X&;6_@0Q?\ MOC`SF\Q5!*H&D9LOG87I9JMVI/#NDC:(+@QZKN)J)L7>=5H(9PIWM"(LMMQ0 MELIPOS>H*A7&''&Y0A>?15FZ1?])$#XQXFV,6$?)%N#[P2O9JE[O/TL-11KG M?.,!KM<'\5`Q=FITQF+1_TE1D%()YZ:4>FXM.L*LF25@A$=H+=8S>*1,`:)U+WZ)@E,3+>Y MWZ9\W6,DE\\.+=W67XQ15D;7_@O,>*V25IJ3/;-&66C6M`.:-&D*]K+2"LJH:L2AKYJ2CR MQCQ]:!Q!PE#Z/Z).`6I5&AE:4;^%_30 MMD\.V4X[<%?;V/CO6&=_RY4026)&E+`7+"Z+$YGK481K:3&Y7#.BI2R')'H1 M1*Y"AABHN31L+DFYBA=(]^P5C+#7,"1C.B:+"E5O10!J9#3GBCL73MA(E!;! MU#_00GV3Z5[>"\0#NI?EV6*E'`%Z M%U&9&L3';]E3UEGTMUOO#/;6UKWSVN!C#I?RR/`8H739FA@-@5ZJG]?9.H>% M=']T:[)7-M`?:H?7-H>\*SC]8E-ERPE7`4Q7(5'2QK.U5AO+I$RWRQ_40P7/ MM*"%F83_*#:!93.1RIQEU["]C+^W\VBW9GSV;=>NZ\!LBT('6B'WQ7,//'DH M6=N1V#>>VXQ<(YT=J@(I:$C[8D>@84*GM)`Q)^F499W[>,ED!DC7NNM"D#M) M-7=+5^?T<@<%U0YL4$Y$P3ZX9E!O%-VL[J1;CM!NDF$*37'=1>Q%S!-Q MBH.8+PD>0$J0]9!0%=L'F`#5.HI%*%/S8I)O",Y53#(?4^CNA4>1:MPH[J@E MS.+?5$/=_;O!D\JV,K(23%:)"Q(IIQH MLR#$/LF!EZ!>X%$''2>K*^3/8N:3["Z`\`$(:;6WU*^Y_:K3,'7W-V]KFGI@ M;0MWG\_3$+';9?E,M_&:$_16V\3$2"TU!RDEVQ_8G<(TA$7>8:+]X@;AY5Y! MX/`9%%F36XKXQKYVX<9<'P]1/EEFCFD7(Z.(N3OZ>X7I8Y'@(MF#2"!M`JOWJK`VT;R6]S:U.2UV!)_,E@7Q)!6IOE]:`;\U.&&R` MXEJP)';C2EUX)I8::FW#(X#PGE-C\O/9;,E0+/!2XIU;AJSF77-K0K@$W;C$M'9LQ<](&;1#Z$-LS/]#,:K<+E%/G4?W1WY2_8P-59^Q?HWWH6&HH>;%D[4:T2HIX-=D2] MF,5A]C-E8[0'7Y?A![\A-1C]6Z4%%C+\YRU"VU^+4N_X5AR1O/%=S!O#]4Q, MR#NF3.L%1Y'2;ZRUWE(6_!.0F/,7XCCT[[=$"FA..+;;Q/1M;U1\'&[2QKC$ MPB"JDZ6E-@$CF'2<;8)S>$A?'Y$'Z`ZC/%H[XL3?TMB(+A=&J@#L-M4S<",< M99QZ640)DOVA>;R`H.7,N;#%;'[OS98$V84EVV,RN/XOG"0.4X&1D:7-@INL MZQOXP]J7JP1_W;<6$XO")&Z>Y_M"7ZQ&R[%1*H`)8K55C\/:8HPC0Q$( M]C[DY&3:559S16R\"TGR.I.CE#PS:C84X1D1F[#(UB@+8:PFN(S"@3%3.YQI MBI094MY?:K>OCUE^+<*0.0 MH>SJ/BZK"AO>_<3UN#\:_HQ-8+!US,CA@1GF'+$=>L.*>][7.QBJFCN"D36M MRQ&&A>4:;.H0Q(3HIN2P*DQO',D>^F#IN'*DX)->K(=R.N5^"IL:.8#E40?ZK/HZ9N,?FDE_84>4Q0;1M@-Z M(NP31Z@&E)D6G=LQ=;BM@R,4JGVX[$0)OS3#.YP._#*\".-[-PNU?WD(L"&[ M9V(<[N]7=3N?A9ZT,$NX?\*ZQL3K=IJ+(\(2]HV]3785'15<"?5[Q*YQL$U< MK3/$,"5*S0[+`Q4/?GV+,&O/6>M+:%`H6IJN?#O\I$A ME`(VV11'HI=;2/*T;`VD;42>8XA;GSI'V^TDQ&>M$T"`1F" MI-BFZK6:RWA&P$XK&Q`1Z^;BXWL=(&=$Z%"48,._(LC31TTZX-6`4%G8E/'_ M;&]G+V8#(K1:8#OZ#,$4&G#"T)W##=TORC?^TNS&4CQ(35;-S^6YG@"^&/4( MBWK5"9DS8=QB[+ZD+H1&/5)8LQ8`I4L>S]C2-SY?UKC:W;5 M/4%ZF"5\J0G0/(CZD\D[XUABT`?I!&A(]WCW&HM=AY0@?,&=)A>6:(9-4/;F MJM4L$OL\5=WJ`1*!`!+)(+D91.3?'E-O0\WUI.\[6.^\L(6PZML\R=!;T4LH MZC->Z$;23':W)B[=2/Z.Z*5*1MURB?.#%X@UDMU*EV])>\_X\*"=;3/58J<( MJBR@IAZ%$9>=DI$1QO`]60$F.1__@(;EM7@5B_EET40$`D8[S?ATSX<:2*H5 MDW;8Z`T**.P:J6/#1#I^R)>58&ZM;UD8CPIH\<%&XC;3])A&SA8BW'N!S7C6 MO9JQX:"6^H:GRIYKSB77GA,V7%[S22FC/1(385&':H M-\*7_*4&LGDK^,S.IA8B0+@82+.BDXQ]9SX=],=GUWD?5U8P6_#H:#;SI$&\ MN2""W,K*)U+4+*WWY`?T$M]Y1C2'I3-Y3MR6;'1.+2_:CU2/%:Y MF^V3%X3(R#VS>*("!:58R<^>>--B1UV]#;K<@8P*VB+I<.S2K"N9$(]3@DS2 M+$B?P$5Y-AA^CTH&59:'5JS0JY_68*[M#?_M_S:?*,?^[*A>R7_-,GN_1'9- M],U@B$K=-PS!Y&G+`CEG$:F2JK"HAUSEDNN+]5G4V'CAZ2*XWJSC6B:U)7LF M@GM:S>X6&)/#PJ3!%';6_[SX';[YO`C?-Y-OF']E"6OBT4846(A6%PP2I!DC MRAORY*MJ#>@KLY^F&-9)F=>&T=&L4D$Y756+C_J3G%?S(QR MNM):8:3?!;)&C9LR"VK5B!$ALPA42D`_]O,C*07]&"FDO9SR-ZJ1OF2I50M3 M>EDY8WPI\223NC`#&VJ.#FOW\4&0/OBWT>W:7T4ZL9F29`G$7X7]6W`8^]OQ M#+>RL;&A;[\!.68Z\8>#.-AE!7@UX2!^\6$V67%"$+7555A)ZMH8.Z"JF'+CU9NWFW78FCG47?SV;=7C=OE12*V7?]@X$]O% M)>*NX.&K8.C,8/O-V^;-8OO6`ZN?H#ZIM"Q+9Z@.]AI87'4;1EH\)1X_,2 MG,^?/Z1*KK<:>O7,7[]=A%]2CBR]H$\HA@1W3,`Q/"3`:L7E`.9EL+GP2 MIMV#^@(OMKY:QSQ1W!_R4BX845'-YQ,E;I[)QV>7PZ([3FU^4,0\7O-`F MA=X[)T'"1RI_P[<>-A."VXWR8@RARI+ER:Q.A0L58,]/.%/B0#M8%T'\ MV1:L_Q!/VB4S]CPAS:]W%&.MW:Z7_*2:W-DQ!JO1*]K%.EXGH/B*/,[0JDMD MH`Q17FJ1T)`]F'-AEKEU(X"S!F6%&38T*+6/X7/5?`L%E*$'ZYNZE7W`\E;@ M3W%.UN4L23-EZ0J*S3T/W\A.TT,``9`F:`-T`4"XRJ%-#(E2G)Q2VQC_U$F6 MM7C>#,/+`%6XM`+)MJZN1A[2B*,RNL?-]6;C+EM-8SE$UIVESKSD<<0>-;.$ MH>74F[?#QWEMN=1#!8JV#C+ MGHC%?I7+>)[ID[5F2-`-?.X%3,&5QGL(SEIN1N7Y#7WD)6?Z&#F#0R.%/LY2 M?]E84F+M1U8BSODD<<5PPB10B2G@#WPI76@E^Q83[&I*0`+CM7K*T]:?%4=R MM$:$U"MN>I+D1^5S&BB"?V,%#);*65?#$SBWK=11&+F4-]2$E![FRBM`*FK( M=-%ZK(O[7$J\&4/V-&+?A_U,V+5@5`)W+J'(0-4*(>BCB*R$9\_')"2MZ["7 MA$?@>\W]J9!@:>\SZT$/KJLT/$HUM.BA.]6]+DX,Y(WH48@%;+?RI_E"0CA3 M40=5T(.[H&Q"Y[O4&Q8&<=$:B*@VV^[&J36^?>,-;R^D3]LCHGIM/S^A4>ZF M]UX3A6*C9XL.1*^CB0*9]-_0I-Y=];/V&":)\G5GA;VMAP][ MP-EZ^#1\G[EV_3;VMI[L[W9FV-]Z]*0S-F'7..%6?NE,N@<^'G?7VMO;VMO? MZXS>?[#U=*\'>P^VGG0W][R>MEDUKRI_I3@CA9WW#`1M1S;_'EX]5_\@_,_R-O6(SY\W!MBK(WRB(J M0,.NA6(8G3%9K4G.C3=O6/Q-T5!%?37`B#V]CN,,R@RIF!]G]0J.%57/8'`M M-8%6J&68W56TA2ZZ^>6\]*[Q"S[`"J.I32;4LIDY)D\M#RJ;+7*'[A,Z-\A8 MVT>1T\&QN(.P)W.W+_@`NB6W6=Y*T%GB*9X3:/`H7#VF?9Y6]]\='BJ+JG(K M75I(&8:&<,8ZP/`,Y><(*%W#1.>E^?J*K](`4_HK.166G#FG7D0`;PWEM<$4Q(W>`Q^`VIPWQ279IV'(D0,VI2<$6(D(]1,.E.TI]TY5,X'-"=),80.2P%$.HE[ MG&-R&%H.5U?FRV,)(K"BN1]D#BW`[IT:N-KWM;H4XWUB`[_'/!^O$P=XY]1L M,5XP588(@-%?"=BP^WK#[L7@S_7ZA"]U/.$/=C"1F5XF-*D4%DSZ[=D6Y6]T2'&JT M)MZ,3E,WYF%-:S&%\VTIY<<@5JR+A3GFL:)A%LC+97R]58QI3'H7#EW"=+T66BPX_JWEJ'?_@Y_*C M=UM%]R2'JOZET;.L8VM5ZK>%WO&@M^NZ!96QM:ZRU%9EK6, MITH]\%*74DC?B6<<)Y&TQ,<='\`7\,N\CQV-[DC`D=,B+F_L*067@QWT2JH= MPV[QX(&.6L7NW#\WP!;?Q8O%C/?,I&00;O'-M]8^G=TD-ZKX`L44->2;AQ#Q MA'-@@C2H!E5CPKEHHVZ/S6NXVP)DO[@2SE63=;FUQP9N[W^\W_^X$_,> MFMQU8O6__^5?VQ,<-0_./B>"Q_"V1]$$C$OBL[9_>Q6:]1'LSH*)-H$TM./" MX5#&[4]B)?C#]_T@\F,BT8U$R4I%-Z6/.W#5I"J^J6V%(ICV[HX\K#NQL.Z[ M>.G%>_5PMX?F!WH;(N8JK3U\(^RXD_3X:D"W,4XKS-DY[]>>Y,4/=L>(N5@Q MW]4>L_'@\:/.,V4G#MI/LY4;X?`-X]H0=CAT8W_KX,E=5^HPLA@H5RVYS8JL M8G8;2R1E>"Y7JRMI0?_@F5N)PX@9T55K@UY6DZK7S,VF#)P'+UUY0;4Q<71, M9"*S/K6&SG9//KLX@-)7-,YJ#]S6QSK9("^5F&I2;VJ4EH-B[D!HDSV-"=IK MN^8?Q84+#2:"%PT#"?)FD'DP-\'=C4,]9-^?&/Q M=5^+6FVU!SP2C^X54J*25Y360VY4\-F1EC'W,*"/Y9_@9)%+#20+_NJJ?`M6W-GG+`<5LQ<>0NBPT#F/R7%.PIY+&\'YM;0YR.;W"2W43055QMX<<*!`)*7R:]G5SJCH'^?=W. M](>9:C:2G/:LC_;_R?S+@[U_:O]T$'YZ?-#YZ45L`CV50Z3DN'W-I*-2__;7 MW1W_6L/>3D<7Z4>/K_9W.MG2=_W"V(9Q=V?WB6^`XQP/.W#F/S_L_IR9(V&4 M`SG;MJ'G?!"EO=+ALGE6PY-=*`GK!R=:JS5@$*'Z@A7_#@C!'Q?[9E=>H+V( MHM`MDE2JS5SX;M(-58?Q9L3^J4 M;8RQ?B*"DJZ-VY8ZD*3&.X9#YDY-2W9WE7\@05$Q@^9(J+24&2*'@'".4X@3 M3AT0:$H$Y`-%+1I]GUXE@5X)GU238ZII_9@JM6^_.4@+D$FTKFF+1/^T&EU8 M[,M:(9MGM#5S`FPZ4&#G/"W,,)VK#^Y:BW81$67"73-3&X]9D2I%0^NO4?`L M80B>2/32A6\9!AWWA>^DN\D"^>X";#$'&!<.832'0/KVW(WCTRQI>'K MYX%<8G=TO^R\1W?>!R3NNWL@DOMDZU8#'UAQ1WG'/7XW^)CPTU'GI+S&].6/ M"LO%)OT@EL?]Z`R/^[8%=9QQW:(>8W#N`Q:WL_TV=1O^!F@PCH]6:(Q#``*G M1.6>6'9]!IM%_U!.6CB&CV$/IQ4PS$@C*2IS\_`@]K@*R`NHJ=)R%AQR=HWL MR(722LU.@`$KI[V%,@B,J8R9>Z:-22)3-\\W*`G+0=P:]5IFGRMD'KE9ZQCN M8SD\?N&C)7#@F8;?;@!545<@C^HO'@0T>Y]Y[&R![SQI5=I'H=%,S)/1 M9MW9J8`S)+0)?9#GIMF2^/Q8+CCL'E*=WK;%?N(661;L)BU@!P/%.%QR8`K) M]+C5XS57>HOIQ.DWW9'@GKQH^3>P!P>`Z+*$K'*S MU^U8T\EA]0\-F6H_J]F\V6>7M0S677.\G>[S-$,1`G$I2?V$/M;VZYDLOLQH M%`C;PY!1'J,Z$/[;;&EKY$K*.,O/9G+QY&[R*VP@O/LHN@.M7BL,7U0OYA6; M`HI8-C-IB\>&VG3)VHE,7N62%=`C>O)X\0#M;91'G"Q53K^UHQ1NTR0O[<`C-UUF MSYKK-[,DKB+WXB;2RS:O^%8%T'H8!<(\(:F:`]IU$_I";A9@TV.-F=E`^#CT M*\LVP*\^WS`"(IE8\Z_".CVZYF_9`C9#;X#OD'67V6D02!.D_)M02:YXG[3I MQZ3&P7'"(AO%?X.EADR'*D-H0$GX0:GF1EX/>UX$8`WOBKF5PO3W:"E_#=\B M04-?G7^!Y4.BBS&/\-[5W19.[$IT2K*#"52GW8(NVM!46&(H10D9?*36KZB_ M"=!^=WF-U#K)B]X\:I7(;33)]XM'(M$:/T-YKV&VI(S)CPZ*"C=E`W,RM>>^ MT&*0J[13I]-BD4U2Y\SD0(*61(9J]&6A8.&6_7C(^O2Q16.:[DW"B7(NR\^K M7J#$%:ED]Z.=ILR<'UL_XV)F"D0JYPD4?]9"2Y-C!H<$Z>&4H-TY0K@:VH^> MA/[7BMXDZ(78).U;P%G^M;5$:UQ"3Q2WOL5D+)E*.B%4FOTAQ1HY)Z7/3B76 M-O*_C7S2Y5&:/)>1UC]T,^HV,83M[!(7K>Q`UB(PN&HNDVQ&/W_`15,Q[O.28;!NZ74^I2OR12P:\O?CT*JL/S]E'FJ M\L$Y"KL83]4Z0$CX*=:VIZ MCDSMC(3!)VFFR,"S@P:7-V!CL:%`I]"?%_];#`8>C"Z2(^7G,B.J<49`SE"M0\;J<76!7[+F+3O"$1^[38]@K\K];? M>?O;^2SA*+[\=O8X=8)J1MWL9L=/PY,>87,+2K_[VAIEOO[X1/6 MCYX`#,-;KJ-\AM4:3_>JO-D&Z@N^>5+]G%/,X\-]@T-`4+PW+_`0TL'D1-6U M6,G"@$R,Z^T$:([$_`L=0IB[ZA$&/U`;++&5[/N;CVKZXC@AVXIWD#JX7@.% M0@-*G9G\XT2;&.8U_&LI[<'4J0!YRBLC0XA`K$PY&(J%MM5F2TDF1MKX(\WS M"SHH!#8')<2K_`3UB]YEP26F1X%3PQJ;)1RT->O?[+M?(IJ]8C&;6.H`:XH? MO+.[)0(TU!*)W0#K4R^1>+3K??<%LR;>`,;7^("B6CD%2)Z^XR]IO9IO_/TM MKD'EM09C%.!'R`BPC9CSD,Z@9KSZHO(_0L\YO*,97@/@-UR1)5%:<"/((V$]O-#86KHZ09]F< MHD-$DH!^.`T\=9N1VQGS1^3_KY7"^1[DCNDI$X/4#IZ`=G#8I$MM;A/#!7)_S%U/C25@,ZG/D M1JI@+E7S!NU+U9L0\@K-]Q#GR+MG<\_C\^0?K3_`?-P>30\)0AZ,Z$"`([,4 MF=UWGN:;GDZ^2$PC>AI&PUEZ)]Y;<2.7RER<(S1Q(*^X!8H+2\JM2PW=\MLJ MV?\/X?/EC^&<)G-[]/OWN][R>;A_`#5G4+3Q8[RDD*6N!8OPL-"P=#L:>2HX MB=(OWBQJ+P]B$E8N%T$A(FX5<'HF@6P%J_Y=`&7J#LLO6X!/@U./K&$R34M( M83G:^6FX>7Z/(<:L[6>2];G'P.7:D/)A.DZZ?%/`3:Q=@L6U)O!S2[$]YSBD M\-9`?L3.I8.TDHII?/L%%C%F`AHAJ\7@%52IM%.OR#0H6J:P08G5@(/@LZ)W M."+I=S$5@QUK'@#K;>P"!IN3!'U?T/KP@LX)#%UA+L`RI%."Z0F-U_*DVT[! M7J#%'9I-P#(EFH)6MF#IVFH_`YF)5:*QR$[(RL&B_QDLN8Q`4XF"-;(V+,>^ M1J.C*OI-L$`5JN5U62%,*T2:$?[2"TOL?X<^8>_04,)\HS^6[E)1/;0WN?#9O?= MCY\DH:)O[*]88:777OQ2F5]BI%4C3;YXJ]NPJV$J&.ERQB#?TQ*K6S0<6.,2 MG`K8>JNQ3CSE/O(P([!805$DY8>X-KX]-Y"[C6HLPX=#;]\D1$'TK=[ M)$W0HE8Q&HZ[*8<)NURFY1X1!M%+V:-6`@>?UPW!8#7A&'$7[6!;N9;<6.B= MF_$6+0@3&SD]KUFZJ1S^V)P0<\;2-_V4DTGC(2_'4#K-LC1Z]V&"<,MZ6\7O M+\9/4"CDIE3['+-;=*9)W MJ/<^U*L_ONHV?E@>=H\J*0%DT^-N;T>\YJH<)G[4.+0%^;HW)])]]I_ERF#< MHW?!KHQ8(=09[P=?N0-@S_6.MI_\)*V]N?0B$/.#`F[*&CHAC*00WBB95S'[!?$YGXM69D MB)@XD\:&0POPU(N=8(__)WW56&Z`4!2<^HH%+-="EUW=-Y<$?&N%YG[G;'T, M^TQ&Z!M`O'FUVK@'&Z3[=!4LG8`WO(!'Y.Z0""EU&((!D898[* M'#M8L4W.F_T+:O]W-Q7K)/UJ!AP2>$+`"'TI#4)CKKJ'WL`.#^_3Q6:(9#(@ M3O3#+"_R@/(J^8$9&(,[\;BC*[%Y)"$-4[NS4G.(!PDCA;8&R M#XHHC01:L!&A53&8Q9N`BX;0OG1)H+*/EY-P9:B^(#G*"U/9!T<=O$0;$YV_ M8D?>=&NC`WBH9O*;DVC7_0>7,=E"^M1&9+;H6((?DDA4]&>E/`:XWGE8L[IAP`=U5#>&6!+,YMM7G]I]SXO M[.7P_H2=(70`0&*;I]KHS M&*_0:]#]N"QP5!2'E_HD1R*$DS)U,=@S(\4M#0VF)G7/P%PD_5-"[&'C2N?] MJGO#Y3)>SO56UN*WL=5"3/73WP"D\_.JU`?)TXBWT31J/S>)G&GP0XNNUVDC MH23Z(=0PZGL`)'-$[5\C<^5/H*KM1*O:CEIM04\03J/#9>^7.X\[V@Q=0,10 M2A5MZ*,A#0JB/J`:0>+QVC4I+6\HD@'GKUDN+A;F1\!K8!$!,5[M;[&MT=4. MW9EUG]CQZORNB@KX@[@`3Q_@(#"S'7M8^2BQU9:(=R/)W^ MF^;LB]VP'UP6R.>Z]F-)U&OL)**.[W&W':KXRN]KX\!B\JK0`=,I>YP)DU#3 M.?#*R\OW8F=EM7OE,FS7Y>]G65$D`HN`NJ%$\1:-LB2E!2\;AC8,S:)8L1S' MUAV+QC")\<# M+:]#6`CIE%!YUUR8CYU$8=BZ*^@EQYJ"!XTMO(*6;PJD<7S)I!GDS%(\Y#(HK6+"%J$X"(_SNT(9/I M%V__O;V]<_#688?ZP^%;QVL]%/8PG2T%(?J$L!7^J$C$=.\/2^D6+C&=;0*E M$Y1B*7S$1W8DGH#68)=!A,@QM-,[9K`=0.X*@-PC,"XA]C\`?"`H\@$M4B:O M^A]]@:T7\%,SSN#8C5F^_#)KA#^TLV6)KFV?`P#4`CB3F(>2?BGUR=S#3R\+ MU#($:`C"3%F\59!8^D(_%&.OC"^'&I4AG:J&T,P$WY@I6F7ZZ<9\ED4`GXQZ M0=7\/:"3L7W`:BI`**-O&/ILB68-S(V)X1$P6;"^'8`"1Q,W8(7+<,`1\"D5 M\K7J8*_`.T?6E&C0(7O"@29T%Q*8B9^ADK,FX4T:;_]EO;YY_E\```#__P,` M4$L#!!0`!@`(````(0"$P;L:;0X``%^.```-````>&PO`F01:(31V4;7DM+\8:,QE@,EED)DB`;!!0$F5SAX="4K/V M!OGOJ6I>U>+1S4M4@HV1'8E25[UZ=71UDR+OOGUQ[-$7TP\LSUTJD\NQ,C+= MC;>UW*>E\I=/^L6-,@I"P]T:MN>:2^75#)1O[W_YB[L@?+7-C\^F&8Y`A!LL ME>X.W"2Q"G>KN=M3'S*!?J0@5)]W?NP=&=,!AMO(,;+I5I>F@4??)N MNU2NE%%D\LK;`HC?_.O@A=_\*OKGJ]]]]=7XGU]_\_<_F]M_?/_;_&???ZVH MB1HB$WQ0+?-R7"D6/HXDJ[$%]W<[SR6&S($F9.OVL^O]Z.KX&00#F(=?N[\+ M?AI],6PX,D%X&\_V_%$(7@;[V!'7<,SH&RO#MM:^A5_;&8YEOT:'IWB`!4;\ M/<<"-^%!-=)P6CUK1)/8=(,P.)MF>(3:Y(!)!AZLMLGXH<`F3M=7T\D9YK='Y_YG#QU[-)J.M`X[UG?6E> M"?5\?'76GHU,TQ8G*MO/AA]`E\\Z0-;(<3U;SB92Z[M-*:8V`(26;:<]^&R. M72H^A175BYH&EJ]#W!MY]\XW4R99V:W(#`LZTM MHGA:L;U8+&XF5SCZ_F4\64PW^SRI9_PBZ MYA06\P-[E2`8R*L$P4!>98LIM8/*'V<*["L-[%6"8""O$@0#>94UHQUZ]7IP MKQ($`WF5(!C(JVP+L$.OPG[MP+E*$`SD58)@(*]VUGS&%7@QN%<)@H&\2A"< MVJO)LFKU^*BS#:%\9]99?QSKPB:^OBZV:H1UZMKSMW!B+3E;--%@C1@=N[^S MS5T(*U+?>GK&?T-O#_]=>V$(IZ'N[[:6\>2YA@TOU61$\F_%2#A1!^?DEDKX M;&T^@S)NTR3B)E+1EX:TZFFXFM"NM?&U-I]>10NVCE0[YM8Z.'GK4MV%<0DT M(K=BPPF';JHD#H=L+U)%+\3NDQS!7,T\+3D`8B()"6Y`,D1 MW]S7F\$`1=%`@H=4^+@\X9F9Z-R,=/3RUN;4'%G2E1Y9*PBW`*W>I-A`A^R0 M*A_&TS7,_AO3MC_B?/RW7=H"P*[:_=W+CES9`9?;X*4/>.$(OH2MZ_AE--U' M;\#XLD'3TD$C8[^W7S\-?JU$/_`DS4<;_;#O5.A$X&50_1!< MTOJ[C`>\&BH.:G`!#>HJ/%TB@-V%!`$X80@$>/56S`&$YQ`(8-66((``S1`` MG(JH:),'$U+-(`8RE:"_+Y508Q(K.94]6EE6?D%_A94Z5WY;T4SJ+01Z1C.\ MJ0#02F59B1VJQ!"W0Z9E%,";"@ITF'6[F?(F935_,$)(T04,&2-0!JH8Z2XJ M2.NQ#2%!@*1H:`L`9!`)QQ&2@^7=",0PT`]-H&&@*IA"X.?B$ M.4$]P^%@H>2]?^QLUYVPIW42=FJ"60EPZ/E4[1T!&>P MQ1192^,/YHQD\W3T[/G63[#*Q!_.;6`WU?05_*%E:&WHD1]]8__)?(&U:'3> MZ677RD`!IDP_[*TKHSK*.^>G!18)3PN($%J.&RO"C?FCP.`WMX4!(L3`=A:& M!H%\:=N*8-%BB2/?OE7-']<`A":_=*>X+:34M=<))1`9D(<9!O"Z1HZ8= MNE[)8M>!U6PT2/+US58#>+W25;LZ]4U0?4#'6XWG6I0$..4RKVE1XI3CZIO/E7RQ&7SZ$`&LX*]1[9'ELRP(!'CK1T&O5F`HQ*%, MHX*+Y(*"?[*H*&-9`/!\69["[-GSIA;M)--E=DDI*_8_'%VS3C'^O0'?4I:6 M):I8V/#\O#>DX`5&A;%0T,9S9:Y124@VS%KL>9(2P84(7C[(QX@TPO-"ZA\N=R2^SC7A4O#RLXJH/Y1B-[]`J$^O=,-`IZ5.Z"[B2FBF3RL+C*\Q79"69RTMS(+=`[C#"NL(HX$W: MIW2&;L@CS0-(SBS4!!@;Y$&"4#B'4#]3?-RL/"`^J7DCAT]FVJB5,4(>I7#F M2XH,T%8A*@1.`@!?=EP)A>JE>.O=OZ(2>()M#;[><2V`:#E#7'@FZR[V*)SJ M*PC+)I6QAI'5<(.J]*KB3A MMI)9@E6.B<`X>[+5-)(]L"7^GDG6_'^+FF5>/5`C!Q+L=G'F\CA))5 M5L;#^5.D'3!8'U\I8;D%:G/"1)/U*3!P7:$(T$G2LD[-*@64C^L.HB@I''40 MEOD0CO.[O%(=UMD@$$9*G[UXHSZ3AHJ@J^-#I4'_%I6;BG)=8_E%`D@$NY]I M&1O)9-ON;)K*"FZ%H4F-J.[.SBH0N`#N&7=29^K2C&7WYV#!6P9W4#42)]#I MIEGA`*]4M-"E,T_F_2(HM?*LY[WIXX);A+<&=5RJG1-T\6]`3[')U/(&+*40 M>VW:&@0SK69D&J[.IN)MB=(S& M0W"K(7+C=OZV[>F-B4;X(-VE,AW_>G0Q>K-!->G/I3#]U@?+AJ<_X2E4O&G4 M!G[G[SD/T<'X1]M5LM)5&MZG@I3O)$8P04];EU9H#Z2-0-K MB2RXIWUM67!SMU@6WN8MPZ5!E-3%!4-B63SW2ZN#(_@E3"EP8?U)65 M^9&O$YIDG:`V9G[DN9]+2 M41Y)R?S%Q[[ M?QG@?SJ$A$8<183@B2(9(9^L$!ZD%GN3SV&$)27"@YMDIB*.*HJDC+\:OHO9 MPJ7N48R66)3=*>GM=M;&5(.]#T4E>#;-T+'5Z7B\4!>J8["G MN8&0V\"&;_FQL3'XC]FQI4+>1/#9`]\`-MPB*S%"#?"I5Q]1R?U_`0``__\# M`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P```'AL+W1H96UE+W1H96UE M,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM31O$;H<>:9F66%.B0-)) M?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\ M_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ( M[]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\! MW8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6 M-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1 M+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P M]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS) MBZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F> M"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8 M>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20 M$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3 M>H<] M,9&R;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_ MD%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G? MP9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW M"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8T MO;>$#6C\S210*:D M`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5- MX*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY M"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R M<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]3 M1>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_ M((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%B MC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL M,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q; MK:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$# M47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;, M9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TP MP:&PO=V]R:W-H965T&ULE)=1CZ)($,??+[GO M0'A?H%'0,>)F9#)WF]PEE[O=N^<66B4#-$>WX\RWWRH:@6[4X(N*_OC7OZNK MFG+]]:/(K7=6BXR7D4T/[ZY>E;0E)RY3FO&21_UX75,)E?7!%53.:-C<5 MN>M[7N@6-"MMI;"JIVCP_3Y+V`M/3@4KI1*I64XE^!?'K!(7M2*9(E?0^NU4 M?4EX48'$+LLS^=F(VE:1K+X=2E[370[K_B!SFERTFXN1?)$E-1=\+QV0=O>.LW^,J#(*(!,(CX_Q+FV<LKEW_S\.\L.1PF1`D@#9F.5?KXPD<`V0"S'#U`UX3E(P*M5 M9%A/D$;ZH=QEJ3Q&]BQT@H4W(X!;.R;D:X:2MI6#^W M(C-G&03S<+F8KC)K5>"]52'$F?O!8CG!BZO6U:3LA4JZ6=?\;$'!@G-142Q_ ML@+EZWF!A"#[C'!D+V#G(EO`YKQOO+7[#NE/6F*K"'CM"*(3\87`'00/G1%( MSG0C"*,1W#!TME5?#./Z1MPQ,>L(S0AD86@$*V8&Q7H_,W@3<(-USSMUY5`1 M\P$1Z$1\C]`<@LC0X7UG"$&L.YL MJALC-[P]/>(-8<-;+ZM:5"&:-Z-7 MXC'2BVB=0.#(F)ZXAC;<&4VX;1G-GM$P\17FEC\\AP<;.^V8(^KT'IXFQ&C) M;5/6U2-`\0I:![X4AZ3.MYQ'/[8'/^X<=4:?\T)]O=F[+#/WY9NM> M8?HUZ/[PU)[N3YWQFC^S>\GX.>";[7N%N>4/UOF`/Z3U.O3-#B:*T?+7!V\W M>,STB)Z_AQX9.+J9_OK"45W<,IH_HY?B*\PM?P\].&#^'?DS>G3;,F%3_'.R M-`L4AV@4&2[`-*=F7S7(%:P^L)CEN;`2?L)9EH!T]VTWG+=3<_<#C+D5/;`_ M:7W(2F'E;`^W>@Y.I+4:E-6%Y%4S)NZXA`&W^7B$?T$,QB[/`7C/N;Q&ULK)K;)^P.8,E60K8)OS ML?9P37 M[\EK&*8EB'!*[LNO:7KN5:O)[C4\;I-*?`Y/<.4YOARW*?QY>:DFYTNXW6=. MQT.UYCBMZG$;GSN&IU0&N82';0K]3UZC.N-WXYQ9?MTP'R_NDVMCN,G?W!PA^C MW25.XN>T`N&JLJ,\YVZU6X5(#W?["#(0PUZZA,_WY4>WMZG5RM6'NVR`_H[" M]\3X7DI>X_?A)=K/HE,(HPTZ"06>XOB[,!WO!0+G*O,.,@56E](^?-Z^'=)- M_#X*HY?7%.1N0D8BL=[^EQ M[=/7^W*]56FVG;H+YJ6G,$F#2(0LEW9O21H?_Y%&K@HE@]14$/C$((U*K=-T MFRT1Y8IG0WG"I_+LZ-:O^$'4K-OPJ?P@PA7[EK*'S[P=M^%\UCU8)5DS\*G< M(,4KS725/7S>U"T71TY\N:D%MZZ:$%^41[/2J#7;G4RQ*YUS<1#$E]L::V-C M\.5:0E4YJ[))ZFW3[9.Z]Q5?\#"V"F;/K=Q;8L!6HA5(,)Z%/@4!!0,*1A1 M,*9@0L&4@AD%/`I^"@((A!2,*QA1,*)A2,*-@3L&"@B4%*PK6%&P,8`D"*YL)4H<[0_&> MCFM$>,'N;:X1Q[$'O"]M&N9":MHF@]PD%X41GY&`D2$C(T;&C$P8F3(R8V3. MR(*1)2,K1M:,;$QB:02W&Z:1N.]^<6,386!OA&:,G:UK2]*71E=5RTURU1CQ M&0D8&3(R8F3,R(21*2,S1N:,+!A9,K)B9,W(QB26:B"0I=KU%26L,W%P4/N2 M-.%#R^74;;D&N1&Z>8SXC`2,#!D9,3)F9,+(E)$9(W-&%HPL&5DQLF9D8Q)+ M"RA"OJ"%L+:UD`16!0[S@!&/$9^1@)$A(R-&QHQ,&)DR,F-DSLB"D24C*T;6 MC&Q,8@T\[/Y?&'AA;0^\)-F9)BNC!A1X$C2@WLN7B=MNV,O$SXU0O\`D5H\A MD-5C6456VC"WTM=H][T?0SM0WA0LYSI4B[*&%$'L1"0Q$J'`DZ!5RTK.FN/2 M'.3U1CX%`^J@]P8K(3@?7$WHS_C\44)PH,*,1!0[(TET?P82Z!0]"GP*`@-8 M?7:A`K$Z73#:1NYF5[:7LXZF12DLO?597G0SN0. MJ$?%=:Q_.H2=I:B2S1/+)UG*HAINX#B+^ZY"#@RDD26MLY195XOEH:?HNN'9 M(@M'F4%%B&T&'WBVA"RK1!UM!] MV5)4>K;-J5!SR3#YRM$2]!-'6T]1[YAZ_M=3MJR;1'=TFG5ZAG#SZDI;LT.'672#@0!Q58EU#'HA8>1SY'`4=#CD8.(NEE8^(IX@K MYI4A'JE`?<,,QR0H8,,"-BI@XP(V068J2/L[4T;73U)S;86]77"TY&C%T9JC MC4)%"HJSP@<*WGXP@\!9E6C6T`I9:DIFJHE6[8_.9Q@:)B$.38!,#_Q0(1UZ MA$;@**I4./J1!3XV+##T!)D./66A9XHT'8Q,9M]<&V#@!0^\9(%7VJ^XRVMM M@($W5F!K=8I]\:JVMYU1LS#V,1"1J(/R15AW]8%,WAB5F7$(\!"9CFZ;EM-H MU9(#W"5U>H#7]9P8(M('Y1&BJVV-T4JU11^X3_"Z;FN*2+#UKRYXW]`!M[.JW[PDU?JY& M9)_"7'K#5F;&8DX:(]+%[A$@''B-2@1TB MT@2OZ\!31#KP#)$./$'T`UK5X+(<[Q!=D5Z=\G40?UG]V=Q!EN;%;D.UXH,RLW4)ZUDW' M@MU"6U@RC M7,UKKJQ:XG$A/&9I=$C=M\#(NK$E(IW8ZJ;&UF@E$^NVB#KB#1@AHDQ,SB'Y M1HM\6>`87E["07@X)*5=_";>5H%)]W"78WR5IM%[A$AP\R)7^FZC)X[515>: M<"4[YS*?%EQI%?C`*SN/Q:V`0X%]OP:O^!3Q>@]^/^1]>H0T9&%#NP19%"8! M.12F`!D4)>"U>_`LG3?LN>V>.$SP*W!4Z(GBG5^!DAE\LE,,Z2T4I^!3=,5S MNST?*@L>#>HJB%9T!83IO7\+Y]O(2G9+2(7R& M2>-DOPA0GJ$'@%!5Y6"^$>X(A]ZCF.4_P#FJ[FK[\] M_`L``/__`P!02P,$%``&``@````A`(GK4/C/"@``+2\``!D```!X;"]W;W)K M&ULK)K9:=0RN?"TSYZ/)R>[_/K5>>O>CYWN>Y.C[O7Z!3>YW^&E_S?#___W]U'=/YV M>0G#:XX43I?[_,OU^A84BY?]2WC<70K16WBB)T_1^;B[TC_/S\7+VSGB6RK5BL?=X927"L'Y,QK1T]-A'[:B_?LQ/%VER#E\W5VI_I>7P]N%U8[[ MS\@==^=O[V]_[:/C&TE\/;P>KC]CT7SNN`_ZSZ?HO/OZ2NW^X51V>]:._P'R MQ\/^'%VBIVN!Y(JRHMAFO^@72>GA[O%`+1#=GCN'3_?Y+TZP=;Q\\>$N[J#- M(?RXI'[G+B_11_=\>!P=3B'U-L5)1.!K%'T3IOU'@^QI>KIV#D,SG]N^7:W3<2B-'24D15XG07R7B M%RINU:O_C@@5%]>$_BJ1>J%>K59J=>_S-:&TCD7HKQ*A.GVR%;[RI;_*M_9I M7R?I1_KQYWW@E%4=Q`_=@!M=[U38@WXHCVK!F'+NN3G>5P M3XL?2;F_'727^TW\4#+4]!O5=I-DT]E6+[CUJE.MB91%UZ),^7@$M7;7W=F*2V730!O'M&BRA1BB0K9E@[8-.C;HVJ!G@[X-!C88VF!D@[$-)C:8 MVF!F@[D-%C98VF!E@[4--C;8ID"18IX$GC+GOPB\D!&!YY`U&.A,<*THLP6[ MM&S0MD''!ET;]&S0M\'`!D,;C&PPML'$!E,;S&PPM\'"!DL;K&RPML'&!ML4 M,*),(QJB7*87;/:KD4>S\**78&HTNS4KB@UI4TD/^:H5Z,0DB320-I`.D"Z0 M'I`^D`&0(9`1D#&0"9`ID!F0.9`%D"60%9`UD`V0;9H8T:?7(41?+(Q^R`+($L@*R!K(!LDT3(_RTE#?"?_LE M(*S-*$M"4>8`-H&T@+2!=(!T@?2`]($,@`R!C(",@4R`3(',@,R!+(`L@:R` MK(%L@&S3Q`@IO7Y_(Z3"V@PID*8DJ2"WP*8-I*.\_"0UNJ#3`Z\^D`'H#!,; M_?)Q:W5S:ADI-YV98TE\&@O).\NM^:;;)#'BA)X"F0&9`UD`60)9`5D#V0#9 MIHD1>-IQ&H&7^[:"V.]>7P[[;XU(GEADC/$R[<_DKDV(F/D`I"E).A_`I@VD MH[Q2^0`Z/?#J`QF`SA!L1LHF%7Q)?!HU2?`=SUK`3A*C)/A`9D#F0!9`ED!6 M0-9`-D"V:6($GTYG;@9_%;U16'^URAO)4&\I M8HPUN[O;B1%W=T>22BI'0+J7>*5K9.TS^HD12P]`>BB)8S;-6J&,E)!NVE@2 MGR*1ZA%[&DF,N/RI(KII,TF<4GR2&8^^.;@M@"R!K("L@6R`;-/$2"6'-H-& M+F5,&'2DQ#-&;&XF#2.S:^%H1Y1SGT^GC7*LFGECG1JUM17W;D>A=.:PE0Y= MCY$I7S.SN:^M6'Z`\D.%K/2QWT*LI2LQ9F16PAI2$VW%E9@JE&KCC*VT_)R1 M/-461V8+1$M$*T1K1!M$6P.9F21.FM)'B;_()'DP1;M*;G-#'""+&4F/D:9" M1MI(*RMMK.UHFQUUSW042G5IEZUTE_80]1$-4&NHD)4CUC@8H=:8D9DCEN-$ M6W%_315*-6C&2+\,YPHY)>JW9!)S/*O#%BDS+F#):GH>6S'2!:Q3GKH`MVJ] M;S,=!OG"CDE-S[#=TL.I(GJ M4;+@*"Y92'?IBI'67J.V-=5O4A:LO66AC`P1QUZW,N1SJR!QK&6GB#I02UK8 M5$:5A+04J>IN:"/JL+CNF2Y(]="OCVB`4D.0&@$9H]($T50A1]=S!E)S]I/W MGO)E(WNJJM$2I58@M68IW7L;1%M#RIP=Q!%7.O:_>-?($S'2X[QJB#M#"KM? MDI=5OE^Q5@9-94%W;>S48J1UVJSCQ#J5&OUGK2H[[*7'0I>1UNXQHGJE9FEK MB=%GJUI26K?=J4QSHDQ/=ZN@\54AW05M9^3)0OD-Y M:FUC.BRDL[O+2&OW&&GMOD*>U'9<.H6PDU)52$L/E1,WS"U5K4".N"1=^)B1 M+GRB4$4.9/IJPUHX3=E'ESUCI)7GC+3R0B%JEAZ1&>D&35NQEI9?,]+R&RTO MAHXU^VS9(:ZUF5/B,#`]]_W9RDBH6*DF$4\3I:IO5:KI2`MC2E1(]VY;6?EJ M2JQ6W5K)FA8ZK*3[H\M(#](>(RW>9Z0FP`)DFJJ/%AXJ%VZ76W&M(31B45WT MF)$N>J*0FNOJI9*U-IJRCRY[QD@KSQ6JZ'?F@I&:15W74EZRC%9>,=+*:Y;1 MRAM&4KE:<:Q!OV696-G,,W'V"'E&'T;1]+@H6RJHA#&O'9#2:/ZCU=V`H+6W^JL(U96)6^ M=3)G>O&=7_PVB@N3^22_VY-?'1W#\W/8#%]?+[E]]"Z^R:,5],-=@I,/!K_$ M>6WQAOB04+SF;.X&]`5$!B\'=#F._$LE^$(5Q0>-2D"WIQF\&M"U6@:O!70W M@YPVME33K"K1QB$0.P7TH7U`(!;^^(06\8%8M>,36I,'B\PGM,0.Q)H:?:9^ M(':#^&#F!^*,"1_,?6I,U@,Z;B"7+"TZ=:"*9<6*]ICT),N'CAL"L9?$"M"I M0R"VE/B$#A^HF5GET'Z3GF3Y#/Q`[+91;.0'8H.-#\9^,(FW1E;>T?$>!2:K M9^A0AYYDU8OVZ_0DJY2.'X@3!2R^ZP?B7`$?]/R`#K\S.-5+G&QF/7'H25:] MZ)B"GF25,O`"NH=!K:$7T&T,\I$7T)T,\K$7T'U6!J\'=-6!O.D'XF@&'[3\ M@*X3,C@U6YP79SUQZ$E6LUO4;'&T@SX-+VAD5LL+Z%(,[5M>T,[B'2^@ZS"T M[WI!-XOWO(`NPLB^F&0;?:S\MGL.Q[OS\^%TR;V&3S1QEN++OK/\W%G^XZKN M?;Y&5_I,F59W]#TG?98>TKEP2;RWGZ+HRO\0!20?NC_\`P``__\#`%!+`P04 M``8`"````"$`NL7Y5^H5``"&=@``&````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`C3QU9N1GY7N>50;"_>C-VN/H?4]HK M>V+&+E>#]-B*LL-FXK$#%667J>[CGES(^-[7H^RSF3CM@+O/]-P:IFIX_7S] MX=WC[L<)K7_DDZ?OUVHUG:V5'$]27?PX;5^:M333E,I')?/^E%I"$_*)EIJ_ M/@3GP;NSOVAYN#$V5V@ST8?T=C_'3Y2,LI'W+M7#"RG>0YA"\X2^B#R0>R#Q`>I M#S(?Y#XH?%#ZH/)![8/&!ZT/.A_T%G`<0DL+.&1.R]STSL9S1.6B/2$O79#.:C$X!$@&)@21`4B`9D!Q(`:0$4@&I@31`6B`=D-XFCH]H M,0DMXGC-7*0X[7],TI9#\[A3KW29.FZ:^'-H-&(LX5`(B`QD`1("B0# MD@,I@)1`*B`UD`9("Z0#TMO$\05%,D?X0EF[OM"$9@5W\P9(""0"$@-)@*1` M,B`YD`)(":0"4@-I@+1`.B"]39R.I]7_B(Y7UF[':[(DQUIKEK^-C$;LG1!( M!"0&D@!)@61`ILXOJ"0^`A?*&O7%YK8DP!(""0" M$@-)@*1`,B`YD`)(":0"4@-I@+1`.B"]39R.I_/E$1VOK-V.U\2;!"MO)QB- MQDD`)`(2`TF`I$`R(#F0`D@)I`)2`VF`M$`Z(+U-'%^H(_P1SAC,76\8M+R4 MS0!1B"A"%"-*$*6(,D0YH@)1B:A"5"-J$+6(.D2]@UQ?J%.B?V(/EF]HM=\? M+*GK%V^.&+2PG&*,*$`;]X[9RCO)AR;?BH;%:!6<7XR3RZVP.D79%3Y037WH MHHB;Y^25N@6BFCN#!U"(5A&B&%&"*$64(H=Y/I" M'9=L7PS7/>?4F0>.,3HP=K25-W8N7Q@[ZJ!@U_=`-?6YPJFF M1L[8`12JJS]WA$6(8D0)HA11ABA'5"`J$56(:D0-HA91AZAWD#MVU$'!]H4: M.TM:+P[X1)\O')]H9`\=8T1N&!>4B65'6WE#Y^T+0T>%UW9U#U131^-.->T` M?;B/W*C;71HG5C@7(HH0Q8@21"FB#%&.J$!4(JH0U8@:1"VB#E'O('?HJ/#Z M"%_H:-SQA0G0[0$2S,Y'UQOWC%:\=X3J=EW-;!EL$:(848(H190ARA$5B$I$ M%:(:48.H1=0AZAWDND<%X4>X1\?LCGOL,-[X`E"H/E]P9T^$*$:4($H198AR M1`6B$E&%J$;4(&H1=8AZ![F^4$'X$;[0,;OCBS&,E[4TF,%'+:.53!5`T0Q0 MC"A!E"+*$.6("D0EH@I1C:A!U"+J$/4.`9)"ULVP0A8@B1#&B!%&**$.4(RH0E8@J1#6B!E&+ MJ$/4.\AUD3K"V#-HH M9S0TVW6J.N_]7J?J$Z2]<@8&V4X%%!JKB_/A8^[%[#+PPI!(++C'8X-6MD-! M.F4KUZ'>QQ>96+%\SDCD"X-HUV>KDJU<>>]BN!(KSE@S$OD&Y5NVP!I)6+@Q1D)"0Y;!V(41HIC%WXY6 M"4BEF"]#E*-4`5(EYJL0U2C5@%2+^3I$O2/ESDIU;+;=<\`-^I3M3#F-U&IN MK9!RDZ1CR4!;V:XQ1$9WQ$:"8H-H.^>QEK#52%(FDB]#E*-4P5:C5,E$I"I$ M-4HU;#5*M4Q$JD/4.U*N:]19^0C7Z*.UXQJ-YA0"CJZ9>YO+1GT3CT)ZFL'< MPR$C\M"8;W8A%SR#2R-CM5)!T5\?5LOETG-ZS#K2`PDC*2UEM+>T[&!I.>M( M:04C*:UDM+>TBJWHLF#L@6#F]4#-5E)BPTA*;!GM+;%CJ[TE]FPUE.B.%G6O M88^6GPMK]>V(,X@T6MG5#V9R96/FM[:BK]#(*#)(MIPH,"@8ALP\\#:NF--E ME4\8B7#*2(0S1B$YYPNP@4C$2X9B7#%B';Z?0/!M$OD&\XH\BTCD>\8[97O MV6J0=[VN[D;`Z[\4*>O;%F<$:*1".^D#/V3:!,9*1GYHT)Q6F#'CQ#JB,ZZ6 M9AVYO/3"ZYBE99XEC*2T]%6E9<;JY=)REI;2"D926OFJTBJVHO$Q]L#$.F*Z M3DILL,26M?;V9L=6>TOL67YB':'8#T?4\?&:DO'.QQI92\0F`!0RDKZ(&,DG MCS$CF7`)(YEP*2/1RAB)5LY(M`I&HE4R$JV*D6C5C$2K821:+2/1ZAB)5L]H M8M:K.QU[UA\(VO05D#.E-7(B@R#P;Y@";>6$!@9)`R.VT@\`J)-NS$@:F#"2 M*90R$JV,D6CEC$2K8"1:)2/1JAB)5LU(M!I&HM4R$JV.D6CUC`8M9U%6WR-U MW/-36_&@XLX@@YRM>.&=SC;&B/Z,.S'GL]<$7(>-U4*OP_,@\$ZM,2M+OR2, MI+#T585E;$4KW\L+8\[R4F+!2$HL66MO\RJVVEMBS?)28L-(2FQ9:V^)G;%Z ML4-[5AX*6)F)%$IPG*IP9= MN`&K=Z;,Q(KEH/TM9[KU,F;JU^)K>=XB<7(=JJQ M$A0:J_'"^>^2JQ8OF8D\@W*MVSERGM;8B=6+-\S&N1=M]-!%^?RT0'P7,EXV[=&<@>V M,49"0D/L"TM$,8M;MV(@E6*^#%&.4@5(E9BO0E2C5`-2+>;K$/6.E.L>=5UE M+[7[8U]U]O3=H-&!"TN3T7:-SF=MEQ$;R52-N4#;-2;C&)"EF"]#E*-4P5:C M5,E$JE`AJE&J8:M1JF4B4AVBWI%R74/AT#&N4>;>#-'(.9;`A>5<&]FG$D;V M'=5$@*LSF@O+RU5PZ>U;,>M(#R2,Y'R0,MI;6F:L7BXM9QTIK6`DI96,]I96 ML14UT5K&_0M+MI(2&T928LMH;XD=6^TML6>KH41WM*A+#WLB_]PI25^=V&?; MN4;.*0DO+(T5A>"$X2,9,N)&+UPKQASNH1I"2,13AF)<,;H!>&]KFY\P.N_%%0I16\9 MT>C`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`B-%8F3NYB8B193!&5H]) M.I[9/TT&!\*Q9S1Z91+^:Z[ MLX311PYN`]5D4M\3>OU3%H.$UV@=O3D.O?3JN3'Y''^:J,\:BL9*Q3?2YKFT M9O@B8LQ:-,5&J]F+;9Z,B'[E-DJ]M\A;'@UR#D'!W/^NC;%R_*ZU#IR"3$83 MM$]\;8.5,6BG1RK1Y;-?:KZ.'^RU="C$V<4VB$)$$:(848(H190ARA$5B$I$ M%:(:48.H1=0AZAWDSE`5M_SZYJ!>J.(/41,D470AD^;"#Z5,1GL+-.A`*"56 MO*_$K#6QB:@0QV[E@8561T3.B-/(WKV7!LD2&AKDQ2/>!]^16$G5C=9$U56D MRJ_U0H1>]H@*%E8ATK MKC56SCC25@="*9/1#J58:Z)%OR>46F(H99`$3AL@H2&T`W/G1XAB@R:.3>H- M"8X_]L^"P=S=>0UR=MY@[L]I8V5OO8R_C!6_/3'_-P;?C'+8"A%WTAQ MVW9\I#%(>.V="*\@TC#Y[%V6D>4I1FZDX1T08[9R^NFE2&.EXAF87[^RU0Z* M7A?HH,ESN;>D;4Q&Q^4F(VT#UOKOA::1R6@^B9JO_(=`8E:>4$X*'E#4P>&:ML?1U@P]]:,C(0O=##I^,(@"HFLJ>)=*VW4J9`\ M=OGB,^RAL;!\&G$F_$3FLTLM:3C7H,P-TV M0D01HAA1@BA%E"'*$16(2D05HAI1@ZA%U"'J'>3ZPH^&#_@"HUYU\4L=K^Z* MK!G@+Z-B-893B")$,:($48HH0Y0C*A"5B"I$-:(&48NH0]0[R'6/'P@?<(\. M;9VIHI$S50"%])FJ-WLB1#&B!%&**$.4(RH0E8@J1#6B!E&+J$/4.\CUA1_: MJD!D?JE^;NK8KRVHZS*:,XZ?-')/)0M_\S09[5,)H@A1C"A!E"+*$.6("D0E MH@I1C:A!U"+J$*F?'QM6HN'(IEVG?TY,_T;1_?;QZW:SO;M[.KG9_:E^*HSV MN0_O1JQ_Q^QJM5BK\PTM4Y"RI)1!W$^Y".C'SX9P$%+FE#)\W`$I5`X-MHER M+J@<:LM$2G"^5N\JFTB9T\^OT4.!$RD+JAM]4#650G6CKWI,I"RI;K2@3Z2L M*`^=VR=29E0.O2MX*H74Z$VP4RDK2AFN8_W>F5U0RG!Y`RF7E#)\U1-2WE+* M$('[*=2AD_U)Q4^63H5/EDU%3Y9,!4^6.R-_T5T*;M6M["80J>I]8:. M$YA"IZBU.GM@"AVFUNH(@BGTJWP?IWU"%9NPOR(G3MJ3VZ>\_G&Q_C@]5,GG M4RZG+ZZL8_H>`E:5/O)?J\_X,>5JN5Q?T>TZIFPH93.9$E)*I)=);S#0IRV4 M,N7V<'E!*5/=&"XO*66J!O3IT3J>3`D7"VK/5!]<41]<3?;!AE(VDRGT32%2 MFQK$X8+:HS^E\5NZH/;HC1]2J#W3YJ>%.CZA2W:92Z.E2JMM4"CT82N5,I=`KX=;J'7`3?4`IZI5N MF$(O;%NK-[1A"KU_;:U>N(8I84`^I9=[80J]KHS*F4JAMX]1.5,I]#(Q*F5,+2OTH/<74MVF4NC5@U2WJ11Z:R"5,Z2 M?@7T^_77;77]^/7VX>GD;ON%MO[SX:U_C_IW1/4_GLVK/#_MGNGW/RDZH]\O MI-][W=);1,[5^SZ_[';/_`_JRK/Q%V0__+\`````__\#`%!+`P04``8`"``` M`"$`$7`X3W85```$A```&````'AL+W=O0/B601B0)0!8A\^_=_/GP[^7/S^'2__?[N=/;F_/1D\_UN^^G^ M^Y=WI__SC^AO5ZGK9O-\ M(AF^/[T[_?K\_./F[.SI[NOFX?;IS?;'YKLL^;Q]?+A]EO\^?CE[^O&XN?VT M6^GAV]G%^?GJ[.'V_OMIG^'F\34YMI\_W]]M@NW='P^;[\]]DL?-M]MG:?_3 MU_L?3S;;P]UKTCW/O; M-WG?_YPM;N]L[MU_D/[A_NYQ^[3]_/Q&TIWU#>5[OCZ[/I-,[]]^NI=W8#;[ MR>/F\[O3#[.;[G)^>O;^[6X#_>_]YJ^GT>\G3U^W?\6/]Y^*^^\;V=I2)U.! MW[;;WTUH^LF0K'R&M:-=!9K'DT^;S[=_?'ONMG\EF_LO7Y^EW$MY1^:-W7SZ M5[!YNI,M*FG>7"Q-IKOM-VF`_'OR<&]V#=DBM_]\=WHA+WS_Z?GKN]/YZLWR M\GP^D_"3WS9/S]&]27EZ'W[!TNUU;Y>>PXNI5ZUT/Z\G/(]_C3':IW4N:7XY[ES.[F5%39_I&^QVH_GK:CJSNY'Y96CQ*]^K MW8]F;D=Z[;X[L[N2^>55=3WKN_[N2!+M$#L]2W:PQI.^X^Z/*SPXJ))CH1_OI\M+M^>_2E'K[LAYN-$ MC(Y8VPASJ#)I`Q]"'R(?8A\2'U(?,A]R'PH?2A\J'VH?&A]:'[H1G$EY]C62 M;O2?J)%)8VIDM^Y'"ZYH%UY!;(1=)?`A]"'R(?8A\2'U(?,A]Z'PH?2A\J'V MH?&A]:$;@2J(')U0D+D<8J=/O+:/F+7D%*OZR)7>X!_[F,6X(RUUR'H?LB\* M)(1$D!B20%)(!LDA!:2$5)`:TD!:2#<652,Y"Z!&YD!_Y('-I)%CH[S,@2-; M'W2P:ON0?=4@(22"Q)`$DD(R2`XI("6D@M20!M)"NK&HJDF!5-4.]R@3O2N. MW:@?>UGJE=#)WS%J>>YU@'V2K$T!"2`2)(0DDA620'%)`2D@%J2$-I(5T8U&U MD$OB(VIAHG4M>AEW`D@`"2$1)(8DD!2207)(`2DA%:2&-)`6THU%;7@9[:H- M;P8F\RLSD7'L*=QDTD7I92FI1AUDYG60?="^@T!"2`2)(0DDA620'%)`2D@% MJ2$-I(5T8U%U,E,+JE"'3]F[<%V-@<9]A!200E)$BDD)*25EI)Q4D$I21:I) M#:DE=8IT+4IQ]^JO+TI+H**#`3<%+$451( MBD@Q*2&EI(R4DPI22:I(-:DAM:1.D:Z%&3B.:_'KYQ#(Z?M9/VY59=H/9<>]R+_+ M,JRH3CC[%6W'"AD5D6)20DI)&2DG%:225)%J4D-J29TB5;F+XV8#=N%Z-F"@ MT>!E30I((2DBQ:2$E)(R4DXJ2"6I(M6DAM22.D6Z%OYLP*\/<2XX4S"0=]VV M\DY&+LKVF8`4DB)23$I(*2DCY:2"5)(J4DUJ2"VI4Z1+9T;PXP/@X2'.13_@ M'Q_E!E+="-,"`:-"4D2*20DI)66DG%202E)%JDD-J25UBG0M_)F"%VK!V8"+ M_:!^?,;Q'H]9NRC75?8K6@H9%9%B4D)*21DI)Q6DDE21:E)#:DF=(EV>XV8# M+C@;,)#J*I@@"!@5DB)23$I(*2DCY:2"5)(J4DUJ2"VI4Z1K84;I1QRV^D&] M.FP-XWS9_F[^>>D]);,V-X'T>"8@A:2(%),24DK*2#FI()6DBE23&E)+ZA3I M\APW&W#!V8"!5%?IHT84,"HD1:28E)!24D;*206I)%6DFM206E*G2-?"#,F/ MZ"K]"%YUE6%0+WUAU%7\9UTN]E'V%!*00E)$BDD)*25EI)Q4D$I21:I)#:DE M=8IT>8Z;#;C@;,!`HWZQ)@6DD!218E)"2DD9*2<5I))4D6I20VI)G2)=BZG9 M@%][%.""TP$#Z7',RK_CZ:)<-^)T`*,B4DQ*2"DI(^6D@E22*E)-:D@MJ5.D M2F<>BCWB*+<+U],!`XV[$2D@A:2(%),24DK*2#FI()6DBE23&E)+ZA3I6OC3 M`8?',7,.^0?RNHK_W(R+VG<54DB*2#$I(:6DC)23"E))JD@UJ2&UI$Z1+L]Q M0_XYA_P#+:_VL_QK4D`*21$I)B6DE)21KK+R;G)MP[ MS/:D]AU0,*PXB@I)$2DF):24E)%R4D$J216I)C6DEM0ITK4P8]-Q+!@F'%451(BD@Q*2&EI(R4DPI22:I(-:DAM:1.D:Z%&;H<48MA MI#-ZMGO1D_KKQVMW_=H_E^>";+<(2"$I(L6DA)22,E).*D@EJ2+5I(;4DCI% MNCK'C147'"L.-.H#:U)`"DD1*28EI)24D7)202I)%:DF-:26U"G2M3`#M7%/ MV`%)(B4DQ*2"DI(^6D@E22*E)- M:D@MJ5.D*W?#NY$W5&R8:G#W_2.WHDT?DQ)22LHLC2N&R8W"1AUL M:NFB;+LJ4DUJ2"VILS11,7]>H9_A?F,^LO7YZ_W=[Q^WTB?DO#31'>?R>9:[ M+?W!G)[\0O8TNED";.**B6LD;MQZ0V*OQ:T+L(D[E5CW0W\^PJ_J/[8_ M?E95>4QZ7U;.4Y@/0#$'V7U!UI!@$#GOVJ:&I&@@^9,Y&Q4C56+7N]@'I:2, MJ7*D*NQZKE4EJ6*J&JD:KM>2.I5*E\>?HICH7.,R4.4*U9@Q1U+0U(TD"I-_X(N5<+U4E+&5+F-VI>TL$%NB%B2*DMNAZF1 MJK%!+E5+ZBQ-'`_E.*W&O2^4QH1[HZ>>S-^PC4KCW]B3F[.[`KH=.[`DYY#1 MBMZ]C-!&Z:L<;P8JLE'R*B[7E3?"CFV4:T1BZ6`C4ANE&G'EC4HR&W6P$;F- M MI/\=<3[FG(NYT6R.&/)CM$=X)]SU$"4/R]J#7RKD(C&Z4V M(/?!OEVC5TSLBNX54TOZ%;WC76:C#KYB;J/<>RPLN5E7]+IQ9:,.OF)M MH]PK-I;<*[:6]"MZ_;^S43][1;4KK?RYH-U<^*6[NK/7`:_?M78I]1%O('W$ MN_(.26L;Y;I8,)!YG,_M1Y?>.PYME.IBU]ZQ+++I?];%=F?$V$:Y1B0V_<%& MI#9*-\(_XMGT!QN1VRC7B,*F/]B(TD;I1OA'/)O^8"-J&^4:T=CT!QO1VBC= M"/^(9]/_K!%Z-_6GR7[M7-2FP-+HJLC0:.UIREQ:Q)=>Q$TLN M5VK)YKL.1RE99KM.1R599GE&V>D M,Q^^A%UQ)FT@?:V`9P6&J%'?"BRY]QH.),_8F8'MU?)\Y1TT([N2>^NQ);?_ M)I9O54SV]X?6PHNJ8 M_8KR')[MJ^$0)8^#[XM&1FL^3;6>8+;R>J;!J7N;;D,CX7OR^KEWC;M>]5&JG_S?S.6-D\+G5MR:5N M;!Z7NK4TM/KR\A+72,.&G>CG$>UVE)]55 M0,$*%)(B4DQ*2"DI(^6D@E22*E)-:D@MJ5.D:V'F>([H*OV4D.HJ/7E=!5,, M^RC754#A"A218E)"2DD9*2<5I))4D6I20VI)G2)5GDM_ENCPD6P7KKO*0..N M0@I((2DBQ:2$E)(R4DXJ2"6I(M6DAM22.D6Z%OY4R`NUX)3'94_FEN_^K"+? M/^M]_J"+VG<54DB*2#$I(:6DC)23"E))JD@UJ2&UI$Z1+L]QLR"7G`492'65 M/FI$`:-"4D2*20DI)66DG%202E)%JDD-J25UBG0MIJ8\?NWC;^3+B/VS_T#J MC"-/*/C=J%]1HEPW`H4NEXV*2#$I(:6DC)23"E))JD@UJ2&U)/,5SV:K]ANG M+UW_E3NZV?YBO8[Z\EL'CGOOOBOZXNKHQEQ:RY;#D M6I;L;N'Z2R[/Y0NF=\,S+#%?/;T;HV/)A2S9#>BQ9"Y+=H,T?\E"6B!/XDZT M;2DMZ!];\==92@OZ1R.P1%H@#\A-9%NMY)WN'HGRUUE=RI+=_(&_9"&MEK_M MFLBV6,B2W4@5ZRQER6Y?QA)I0?]0%I9("_I#%Y9(Y>0)\XD6S*4%\DD14TOD M=>1S`*:62#;Y*^^))0O9UC*_.+5$MG4_.X6VR;:62:J)=2[D_$3JTC59#/K)Q:(ON!S!Q/+9'ZR(?W32R9R3KRA0M32V0=^?C_ MJ26RK>63YZ>6R+:6ST&?6B+;NG\R!>]4MK4\$3.QCJPR69V9K"'?&C6QQDRV MM'QAT=02V=+R]3E32V1+]X,6OV4SV=+RN39=Y'6F6B8/+LGK3"V1YY#D=::6R&-%\CI3 M2^2)7%DRM>GER4]9,K6-Y0%:V2CM.#C9`OD^>@;\\3MU!:=2PNFWJD\CBM+IM:1IYIOS'.RS"8/-]_D M_9*S?6]Y>O_VQ^V737G[^.7^^]/)M\UGN2@XW\UZ/MY_,?\O_^W`````/__ M`P!02P,$%``&``@````A`'OAP3)1`P``10L``!@```!X;"]W;W)KW-.Y+$--'/#PD17-Y^U+DSC.3BHMRY1(O%G*,#Y&F/&;W(MX7K-36 MB60YU1"_RGBE3MZ*>(R[@LJG?745BZ("%UN><_UJG+I.$2\>=Z60=)N#[A5.@)@G M.ENYX:5'\LR!B@K*^3&CW5-/U4HJ#`_4&M*HH M=@]9@./A6"`(Q&X0O'+GK@,T"A+XO";A?.D_@^CXB+FS&/A]P]0('TAK9F`; MSXQ@9,:L8"AWUM"DF0S3A&T:3'H(I7M?*!X"7%-$>%/[MQ%8S+2!N:X1+:$` M&2\4P5"+-G4WQQ8T@AKZHDF-XB+!-<;1`$[UUZ3085H/C=_0-07";ZFBQHZ$I M)VK[-;4A<^]B;?!5#/ M]UO`'.RPH"\PM36=N>*(:A)?8$-TA\V:^BV'][#IV4Z/F3>_6"5SLL-B)T9' M4WBF3A^:&J0>&_6%/9H&-.%5'BC394EXL"/)FIJ3B$RG9Q1]:"R0_EPXF@84 M#4R&<8W7GPQD<#2SD0[/!H#OY.SL=8!'I52FZ^-TRISH4@]-AUJF175KL M9E`PN6-?6)XK)Q9[7$@F\*VOK?6RM#$CH&N?+C9VB?+K-[#$5'3'?E"YXZ5R MH,_]>@%>_P<` M`/__`P!02P,$%``&``@````A`,U#"J51`P``>PL``!@```!X;"]W;W)KK7=^^9JGSPJ3B(@]=,O)=A^61B'F^ M"]T_OQ]O%JZC-,UCFHJX;4^[MYO.G]5'(9[5G3#O`D*O0W6M=K#Q/17N6 M4342!Q#1(6.Y MMB22I53#_M6>%^K$ED5#Z#(JGP_%322R`BBV/.7ZS9"Z3A:MGG:YD'2;@N]7 M,J'1B=L\=.@S'DFA1*)'0.?9C78]+[VE!TR;=$?H48P@6>YW5CR8#/Z43LX0> M4OU+'+\QOMMK2/<4'*&Q5?SVP%0$)PHTHV"*3)%(80/PZ60<2P-.A+Z:[R./ M]3YTQY,1F?@S0#M;IO0C1T;7B0Y*B^R?Q9"2R7($)0=\GSAFH^G<'Y/+))[= MC['W0#7=K*4X.E`S(*D*BA5(5D#<[P>,(/8.P:$[=QW8JX(DO&Q(,%][+W!P M48FYMQCX?,=4"`]$*V50&ZZ,8%3&D\6MW-M`72;HEQE?(X-@2$U]\\&BXK7* M%C.I8:85HF$0(,,-(AART)1NGZT%#9"&HAHNC6`C71UN&:F?+@F6_2YGUT@A MN"EE(Q-S^>K5`456=X#W;4R6(]C9QR6*ZYH*900*YKTBQWZ_&6S7@V\#@IM2 M-M(ULVS2&C/^;#2_Z`87-B7*2-,-Z7=#H,T-MV/03;$RU#5$\);7#LHXFLX' M.#(K6RI(!J&FIS/7&5%UY8^KP:!;:D@0NCV>\&*W/0W*$M[:5II.H::G\9D\ M7=4I2-4JJOM:AGH\X4UN>0H6!-]1%^X1OMS:GLI0T]/DC*>K^@+I-H8RU..I MKS4,J[UN%,0R=7M0>#;M5>V3*"3KN#V:6;J-GB+M7T6K$NC,;;\GG5/S#Z%'3'?E"Y MX[ER4I8`IV_:@[3#DWW0HH"]PP0D-$P]YN<>AEP&;W@?O2="Z-,#5+M7CY(N])J MM9=G@K&-8HP%9)+\_593;;JKB#'9EYDX=;KZ=%5Q#N[-^Z7AY]_NG^MZN?FD.>M M`QE.S<8]M.WYSO.:[)"7:3.OSOD)(KNJ+M,6/M9[KSG7>;KM%I5'3_K^PBO3 MXN1BAKMZ2HYJMRNR_+'*7LK\U&*2.C^F+?!O#L6YN60KLRGIRK1^?CG/LJH\ M0XJGXEBT[UU2URFSN^_[4U6G3TJ>E;0[UOU*UCL#59_ZSKP1^UL\UWZ-&RSFT=(/!,"= MI[QIOQ4JI>MD+TU;E?\B2"A2?1*IDP3`7L?A5^.+/232G>LQ;=.'^[IZ=6!8 M8*OFG*K1$W>0\'(@W+X_XK43`BN5Y*O*TN4"\@VTY<>#\,6]]P-*F6E,C)BE MZQ@,1207A.H`T.LYPNDXQP!:]W'1+Y34(DHI\.E^\1`B*2(9(I:K'D(X0NUL MCN/<%!A:;Y?"9UO'B`DM3-3OW!4]&4,0;I!D.C<%WKAP\+Y-ZY!N'"-DU?5Y M)J6_7E-`0@%"+H(>0(C!S-O$U/#=;JQ:Q(MG\G>EB1$#-/I#\.*-(0C'!>4X MWE@%IL43/J\>8L*N>L&2/24)B2[,6L()'B*[;N.<%)AS8M6($1/ADQLN6#C! M,%(V#Q&AI!R.Z*$GP`Y^WSYNE69V?(_ MN\Z,.<"-FJ'R0^K^=5H(KAH20:,]'8/0RC$+F.90ZCOTH+=,56,-^EA(=%!+ M2!54U^F;)6;5K5N%5,[:?J"_#0("83\P4YT&&=.AFMI-(DR9#XQ MD2'ZA?WZ)B3WBP!!O9LM!Z^]!!$&"W-&RI%YQ42.'W@&M_HX0!!R7"WDP#0( M`+X*KLTI*4?F&A,Y?N`>5J=TIQ&$'!=1%)EAZP!)8`/4I:1Q/LI1*;GEN1,Y MHO[#'L9')/>18,PD-,LQ".7)?&3.`??-)B#<+;+Q'XC+^Z?E9),!X$ MQGZ0&%XMXQ5LF=?[/,F/Q\;)JA=U;2S@!J;_+5YIQW"EW=W_>GT`;I3/Z3[_ M/:WWQ:EQCOD.EOKS)>Q/<^$.`DU@%.8F;]+QNGN^S$Y7:3(.3EL M+_#\V>O^+4.UX^X:N>/V_.W[VQ^[]/@&$H_[P_[R*Q=M-HX[+WHYI>?MXP'Z M_=/J;'>HG?^#R1_WNW.:I<^7&Y!KR0?E?1ZT!BU0NK]]VD,/1-@;Y^3YKOE@ M>1O;:;;N;_,`_;U/WK/2WXWL-7T/SONGV?Z40+0A3R(#CVGZ39A&3P*!B8]_1KG&0[B"C(W-A=H;1+#_`` M\/_&<2^&!D1D^S._ON^?+J]W3:=WTW7;C@7FC<^"XT'J-8T^*Q:QSA M;MY?N"K'_HW5:7_FUE-N<,4'O>HY7>4'5_2[KH,P/_/GA&O1P2(M-?T;*#^X M*K_!-?VS8.#)<2!&H,KQ53VTBA$$?Z#G=7VT<-R(/XI>7I5&"T>.^$.Y]JX; M`1:.'3%-OOC`.`PL/0ZN''<6C@3QAVJUHR=:348M'`KBCZN>MR7G>+YDC+>7 M[?WM.7UOP#H,&MF)5MSRAAHN%;+U8/CY:/6#9$"H/0N:N"?V`A2&#)>_' MO6-W;UL_8)G:*9LAM[%,BQ%:B#5)R(XIF%#@4Q!0$%(041!3,*5@1L&<@@4% M2PI6%*PIV)1`"])3Y`BFPN_(D9`1.<+H#A'HI-DD(6B!+F,*)A3X%`04A!1$ M%,043"F843"G8$'!DH(5!6L*-B5@)`06F-^1$"$#/ZZE26/W'3,#0VG3*<\L M,J]&A4F1)48FC/B,!(R$C$2,Q(Q,&9DQ,F=DPPP_E"+H2UF0M)8%9@F$>,C!F9 M,.(S$C`2,A(Q$C,R963&R)R1!2-+1E:,K!G9E(D1>%C]OQ!X86T&7I(.Z!>3 MP'+I;[UR:^>5J=Q^*3_8%I;\.N;DF11&F%4?E3I%H@-$6CPL_+2XW24/%15& M*!ZC4BYN1`D>TXB2W,K>B++Q\KK??1NFT`O88U4L(0YL6>5&5HB8P9,$@H>/ M,%(VY4A)Y%KYUM=N6S1(Q7T4\5&D%"1$I2`5?F)+#;ID>Q`5]U$W1A$>'ZC_ M:N/S5_KV47R@@L8`"14S0)+H?HPH&$O0E2<$8F,_8<27Q!H480ZH3,B<(D;B MLHPQ.D0Y:W2_8AB4NIF;F_U4R($FBNE@]\E/_TA9V7;1D3$B^)$K'"VW3^:1 MLNJ)L0CE4QO^,RU\U-$+:(!(MQ8BJFTM^K2U&'7RULQ0BD*%%XU?G&GBE(", M)(5ZY4>W^ZX9AI&R!LO^BG$MK7IB"?EQ;PWL'ED82Y9>3QDWP)<[+42]2'']-B9-L# MLCD9B6-#<`0KG1Z&)MS*YRC@*.0HXBCF:,K1C*,Y1PN.EARM.%ISM#&0F1Z8 MP5])CS`GZ9&H7$F(DULYG70N&)IP*Y^C@*.0HXBCF*,I1S..YAPM.%IRM.)H MS='&0&8N1,U17O(^F2JR1(&IAU$>BG-O$?CZX@*M]!(_1E2>8Y9+-K@3;84M M^AP%'(4<11S%B/2V40F88R._K!!WUJNAS%'`44FBJDI6;HI^ND.4<+A>""4DN%M-2*^ZTYVB@$ M%Y`RTF-_[00@-S?W'0J12HG\9(V45:EV&2."W6&QG^25$EKU\HG9HY6+C_?U M+U.`2&F\*# M-CGY6*"+%EXBTL(K1%IX;0I;+BFE-^B2"YLI%<<(=2OR56?",)/I[ZQ"9"4@ M.\*1LC)6`JG5T>OA1%EU['S:$PT?-70\`D1Z;H2HH64C1)6R,6IHV2DB+3M# M#2T[1R1E+3(L%RBB=9>(M.X*1;3N&I'4).CLIXZ`2(]=4*%ZAN+ MT,K-AYO3(0MDC,*ZK2DBW=8,56H[-E=6JF.V;9/&%JBL&ULBTHVMKFILC5:R M8UV+I$=\'70]> MD,+6@O*>!^_O.'^P'.\!6N9WX`30$X=857JGGN`]L_;R(W M/<0'=G.>V+YQ']B<>6(WQN_`7LL3FRM^!SY>?<@G,FEE"!^UYK.9X(26-SR$F%2%!.IU;PJ5%O>`LATZ4944*`_A3I4/5-G0CZH[ M4#9!@/.BEG01ZAX(<-4=*%P@P%5WH/*`)ZBZ$[H>O/7DO0FAD2K[V/7@G1^W M'\-XJ$I@"*.ABL-!CC>L[/D([HPJ[\`9#O2\*L)CB+"HWOESP9&+)XIX?F?H M>L.JGHQ<#UZY)9?E`M_W%1KTP?TPM\"`W%`GQ`"1^^)_"*LRU>TCRG MZ07_`0VWBD_I[_\'``#__P,`4$L#!!0`!@`(````(0!:X+NRPP<``%0A```9 M````>&PO=V]R:W-H965TWBKFY?V6);=!#Q3NMK^4%6@YU<\X[^+-Y-MMK M4^;[OM/Y9-JSV<(\Y]7%H!Z\YB,^ZL.A*LJ@+E[/Y:6C3IKRE'=P_^VQNK;< MV[GXB+MSWKR\7C\5]?D*+IZJ4]5][YT:DW/AI<^7NLF?3A#W-\O)"^Z[_P.Y M/U=%4[?UH9N".Y/>*(YY;:Y-\+1]V%<0`9%]TI2'C?%H>9GM&.;VH1?HWZI\ M:Z7?)^VQ?HN;:O]'=2E!;9@G,@-/=?U"3-,]0=#91+VC?@;^:B;[\I"_GKJ_ MZ[>DK)Z/'4RW"Q&1P+S]]Z!L"U`4W$QMEW@JZA/<`/RWJ\W^LD;F@G6W6&:ZL\WPQ=9>SN05CW>HX9QWA MRCK:SM1R9HMW^CFL'UQ9/_!F^B#ARKI9LZECN\O5>S>Z8#V70\^/W2@L MKWY$N-YSHR!]WPVN=]ZH!9E#)Y*D$)VLF[=JTD3H\RK(NWS[T-1O$UBL,.7M M-2=+W_*(5YY1-`^&'/M9BD%N$2^/Q,W&`-T@BUI8%U^WEC5[,+]"+A?,9C=B MHUKXW((D+G$;Z"#40:2#6`>)#E(=9!(P099!&TCT7Z$-<4.TX5'M.!!BV9H0 MW()W"700ZB#20:R#1`>I#C()*$+`POT50A`W&P-^#DEB.VLU\AVU<>1,-T6`.V:VG;P&#$U0@0"1&)$(D121!)$[46FIWZC,K M23I&W%E?B]DS2Y=-&/#H(H9DX9#CA)&EQ1W/U?E(A0%WG"F.5=U(Z26O%EVW M+_7U9[K!R\,@'*W@X*')Q]Q9%`E)?$0"1EQKZ!9B%#&DR*([3W"_%*-,<:4* M04HO68B11)$#II6:$C!%-N30D"FVJ\V.;U$K(4O`B7BJA!A%#"DBZ*X2W"_% M*%-P*.U'6V4G,[Y%:+/ODM M9ZFV1[Q=:!ES),9*.+HY5LJMZ%CZYI3QYGXH5452>\DJZFOJ8WL1\:+M1139 ML`M*XNK5N46MYOU!!GN+8TA>9PS9=!M9+W0E6;M8T3%VG'`D'*<<4<<+K3+, M>'/O5Y6-E&VW9/O@5D2K/Y@>L151)*6;3\YL]`QD2'0,N15-`2B]1\LDKO[%.T1%34H&@!$RQED3;_OD6ME"QB M2$0;\I&`48A1A%&,48)1BE&&4*4K0@E1'2PG9)UMUYV-E[ M4I^-#+EJMFE)XPLK_G`(,`HQBC"*,4HP2C'*%*0J1,I:.5MN9P79I+02@2$Y M*S`*,`HQBC"*,4HP2C'*%*3&3*I8.6:RD\,;P=TY0:MA>0>"!S[11\L)[<#3 M%U8B)X:.'(78*L(HQBC!*,4H4Y"JSWTUN8UKP(';8/`Z;?1'?V'#Z*]H\. MU.+PSZ5ZR]*#$S:(7.XW'@Y=K#TX9<,\67MP1H9Y8,U`I#')X?0(1!IK@;,8 MZ#,F!QRM0)^^Q1P"A&_:U_RY_#-OGJM+.SF5!TB^65_6-/2K./VC8\='3W4' M7[7[DZ0C_/=""=\69^3!?ZCKCO\!@9C#_T-L?P```/__`P!02P,$%``&``@` M```A`*<>@LI/#```\3P``!D```!X;"]W;W)K&UL MK)M=<^(Z$H;OMVK_`\7]"=A\NY*<&O`W-AC7V=UKAI"$FA!2P'S]^].RW):E MUT/"[)F+@3QJO9*Z)=EJ[-L_?^Q?6M^VQ]/N\'K7MFZZ[=;V=7-XV+T^W;7_ M\Y?_Q[C=.IW7KP_KE\/K]J[]M]MSBQ1>3W?MY_/Y MS>ET3IOG[7Y]NCF\;5^IY/%PW*_/].?QJ7-Z.V[7#T6E_4O'[G:'G?UZ]]J6 M"L[Q(QJ'Q\?=9NL>-E_WV]>S%#EN7]9GZO_I>?=V8K7]YB-R^_7QR]>W/S:' M_1M)?-Z][,X_"]%V:[]QHJ?7PW']^87&_L7?P!\OO=YG@X'1[/-R37 MD1W%,4\ZDPXIW=\^[&@$PNVMX_;QKOW)U>[ MSQ3N`8U(#,QY^.EN3QOR*,G63]H_C\OGLX/]^U M[=[-8-3M663>^KP]G?V=D&RW-E]/Y\/^?]*H&%$E8IJ]+.\-E`HK6H^T)?KQFGQ+!!?KAJI M1?-&]E=-(-NZZ=N#T;B8AA=F@L532$SZ*SO,<\%2D^%CT\_BR2"^E(U:@P_- M>(NG@_CRH?YVY(HM-@!W?5[?WQX/WUNTJU*$3F]KL4=;CE#CI2^]56T&O]H+ M:!,0*I^$S%V;!D++_$0;V+=[>VS?=K[1IK,I;:9H8^D6,[80.XR0=4W@F<`W M06""T`21"6(3S$V0F"`UP<($2Q-D)EB9(*^!#H6GBA$MA7\B1D)&Q(B].V50 M"YH1$+;@*JX)/!/X)@A,$)H@,D%L@KD)$A.D)EB88&F"S`0K$^0UH`6$=IA_ M(B!"YJY-_]<634^/P%3:].LK:Z";S"J3*DI`/"`^D`!(""0"$@.9`TF`I$`6 M0)9`,B`K('F=:$&C/?Z?")J0H$!\(`&0$$@$ M)`8R!Y(`28$L@"R!9$!60/(ZT:)&%V0M:LVWI'P9$M9%<-BITY)TZ;,6K[ZQ MA)055W01>8A\1`&B$%&$*$8T1Y0@2A$M$"T198A6B'(-:<&A6YXK@B.L]>!( M0LN$O3X#X@+Q@/A``B`AD`A(#&0.)`&2`ED`60+)@*R`Y'6B.9XN!U)YKC MZ4Q[A>.%M>YX2?JTR*I%8(V,*_FLK-;M57N46]:C?M7J&5<4KS+BQ>.S4K]2 M"A@I\;"JI\3M@=&IJ#)B\9B5"G'-2^(:!AT]&BX MLO;H)%>>[X2*[KY"^*Y-_N->S$IDU;U5LI$E3X5=R_24,F`=O]*I^:IB-6>I MJL6)LVL9=\^1,F#MN-)I<)4X@.%A6+GJK\/;KUQ%B:[*5_(<1[>(W.A49$3( M?6HX,R!N208R*R:.OQXBOT36I!(/0"K$>A&B6)/2YXPX^-0=T3`WZ@.6YR1M MP!+U:%Y6B\0>#XW;+I'D(;?8=C48EQ'=$%85K=%8K^B55D,Q0;_=][KT3[?P M64?=6P2,5&LAHXNM1>^V%K-.T9KN2G$>J;OR]Y:?/-5H'I9H6.^Z/1[I;IB) MYJLT-.40B[W.5Z\5VQZ0M'8]"32Y_7$\,%,Y!/->5U6K-]R-VMB#XW=TF?I^KR&UL+2JG>QM:BTXM;&O8'16JRUIGN;I-';@ZOW M2B%CN%BB^@V12,N250VYB#Q$/J(`48@H0A0CFB-*$*6(%HB6B#)$*T2YAO08 MB?.#N??8E&+FGT4^GMZ5)Q%:C^J2)I%^AIA`1K>RXHJN2)13,*DB(P^1CRA` M%"**$,6(YH@21"FB!:(EH@S1"E&N(3URXK11C]P[%V!Y.-'"(U%MR&#?U,_'K"X6'K'A=N(@\1#ZB`%&(*$(4(YHC2A"EB!:(EH@R1"M$N8;T M\(BCSQ7A*4]*]9U,(FVI`'+ICMM8/1XB'U&`*$04(8H1S1$EB%)$"T1+1!FB M%:)<0UHL;/.L>7G;*LSUBW^)WCF4LY6Z"7(9U=>8-3+.@YZRXC7F(PH0A8@B M1#$C=3B;,U)=31CI736R;ZFRXJXN$"T198A6B')&15?U()JGX'>"B*==NSSM MUC(#C)0;7$:Z&XP[4$]9L1M\1`&B$%&$*&94CUC9>]75A*TN=C555MS5!:(E MH@S1"E'.J"%BXAA=WP)_ZXQ)IW"QP=4O7"6JI2V`N"49='^5WU$&[!:_1+21 M,`I`.%3U?I'<40:L$J/P'(035:\4-N9('"2Q#.5+WF'J^4`0OGFK"^ M#L6A_%)4^4#[SOJ49WLMK!+5PVH2UY:DGHU"Y)=("Z0I%7(]E7>)$,4H-2^1 MZF?"]50F(46T0*DE2&58;X4HUZ3T\(A3=ST\[X1!'M*U,$ADY!*,2];,AM.] MRXA*JG0-YA+8:E@LS*%YMO>Y7.US`2,5J9#1Q;8BMI)MV9:1.HJY7+4U9Z3: M2AA=;"LMKH:/D7*`5Z*13)CV1T;&RN%)U\@-+KB*$EXR4L(9(R6\TH6MD9$R MS;E*(:R'5&0NZB']O>NLS']HD9;(V`F,.\*9+:WHBL%7#[=$?;4?>HSL8MD; M&CYK*'\$C)1LR!I*-F+4*!NSAI*=,U*R"6LHV921E+6,:;E@$:6[9*1T,Q91 MNBM&4M?8CG+6*&3U$(N$"(3X_TDBVS+%HH5;(IM.E-7^;4_,'T?*BMK"EA6' M-!&JB@T;O[3JETEDRS:6CL_*:ND$C-32"4MTN;&(K4;%=.OUC0TR9F'5UIR1 M:BMAE8L#2TNKJ:BM*HA%Y&'R$<4(`H118AB1'-$":(4T0+1$E&&:(4HUY"^ MSD4VI[[.W[E[D\D?;1%+9.2_C8O)3*QQ"F(MV>TB\A#YB`)$(:((48QHCBA! ME"):(%HBRA"M$.4:TL)#F]XUX2G,]:52HMJZF"%R$7F(?$0!HA!1A"A&-$>4 M($H1+1`M$66(5HAR#>FQ,/-!\J[GZM^0Z`4FYC)M\S4N^Y;'?'I^V ML^W+RZFU.7P5KW"1Y?UMA>7[9=->]8*966*-'/';"'D>2L944OQ8`243*BER M.V:)375H4VY0LZD.[0<-);TNO?Q67+Y-M8&3%S\BFGSHY$7JT>0TE,:14*<: M^V11`_3K:D.?+&J"?KW#$LJ;.!XE#;"$TB".R'M@"64U')'&P!)*4C@B*X$E M]$;@I^(.V!PC!;*X#3:Y3>YMT)GVR+D-_%/?^413"QN>]IV\2,@8#5"BVYE3 MBA)K4+Z;!M$40,JK4DE3'4I/4W^;2BC?2`YN&@HE#,G!3264\2,'-Y50RHYZ MT%023AQZS`Y'$UI=1SQ6AB7QQ!$/EV$!/=GEB$>YL(0>U"*QII(I.6#:Z(`9 MENRQ@9/+ MO,8:_L01S_IAE6#B!+*@4\TS>N'T;?VT3=?'I]WKJ?6R?:3=K%L\<'*4KZS* M/\[E0WJ?#V=ZU93N"NBE-GJU>$L/U'7%HP^/A\.9_Z"6.]7+RO=_`P``__\# M`%!+`P04``8`"````"$`/DN`YCX&``"9%P``&0```'AL+W=O]7VG=`W,<8##9&MJ.Q`0/:E5:K[.XU@[&- MQA@+F$SR]JFF*.@?QYFL?ID]7-^5>??Q27K3/>=T4U76MFY.IKN77 MK#H4U]-:_^=3^,'5M:9-KX?T4EWSM?XU;_2/F]]_6[U5]4MSSO-6`X5KL];/ M;7OS#*/)SGF9-I/JEE^AY5C59=K"G_7):&YUGAZZ3N7%L*;3N5&FQ55'!:]^ MCT9U/!99[E?9:YE?6Q2I\TO:POLWY^+6D%J9O4>N3.N7U]N'K"IO(/%<7(KV M:R>J:V7FQ:=K5:?/%YCW%]-.,]+N_E#DRR*KJZ8ZMA.0,_!%U3DOC:4!2IO5 MH8`9,-NU.C^N]2?32\RY;FQ6G4'_%OE;P_U?:\[5V[XN#G\4UQSHORXG1N8;D=F!&;F'?XZN=-!HZ" MS,1RF%)67>`%X%^M+%AJ@"/IE^[Y5AS:\UJWII.%.5W.%J#RG#=M6#!)7 MF[8J_\,@LY="$:L7@2>)N!/+=4QG#H.^5\7N5>!)*A/;#`^MW1S@ MV7>T)Z[CV'.7S>%!1]@$74=X]AUG[^NX[#O"L^^X>-C10->[1?33-MVLZNI- M@YT!OC:WE.TSTS-A\6GY\*6'!?W>>L)",I4G)K/6%[H&2]5`$G[>S"QS97R& MQ,GZF*T:(T7L*()E"9/U91#(()3!7@:1#&(9)!PPP);!&\BF7^$-DV'>T*RV M!$:S+-&J'450%U\&@0Q"&>QE$,D@ED'"`<&(V:\Q@LFL=?AW2!++7HHSWV*, MS6>2(X;LAI#!'84$"@D5LE=(I)!8(0E/!)/@U/@5V<)D8#/",(-+,TO*CRT& M/71I"!E<4DB@D%`A>X5$"HD5DO!$<`G.0\&E^Y\).E98=&<&36*+Q(4#<[#' MW]BD5FT.%$DUCA/!/8`?`0NO,&0!N;"%@^*8`@BOT(D MYG(0VLO*4=\)'H.RY4C[+QZ"2#E!@LJ"%ZS.53^P$U88M.]E6,`Y\@>YL MA!E\2/'SRD1$BY"XL,^&US07TFON,(BS#8$S[;[0UM24'1O::5XA$MXQ631" ML#!)="8N0SRTDVC"BPIF03GST*Q/U>U[9D&)1FXQ%=$M)*,1.QGX"!PL*UGM M$2@D1,)[(U5_"]._D!#?-+ER<9X\L$!K2PG*D!=GU4:,= M/I'Q:`E4%/:(-X"BA@T5$1FE8A4E@I1H`JO&^`WS`Q.P>(/O)677UD1DP8,S M04KU'46-IXQ/2-Q4KIC.`47-NWPW[878'E+[:,">T#A61.CA6#%%X5CR,910 M4Z"(KY7@7L:[_R6/'Q()0,!>1!4G,F2N7:'W'6??3L2_EL>.,VV$49>') ML9S+3O9=QK7=4Y=1."(T"L>$4'@^%743:NYT1=M8=??(MO<=0*QZDTZ@'EEC M"NQ4Y!,:9QP0PA2P;6DSA]3.IQL.SXT54=0H'!/J\]B4/AX)M=])+E;=\2[] M8(NR<.F<0C3GL]]RI/7?F1@E9%&/QMD&%.4.)T!(:)SMGA"?.(I63%&C5D+H M3K*P0H^WX?_M,2P7P>WQ`$/THP.LCQHSRF?W+N"T/6Z%@!!N!7LJ[86P;[=& M0_>$1N&(5$;AF!#LT?$@,*7#,B&M.TG$JD?%O?D$IM#51;33WE\DP2V7DF>( M7"9*%Q-PH2.>![N^HY!GV'$.CZ&CN9!F%_0=YXON`'/5O8DJLW%M]^I8$:D\ M'"NF*!S+5+:GAGA]<]95Z?\EU^N31:5KVR^S@0W*P&C)>%4`AX[,L/ MJ2BUP'?=8Q]RM04N&)^Z5)%Z;-G%XYWXK>7!18.JLYUY\.-:Y4^V]P3OJC9L M;0]^9][AC@>_P>[PN0<_653N+SSXJ:#R:.%!H:]RW_6"[H"0)ARY'M2Z=^*7 M'A23*H^6'E2'P(U!""Y&;^DI_S.M3\6UT2[Y$18*KD,A?VN\6L4_VKX.?JY: MN!*%M82+.[@"SZ%NG;(==*RJEOY@`PR7ZIMO````__\#`%!+`P04``8`"``` M`"$`:JK!S_(1``"Y6P``&0```'AL+W=O/*P\8)`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`XWI\WGCX?]KRM: M',E%QY>-6FH[8Z7&,UC[MY[3KTUIFLM*Y8N2^71-#:'9>J1UZ,_/W<[PX^V? MM';<&YL)VG1P!1<)?1#Y(/;!S`>)#U(?S'VP M\$'F@]P'2Q^L?%#X8.V#T@*.0VB%`8=T:=5KWO9XCJA2M,%9,+BF@<7^C0X$8%G*F]SBBX<_>SJ#;@+HXU&5C>`]G$V-`?:V#T7.FT-F+I MN2$BO="$CD5LD]6E;&DO,,IK(RZV!.D52!=U*5MZX-[UNC9BZ=*6=GQ,YV7T M<5]639ZF#:LFG:MYV50JKF,UZ=5],O5!J$$_J$TB(+$FG0^US<(T^&U,ZY/W:-5UOLY@:HT`F1&/C#2"-KB9@:*PN%C*0O(D:C>FV)&GH=[@:!=S"-65GZ9<9(!G=BT*"U MLI2M*!%0WQ($6'.6EQH7C*3&C+5::\S9JK7&)T1+1"5"!:(RH=Y+I+Y3K>UUTZ>^*XRR!9O*;J<;1:(P2%!KV1?!0K'@TQ M(XE.9RB?T`U;O3)F*%)+'3[ MQ0%P)>-NWP9)#FP*)#3$3E$BB@VB1G"#9B"58+D4T1RE%B"58;DWWC(G<58YHB5(KMJJE"B8BM494.E*N:U06Q%XPVX\E=*P`UVCD M'$L@86G*V:<21G:."A,-QLHD+$>#8.3M6S'K2`_,&,GY(&'46EOZ9FUSUI': M%HRDMHQ1:VTY6]D1*<332[:2&E>,I,:"46N-:[9JK;%DJZI&=[2HM(\]6O[1 M*2G0R2,[3C+(.25APM)8V<R2O&?%UV]!DCV8D31B*<,GI%>,[7 M17C!2(0S1B*<,W(#-#]SS58BOV(D\@4CD5\S:I4OV:J2=[U.@PJ]_CL)RT`I M>ANM1FJEDA4>$I:F((U0WD1#@]I3B)&Q,BG$T6!PYW5OS-(RSV:,I+;DK-K2 M-VN;L[34MF`DM65GU9:S5>NL7K*\U+AB)#46K$4IH]H-L"JOV:JUQI+E&]81 ME9%J6T?.>YRLWMCVAY%&UA(Q-586"AE)7T2,))D7,Y()-V,D$RYA)%HI(]&: M,Q*M!2/1RAB)5LY(M):,1&O%2+0*1J*U9B1:):.&64_.=7ST1F2@S+TIK9$3 M&6#",M!6SI0V2!H8L94D\V)&TL`9(QG0"2/12AF)UIR1:"T8B5;&2+1R1J*U M9"1:*T:B53`2K34CT2H955KNHMR8;;*./&>]QQ9@ALD@9RN&A*4QE#!O>A9,S*TB\S1C*X$X/:*TO9BNZL7LP@P)JSO-2X8"0U9JQ% M0[/6@H4Q9ZO6&IK9Y#=YJ>ZL);Q2<3=>@V2WF1HBZ8S0D*&@"%%L MD,Z,N#?OYW3\H^!Y(5P75*KEA3ZWV(*BKC5&+>S.K1MDW[I&WJU[VWIDM)Q;-UH-M]YXX+PTMNGB(=,@ MIT7:RGJ@%AJKH;.)!UZ".A(K<8;1:FC1^QQXU"'7"[(-DFD\!1(:TI><0(0H M-JAIKM.,NF06*'-O1=+(.PKX^=NNMK*/`HRH9U\/NR)C9;*$#5$ERV`^\32E4RGH]T=/5&*&4*6IX,#7HCE!(K'MLQ:^$6V+LLE*K,O=;H(,G> MO8V5<^MGA5*FH!V/L%;#K:M(Y?P]HJ<#&SL*-,BY=1/^R.H?&JLW0BFQDEXW M6@VWKD(2^];],/VL,T9/!S9.BS1R6F20W2*-W@BEC#Q928N,5D.+WB>4HG75 M7]`-LD(I(*$A=BB%*#:H(9124]'Q1WM47IE[LZ`IE.KZQR-3T-YZ&5'/R@X* M7X@8*_Y"I'OG1?(QRU3.>"[K>^S[3ZE;<-W\-4I%] M71"2EI&Q,L_&N@,_=Q>ST1+1"5"!:(RH=Y$S=?E/$&/355]@7 M_K)$I>2N6`:Y/U_0]3TG5K7G$$6(8D0S1`FB%-$1ZS@\>VS<4VKC\!=8@FE;<\5-$(:((48QHABA!E"*:(UH@RA#EB):(5H@* M1&M$I8-<7UP6XM(+@^`+@^Q3;M#U4D]34W#TZJ?NH;&P?!IQ(?WI9Z]COX_J MML*/=O]1R-C'(-B@@;O]^DD@8S62?3MD)`GMB+4P/NRKR!%VY(NWI$K&6\=, M3&K-$Y^$IIC$D)%-W'[V`]DW9BX&K&I%I:2$%Q?XF2=C-73'E)>K"8V5%3!& MC05[DIAQ6W-98-O74:P=Y1CDYE-Z?C[%6`V=6*CGA;^AL;+BP:BYH`1_;FO\ M4/8-WV#82K]/B;[I^3&;L7)]T_.VQM!8.;[1\EY!62AT:_0O7.I?QGO:'KYO MI]O'Q^/5_?ZG^O7**N"KL?EIS=Z'\1>JC[8"[PJ%7V,5031K`P5D\2 M\,JDUQE/Z%B/5Z9T9=IXA9).U,%-30Q[U%F4GD$U2IG0E:9FAKT>76FZ`\I1 MC>/&*_10E-K3Y/P)]<&DL0^F=&7:>(6>1Y):8WNZU!YZC$^C=>*JGZ0J]ZD[U-%VA-]>IGJ8K]#G4.*)/?/`.Z$NFL?H>"*^$G0]4IFE" MT\4`5-G'YAA=K1 MU/OT@RG4CJ8K]/LGU(ZF*_1S)M2.IBOAS`;C>F'BY`7Y,"*W];#FWXX^67S?9MO#M]WS\>KQ^TWVIKNJI<@#OJGE_4_ M3N:'P+[N3_23R129T:^ZTD]D;^G;Y3MU3OVVWY_X'U3Q;?VCVY__7P````#_ M_P,`4$L#!!0`!@`(````(0!8:&PO=V]R:W-H965T M7AR.JY?[U=/N9?/Q\I_-X?+O3__]SX>? MN_VWP^-F<[P@"R^'CY>/Q^.KT^DZ>:&2A]W^>76D7_=?.X?7 M_69U7RD]/W7L;G?0>5YM7RYK"\[^'!N[AX?M>C/>K;\_;UZ.M9']YFEUI/8? M'K>O![;VO#['W/-J_^W[ZU_KW?,KF?BR?=H>_ZF,7EX\KQW_Z\MNO_KR1/W^ M9?56:[9=_0+FG[?K_>ZP>SA>D;E.W5#L\[`S[)"E3Q_NM]0#,>P7^\W#Q\O/ MEE/:P\O.IP_5`!7;S<]#X_/%X7'W<[K?WH?;EPV--OE)>.#+;O=-B/KW`I%R M![3=R@/)_N)^\[#Z_G1<['YZF^W7QR.YNT\]$AUS[O\9;PYK&E$R(77S:'H[L5)B\OUM\/ MQ]US60M9TE1MQ)9&Z"<;N;ZR;_M6?R"LO*%Y+35[2M,^3Y/L5@VGGURG=9[F M0&K>*,TSZZ1)4]5)/V6=@ZO;?K\WN+UYNYM#J4@_I:)M75F][N^&QZ)XJ-TC M`D/ZY\S&6B?7T@?6/=,M%GM4?&#=<^MEGUKT0>J>.4P6A4'=714/UNUY0RR" MOM8E_[ZWR10*M:Z*B7.;S#%AJ:`XN\D<%O;[O6NS=\6']XVRSC\H$5S+67N4,:0&+&$6"&%V;$))B9P M33`U@6<"WP0S$P0F"$T0F2`VP=P$B0E2$RQ,L#1!9H+P M^W\X7I@1CF>7W3%H1((>!R.68)6Q"28F<$TP-8%G`M\$,Q,$)@A-$)D@-L'< M!(D)4A,L3+`T06:"W`2%"ST*(]B#:;;=V+=[5, MKSGE^[K(Z"1R\C20"1`7R!2(!\0',@,2``F!1$!B(',@"9`4R`+($D@&)`=2 M`"F;1/,^/<#!^^(1_<[%79BAYP-5\\;J7@N]&0\GD5,\`)D`<8%,@7A`?"`S M(`&0$$@$)`8R!Y(`28$L@"R!9$!R(`60LDFT>"#7:_'P]BH@I"NWL[ON:M+7 M`^':F/4G(58;`YD`<8%,@7A`?"`S(`&0$$@$)`8R!Y(`28$L@"R!9$!R(`60 MLDDT+]/6^QU>%M*ZEVM",YD=.`(R!C(!X@*9`O&`^$!F0`(@(9`(2`QD#B0! MD@)9`%D"R8#D0`H@99-H+J6G[#M<*J1UE]:D3R'36,%[QL0]";'?QT`F0%P@ M4R`>$!_(#$@`)`02`8F!S($D0%(@"R!+(!F0'$@!I&P2S0A\A'-$`6(0D01HAC1'%&"*$6T0+1$E"'*$16(2@WIKA:I%C.7]D>3 M762-C=DND3'=!\8C7$F=YCNB"2(7T121A\A'-$,4(`H118AB1'-$":(4T0+1 M$E&&*$=4("HUI`>&R,XT`^,W:T"=S*'OV^S$.W$"0`&AK0&`QB@U0>0BFB+R M$/F(9H@"1"&B"%&,:(XH090B6B!:(LH0Y8@*1*6&=%>+7$S3U7^:3Z]S.EH, MU(ABH+F)OS%7@),4!\]8)&[TX)D@8>KZS2.YFI`(Y&T MU;T_EJBA.$'DLF)U^:$Z4YLR4OD=#Q5]1#-65+8")=5!I$^Z:KSZR154OU;T\C M-F:D34ES]"=*BH?:E:BG_#UE*67>8Z2;-_(5OI)B\S,T'T@DMF&-/AI;H9!M MJ49$$@TI7]-0A&6G'AR2XD;,65'U,>%&=*N[8=4L35E,:2X0+1%EB')$!:)2 M0WJ(B:14,\1:UI=F*-4Y+"V4)-*'&2YMU%):*$FD^]HX*)J(RSKT4*.OM#S, MKD1:*(%Y3RDVO6A\%_:5%)N?H?E`(B.4X`D&C8B4^68CC'D6*RENQ!P;D;"4 M"IN4D1JA&@K8J1WR%",E11W:"Y1HT,) M(_6\3"6RNK1Y."UGUHTQ8(N&&%>P9&MJ/US#!I2+`7EVQ(#6G&2-G. M&YK5S;^N92SU14.";9=LJ"5"VA*I5E_MF,_;'-F8196H=WKBC(",)>G;)Z$) M(E:CG(YJAJ0!,A4`BM!0CFDO4:&<"IE+6JR^4BYN7"T1+-)6! MJ9SUU.@5B$K-E+XZB+3F^<\:<7N6]A#-9XU$PVX5Z-?#8<_8&8RD!/U@WXT9 MJ8S+A.U8E9W>@/X9.TR7M=1U9-^9^/60EU9Z(T9OMB:740'P%_?'I^GI@;&WF;$8U)V&D*DL9 MO5G9@J6:W_QLRQBB)4NI&C-&JL:/9'ISV&, MC=.<=53="2-E.66D+"\DHFZI&=D2;M"UC&TI\SDC9;Y0YL74,5:?DA6J5NLQ M12&KQ=2?[8R$%6-)K!$O$]W^T&C4R*XE*-Y5J$FD1GSW[4'76!9< MMJ3&8\I(&?<8*>,^([D`7D&DR?8HPX%4X7[9/=N80B$;555'C%35L41RK;OM M=HV]T9QU5-T)(V4YE:C7?(S6C>[)5=2V#94SZ MDLU4EO4XH^\C&&?T%VC87.O52-M/9-(=7\B;5VK MKVDN(^6R*2,U$SU&RI;/2-F:,5*V`HD:30U92IF/&"GS,2-E?LY(F4\8*5NI M1(/FT\>Z,9;)A93JB7P?/8);@D>.GJHLP\KRLRHK],KZ/7/[4;+EJC(]GD3Z MM?DL--(A_1#%&`*$04(8H1 MS1$EB%)$"T1+1!FB'%&!J-20'@(B9=H,@=^X6B:I5>#>V3(C32%]VB7;M\;3 M9:2DU'/JI,AH@E(NHBDB#Y&/:(8H0!0BBA#%B.:($D0IH@6B):(,48ZH0%1J M2/>^2(^^P_MU-E7;#->H,:M'-J`QH@DB%]$4D8?(1S1#%"`*$46(8D1S1`FB M%-$"T1)1ABA'5"`J-:2[6N15W^%JF?AM3G29F=4GNK&W']&?ZXN'0>-P8(QH M@LA%-$7D(?(1S1`%B$)$$:(8T1Q1@BA%M$"T1)0ARA$5B,2K$M38U]ZO7WU0 M_^7P\V;_=3/:/#T=+M:[[^*U!H,>[5!.N'[GPIT]H)R4')#)=4V"DIN MJ:3:34')D%_A8)90096$,[G5=<1E37HH0`F]#H)NZ[65V%12[;M!YYI*JBB& MDAZ55+M.O&YW18IM-5.E;?*4]5M-7_ND?W6KE.+VAITUW?HKX9:NDV> M:G44^:G53>2E-B=1TI]ZT#;DE%1U1!85ZZ8DVE&'#F4NCFDR-NM6`]=`'*$9=;L(0N/3GB MC@N6T-TGBJJV>4@78*BD38?N:SCB,`NMT;4-1US*:"NYI9*V,:"#5BII&X,Q MC8$X#D-K=]1J<>,(2^ARFB,N'F$)W5&C>MI*Z%Z:(^XDM.J^KKYMHM?^Z?3EZ''4K4Z*]O5[>.I?CO(ZS9?=D=Z? M0U\RZ4T7]+ZD#1UU=$7>XV&W._(O5'7G]`:F3_\#``#__P,`4$L#!!0`!@`( M````(0#+>4"2N!4``*R"```9````>&PO=V]R:W-H965T-V.]`\#Z&NG()VQ-0NM^EF-U]QE"V"0/EH.AV][>?DR6E M4IE_N:#8>6G;IT_'DP^GQT?KI=G-W M__3MT_'__"OXQ_GQT?;EYNGNYF'SM/YT_/=Z>_S/S__]7Q]_;9Y_;+^OUR]' MDN%I^^GX^\O+S\N3D^WM]_7CS?;#YN?Z299\W3P_WKS(_SY_.]G^?%[?W.U6 M>GPXF9Z>+D\>;^Z?CML,E\]OR;'Y^O7^=NUM;O]X7#^]M$F>UP\W+]+^[??[ MGUN=[?'V+>D>;YY__/'S'[>;QY^2XLO]P_W+W[NDQT>/MY?QMZ?-\\V7!]GO MOR;SFUN=>_<_2/]X?_N\V6Z^OGR0="=M0[G/%R<7)Y+I\\>[>]D#==B/GM=? M/QU?32Z;L\GQR>>/NP/TO_?K7]O!OX^VWS>_PN?[N^S^:2U'6^JD*O!EL_FA M0N,[1;+R"=8.=A6HGH_NUE]O_GAX:3:_HO7]M^\O4NZ%[)':L;!VF`_/?H\5Z=&G)$;O[Z=#R5#=_?O7S_=#Q;?EBY5RN.CVS^V+YO'_VN#=GO4)YEU2>1GEV3Y87J^F"R6*LF>%>?=BO+S M_5N73>QV07YV2:;SMVU^V:TI/[LU%V];\:Q;47[J=D\^G$U.+V9G^W=8NMVN MK?*S6W'YIO4NNO7DYX'[.)%3:K=)]8_#]G*B3P[UC\/V5M.)/HW4/[H6OW%?]7DT,2?26\_= MB3Z5U#_>5->3MNOOKB3>S129=/7D+;C]E>5 MWUU4Y&JBLERI-)^.94_D>K&5*^&?GV>3^<>3/^7J==O%7#-F8D>L=(2Z5*FT MG@N^"X$+H0N1"[$+B0NI"YD+N0N%"Z4+E0NU"\T`3J0\?8VD&_TG:J32J!KI MHWNMP11MZA1$1^A5/!=\%P(70AR MV;D:PQUZ]5*9[**TLI!4@P[B/H?U0;IR'L2'!)`0$D%B2`))(1DDAQ20$E)! M:D@S%*M.\KB,.KWC%J/2N+>8B7N+:8/VWF+ZD+YJ$!\20$)(!(DA"22%9)`< M4D!*2`6I(U`K"^F]I@>YY5KU07TM(#XD@(20"!)# M$D@*R2`YI("4D`I20YJA6+50\Q('%&,7;E>CH^%=AN21?%)`"DD1*28EI)24 MD7)202I)%:DF-1;9M5##3W-%%]OR'YI(`4DB)2 M3$I(*2DCY:2"5)(J4DUJ++)+IP:JP]+MOZ:I"3JW/"U9W0CD=2L.HGQ20`I) M$2DF):24E)%R4D$J216I)C46V;50(](#:M$.8&6`J<_X:S78E/(X765FCSE7 M)DJOZ)%\4D`*21$I)B6DE)21.^'9#F'5ALQC MP`)3GOU`UT2Y\SEJOEK*/>A4'LDG!:20%)%B4D)*21DI)Q6DDE21:E)CD5U( M-6X=%O*5:UX[S)5ZZ>YRK1[553^3X__[$JY,E%[1(_FD@!22(E),2D@I*2/E MI()4DBI236HLLLNC1K<'E*<=#%OE&8Z/=Q\'K-2'+&Y7`?F,"D@A*2+%I(24 MDC)23BI():DBU:3&(KL6:@0[K(6ZYDT7'^3\/W`V5'U6)06PRM0/CX>]"!>Y M/LKT(I#?I9<[GXX*2"$I(L6DA)22,E).*D@EJ2+5I,8BNW)J%#NLW"L7N7;0 M:Y5G.`[N>A'(4Y_\V1W+)P6DD!218E)"2DD9*2<5I))4D6I28Y%="S6*'=;B M_=-RDW9`;-6I&R-+GQSU>/\@:-J._ZTZ]5," MYG%@LG0^"E]U*PXZB$?R20$I)$6DF)204E)&RDD%J215I)K46&273HWQAZ5[ MY8[33@E8Y<$LP6H*\D@^*2"%I(@4DQ)22LI(.:D@E:2*5),:B^Q:N',)K]2" M\P73?B9@V%7<%WE,E+GC]"MJ\AD5D$)21(I)"2DE9:2<5)!*4D6J28U%5GG4 MN[P'=)5=N#U?T-'BO'\$7I$\DD\*2"$I(L6DA)22,E).*D@EJ2+5I,8BNQ;N M?,%N\OI4'G[W]YD9)PXZ,L.2E0Z2;&;6;>F\E>#I*'DP&T29#V3M]KH#Z%>: MV8^3=7>\GK5DG3L@CU$^*2"%I(@4DQ)22LI(.:D@E:2*5),:B^Q:N&/@=C)# M])6B<#`\:VEX[G1!KYP[790\;@[.'?,YL=U>-:1[^RUZIL*=ZTY+UKD#\KH5 M!U$^*2"%I(@4DQ)22LI(.:D@E:2*5),:B^Q:J&'8L!9O/7?:X=OPN6G6TO#< MZ8*D-(.S`M>=+DI^#*+,_)C=7C6@&;;WE5.\'?]8S6QI<%:L9B"/Y),"4DB* M2#$I(:6DC)23"E))JD@UJ;'(KL78*&ER*A?Q5XK"(=&LI>&YTP6],(Z,_/77=3>25\3HV^+'LDG!:20%)%B4D)* M21DI)Q6DDE21:E)CD5U(=USQWD)RP#'KQ@WR8W`Q/O:/@!)*E^YG*B9*=QF/Y),"4DB* M2#$I(:6DC)23"E))JD@UJ;'(KIP:)0T?@=YY]9NWHRUY-C*7N@OSV+5[B^:Z M"]I[%S,QIHYM[D$_]1D5D$)21(I)"2DE9:2<5)!*4D6J28U%=AW5F&E8Q_U/ M3?-NB#5XM;,CZZ-+MX(K$V2JTZ:2]33YC`I((2DBQ:2$E)(R4DXJ2"6I(M6D MQB*[.FH\>4!UVN'G<*`Q;VG0!U8DC^23`E)(BD@Q*2&EI(R4DPI22:I(-:FQ MR*Z%&B$.:Z&N>.]ZLW/>C36'G:@EYU[E?JC9K3C\-(;DDP)22(I(,2DAI:2, ME),*4DFJ2#6ILP%[5D]Z(S]S--*9GSH;]'\DD!*21%I)B4D%)2 M1LI)!:DD5:2:U%AD5\Z=N'CE2:&?G]"W]^MY2[()32N21_))`2DD1:28E)!2 M4D;*206I)%6DFM189-="C?.'O>B56K33`M9S03=38,U9G;F?:<[[*%TQC^23 M`E)(BD@Q*2&EI(R4DPI22:I(-:FQR"K/XK`IAEVX/<70T;"KD#R23PI((2DB MQ:2$E)(R4DXJ2"6I(M6DQB*[%NX4P_ZNLN`\0D?JGF9FX\Z<#Q!6.LIU()6D MBE23&DV[IMI%=&<;7BEB/ZF@VWF]Z.8"EOUA6&DRA\'39!\&\PEB5[$NEWGA M(#`KZBV&I(@4DQ)-PXIU6S1-S734WJ;F)DJWJR"5I(I4DQI-(Q5SYQ7:^:$/ MZN]VOGR_O_UQO9$^(9UMI)(S^:.&NR-]M>!T0T=FUF`%\3J1BX+ZZXC34_?/ M(_HF0!^6H"/YQ19-(1)'9KTNL=.98Q.@LR1,G")Q9M8;;W%N`G3B@HE+)*[, M>N,MKDV`3MQ8B>U^Z,Y'N%7]U^;G[ZHJ+YWV9>4\A9H^4K\5UQ_]%<3K1"X3 MNJD^*>C(*J2;/-+K3?M4,2EAJK0CT\Y,KV=:E9,*IBJ1JN)Z-:FQ4MGE4;,( M;W\L5.,DYYV&CM2O%`UN6>:CS%VW7'51YB!X6LP%RB<%'5FE:=M@4D5<+R8E M3)7JJ+ZDF0XR0\2<5&@R/;]$JDH'F50UJ=$TY\\BTZJ+DU4-S6K8K MR@M_FGP=)4\[@US.4VB@HZP#R'.P2V^V&.D5S19C3?86G>M=HJ/V;C'546:+ MF2:SQ5R3O46G&Q0=*K6B=<5K2;T+9LZC,V>/_6Y%]6J1 MB;IPKF6!3B\I313/-C0BTNGW-B+6478C<,7KTN]M1*J;:BXVF4Z_MQ&YCK(; M@2O>6QI1LA&53K^W$;6.LAN!*]XKC;!/4S5]-7P>>N?C:CL+9EWU6AIAR>0J-9E M+5(#V_/%Z=*Y:`9Z);/KH29S_D::3.K83CV_F,R<1Y!$KV12IYI,ZDR329W; MJ<_G9TOG6:/0*YG4I2:3NM)D4M=VZOER/G$.2*-7VJ6VJRS/!KA0JE]O>_O] M>ZE2.!VS)?O^?>'L\*I;T>J8[8KR]E'_:-A%R8LLNW)/G7T+=!9S0$)-IC=$ M.HM)'&MJ$Y_-G,2)SF(2IYI,XDQG,8ES36HVZ\_/D]G<.8D*G<9D+C69S)5. M8S+7FG1F]Y=H&IUFE]DN]-BTW/3_]>"VY!Q=1TX_=YYQ5UV4U<_;7/(2ABE\ M1VKV2/7S\W/GN230>4R/"369'A-U-$@=:VI3SR_.WDG\O3/?KY9,'G]E5.ZM5HU=J MH<*=6K2D)J,&#T3.\&>U[*-T7_-(/BD@A:2(%),24DK*2#FI()6DBE23&HOL M\LCXY)#RJ'"G/"U9707D+4$^*2"%I(@4DQ)22LI(.:D@E:2*5),:B^Q:J#F> MX?CNE:[23@D-QW'+EIRNXDXQF"C35?H5-?F,"D@A*2+%I(24DC)23BI():DB MU:3&(KL\:JP^+$\[_#[X5YV6[9A?ZF:N9_+UE_9??+GNHJ1;F2CGD6ME8G35 M/))/"D@A*2+%I(24DC)23BI():DBU:3&(KN0:H9B6,A7^ED[H6'ULY;41U?] M+0DE7"W[*%,>D,^H@!22(E),2D@I*2/EI()4DBI236HLLLIS=M@4RB[_[9@?Y.EOWT:$C MZW8EKS?85\*5B>J[$24M'MO.N:RSFV%UUKE>7LB2W2?0[I*S M4_F2Y-WH$DOZKT]VEES-IY=7HVV3W\JZ5+]8--*V^4R6[$:?3K;KN1RW=@B. M)7+.N<[U3%HM$]PC2^;2 M:ID$'5LB-1W=SM54:BJ_[#ZRCBQ1?^=R;(G45/[$XM@2.0;R!__&EDA-949X M;(D<'?G+9V-+I*8R\SBV1(Z._)FGL25R=&2R:63)3(Y..\'D'.NKR?SR2F8F M1]:1)>J[$,:6R/[(G^$?6R+[(W\4?FR)[(_\T?&Q);(_\B>PQY;(_K0OR3BM MOI[*_LC+.2/K3*7:H_MS):=;^RCF)I/MCVY>MCYZ,">R0%<8RJ7-VS&4#8R?LE51^M"#JVC261ZH^ M6G2I^6C)I>)C^>7]M4OUPAJ/A;R.=JG>/^,2>;OL4KU.QB7RLMBE>CN,2^1E M+-G.6(OEW2K9SM@2>55*MC.V1-Y\DNV,+9&7AF7)6$7DY519,E83><=7#N;8 M$GEI4UH]5B]YZU):/;9$7IN45H\MD?<>I05C2ZZE!>IM8!XW>87[4KT4S"7R M)K>T8&Q/Y8UA63*VCKQX?:E>Y64V>?_Z,FV7G/1=(KV_NUO(-WJ?J2R:^ M;C8O^G]DTR>_-L\_=M]$_OG?`@```/__`P!02P,$%``&``@````A`&O#5E/O M"0``]2X``!D```!X;"]W;W)K&ULK)I;<^*X$L?? M3]7Y#A3O`]C<`I5D:\`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`$(*Q\%V8>RN0'+?$C):^?CWZGD3,-<2$U; MI%^(%$$!$@*)@`R`#('$0$9`QD`F0*9`9D#F0!9`ED`2DU@QHI0.,1+I_<;$ M)LQ0;J1F+F0V*70Q:H5($34@(9`(R`#($$@,9`1D#&0"9`ID!F0.9`%D"20Q MB14U"I`5M%![4G2-,-5K[FOF4*(U0(@(9`(R`#($$@,9`1D#&0" M9`ID!F0.9`%D"20QB14+*FANB(60MF,A":T*'N8^D`!(""0",@`R!!(#&0$9 M`YD`F0*9`9D#60!9`DE,8@T\97]KX$5-YC8[ M;YA"B`,7``F!1$`&0(9`8B`C(&,@$R!3(#,@D0*,8E`A4=/*P_1*[DTM^_9F]?^47GT MJP&0$$AD$KOKHD0WNWYFZ,TNRHJ>S'&X>^)0323>&M4YQ42IUYS1[1=BNDX, M"G:7Q\2IWT/UV->^1JY&Q:M9_[0)VTM1_-[@I1!WLI="-(%'-OI"LUUHVCZ*.O,&'V59:D52(2>2=T5[^?KK MBQ/0/.!F)!6CM2\.!;U**_SFE)NATK/"::NU*PTKFK5Z^.VK)2?*M1N\E=6= MY:U"8I$;<7%.,_OBT-:-J$1MRC+(\-"LK M%3M`@3@-)@>-]W*(*$(T0#1$%",:(1HCFB":(IHAFB-:(%HB2BQDQT+413?$ M0I915BPDLHM1SSD6['N%%">!`%&(*$(T0#1$%",:(1HCFB":(IHAFB-:(%HB M2BQDA<>_K3C-Q>WTKI"Q"/J(`D0AH@C1`-$048QHA&B,:()HBFB&:(YH@6B) M*+&0'8O;BE,?BU.%1!-%7O;:SMNDKZ2,%RT3RF>&GGY_Y!DPU%*\Q")$`T1# M1#&BD4(T5]G\F*4*,F%B]]2I):9:BDW-$,T1+1`M$24*R9[:(12%L)GMC#+] M4T2&A;'\@D0>T.@,&YQAPS,L/L-& MS,P(RM[I_DZ4T.7-T51+Z0@J4W?%;)BCU`+1$E&BT+D(_M.&Y*J-EH_[$496 M--T]2E!(M;_::QD2/#01,SWP`X7TP`]9B*JK_-?GFNR-E`,]*&)XRTX2DC:;A3 M=V;]C)]KPW-&VO""D3:\9"0-MWQG*!)^GANV0RVVU1!JNJ9'ZUHC1)<5\)HA3"B-;..FXK\2L;"$UZZ;BF6RAI.1,;]\Y,SUBPWI5#1CI M5354Z');,4O)MEHX.61??-W6&-N:L)6+?DV55$N<^]%)2>/.J?MF;%DW-F>D M'5M M[PLLKZSV.EWZX8!>!B[W:MV$CKW./;FC)WD-!#ID3%8T[A.?K-&F`*W1E=GO M^X(_^]0?;SBM-YT&MTD[PV<7FSF^1W9UW> MZB9G[;2[]/,C.M:C43HW2'0VWQ7'[*@1^%XWILH>G]"FHRNV`?@D\'W2.3<@ M5.:2SKDG5.)U0ZI1T!I5:&3MW!,JL+JBAD(=JI"HG?Q)M1@RNG3\OGI-IZO# MZV9_+&W3%YI^M?RW@H.\MBS_.*FS]:?L1->-\V/V-[I>GM+;I"8RWDN6G?@/ M:KI:7%A__!L``/__`P!02P,$%``&``@````A`,/XH#"O"0``-BL``!D```!X M;"]W;W)K&ULK)K;!^#.*,PO:$ M.0@)22`I9F>O,99MH@$Y`-O=;[]9*J52E8EI,[$WC?M3UE]9E95UDF[__+G; MUC[2PW&3[>_JUDVS7DOWZ^QILW^YJ__G+^>/0;UV/*WV3ZMMMD_OZK_28_W/ M^W__Z_8S._PXOJ;IJ08*^^-=_?5T>K,;C>/Z-=VMCC?96[J')\_98;6%=MM&J]GL-7:KS;ZN%>S#=S2RY^?-.IUDZ_==NC]ID4.Z79W` M_^/KYNV(:KOU=^1VJ\./][<_UMGN#20>-]O-Z5-H8-4+J_?=I`"U2WUP[I\UW]P;(3 M:UAOW-_F'?3W)OT\5OZN'5^SS]EA\Q1L]BGT-L1)1>`QRWXH4^])(2C<$*6= M/`+1H?:4/J_>MZTV:FA`CZQ^WM5;4/'FZ?1Z5V_W;KK]9ML"\]IC>CPY&R59KZW?CZ=L]U]M M9!526J13B,!O(0)RWRP+M>0.P&]1MO_MLKVB+/P69:VK?8=$R.N'WZM]'Q9E MX?=JWRT(=5ZQ^N,?>V]!1VL5"N#W^]YJ8VGXX_H68-@MBOOU_6]A$-4?5T?` M@L&BVP]_7-\"#+Y%T?]V"QHZD_+$G*Q.J_O;0_99@]D.86#[NVU;WMO$!D\&ZL!E)&\NT&*.%RGPE M.^%@RH'#P8P#EP./@SD'/@^.$%#06BP@:(%%)AQ,.7`XF''@C5IJ441-D*H@CR$P05Q!/D+D@OB"!(*$@"T&6@D2"Q((D56)$#0)D1.UR M1BGK/#C8J2--NO!3ALOJ\V6F-,)B$T&F@CB"S`1Q!?$$F0OB"Q(($@JR$&0I M2"1(+$A2)48L8(MS12R4M1D+32`KL)O'@DP$F0KB"#(3Q!7$$V0NB"](($@H MR$*0I2"1(+$@2948'0^S_Q4=KZS-CM>D`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`FBZJZHL!J4$ZK2UF"&B MQ'81D9:'B+3FB$C+1T1:`2+2"A&1U@(1:2T1D5:$B+1B1*25(,JUS!A!O(T8 M_286RIS%0J.VL0(-Q0JDK8QIHD#4P*EZHZ@F$_W>6QTQ'$34P!FB:K8++0^M M2&N.B+1\1*05("*_0D2DM4!$6DM$I!4A(JT8$6DEB'(M,SSJMD5L&GKJRX!S M!_7JZ4+?T\"Z@DO^2+UZ5;UK1HJM[^/"RD@D7;!-;9T65AU]JA]TFSTV:3JH M0P[,$-'X=1&1M&=*=X96F[DXQT(D[2,BZ0`128>F]*#3[[&]Q@(+D?02$4E' MB$@Z-J4[O8[%.B3!0KFT&6586&24H=.O6+^5!$M,C\@:/%;ON]6@H$$[ M*5"'-C%31*W\$F?08FUS4(4Z9(:(A%U4(6$/D1;NMYGP'%5(V$=$P@&JD'"( M2-U=?=Q;[0X;1`N4(>4E(E*.4(:48T2HW&,K=8(RN;(9:'6U(]*Y+U?$*P*O M)%G@-6)YSO:X8[@&4`6-/->H0](B+I"'5(.D94>-WO M]\4>J>C82I[KC\'T-R>[]/"2CM/M]EA;9^_J0R\(U/UMB>Z!*ZRH)YS3^!F"NHY M]P0NFJ">ZW=W:,.EM;0/AC;< M.TL>#>WX'!_U[=&Y>L=]&]ZG2)U)WX;W4&?XP(87()+/^S:\!I'<[]M^SAME M1\!7BV^KES1<'5XV^V-MFS[#8&_FD]U!?_>H_W,J;JT?LQ-\KPAS&7R!!=^G MIK#]:][`1NO\_````__\#`%!+`P04``8`"````"$`+LM@ M%C(!``!``@``$0`(`61O8U!R;W!S+V-O&UL(*($`2B@``$````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````G)%!3\,@&(;O)OZ'AGL+;1==2,L2 M-3NYQ,09C3>$;QNQ4`)HMW\O[;HZHR>/Y'UY>+Z/:K'73?()SJO6U"C/"$K` MB%8JLZW1TWJ9SE'B`S>2-ZV!&AW`HP6[O*B$I:)U\.!:"RXH\$DD&4^%K=$N M!$LQ]F('FOLL-DP,-ZW3/,2CVV++Q3O?`BX(N<(:`I<\<-P#4SL1T8B48D+: M#]<,`"DP-*#!!(_S+,??W0!.^S\O#,E94ZMPL'&F4?><+<4QG-I[KZ9BUW59 M5PX:T3_'+ZO[QV'45)E^5P(0Z_?37NW7B)6D'R6DGE*KM=%3LN"DMEKA4^M\3Z;@'H4^#?Q M!&"#]\\_9U\```#__P,`4$L#!!0`!@`(````(0#C$.P$'Q9ECOE)M0,,6\2KM3T6-%?,\3.O M\TU%A)/XIJH$9V"IRN2),ZV,*FQP]\%0Q-&A,R9V*;):<[M)!G%T^!FG#`2. M"3@I0!B,H[TA?D!PHCT#UR:)U_9JCSAFE\DP\LF@E;=2(?0,B%'E^.<6X%F M5CR#MC[*EX><&Q8MXY;0MHL9S49V)RWIE3W*MMM<'3+?U3!6TBC!<["89[<@ M0#+,TJ;2[$4>D7+V_YS4TFYNVDRFBFQ64=-V?)S\;3$=9MV4,73:L$N9Z05( M_MF,5*/!;6VX1../GO*_-<^=1G^X69DFX0DD+!IN7DYI79:@-XYVRA>2T]&A MHQJ^[!5$C2[KGDM2F(.@OM!>+UC599*9JE5 M;)6]@=:.P93#.Q=4BS=E@J@+CB+/I@K\36WA9I4[C:T4C>66#@B-DA>U7PS_ M'/3G#+W[]"OHWV MTX9C]KGP1WXSFW^[?Z>C&VSY0 M76.<+D%C3E?WUK\WQ`_T-FGA0,9+D`O,MS'_.MQS^MK^,R1G%Z>#\P&]E`>V M.-K_'21?````__\#`%!+`0(M`!0`!@`(````(0!F'MSGR0$``(03```3```` M``````````````````!;0V]N=&5N=%]4>7!E&UL4$L!`BT`%``&``@` M```A`+55,"/U````3`(```L``````````````````@0``%]R96QS+RYR96QS M4$L!`BT`%``&``@````A`%"KK&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`-!\67\Z`P```0H``!D`````````````````91L``'AL+W=OLTG(&``#K(P``&0`````` M``````````#6'@``>&PO=V]R:W-H965T*K204``#87```9`````````````````'\E``!X;"]W;W)K M&UL4$L!`BT`%``&``@````A`(J$A6]F!0``LQH` M`!D`````````````````_RH``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`+"3[IN+!```^Q(``!D````````````` M````\CT``'AL+W=O&PO=V]R:W-H965T M&UL4$L!`BT`%``&``@````A`'\M(.ZM`P``[0P``!@````` M````````````7D@``'AL+W=O&UL4$L!`BT`%``&``@````A`/MB MI6V4!@``IQL``!,`````````````````(:,``'AL+W1H96UE+W1H96UE,2YX M;6Q02P$"+0`4``8`"````"$`-PMD9\@#``"<#0``&`````````````````#F MJ0``>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,;[ MUA[J"```0R<``!D`````````````````Y*T``'AL+W=OM0^,\*```M+P``&0`````````` M```````%MP``>&PO=V]R:W-H965T&PO=V]R:W-H965T&UL4$L!`BT` M%``&``@````A`'OAP3)1`P``10L``!@`````````````````U^T``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(@*2M:$ M"@``CR\``!D`````````````````Y_H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`#Y+@.8^!@``F1<``!D````` M````````````(AH!`'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`BT`%``&``@````A`,MY0)*X%0``K((``!D`````````````````>$$! M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`"[+8!8R`0``0`(``!$`````````````````&UL4$L!`BT`%``&``@````A`.,0[!RF`@``8P@``!`````````````` M````W&T!`&1O8U!R;W!S+V%P<"YX;6Q02P4&`````"8`)@`\"@``N'$!```` ` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 15 0001140361-14-031321-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-14-031321-xbrl.zip M4$L#!!0````(`%R+!T5G75(J.ZH``*TH"0`1`!P`9'-C;RTR,#$T,#8S,"YX M;6Q55`D``Q_OXU,?[^-3=7@+``$$)0X```0Y`0``[#UK<^,VDM^OZOX#UKN5 M3:HDFP])ENW,;'G\R/HR,W;L)'NIK:LIFH0D;"A2`4B/E5]_#?`ADJ(D4J(D M4&:J)D4+#:"[T2\T7M__XW5LHQ=,&7&==T?JL7*$L&.Z%G&&[XY\UC:82?;Q!VG'O M6#M6T)4[F5(R''E(/3OKHC;2%%5'/X_<,7,=](A]#_I&EZ:);9\=HTO;1@*< M(8H9IB_8.FZW>>^OS]1&@*S#SODG>7_.^GCT_F M"(^-=A8?WKTUJYC$IG<2%$:@A+D=33U=1FP`$5=P7C#STFTS;!X/W9>3H.R$ MCT!;4=NZ&E6"<1X:QB2N-3#8L^@A+.!5.NDJ%B;YG4!!#KCOT84TG)U`:03H M^.-\0,NC)]YT@D\``E-BQA5DC?HS'3C M"A:HOPN68VH;S^S8=,>B@M+3E1"\B(:"9B/T/5>I-/PM_A78O'?!P13)!##*6HB/EW=_7CT7H'_SCJ]3K_W_4FV-9C:]]$P*&K4RJPL4PD[5J)*KZTKLXZM1(7HUT37 MT4\A[Y:S\Q1$H@Y,#,3,"_EQ"I(<-QZ65,$/7=7JQP^]#09J._RHCY*EY2.I M+Y7*A]()S8]>&\ZDS`^XP$Y)\Z-OS_SHL36O+SO+6O,MLK,32V=]]#;K',M* MYQ:=HU9'9Z!MSQG41T=3SG%KSD`HV9N,'Z@ZI,?Z$Q\^8[H%],U7#PS&.:8\++$#C=6(3DW@!CL@B`!=D$7A\ M?IY+XM%[4;:(T.]/X722AY2L?C\8ZBN*+>+=&B:Q`3LQSM<84^"U;7TR M'&.(.2E7[GAB.--ZCG>8)3B?)S4<[U4$'^2XVP9C]X-_&91"P_?TD6>UQ/#? MDA?\&S9H6*37?-`7T1F.?3ZUASCBCYAYU#<]GQ)G&!OU)_R"*;>!EX[UB#V. MNNOPTGH/>RZQX9"O(/G0QCZ57&JD0#(ID#J1UFE$IT:B(]$T,T=@KESF"7Z) M93,A.C?CB>U.,8[Y&3#J#0O:/)..WD>`"[BU2MH.3.@E\)J-)#>2?-B>7RP9 M?;DU"/W5L'W\`>;!!M](P>F]I?@/GR\B!Y/%""8!P1XQ7V@&QM=;G@O0/Y/I M(HS8@XW<]CI:4DCBSW_"0!C4'$T_@J;9:3FYJJ.U-=@XUN_O#)BV'S:@>CM+N1RFI5-V\HMJ2T:]LTM5'7 MO:KK07O:.BKMSOUMH[HU#9(;3RN-TM;!TQ:!SZ>JR09;>!%E[BB(*[K=J_%&S<-"HZV&J:[U][#JVY(UYUR:% M(8_H29HED-I@U,N[UB@8;B:,NW5FD@8`]9K'OJ7`^`#44"I)/P#/)?-:6>.Y M&L_5>"XIYHB-WDD@0U+K?\U#L[<>5]562)I,V8$:TD,/8&JV7;]>]GU7`,J<9=K9K*[SBN^9*LLI7I:B4S0$TFRISU5/F-,C.`LO#4,_=14E2*\G^ M3%J]O*=T6.KDXY#-V2(3)M0L`:;`-J]$#>&5J30*F= M>C8SM&:&]L9G:/4_VG9HNM4(L4SS&.G6J-Z,'D@5B,D0F=8V!)19/6O^2&^S MBV^!8&B-8-18,+1M)B;3#Q0V(E(C$9'YY;]8KO1&KFHM5WIYN=*W*5>---5, MFE(1CKS9ST8P]B@8V\R[S3Q157LD'@UG&+S7_,EX)6-_W(C.%O8+Q%R>]9QB M=WV\82IZK](;5A^])V6;./67[3PA2M(EV[)I,X/8C6PW=OMMV6VY9'N[,"9NK'X#:&/5Y;+JV]_R MV^BX9#J^];/DS8A+-N);/]G96'7)K/K6#PLVL;IDL?HV_7AFPW0S]C*,O<0[ MH3M*)[7*U@B,=`(##J(CSZ)<=EFV$1@9!4:B5=Q`3"X=!QA$F4&GG$LLD!#7 MI]XH4718NY"$7.01'HE,/OFK9*:,U,JRSV27,YQ<47LBKV]8TO*I;P2MJJCI MSC'=,7[RP&9R[#^ZIN$!>X1@/6*&^7[#2["I?#^A.^$@-Z\38"&NI[A%([R$ M[)D8%*"_":M*2=0/V,'4L(&AE]88E(QY%`I?\-N1J4(<:*1*U6.ITANIJK%4 MZ>6E:JNGIXM+5>/]Y/1^LDF4VMBIP[!34N4VU29*K[F=DBV755RB&CLEKYV2 M2ZK*>+_&3LEII_;K^7R'!.+TBZ*HF?$?!]=6O@\1&QD4LZBIJ"S9/&]K4=O: M@K8)GK^R]/UNDWKF:8M\@)BEF4?K_'9'X-9\=RY1&5A?)(,SF\QT=TU M=ERP7LL[7,7<;(_SC4:E";J+L"U[/B[J5*1];\83VYUBO.Z8=)>*T@0^UVVY MMPQM?A^L8=M<.8NU_Y=V^Q*@+5X#W=K&L-T."BQ,SN,27H!"Y7G$@UR/?O1^ M8-@,R)JK&?=TY5,J^B',-&S$4^WHQK$05]YDOR%<`,:A;@(%7XU".]H?LJR9 M&)]KUQ1WYZ('82IR<8E@`I#"B"3=WL)F8D1NA.5$_\*VW?[=<;\ZZ`E&S76P MA>X8\S%-8A0`<]@?.6@$&0"NQNRS&V"TM)DL9K^ZMN^`89["V-F8LGE\8H@` MH"P>F>K9_B/)><03EWK$&2+N[/P01#T6,""SZ;(SQ/"8S`%Z^&I7K MNZ>K^U]O'G]#'R\_W#]>_GS_>'?SA.X^7Z&3ZYN3)&+IIN=&#K@(D2RZ^QY>V+!CA'+Q$ M#5$A`$]`YR!YJJM'B%M6\9L()Y"%33(&L_CN"-#N=S6EUU/32"_I8]Y.)0WG M+?S(\BS5S-X)D&*V*FVE,DTL1"2TFRM0":`*(O.3EH=*HHEY9'Z>3G)--O]] M=8>JTOXIW26O-_..INF"96*(8A.3%^/9CON*`NL(Y#&&^(R]R&)E^Q<;2]-R MHB7EI`W17.\4!/S[DR+M;PW/@#O+\>RH&^#Y8$PY2"NR[8NP#>$VP5/M*OD< M3;>]-1R+C+G:T?62.%(?_,1'8CP3FW@$LV5HAX]/ M,`>`<*.%PJPC^@:ELX[[9&2Q7/`*(]#7=L3*:OB3625>%2UDG9ODU&5&?P5U MIWWU4-6@^BTF*]1@9X*R:\M<];:*%99946JE<)E%DA74G?7TPU6XJO=*K+#, MVJ[\SNY#H6KW!ZR**'=EN/80"E6]++Y"N_7^@8IDU4O!R_FH9W,?DON`;-IK M53(B.VLN2=Z89\W_#`AQ!RA\K]`9`HG,8W,T)<#O!S&P@-TP?,R0L:2CG2!? M+K*7#ODR<41?+N1+*H!2'OO/KM,V#08&+T.&A9\]9!$6Y/.64W$-L-GLA-43GO.E+,U"5IA`8)8 MHAA9:2WEGCZJMU7J%G>[9R*KE,D"1#ZX'M\/!B&T&2R\,I%0)HSY?#D#^1/X M#;]B:A((5X`+0;D[X3T$//@:G`=GZ%L"U<7JZ'=S[(`^+&+[/`Y^XB\+BY3^ MS:MI^Q:V;JD[YG&*[X6(WQC4`;39`Z8BD@&R_-QED"4"D5K6;7>!5[U.-B-0 M!5:'P,H9S=$K\NM9:3?],5S.:(AI;K$5:9;S^LN"Y^"$KC#NEP53 M"HW/N@.3P^; M9XPV&)P5>O,F1V9MK=&U;K6C4U1U-!D&:'=F;0W567=4"@S!5GV+/!S M2I>4WI/[TF60RYJ$]^MEVPY8_V5R7VN$^&]R9/:9N7XKJ;8J[4\`L?A,M2C> MY!QU_U33SW)&=N[P]":(%-K^TNOT\[:_9!'Y8##"N(X_4,R@0.P/RJ(C@.X' MX5%[&)D'UR;F-/C_SX#:!SO_%'3F#HEO;._"(B^(>5,;OSL:`'Q[8(R)/3U' M?_^9C#%#G_%7].B.#>?O%TB4,_(G/D>J,O$NCKX9>A=Y;21@PDJ\\!SQP]/$ MO$`>^!'<"729Z#WZ?*;H9`'(0@3SD?EYA)$! M_!U/#&?*-9D`+RD9PR@;OD7X$0A@+P..6^(\Q"`R2=!/>'2#H9'Q@M$SQ@Z: M4#PQ*,`11S1++8#&Z"OQ1N+O8!@!C$`C$QL8/PQ.S=A37HXG7E#7`[1^.7XZ M!K;2&*59W\2!W\?!#LVRQ\UQT"Q54Y1MC/+GX*P1A9Q<_'0=_ MJ#WE`EV*%@`U>]KBU:?(M",V,F&`$,^4D'+L\YY(#%P70]`,;_;`]PE MI_YY6IY:1S!;'(AA@FP^*#8.;K-:/@!)2NZ"YMP)<<+]JR#4QE``M@09AO4? MGWG!R'W+VR9,H`F@#B>,8T=CRV[P"QE`O;\3:!`+<_HX>@/N&"8)R4V(0<@U M*XG8_81?G<2;A#J^[05$_PO&)FO=&A@?$3P$EA%\GV/1"S#G0E-_1@X.[ M@JZA.6[QD:X&'271!@6!7F>D.2XR1_Q)$"%5K@_CQ/<\\NMVDD/.310!&$:X M5&9[T),]@&0B0^P&]QD+QXRWF]-<"W$MYZI=Q@X)16<8"VO!R_G?+?099!;I MT&2H$YIR,;.TZ"&B@(\+OS(&^DP64]>!;S,0P%;T?DYQYQ(;%+ROCXPZ^&X!!D"W>`<4O!"RV-W(9%JP+'*YH$SK^#V`F M1#(T!V!F?_(-"F;$GH:7E"$HC3H%4Y`QI-'WS(T5\T6Q?XNG&>(C$4:WHEN9 M[AR30O2!T;<@'>)K;LLOKWOI6)E`/*@?58\J;[AKOJTIIUHOY;C+]"X1W>4V MTG?TGEHAU=E)93'*+KTK@U+N?D4`N5X$.#?S*M37KD@H%#O.;5&2B@2MP"AH MO?Z9)B\)130"A*V[D2#QYP2Y#PO?"T3@WL23@JW4=7[7&-,!P;:%/L7QB3AA M"W'HPNED[E.%RZ_]$R\Y0LQ"O%O#Y%=*!3/`N/M9[V'G>;._]$&(WM%[<6@O MQ:,5F)5E3R6$KSK-T=D&%3?129<'2DR<@&$Q$&OS-R6#>Q*C!A;G,'.1BGH1 MG<2%+"QEZB))*/NF9XJ#>I*#&C#PN+N*>:OPK(RCU>G3NJS=5,FRW-6.^ZHL MW)V7U\49QTJ8JIPI754O_Z;]MA)!JA3BJ'9]6)Z2)$YDM-`'6O(C`B)^SM%S;-F!V.>$O1?##B//SD-D% MB`\&O:/?Y]NB]1?6CQ+Q%-"(*#V M]`+UNRU-.VUUE;Z`[W=:O>Y92U75J`=^FG>CUI5>JZ?VXM;U?DM3SZ+6W40D MMTX72X9Y_>E8YHZ9;)O-^.UQ_`IE!-8:OS2_EIQ'O\I>C7X75"D[$PEN7M=. M8>QRD4TVOBN<<]@[AW,')`P$;$.<$Y)?!N_+6;4U^"T6@95%TI'M8=<$%&"^ M6B$!2=TM0\$FL^_4:P-%>M@]"<540.^#%2Q-`O-X!#NAKN6;'F*&C>?S6P!T M/_C!=2WVY-IY4E[JEEH]D^1-MUXU:J6NLNJJVNYP*Y<C:FVQX(^"YP#%4B\@:V,#[,K?-`6- MB6T3UVGQ/,>W)-,;7X[@SU_Q>#;N$)B=;"%NXD)P,F;*@!.-:6LE=\)!F#'G M6\\=8D%]L*_%F4958VXMY.QW.:SEZ\FV@,\.\W1GG-8WYW0W;N)XD:8FU2K' MJ%C"J$3WXBW7T%^<\%(]'-]NMM[C,\JIWEMB7'+ZV0'FA9ZD47N==3$7ZXQB M7Q6&L>-/FD%?%DB9,%>#,(DO@LD1%("4>J/Y@#+=WUW8W".T%N1['C#E^T:, M8:$$1#M@!SL4>:]*RLK\QSJL.W90GHH)S M-W7G@[8;/H"4R\T'O:(;`%::(37KK>3B0U4W(6S%IGW$C)WS7<[N&()\ZH[# M/<%\=B?V10=KNJ&#:6O=S`F,^2[V1$C)+:EJ/_/, MGD2$E,D^MM5.YH44:0@IEWEK:YVSPJ*5..L%R%XEW\YXQ+;8%2ZNIVZEWM@( M9X@,_9OOJ49B4_6\(8F;OA\D&P[;%*<8KI.SE-]"]^^L)TAPY`1MO[ M5Y\#X/D0L:`1RH`!DFV)XQ4XI"2@T8&`/?H%YMK0D^=2AH)*0<:%T)22!%D8 M*SQ..N3JTD*F89M^((`^XYD1#O/!-J#_)W/D\F,ZP=W<[0DEXM[WL6MA.WDP M(27-.'S3A892#7CG4$/8C#46GW$;S_84N2\XR-F\X.`03I"<::&O(V*.1$9G MQ@-HPIM.^%$3J!DF%K)\72!@@;@&+`JH!*CN'_M_?VSXT;.<+P M[U=U_P-OWJ3.KJ(=?5O.[*;*F8^]>6XFXV<\V3Q;J:LMFFQ9W%"DP@][='_] M"Z"[^25*(B62HNS>W6QDB>P&T``:0*,!Q&-!="BB?EF*XPTK6*/,VL*7CN,] MX<]<;)"X0#\,+QA!$"VX./RX!S5""O@1RJ`1&`867H%,^A;S\:1+,YGC+`T+ MXVCQW\'2,.7?6V5\H^+0-?I&UP)8]-EK[P#L_:AC6C1:H!]EKP9X7/B=1YJ<-A)>O M\#]_U`;+;QJIYO@7E/;<6`+.Z^]K7S?<;O>BGT1'D1#MMOK8/D?78W/^MI>O M#WFYB9D/U#"PT9E_//A>Y%H7H$D]_T?-?[@_&_1&^@!3S<;C\W+,L[9W:PO# M?[!=P9=7EX/X*=NU@)5^U"[XE\*`RVVL\<791P^L&W(SZECY2OCNLT:-$#0M M>OU>;]==7'KN^\RMVYKT757L:A;=5NC;[WW?W(Z^"?SQ6!?_'%O>\%BQ24DK MQ+1.3CB(E&E.*"5F.>Z6\C:^'.V\,D_ODR/5IJAN(D][HEK;`HTNK[2$?JW* MZ]'W1]\._KB8H2N>.4U7>R3I\,N)VB,;I&_O\FI4XR:YL"W+89W<)]_);1'F ML.%G:YNN.>+>F&/#5K;')"Y\NEM69^F6$J$?*$J8Q]NI.\;*8Y'WS/&>M"!: M@)C`:P$OE.2%1C94;A8%HF7U)5E:*A5JQ])"O`X3'AS(A$$>=`YD-2=F/>,8 MZJ.`D'/5%@@(H[WRY*^V$2!S^R`ELPGK<6=_.X75V&3X ME`0@9PCEA;_*?M$`1HEF%X[!GH%("@LB?0!S##G=!D8EMAE4%=[\ M"10:Q3T=_GN>.HQJ_ZCN0+XJI&>;(O_R%G3;P:%:T'T6E*(+2CS5:KXLV:S? MV.Y*M/\+"QAFFO/<2_Q'>XNIY=X2HRD-&?[ED:]/O+8M?EV+0<]\5RO1TF!3 M$D\3T7'2EV%&Q8U?8<3CJGS`[ MMA0HZ\K)_AUS'(!3U_[&6^.D;.T;:V&[=A#Z=!VSS?A=>>+4)]9E7,V]6*]3 M0)>6_*I\R#/1IH-N><['6!/%V\^3MWO-&EF*MQ5O'XNWKX=3Q=N*MY\E;T\& MS\XF:H^!NA/=O@H7S'OLE'_8U1.UIL,*VP6&P!.L[SH'M?L1(,/ MU9%K-D1Q-6TV1%'(7UT+HRDA>-E",&G9HU%"H(2@EZ8H]#(#O.8BF M:&U$U2!W`'KK.;:YZF)%1_KQ1\T.0:^8F^YYXD@1?MA(`-(345YC"`CDQ_HN MGO*%=]/0$!A8T0_OF$9X]_I^Q:]?8P6^^-'[%5TA7:O(YT;4[\Z;9=#*]JK* MWC]-%UBDNJ(PFKN)/GG`'@`P&)'-9LP,L00C%I5<>B'H29OJ)5JB4JD6)-50 MR\'R7OSR9V3X(0-Y8GCSK:#)'^_KAX\FR$NL$S)0Z:SF[LWY]I7;PD\.9@`B>5= M[0'?9+<5E"B20EY"0*@08B52(ORJ5%QV0L[1!S-@SMRX3B@":NWB1UTSM`=< M)R,(/"SG#P\3ME0"DYD^,^AF-B]DF2FC*5%_UK^B(*3N1L#[Q(("4M[UAJ"0$F`OEH89-RBBTIDP59KI2*(E M.+MF6A/]C0*?EJK?@-^QGMC_,GZU'0D48>E5*-J[4>@D.1./," MJJ*YDK;@EUIWB[;0,'+BF!K\-GU,--&+$FCVGMW[$;;RP0[4)*L2B?;JMJ9K M"H@&2+B>6&652]R2\R#59N6K&G,__`K([A2`9UQ,X+KF8@*CLL4$2AD4JL!` MLP4&7L;UW!>RW+OJ%[R,Q3[P_+9,PD)>QQ7`<\)WL=5-3W73\P7>]%2KJ63S M!:WF25M;D4FQTC.B4;.:L:E[<;]$"ZS3 MZ?EKX;,.+[_2)(I,SUN9*!H=0^%VYB9`?%YOX+G8TO/#735056F!YU1:X*S? MTR>#9AW#UA:AJ>,?Q;E=Y-PI,.XIE&E1C*L8-\.X@X'>.XGR:XIS%>=F.;>O M#QK.:^\$Y[9TGMQ6R:*=7L!'%@0_8IL5;\&TF>\M-'-NN`^4WY?-[1/Y8''F MWH[FF:IBP&D`W6S%@+.^/FJXHEZ#10-:WP65%#Q/*1CHH^N.':@K*5!2T/I> M,!TT6^Q724&W&$I)0=%>,)Z^U+V@(>]J5-*[:O^,19Y\TY62G1=/&M4?J@S! MRRI#<-8?Z+VK=O?;&DL1''V_5?+RTN2EK_<')UO+3,F+DI=VY64PU*_[S1YF M*7E1\O*U0';:.[QN,L#1M8!+3;&4+0`=X:"Y28)U M9[FZ0`W%/HI]%/LH]CD^/"^0?4[WOL.N2VAOF>LM;+?):VBGF[EX9/FI!%`G ML@Q5`T[%/IT@6'>6JPO44.RCV$>QSY':]=80HVLL$8,7A2Y?WE6%![ON896( M1T_'>F_2O?[9RIE_?JPVNM;[PV9[WW2-N-U9VBY0HT6M-M*O)A/%:HK5FM=J M$WW4/^4-],BW.5O/-WXK>PID#5NZURD;"\A[G++!0%"KK;OGK87C9+D<>&NA M4T`WF[PR;3DQ%OQ]O/D[;X^'+7;DE5QM^+N%KE[ M,GANW'WD.Y*MA^9E?\0C!>?W3,L_SHWE0]/RNP5UX]'_Z;1=[;!WNGV3ZZ(8 M_)DR^.A:GS8<"%8,KAC\B!I\HO<;#C\K!E<,?D0-?J5?7;7;FJD%!D\Y,#]0 M\]L4.>3'^GH"WU!'\DUMCL'[&&5[B??6>HDWW-&<^?B.Z438CIE.8J@G,35\ MK]"3^)Z91A10ZVC;ESVCG[S(L;0Y>$SP.T,,0_NBW9[,OS$0'.#2D(-AN"O" MS7.ID32@Y@'$A,O29W/F!M3RFM<;/4-4S]?@E)__\D,47#P8QO)'V?#\EOG4 M[OS6&$V"SBY\N M>I>#Z6;(Q1P-0SR,(1Z6@GC<.S;$H]ZH$HW[HV-#/(PA+D?CP:`\Q.\62\=; M,:;]S%PVLT.N4^C1BWLC`&C>@#R!,)$"6<-`O"U?OG$M>O5G?#/]8C6^&:1Q MNAB^^JD_FE[W>FG6*3OQT1'=*M+KB%Y?C0]$]#<1W;J0T:U'%H38HY[WF$=% MF=E$-J%ZQ_Q'VV3%L_WBN3@LLVY@^[&"KUYH..G?WWA!^(L7_H,!JJ;WX()R MMVYI_O>>+[["Y_H[Z?73[?`?Z^1H![B8IN^Q/O7?J3[U#28W<,KIVKMO2V:B MR/[=^;_S\4GXYN]B!;)%SFJXPPT06I\ M.7HR.(Z]393Z@V'_G_%0/Z_BC_]E`R_XYGQ%@-U\LX/DL0\NV`N4]%8U3AY_9:*SR@W'4D1%_PQ#T\HVM=N)C5R@/4^Z7)G![`#S6P7DQ`#<=@G MVN$M?=O$PS=#'KK=,\UG)K,?\53/\S7#Q1M6##9+7UL:MJ6%GA;"OA3,&/R8 M=,W#QGHX,@P(^"X!87AAX8%);%B/L(T9#\R+`LRA_`,&PY'QZ7CHS#@P)YUH M.RL^E6%2L/N>A4]X&BC&6!IX-`Q3T8$;Q^)"9 M<]?^,P*6C##*#\02(*6[#BY@CP>O4Q.KK6O\\R$@K7J9-66HICRE$Q` M,)C,<412P%]?@06&?P=+PXS_!N#`_GI[=_O^HQV$7_&E5]L50&D=([,,>KWO M4V"EDYS%//+!:5H19?,B2D%TMUJ`5HKGSR=)A-XR`0KGTC)I'^DTA^FP`@R% M\VQ,NC"BT.-S\;VSGU&3_S?R<)LE_1.0T)MTPY,+=T`:PL:L:IR0ZPDN#5)3 MV"RX+)NA48VG-A935NSXC-AQD&%';CR)I`[8#EU-,BWMC:C[TFJ-V?2@9<-> M&<(VAW.1K`(0]`PC!.D0S-FLD-<'8A]B:_`O\\4?-#H&"YB;[$T>*8IM? M^!ZPHVI?F!GY/J9C8*$P[G=$#8!:#!8:H409>6M6K)S6P1N M?2'[O;96"BQ$P<[+FD=9\$TW;%^N-ME8>&MNA^P"-3NP`%^C MXRB03'Y_!UFJF\MWC)42[J!:H\ZO4<6[T6J-CK!&%2^''77[K'8S;=]=A&)+Q9:*+4^@#G&Z]/8VH[ON.L0[ MC6Z$'W.>0LIP>LN67F"'M7+@GE7(CU,1[\`JY)T"NMDJ?L/!B538;[-&I>)M MQ=N*M[O#)EV@8\=XNRTS3?&XXG'%XZ?2VW%4TC]IO;FAP\+07@+5)M>U`+SVLIN:C`)T+2I14\!A"T!'.,ILDF#=6:XN4$.QCV(?Q3Z* M?8X/SPMDG^>;Y_XQ*6A3ZT6D9Y$?=V3YJ010I_/8%/LH]E'LTPEX%/LH]E'L MTX$D[+))#JTG8:?;,(L6RDG)\UIMQ!?>5/TY!?;WRVS5!X.*E<2.%=)O,^]/ MB<'+$H.3.]]2PJ"$00F#$@8E#,I`.BB8GJU'KTJ?GTRQ8E7Z_*3+K;97^KR@ M.UTE=':6-3_^`JI2YB=7ROPM,ZFYI#;L4SGS+I;X[>82JG+F:HU4.?-37J,N MZCI5SKP8@28]/U425=%)T:GS=,JH1CGV7.CV_A34[:L#2;IC,U%%SCO""8I. MBDZ*3D?6P'L3KXO)WZK(>6?OX+9WNW8ZT0?3BDYAI_+S%$%OQ=J?9I`MT[!AO/^,"T(K'3P9H MQ>.JR+DJM%7UH.K9*CE03TGU<,=4548+(R[%B_G,`GZ\^*.KP1+Q;786ZO- M/MU8FKTDAX3>U1?(O3+W"1I.KA1^5K'T:^4 MYQEC.V/3CS]J=@@SF`='+\YL%V38BP*0TN"\LTRXC>GV+@5>GN;9JO-;"\S_ MG0K,?TH*S`>@5PL4?N.AIT#[-2YH7_^,=_`-51QP0^U7U[L' M'?I(6OP#;1@-S7HFMJ4=_/DL%4?[FT?S^\2K1M:O2TO5E72%GPW'<$TPLD*M M8J."%W@"U+K[M-DQZH]K!KQYS^@D#I5*B&C;YT?OOC'?M`.JX"..C]HNFJDR M\W;)W%[1B+/A5?=$;B],MAE>+3E(7=E1W\P-]X%IX#;-DGY2(+KF\8Z!2]:] M.,[]K@/K7G0*Z(;WZ+.^/AU,NN7CU(K@$=3(J*0::7O73QGFF6AIHXI"'8=T M^SBD=@OD939]W1@6>5X'#BJT7&=HN7KS4A5\5L%G%7Q6P6<5?*X>?-[1W5,% MGY]5\'FB#WO=BX0=_49#V1!7ZS<:3C;$U:DJJ5V(=C<8XMHO)#[0)],3"7&= M2J2\;(CKB-M_.L15[[FSJG7V?$)<>Z$WU"?]Z],(<>UE\W$1M$?/,4(R+'!@+_*S`X,F^H.%VA(>9KK&OBV9&<+HX+4O)"#&#/RYF/D,$X246A)J/;70`'@XD/O3KY=VE]M4GT%?:RF8. M>)V1_TBV$9O-8$[4;OAHFA`6#'29K*WV`5`&%@IM'-83*=/;R>UZB(UQ[ST" M=B8PII&UQA;I$(_A!#"J\0?AXFF&:0+K`60P;1!$BR5-+(CBV'\PQYY[GL5) M82]P%<2/GHG+PE!IPS?P/GM$?,(Y(/GD18`]$"IR0D0?1[?^%04AH2S08C*7 M@=:%'@-@?(OV@2<[G/.%<4/[PK*=*+0?^:,(P]+W'NT`0`TDGXE52Y/RQEUE M:&>[)BX/"S3/URPF_Q`#%%!63\!@WTR6H,]P8<-BW19(*:[)/E$PM5UF*#R7G>O2KBZCJAA0T'#FUCP@O2U"HS/&O3M M]AVK1I(.1O63M,*)99V8K$72M,KS[1VN;Y*<53(S-_D0Y2)D&?FJ1KAB]*M$ M@DO.<"P(#Z=L5QRO_TJLJ+_'5E0M:S-J",FT-(PI-HR/;[7[O]?R-U_Q,?Q% MF_2_KXD3*R';68I.!AEB:5>3;?1I3@[:SZP57L%7]`KP.'K%#'_74?3A"W<0 MGNF%*R4(.>4FI:!W>57J]0QG9$;H7^X(U!TL1H6$ZNYJQ(3N78XR9!M<]E_$ MQO*EV$$ZF:VE=]F;9E5A[W(X4IO%+AJ-MM*HJ6!5J92D&-<(/Z228-#K\MR' M"]+];]D]]_2B#4#4'U0KI7QOY"9>?.A'8*KJCM1P\@P40["+LI*/@"$+]6!R:.)\HI M<'(*HD9AY&.TU`U]PPPC,-9-(YAK,\=["F0\;0DZ%L-K-$L6$HR:NH:SPO!I MA"8^EG.0D4(9;R@,@-FNZ408--)XM"\$(`(B@VDL4=#2$[WQW,`&[YA&^%=D M/5"X#^;TV9^1+>A*NP'`&LJPK&6$!H\O>IJ%L'C+F'`4$$EHMXF^@40>XZ!` M*-<+8;5,%@2&;SLKF-,"54D11(Q5+FCY>*C2I%#E/0,8#:0+!:Z-&%L!(_MF MTCEW'H"(7\4R',#)Y1.(-XQ44`>1$Z`BERU8./`HCZ;*SQ5B1U,`?7]CLKZ],5)R] M?J\?>O1I,NR]^JE(9V^,>,JM)F]8)UN#JJ"B*JBH"BJJ@LKII[FK)':5Q-Z= MU"N5Q*Z2V$\WB5U54#EZ.IJJH*(JJ*@**JJ"BJJ@HBJHJ`HJW0=:55!1%514 M!96.7B]1%514!155046%EE4%%15\5L%G%7Q6P>=CN\JJ@HH*/O,4?E5!1550 M:2/$U:EB)%V(=JL**JJ"2@>V?U5!15504154:JB@LB6!NL8,Y3CO^H,H4*&= MO175*<[1++CA-3H"S*=F-@V73YR6;\KW/KCRI>2=M43H89P(/:1$:"UR;?[K MK[T>>'D6,^V%X01_?74Q?/53+R%"F=F.A50^NWL[4A>#2:^W+V8Q"DMC50W^ M6_["@2MR-1Z6!%[,UR#DUWX3`!FE^RV;,QYL+7[`*4%2"H>0;XH4FE5-NJO9QJ:B3 MAKND8Q-"GT.L+N0DR[8;='KE\Y+Y!EXVJT]*+OJ[I&3CS.V@4W%-1H-=NG8W M/AOX[8.+A;,\OQ2"J8_XUDKWX#C295$5(TCM M*@:Z<2T:II9EO1CN5.YEH.@H+2IO$?TZ:?%6%@F4@=.YX8."F?G>@M_&A2U= MAE%E[<&`*KWP)\\+J8+'NH;#3U_OZ+F;,/3M^X@&\-Q/O-[O@!7?#!; MB4WZ:Q(R'(W72;,?**=!GZVL4T"?R>"ET6=4@3Y7PP+)>L[D&<7D*2->TT'] MY'F#]1CB2C?"OUM'F?\N%!E6&GGW3118N%EX?FC_+[\J7VGY"ZRB:0Z_\M=43BE_BCQZD%LG?R)Q;*MF>K7+FJ&"JA/W`<7CH'IZ.L")J,QH^"N#22[0=X(*J+3UX4B@([ ME]IO3%8I`BQAY"3JL/0]*S)YL9\E.AD^5XA88P7M&S1?#`<`C5S`]VG.>(UP MGSE4S8F_#K``>+9%97E\.A_`1QXB>`C6"6O*^QX`GM21%Z]SU)YLQ^&%ATSO M411-"N>^%SW,X]KX`H[`<.*Z46+N;-TE'`\('5'<D!6CM(!3(PQ-@Q%$I6(L]VB8+LBL-M,+2^D$(2,@B_AYWTJG*$1(A M8(:/'`)CBUI.]*38J+*%[I/EP&G8(]6[QEI9`+V]`"WL\W+Q@B:FK"XE@9T9 M)KP?:$&$,_+J.EBCBU=R(GJ*RET;F=.[#SR'!2:6L><,"9#:_NHR`Y[E444I MJM&4+0HFBDAA=7B,ZMO$S7*2(ECV*>U>769_2\A)2\:1HIKUVOU*_I:NZH6H MBRICDKDMMN`LXO#"5L!0\J=@SIR9YM@S1D)V']F.)9^'U6.F@0P),\DUPZER MRZ7#:R'1U;$7-O5C\&!!4!)`+F3+!B\$Z$`$=/D-.1/Q7X:)9?EYW@/,/?<" M$G>-CLUYHP"LMP2LO$;X];/=3;M&4A?+=FU`W=(>/,\*XH)PR/7^8U'@4XPG MW_L;O@:;V^?9%_'*7GOW8"WFN7.>-E$HL_5/\J<#Y3&(G]62&F;:[V6,@>3Y M+AH$F]/C$[G^!<1!&V<*;F;-@F842\8@2>AO!U0P$;0*EBSCN]/,YND"-%\X^1X[S/*/#`=7AH^N>[WXF?>]$ M7-\FUT3Q]K/D[50*^'/C\1;J=K;I>`S&._:UKQ[>6+$S_@<+&]W@5&>:;I?M MK#L&/&TXN'6$MC1*")00="ORUL7>3$Z=MTHS#EB\8:WX%5@[H+N<>-'7Y)G:F6,$@3VS\49XH!GI>)VX46Y@;2C-<]<'2=]!_CIGJ;NL=)\Y\C4_ MBV>@#:2UU;M^/=96S/#7KY,V=/=>0Z9"8NF(*0"8:5^G:T],FQN6]EWO\DI; MV(XCKD9G4:`%>F)XMS?RS;D1I"^)?S9##^_PC'BY<)TH1H3&#\D5.TJ!SV8.%P,Q02(L@A<#X#OO"9;W'BB["W,VE ML2Y;"\.-\&YU1!>>4W#JFS'`2]&/O#`F+[I`4"8CQ0THLD+;#M?C6_CH5FV> M7$.5B3Y%`D+8K;5BYTSPW>"2QP=P_'4UNQ,"*6XX!N M&ZYRE9^FX_$><)&N??=G9(>K+9#=N!:U29Q[#C@@`7]^+SBGU\/^U28X"Z=I M&NI2%?.N1[D"^Z6A?F^[8)W8HF;1+YX[B[_(L$>J_66B7"^*>E3&[ZVTWS_1 M-OP_%Z+%8_)%W#(6'*GZ'X5D^F?\Y,^K^.-_V;`S@DFT(B!NOME! M\AAO;$D_##DUW<57;7L^"Y5L3R!-9STY* MZ7@TV+BW-;>J95>L>55[_!4XCIZLMOL-NKS[#;HH5R]WWSMX/=6^5[SO'6F; M.S[MC[-'K6F^HVU:!UL>ST1#IA[;0M&]?.=A;]J?;.*Q0P$HXP8/>X/)M`0` M+D5"W_C,LD-@7)-X3]<^&=_L1;30?O9\GU#M^ M6;Y;'9,)8I*/QU69,D'5Y4OWI(>N` MHE3(ZWHP*0'%^TRK;<DOLCMOCY?._8#Z)^]%ZE<*<;8=\\TS&0*544 M]_H09+)R1?NS>$6C=[342YOCNZ7F/"3T>S7<`\FUD/#Q<2W5YG1<*ZX6O*=K MWPU[.@PKRQQ8L*ECJU3\_%V_IU\-)_D6X/P4]+M^7Y^,Z,>U`]%MI`$CSSSD M"&*K/DX&/P5\#]\%"_#%[AE@E8GZ^:AUV%KW$7CF@VMZ"_81'SRL.=#%=#+( MGFED1J\1KFI]?B[ZO4FNR69S@%7K$3WH75^W`EC%!GJ#_F!2EF+\:^T,?SC7 M;AX-V^$)`IZ6]L+$L9"N4;NO'?#'HWSU1-^LU!!B@(-Q'$Y'6]BU#`C=I$-5 MZ1A0U\SG1X>*VJO?[^>ZMST3.E152L/K_A:E5)D.U%CLUO<>;6SU^H/RZ#;L'$'4&WVO(.1M>YLZKZ$4XU?:Z*<-*#N39^ M'O3RO>?*S]T1C*NJZMY@/#T4XR_,Y(F[Y/WPUD:>"Y]-'D]>1^_I)G[V-O,H M;V]TDJWQLDG"U`1O%V$H-[3-=GG:)V,ELO,I@_[F[F?-#@)L7W=S]ZOVBW=) MOU[TKG5M5Z)Q$4'X70SVR-R(\8L2;^`A['.%/>7"N?8F"D(P`_P@DR\KL_+Q M:,+V*2M-P]Y:X0IM'?;I;FPP`A\= M?Q*C\JL@@4A*IB\=GK'.OIESPWU@O$>0;[@!]O?&I>.YSO`M)I=2!SIXVY3X MY*]N(#FIBQYX6XYA,FWA45-4F^_>$A.!&P'Z$-D6W04!,'Z]O+OS`^S1A_=0D).NTN.\,WR'.@\ZXC:&O)@#JF5A MAP!Y^NG?6+KUGLS^YO/R-4<2"V[EI*9;&!X'!'D`+S[SKGWQ26#<(%#V&.1= M#ZWX^&EM(6.L.92\DQ<4O#6'\/'O)!D6,@RG;%)18QA\B;CX'VY+)(`G#G'\A9HNE< M53T=;PC)'B?:[:YM`?$3\H$#?5"P1(=9XVQMAIJAJ[+-#@;3P76+T%7S6_N] MZ^M!J]!5LD*'D^FH,G09UWDCB#7&X?I7O0W\5Q#TJA7.BH',Z]&&M6X6SLJA M-3+$CP%GM9!/;]JO`*?_8+BRP3GN/S]CLV`6K`M1ZL$W\4X&?]RXUBUO5DA_ M?I[%N1EW\<[V3'I)]C.])#>2KK5K?[!^-ZXY]_R+"_P*J8Q7V5;:1VP9;I!N90#K39UQ2\%;Q16`\"J^$ M]UVF'M.^S>^0FVA_+>%I,I?(?,?;@[;/6TB#S43GF71)HS[.L'1IZ^NQUNBF*MU]M\?MQC05W$EIJQ%G`QP'E\>QZ0GO'E*5G9@ M@U`8/K_&*W%*WM(1Q.@^X(U_XU[>KB'?%_=9G0B@I:;.0<#;"!/QP;);D)66 MT'D&1E?,]3#1HPTF<8&E+.[0(A70Y#L0>X33L<$=LW3-67G+N8V-RBU^K9B! MJ>OQORTO,+BWM`@*@`)-Z:4AJ(D2`,L@PH'+JECMD=]A*FXZE?L62B'K$LX`N4@4<#YUZ) M5@)YB>1B'/N\/GKBE/,7BFO@,U#DQ&O)]7E\SEC:!;VHFVH"SO6"+98WI:&R MN@2V&^`OV=(]AVU(]`"-8/FTZW]Y>W=.RL9G"X.NBMON#$B:X4QX2&A-O#H< M!9E!097PF@:@N`B@>Y38((IY+B4AJ6H1-A:,L)@O%A3>0_D.^`KNAH40Q?@` M/`S"C?,4:5JA.GYAH'0PG^0#[.G@&0)?OD%J_@K4U,Y^^?#FUW,2(V`F'"9R MN##'N0OIH0$'8-`%[%NI*_@P-(@6,#(71B.(M.'U\ M0BK'PR@:F(FP$_\"@%.>#5KV[2BYVS5&(ALJ`)Z#[Y#;$BJ@_(9HF@'Z_*D4 ML6C706DF(M^#[A2LQ'R^&,RUO)C/;3>,[CF/!=&2IWKP,1<,8YMHVVG$]H[! MJ[?<>_"C[3X:I$M@C<%BP5`8GQAWM$2-;%6:?/OF56[0]I2!OFQ0#1CCT;.1 M'V"#RCRFH[I?:2XI.-I1L?)$LDL0A;+4=&@'2$@*U*"O8G06C-(GP]42$8=! M7",``B"'VVZ$J,`V;1/+&K;_9*RH&SQEYI^Y;VYO;C,<^*L+0A1&`!YS5GIN MXW8CXK`BI8\;&XW&(Y6\$$NP!,)I3PR^.,/5C4)R7G.^`W]M!JP-XYU+@0-* MS&#]Q>I0V'P3&^@;%Y[K=]#T&>D4QD"F/,@="5%N81+V!?0ID(M)WV8H;(]D MG0!!C+B#T4*CI!'2\X.2@6*8DF9#YPO<@J1-F63LPV5L@&QL!%_%CDR'G;"8B+1"(+`$W`\:7M4\,KJ(R MLZ?GE4,7#"FT&]?><]@CR-!`AZX=Q7;S[LMG5,6'[-1B<[-Y:@#/+R6Q7-S; M+M=>:![\P'V!N+`+5X7T$*MG>R36R9OT)MC"CH.?A$^A\6,64'?:V9N;OV5T M@B1'QE_A3,\]%B.[\\-:U>BI\+(W>763T_S$N3I]!H9+E&-JKT!V+M83:5Q_ M7G&D>#FGK/MU*"(8T'G(:>]D,Z)Z8AD_+*8[BECB',D=*G(7+(REW&7">4TO MDE@?%"92*=+-R*AU>.Z!=F9_JX(G.N,.A,)K>I$#.S/PS`QL&$/0EE04;&!H)BP+(1OZ,IX0TTB:O!D\-UF\ M>LJ#Y%L_U\MQ!3VI@6#9`>L_(\,/.5WXV3(%"6+_CH.9I"QPAEV2HH=I8@3N MI;*2<@J;"'FR%1F?:B^W_)\\M9R@TG MWQ.^P6=QP="\".<\.HA'^V3Z40(BP$#6C+$6NX&QT`%-5S2DX)=C+U#=FEB\^-I)L^G8WE(5YP#X!Y\8[$I M?+5TP+JAP3U@.O8'D/8!CW;1]#4LVIXHEB/.8S5[AJJ*JX`'@ZK@^7\P+@41 M*&!?AK$Y]Z>YI@$VH;@$3)-!V"'K`RLO"D7%?0!37%1)0FP\CK`D-!P.Z\!D=^P^&P5`Y'G<&"J!$`/@K M'&@OKM%((;:L_XVI:`9.$YB6R];MG(-"60H#OFA;!4'*66$4D>^EQ$"4?P3 M-0G.^.2FCB@RGJ,X:^#'!"F,N#7"MVYC!B8WV+@AR\HH&?7X):!I.I&%T5?Q M"D`Q`VN`;$JQ-:?L>*"**V)H/RSA#0.V&W,S7'P_PY!#*DJ9!&:IX*&P/N2P M,(65.+7W[,'F&H0@*2HJFH\QAS%N9$B"@'(OU7.Y,H\EE+A1"D2-RRO1X]*2 MJ=R966=.>DIGE*HU+RTI":/?9A'9&JE$H*#A"'ZF5NT32V64Q0']$KPG5'H: M-2F/:0'DR-`J!"O8%]&M!?8J$IB8=C&Y0520OV**RV";C0E(8&79L9_*-(ST M_G`+_Y>+KA!.S+52ZE9FQ"7`\ZPB0T"<8NP`+_\C3"F*4/%K,MQ(36?0*L`F MM@[Y+B9]-\,$`X0S,3U^`Q+LG6087J=T4 MRP_PPX%"%5SUD'=CU\R]4BV)!,3JM!#(91JB"K;FB06$C#9#-)OTG.CURP MF&53AT_2N\IJ[@W10`P]&_X#1@/!PH$!^'YN6&30H^<1:]_X>Y0E<:I!0V/^ M1:"=(9_S\")^.,\(3TH@#1/,77ZX:KO_B@"!O-_337C=TK[/7 M"5/#'3Q]J0LNT[+S_^*Y7CX5L!":](/BN8.3*7.W4C;-TRS(E;)38?&/#G*U M#+QQ[FK7<2"NDHLWS%W=V0=BGK.W$V"197AHVNU6:/DM9K\9#U*.,+T,8[%$5FNA81J9C).\SG17<'CTJ9T^/< MU>O.X%$U4[V?OS)1!9%,Q;^DLDDA"JEG#RRP,AY.UT$N'+YQ<,N9)06:&)>(#WX+1@#J[: MFD*(!Z""#K>&_]DGE\JB.FVWS+^;&YM*R&;1&Z;1^_#+^U<_]2Y[O7X*O5)3 M'1VU`J71.&K?T7@)AJ^U,1:IHD)5A%P0'T,QZS5F`8MOQ45@S\>D%,KA!R6[ MG1![%A[,U@,M&+++V)61QGVQR\**K,F_V<&/Q!'!!_Y6B=7HI^'M;0$W/7"[ M4!=0N1FH$VZI"OE-\N8>T(_S=5.W3W$":%P^F4AWW#(X(@[G_HN9SKM"=>A[L`)?[Z>WA;U.I^)\8X]()N!J'- MLQP%DXK!HD&>V1I`YST>-_T#BV+(2O+#C>7B#\'UGV^P^^SGF7COL_\%3VYY MI7<``2$0/PUW5VT?\TC:@<1!JX#N0@)Q^-ER*/O(4PF-#64$TC-]$$.`(6PX M[/-L4]>T:N[AN-_?C%SQE$='L1IKUXV;DRM_NP]^L^VUW"LMX?5T7&(%9X5% MUH^)9;VK6`:_C1K*6]))_3:DR'KXS)^3PGYHBO'L@OPVSIF65F4^,+A75RW4=="GN M3[Z.%G\.!GN;/%7/(PI^U,Z,\SB',_TB)38;;H09TI3CJVMG]^=)KC/=&HJOMHASUEC# MGYGGFF7[F!&XA/^7&8:4*RG_D"E^J83#=+6+71C%>?PP=>"Y+G-TO`L6!G8Y-_R%8;(HC`$4MT@S:>R2OGH,OIY"7Q=!HXVHIBZT%22, M7Y9!V_3DA6=SCFFRE-F?8()K:O,36.NRH`+5[AS($E*:U@"8B$OEWXU@7B#P MXF>L#DP[9S!'0XO7*SGT*'HX6-LL2D[7`@*E6LK5A$"4YNXOHCSI&V`4G=+I M3/GGQ1UEC*//RI\,12$3-((WQI8R4P!08@(<4(Z.G_L;VGQF7L>)*+(40T(# M"CCPUU(A)AZ%R5.N!(P;Z/:&1"FH@3YBI)TQMR:H,MQ&%`'8$0DP:IP`6[EB M.P%0Z_F/K`8"B)%:E(9\P+4(G-)HQSBV2@D43L*=WB":O%LL'6_%6`R':"QZ M=`K>F*),,]Z]97BEKL!:QTI(S'IG^'B%+TB]\I:_L=>&=S'N#7JCO)^Z:ZJ& M`2^ST5V,KJZOQWD:EP;\;W3Z(UM80`W>')Z+NWSH)-H`H_U-WL+E11UX&1]T@D?G6)T":_/+3N!VD)0_ MP!H$>&O,:J7,V55,/[_[S2XCI0L'QDYZ?K6_&BR,`4@O/ M0O^;2JT4O:8M(W`M#9EC$1I_H.,^7P7D!\XW456!=5C'#Z\:.0_FU MS#*7Y+<5IAFR(M)L/6Z952P-5/%`HM2+;`N";PJ[JM+GO49 M_.D&G$WEEUAUA&/,O?B-5,NUE_#9S!,7A!.H+$\4B,OW/8F62>4!+9B+Q.%M MT^D:OHIES?!Z*#Z67D&;*BUA636K>.SL)?H@9(:5NT`O0?/<5)6NN#QCX#E6 M?#E5P"D7FE_YI0XIZ[U0\$XH\VTC):\+%J[=8UV;,+,(1CP79V.JWPD+B@OK M\V88?"FQBDZFX-/"IIID:U681#&&!]O=V)B&BBR!BJ=D`+E$J5OP&.(!L2T6 M*>(IY`4JW1HKE9@;XQI(Z9>X$K587'^`!_((M5P5A%2E'#DFKR?`QQ`O<7:4 M)0.(MY*R/:+#2"S)"4AL@1/?&Z*0`+^GG]Q?YX-K/LV9E$A8KSG15G7.HBW( MQWY=XL3?,$T_POHA2"!)+DO$ZNX-\P^LFBM:_L+'XA7=M"P'H;AYGP])>YF@ M5)=8\<)]P*1`^CM8&F;\-V8)_?75V[O;]Q\!UJ_XTJOMEL9&\T77Z!N=*@/, M7H.(6.$<7^U]GP++CS]9T"?T ME@E0P\LQOB]^HK(6F=H/TV$%*`IG6EL:.;Q_+^E#=O=A$T+6DZU4,<4HK48.P&'6`ARR[ M?!'K#1LFZG:045T(.FPL>!K#M\[9#/86W'CN6?C$F)LV&^-R9)1_*DHD%RL% M630Y#R%_==M^+L>5!,YWJS+P"(@B/:35"X=(*3"JB2H5-A88<84^Q-9F!7[6JWJVYHMT/\UG\!K]FSU8&JDOO\L?++J,N] M![W,#I-(7O&(?`#>T:,0*E+0'ND4DGH32(XU?0HU,Q=3LM*-^.NX0\[5:W!M M;2R6R*NW>DXD3-`U^RKQVS+*.YYH$6&C0A?])G"ST(K^R*N^P&BW6(+*M)>B MA/W'S[?GO,A0%`B#F-.^CS'@$A,+L^CY20(887!!5I2+BQ&G&J6BQL'.O%AP3?JS MTHQ,&6+;;+A+WAQT%^&,%-(QPJ18)!7B&JHTULQFEM"'^]I:1>(O-U5TRA^P M\A[PW(_:L$^,_DKI%*53=K5TIK#%1J\S/F+Q\A%I#&0&$=65XR$Y(8:LP[;& M=(^$`EP)\NXJC_9>0EZ4Z+7MP"H^'ON->B\RZ\(0U2;CX!T><^1/P>C&*!D[ MV'B0N0$OGY<F_8/EUTOPF":"$O/?"9,/=Z/;TH?Q[X MT^WH']-/_<';!,7FH.D^>=8.&&_'_QA]&HS:)4\F8KI&#?Q2L"$Q7>%]E$JG MT:D3WZ+1:X2KVNG]53;YH6'8]KZ7VSC-JF1BY(IK;85-?*_#5K^6U))^\?"5 M[/=SI21SP]<$4K64E>MAXR`=EG[1#$2'Y*EL@DB40D4/P$G*6F%+,#JDQS`Q M9FOS2C)K()MS$GP@FQ:1<)X-ZZ5*I+U20SVV?V"EX@PR^QG#%20:=NQ!LP; M^@K@B25"BW8->%R:">;/`Y7K$+422E*0AVQ\2081L(F;+9)7$\B*R:P+$"_[WC]I@^2V[!B:%V3)KM[T0>:%[4,_TV3DS M\Y@>4M?]ZZM!3-I[/"GU+\#Q`&?FX?ZLI\-_SW$*C2HMK_LH$BKQI@2J^.4= M1*K089Q>0P'62(*W$]3UGGQC^==7_-^O6B-PZPO9[[6UDOO(P%[+RS604$P4 M6:&DIPXN>,K'4]IDZYQ/F8=*I?-98/)66/EJ\N!_%3MFN!7O]1N^!?\A;B%%=: MBP"I-5>RH>BDZ'0"=*I'U\H@\WCP_6M*-'_PO0Z1 MA/NZ9K@G8WT\OFI7X([,$XHC%4% M,><21O=XK(M_6C*Z$7ZL/\!K3KQEU&.[5@[<1HHM2[9.B?IDN?+)1ED^ZQ30 MI<6]*M/1,\/!N%$QWWEJTX4U4;RM>%OQ=G?9I`MT[!AOMV6F*1Y7/*YXO/:U M:<@_&97T3^H^%.A/=C@H7SVLV<;/;1MU2T;E1+_)$,-F*0+@-,N+[AUVLH&( MZL@U'M>=3BLF`];!8EV+JBDY4'*@Y$#)P4N7@V/9C$H8E#`H86A/&-I+H-KD MNA:`UUYV4Y-1@*Y%)6H*.&P!Z`A'F4T2K#O+U05J*/91[*/81['/\>%Y@>SS M?//<4T5\:KV(]"SRXXXL/Y4`ZG0>FV(?Q3Z*?3H!CV(?Q3Z*?3J0A%TVR:'U M)&QOL?!<&!TK-CY1D\DPKGNXJM5&W#.P?YSQ8(?TV\_Z4&+PL,3BY\RTE#$H8E#`H85#"H`RD@X+IV?8NJO3YR10K5J7/ M3[K<:GNES]=7I!HZ.\N:'W\!52GSDRME_I:9O)OVL$_ES+M8XK>;2ZC*F:LU M4N7,3WF-NJCK5#GS8@2:]/Q4251%)T6GSM,IHQKEV'.AV_M34+>O#B3ICLU$ M%3GO""=O8/;WNW:Z40?3"LZA9W*SU,6JLBY*G*N"HF6$'=5"%KQMN)MQ=N=9I,NT+%CO/V, M"T`K'C\9H!6/JR+GJLAY:2E2=3R;B.M.>M-6U8.J9ZOD0,F!D@,E!QV4@Y.[ MZJN$00F#$H9C'?"H(N?UG,RI.K$=(EAWEJL+U%#LH]A'L8]BG^/#\P+9Y_GF MN:LBYZI.;!<)UIWEZ@(U%/LH]E'LH]CG^/"\0/911O"`*H8#TPS@B!:+$/;
?N;C@0ZU#>3]?J\?>O1I,NR]^JF(26USJ1I3XA4>),F,ENUO=ZX9* M;2_ZK4=J7S`)MQ4$VK,$?T\W,3,!VJ8KJ0$_);?6-FW)3/QBT?/ M`=ME=QBX'/TKX;O/&C5"T+3H]7L]?!6?WVK&?T\8X$]%AL>>^JXJ=C6+;BOT M[?>^;VY'[\J!RV9Y`T(LFI2T0DSKY(2#2)DOZ[]3S'+<+>5M?#G22KV_8H8? MM"FJ=>3D=V2!1I=76D*_5N7UZ/NC;P=_7,Q\QC0;"0+>K^:#PZOV2-+AEQ.U M1S9(W][EU:C&37)A6Y;#.KE/OI/;(LQAP\_6CA(,Q]H;.8^Q$#U/CQCCF)/1Q05796C2!&D*8)+`Q^PT/)IQ\KOMX8*RYY M%D0:<5OQJ>G&8$F]%:YVGE7NT45A(W)KVFNKSFJ[-E/3)\F*\DU3?J=4]<=; M8ZM%G[82ZE@]78XDRY=D.VM63GL:X)?PFMH0"-;]=#].//VIV"%.8FV<[ ML_%DTHL"V)>"\STL<1\VH3I;(U;C^&FY$PEZY@,8*H9K,JT"+>G%MSO=X0I$ MJ%^BT\JM[M78T%&G!-%^B:@/+[!P57(+EM?(!@TJOT[+C&9N);U\U!54[+.V MBN^^,=^T@^K">NO;YC-=^P;T9WX7+R6859?DW;>E[9.OJ#1O/:)39'?NHB4W M*8RUA@1'W#8[)8C'XYZKFK"MF*6\PR;?WI]T=%!_TF,X=%6D[R`#?E,VUSYC M[F^R=S[7V!ND'V:S6.U*9$ M*^K50;WMX37%[5U;K^:BT(IT+X#Q#MPJTVD!TQ;R-L8_](<_#'J]ZX8TT;$+ MA72[<$E_TL(2CR83?3*Y.IJ\J,HY)U)PN[U2VOVKRX8OE':%(3-I7N/V%/JN M:(.2I^DXUE;SO/@ MAP'9*3NV+54NO77'L[8EONZCX[DCLM#I@NN*`8^@V?M7O?Z+$!3%:S.Y*I.`GF,DTA]/![HDUZSH>K379X.@G02=&OQ MX/)R_(*9M]1=TM;VF1W[O1+(;@#9K$!.]5ZO8XGUG5F%XX*TW^6H4P.ZZ7/] MP4!QM^+NY\G=8WW4;_9TZ`C5NHYKF^MP>+JT M[2!()T&WFL*W+Y0E=VKS?0YPE3KOS/HJT7F)VESU'FOQ5*]]%UB)@1*#SHF! M:L&W7Y7@N';Q&\,Q(X>*5V$M.\MV(BS+Z[)0<[P@T);,UTS1M*7O845S;#Z(3>\XK8`NH6&[ MU"K/H]YW9D5*4NEC?!%^L#T+'O!9@.:"]`X)9!=Q:QT0EF@8^_W(01U_N M._N;6NRZ"CUM.[#)Z[@6PQEM51NOK1Y9K2TLNU523*WF`=TTU6J>VFHJV7Q. MJWE2LEEO\<86M^\6*[)UQ/SJ&HWRMK8BDV*E9T2C9C5C^6A0'&0DOGR8W40-O'"_C(@N!'S79-;\&TF>\M-'-NN`\,OBIN$:\Y M(HEM52LK[WEC\CCIH@?>F.P4T,UF@9[U]=&H65.MMBN3>R%8[RZHI.!Y2L%` M'UUW[$!=28&2@M;W@NG@1(H1*2E04M#87C">OM2]H"'O:E32NVK_C$6>?-.5 MDIT73QK5'R4OX!VGG,NA%_`Z$(QI\`+>GN<[`[UWU>Y^N_<5O`Y$()6\O'1Y MZ>O]0;.5YI6\*'EY-O(R&.K7+9=#4_*BY.64Y67:@O;;?(: MVNEF+AY9?BH!U(DL0]6`7;%/)PC6G>7J`C44^RCV4>QSI$X@-<3H&DO$H)*G M&B^7PRS-`-B-!Y9)O@@T+PJ#T'`Q@JK"@UWWL$K$HZ=CO3=1K<,5JS7/:J-K MO3]LMMQUUXC;G:7M`C5:U&HC_6IRRJW#%:N="JN-)OIH5W?T3K/:D6]SMIYO M3!7][<>\84OW.HT@B!9@^\I[G.P;\TT[8$&MMJ[J?-GU6PO[=2UN.3%2=755 MO-T6;U\-%6\KWGZ>O-W7AZ-VNS`I[E;R]="\Z$)VK.#\ M"^]3>$RH&X_^3Z?M:@?5B%,Q>*MG#M.&`\&*P16#'U_1^P^%GQ>"*P8^H MP:_TJZMV6S-UM4ERI1[%<8_D=XNEXZT8`RK`UQ?W1L"P]@PLK:-U26^`W7A`&,4BGU#8YB!;@ MHL%K`74Y#KW0<#924&/?\#,6!#6=R()?J>TNDMP(V0+>[MHJ-"2:'5^%FD1RV_E0BW)ZA*:TD@*JR_`SZ3)\Y`4] MJ4;#)[&@J@FX6LT7*)OU&]M=J43PA07,\,VY1KCC/]I;]L@<;XG1E(8,_V-? MISRAPG'MY:\,3J(7F+IM_%+8L==LM6C%CHH=*\`];KA8IF)'Q8X5X!Z.NG<3 MKK6LTK*!LK:R2G?9V'?,<0!.7?L;*MQ5O/TO> MG@R>G4W2D(LR*NFBM%ZLXROF73;J?Z@6,R^KQ_$;;/UZW2CS'4Z+7)M_NNOO=[@E68Q MTUX83O#75Q?#5S^-1J-)K]=+D:+4K$?!JU\!K^ET`UCO(9E\!J.3@:O M406\1OW!@7BAO,(+VD?;N+<=.UQI1JB]-VQ?^[OA1$S7N'QJ'US39R#1VME; MQC^=7WS$K$)MJ/W^B2WNF?\_ZR00H\>#WX0X-(W,QY7#RD%WK?,_X_=_7L4? M_\L&9'USOB*`;K[90?+8!W<9A0'],.1@[B#I8#+-BW9E+$Z(OCG]T#Q]^]-! M??3]3=1TNI`UG?`RL8E%GAX]!SB>"(ZW4^>P(?H,=LG@?(V*Q9L5%K%]H/O' M/Z^21VZ-%7YU\V3X5@SD#5:^7=+E9`G0#8?G[S$47XRPHA(;IRG7!\)=]E-$ M:PWHYT+KK1MAAM8]H/51*?U.$A8L+MMBKA6T2EM\._KB8X?UV&R]_L"#4?$2M3=I^`1C>`P@?!`0',8AVF.WG@-&!PNT MW]'KU,CM7#>PDG>35^6;'2O-LN.J5E*MY18@\-H] M8RX6L%D"KU/E&QS6M^!IICW9X9S^%FNP]&T89.D`MP@WU%GA[VP9)E5S?KV\ MNZ0*.1*D9&[;A>\7O.A.P4SXMNV"IQB9O,Y.Z&GOX85^3[)*[_KU_[U,`D?$ M'S[&IYR5CJ^O-,O37"^4I7PT@!!7BH^<3([.\\SS0G@4#/T_)8ISDVQ@2R`E`;L M,R][!$/".Y$3)M6/0JHQ@Z0,[&_:@EFLFR3(@)R?>3PX1S\TX6Q`I`2`U_.N6*&CW,@/."+D;NG#?M\HC38("`P M:X*:ZVGF'%4[<947P3KY-D4\,TLN=7)@(U?F9QBF9P#.U`PP[0(S"@*Q9CAN MP7"ZAE*.HEU%#Y&@!XPG<./O^+>N<>VIQ^IST'M=M*O@NGQA>#\VHT5]SX7/ M)F=`/1X#5#"0!2F\6VT`YR.>2`\23\#@XK_3E/G"#."W@-:=N3`W6A463N"S M1QNVF7#N!8Q(YWA!A+6/84R8^%\`&;&D4`>@9O]O9/B@1H!COK"EYX<:_"HG M!570[F:``FC/5KG]X(/["'3Q_%7+>X"(=#][U88U@N)"^0(FE M/W`%9E='#7(A(#$=@ M.+$"$W.G)8$.%9#0H)4).AOU&.QJ;V\2(.!URX\>Y/N!^T:(0S\AI\+@,O@N&"$ST?>>QQ(W-Z]Z"%6`#ZRV2<(0%2 MVU]=9L`3NSVI>=/P?3*%:&BQC[!O)@/`F4W<+"1[5CR M>5@]9AK(D#"37#.<*K=<.KP6$ET=>T'63>C!@CR2!206"+:V$*`#$=#E-U3% M/OZ+VTEDV^'#-R9C;J*%*8X&>7Z]:Q_GC)& M0=@"TH!VR%D#C*"E8Y#.NDU83$E)0/;,9V7X@_0LT7\AP`ZT,ZL>*-8*(KY&BSP)`3RRYWP[`#,]A M/1&[R'7L/QC8$Z0?@I2SF;(/8[CE5K``BT8C&U3LJIE?T5RQ?.,)L,99ST8I MS)%<9($BS2(7C5Y.MAC3G-DJM-2,DR5>&-3$AF`UE$6Q;RT,&ZO*8AE/W!A$ M2=)VE-DNHU98*2`9X#&1'8TV(]@J#'<1A]@)30=W-W\2*=.<'*#%@1KTJQ=Z M3X;VWC`YNP-E\;QQ@89%/"RH3Y>(1FPC3=+48&2;(BVYZ1D%\>8&_G6B[`@. MX!0P6X'H^87+>Q&1>Y?"(BN&GAL%XMU$Y#*;\PS)!ZQ!^YK8 M^-D,7N`"$J`'B$8?L+)_@?*@11C@_]]X!_ MC(0T3PA>;Q?VFKF0W414$QG.$2@[701NI,\]``)&K@8YEL!%$YUW>R17-_YV MG%T?'>6=S*QO-AJY(/3?]2_[P!^.`Y,4+=^%M`1E3>#*SNX3R/MW&9>M=]DO M)2D2+IKEN][E4'ZAH_F&](/-'@,=9(T'F7+%5>R[KRF#5VJ49+NPU\$?[71? M"?X8?%+%&:I<9D;LE'+"_*:0B"PT>Y%LH.Z%?\#A323W:>[1ET%T_R]TBV@G M-#W'X0NEW1O^@U#.Q@,P#RT'YVONK%&\ZLF+P$+#4`<@8).GX<4N2THB^48& MBUXHP*`3`!)D^VSPIOI25^34EI=Z#_/L5EC&=^"IM6V&?8'U1$>#R,SH-,\G!1(65Y:-1A181]UK1;`!6F-G?^&M@EW$SBNJ2"WM&,':*=3`/PL.' M5J2*?=:2U?$Y\E.NLD]QI-"W[Z-\#)J'(@P-52?LW0!U_*3GIZ7DUV2S67A` M3;$=%KVF+2/0LD8@=N[0^`-C%O-5()QSL1+TFQWRV(``5I?1!A<6QG%HMY9N M4<8&1+^-/1AN/M9@NR$?26SD=[]^>7_S_S[\(I&>@2D`MLN?/&*&3U"(#F<% MDT'XD[!:8.RB<[<`V($Z\3("OP4A[9/DPF==3MB9P80*.)O*+X%>`F.^L6^D MVEI@%EU1/0N5<.5CD1&S2*T@[YZ-G M8Y"I<.QL+"0(F6$1K.N@>:2:Q>NQH1]XCI7$BSB)0O7DH[2'L_L`+@T=D/N%7DF%%X M.0_(9EX!%<2^";Q#G!,O4<+Z,N1>+%+$4\@+AIM6*C$W)FY>ZB6N1,'ZD6=% MPGY$U'+G*L(<0F4@QQ36.8TA7N+L**(BG+?B6$HNPJ>G0.*A%=Y4`I901#_` M(352$-'Q.6\B07$HT)88$61#%$C(GA/B/.C;BS)">/')]PXIN6I:#4-R\S_,.&KOZ9)@.;%-_??7V[O;]1X"5^JW4 MW#VCW]O8/D/,(Q^>O[`&JYQK>#G&]S/7$=(ALNFP M`A2%,VV\#V``.Y0SQS<>@+U)."]C66;"[,DSTB(P1<@(XS5D$W$U@XD2&'A$ MEHZ"T%O@.97LM1-".ID0 M(*.Z$/2`;G&(K1-5!,Y[.```.$,RRE(\1$J!XN&Z[NFQ7 MNUUU0[O5>K"\EZJ\XS:15'YKCOA>@^;\^43RBD?D`_"$E$*H2$%[I%-(ZDT@ MN6%OT,Q<3,E*-^*OX[RQJ]?@V@*[>SYY7X^>$PD3=,V^2ORVC/*.)UK`)XUJ MB:.;A5;T1Q8*+^K60*:PESR">O;Q\^UY$B5.!6NR>*;G*2(!#]0CX.A`4VX/ MUT@&PBS#?4@!.T.'M"+,4"+Q3%.^(89)94@Z]HX!@QTJ-`?O7@IS4PA(:5)E M)=9N)=[M\$.RIN-F2TBCS$ZNG![!4O,B\H06`<]12.%;+$,9P$WI!ZT8YF0P?MJ0&8]'9&)AIC0V(8`1!A?B.+/,SDDE+J+& MP70P//B2_JPT(U.&V#8;[I)TQ4["&2FD8X1)L4@JH/K$!%`^ULQ&6S!U<%E= M0Q2)O]Q4LT6+AGUB]%=*IRB=LEVG?.%ABXU>)]_51=9G)B*-@'=/>,9#P2>*L_&\F21PAOXKQEF-!>50DE*;"=N`/%H,MRWY+Q2R MP82B5"(<>)AX*IR<60)<`?LS$C%4S"P0.4B81)%&[S8-0AQKE%>.I?F&5A$3 M-H+KB7/G#/+N*H]VG4*^5\)/I0.D+SN.5EL^4_H-G'X?G?-=1[X\FQT8A0XQ M#=S'<&L)?M3.C/-4+EGR(@X$.B9"VSGRZ0#][/X\3CT4:8DRB3)),.0G&V?F MN4P77<+_.[8;OQ7_`;,^^,8B;1QG\H9W8"1.O`,Z)/-<%X]J9OP(E))@,\#3 M*'_"MHCG56E@EW,#O!.316$,(,^J3,^IQ_358_#U%/JZ".5N1%607J9BQT2< M80)^<%D&;9%HBR>[%+T@@=?7'3C[/47%H)&"&B] MZ"3+'J&(_*4`6`(SG;E8'DO?A''AAMN<`!G\MPM2N6-D9=8)V3`'ML9R.P@B,A* MBKU7]@T/-`.R0J7WS]_SELFAP1,==V,V-K#YH'=YG4F/Z8\OI_$7'(ILEDP[ MYRD?UB\QI2Y;W"'U#=\*M#?@Z<]L4T00;N[>G&M?O27PYR]SDV-M8D=WE MB97HXJ)>$+CA-SUX)-QP3-1E"*BUBQ]UM&%PG<"0]<#XQX?C*UN6K.P@SZ'Q MAA'E5*=7.%Y/LH:YS6_@"9YO/_(T9IF88M.A'+\,A%.ZJ:M/,DXL(7V="BL+ M"<`$=3.4+@YEB5$^5\)T)-$2G%TSK8G^1H'/'9ORM#L>H@^10!%LFIS/^34( M"I^(56"'X%`DSN4O9V5$6V@8.7'JRAEJD)AH*-3+?6"5]3)M!?(Z;GO\077P5?V8 M7^9JGE0_9K6:2C9?T&J>E&S6M*>WOWTWSS\;#O.>N:U=GD9Y6UN12;'2,Z)1 MLYJQ?#2N6J#FEVB!QUB>OQ8^Z_#R*TVBR/2\E8FBT3$4;F?Z]<7G]50Q"LNM MK<<0:^*68S2F.=&6,^TUDSGK]_3)H%G'L+5%:.KX1W%N%SEW"HS;;%<\Q;B* M<1M@W,%`[UU?*\Y5G'MRG-O7!PUWG^L$Y[9TGEQ7\_2#O8"/+`A^Q,QB;\'X M37A>&1'3O;*Y?2(?+"DI52LK[SB/.;P=>YW='Y.CFH9[R+<`=&F]494UA9.A MCT;M-C#>>?A4*X+U[H)*"IZG%`STT77'#M25%"@I:'TOF`YZ2@J4%'0;Z,;W M@O'TI>X%#7E7HY+>5?MG+/+DFZZ4[+QXTJC^&)73'TV&63:+(@"G65YT[["3 M#<941Z[I\YV!WKMJ=[\=[:MI.A"!5/+RTN6EK_<'?24O2EZ4O)0R9(?Z=;_9 MPRPE+TI>GI.\3%N.A7='7MI+I-ODM!;(3GN'UTT&.+H6<*DIEK(%H",<-#=) ML.XL5Q>HH=A'L8]B'\4^QX?G!;+/Z=YWV'4)[2US/6H7V]PUM-/-7#RR_%0" MJ!-9AFVJ7\4^BGT4^RCV4>RCV*=1@AT_1M=8(@8O"EV^O*L*#W;=PRH1CYZ. M]=ZDV0/=KA&W.TO;!6JTQVJC:[T_'"M64ZS6O%8;Z5>3B6(UQ6K-:[6)/NJ? M\@9ZY-N<;OY4]!;*&+=WKE(T%Y#U.V6`@J-76W?/6PG&R7`Z\M=`IH)M- M7IFVG!BY]Y6%)M=$\?:SY.VKH>)MQ=O/D[?[^G#4K%NJN%MQ]Q&Y>S)X;MQ] MY#N2K8?F97_$(P7G]TS+/\Z-Y4/3\KL%=>/1_^FT7>VP=[I]D^NB&/R9,OCH M6I\V'`A6#*X8_(@:?*+W&PX_*P97#'Y$#7ZE7UVUVYJI!09/.3`_4//;%#GD MQ_IZ`M]01_)-;8[!^QAE>XGWUGJ)-]S1G/GXCNE$V(Z93F*H)S$U?*_0D_B> MF4844.MHVY<]HY^\R+&T.7A,\#M##$/[HMV>S+\Q$!S@TI"#8;@KPLUSJ9$T MH.8!Q(3+TF=SY@;4\IK7&SU#5,_KAK-4J^%81B/\$5AOS1J[R[:N2]]SX7/ M)J.&V#1]M`&0^FGZP=4^&=1E>\0[=;^_N?M9]N&^N?M5^\6[I%\O>M>ZAG/L MU4;^"WMD;B3*OKZ!AWS@*>!8[/7^)@*>7C"?HRX;R^O:T]PVYYK/_HQL%!W# MU5!4PA7VVO:9Z3VXV`;=%R,;(?597R!5`1'XTV`$>CMH!\8'$1.!&@#Y$MF4`:R`8OU[> M7>Y<`:+V`W,!4]0IP&9L29&.-+^!3-A+!Z`]^]O-S>UYANY`&)!N.T0MX&&C M;]ZZG80\BX[+GC2*DQ@^D"GU(-$IPE;IFA?YVLP.8+?05LSPD9.NTN.\,WR$ M&A8(-PB756Y[6'$DLN)63FC2%QP%! M'L"XH8$$F=DN$!8T+^(0HSAQZP`&Q0&A'P7A[S&&L.)>>PB.MI9I,2 MPF]\%OI>L!1$`9J8T8*:PS\F0",W\:5>L'#NY=$E$$>*]#6`4-^QL5 M\C6+A0B0"X^D"`-`A6F@/;DLD@"\)0N0@/>P:+ MY88W,4O=`E5-FP5?0<7\[,#^]-.__YNF_>4_+B[N<+>:>PY(7O"?VCL099"T MFS#T[?N(=ZL'@;F%104NON!OQ3.E7A4OP@*B%OO"9G]]9>(R]R;#WBLM`F&A M[W[M]0:O@`JFO3"#WJ37J^70F%MX);`'?8'P_X.<,?3<:]? M%MRO/C.`05?"*#@#`3!!I9QKV*^>6QSG>3CE.S3L';=*2@#:3P/:>_73H#>] M'B1`%HS:.)0%JU\'E/2CKOT=BY%O!8N>V&N1A[WQ*+/&Z^/6#EZ9_S]YJ.5+OWCA'0MAMT4)^^"^ M,8(YCDZ#OXVU<#&E__G&,8+@\TR,]=G_@F[4#>RI_T10$!+Q4Y]#L8,$*>2K M@5>=,(..$&90BC!9'7JRM"$QJ)LV+1*F,6FJ2)C.2=.P*<+T>X/!H#QAAJ4( M,^WU1@T*5`/Z9)?=,AJ,6]4030E"[[HW[@_K%H3A$/7GB:QW*5-A,&B2@5O< M$0"Y087U+K]:^?!WDJ;IOER%.7<%6]BKK-(_M- MC'+#!_DE0CP^S[@7]3D9@\^Y3J9^KQ]Z);PVVAU'5Y.5 MQ%P\O0;"H;(_Z9?#?=/\'<.^XLI?75T-GQ7VU>1^6D[OGPCV5;7^=#JH!?L$ M6;98.MZ*\8,IGYD,+:.`X7AXJK0T5G3P<7$7?Q7;2"KRA=%!-:C-6\=P MUZPI*S"]'R5\[^2D7[TO?,IXK%LQX2XE\<\O+`C]R`PC/&=[XP7AC6O!=\Q_ M9&17R3GBD3E`V?<05'HZ?HI&$9C@KT7FV"B],!]^>?_JI_[P+S]4Q;!@,:KD M`%0[^B]?"_($@F?^`H/O(7?_X:_ M[GEXTDMCM39HK0"5.S4I"1`G.#_(B3W3C[+'K?8['I]J='Z:U:NIA1)OQ2_% M)ZX[K:Z?BO)#9L;"=E8_:O_YU<:C_E_8D_;%6QCN?\I,CEQB0:E\&&YO8UZ8 M4W2OB`8"1Y9I$XT?=D\'_?YK;3MU6DF&*95<@4D(_.2;\APR:B5.Q0+-@0_Y M/'F#TEQ$D@,JFE0R1IS@L?2]1]OB"2>9A(R;NS?:5V\)3L6T/]X_`T>2>M![ M_9;Y]B.E(7"-]E_,>D!8LJLA4(1/_?/4:S*`S2OBXS`#<"HMA^@BPS2+=YCJ&AR<84>;(@QT`["R5W4?Y M+4],YF:)Y)KW[-Z/#)\RN'K:,KJ'!8>Q9XSG)\6)0(*]:!0=7Z8$D4=*18M3 M7OBT(D%4D[QJ-A.\3A$A':6Y&]X6_8=`R'Y1=# M;-"4\YC>@%//\,0TG@*A+8Q5\EQZ(,RZU$PCF#L,%/D].,*9O!W0."B&L:V. MKPIXN?K%35^^+2?00?/CI)@F15`$Q6N#64D6KJ$ETL>"Z/Y?E-_C):8&95SB M%&"`8PR/:(ORMX@"3+?23(PB`MMBJ&*C$,CDS#/[7``W8YC7YL"H)EB]])!C M/`4Z$1]1G0%[.:L+6"R+%B>%00GJ!T1R7-Y[KLGL.)LJ]#V'5)WC:*;MF]$" MR6LRF!OQ.K,!QD+!"V0B)_NVA/F#'(/B2S[C7)49&"?CB7L@"`C6/9,)@D1Y MD?%D%)(ZAU8^J:M(*:?!8Y17R_,010(:3ZC%01W[#^;8<\^S.`+YN4W*GO5, M6*'TO#>T1\"4SDID7V;$.5Z!).TVRR-&$9>L1!H;)G4Q2\?,2&8`R>X-AY`* MY@RH@UEP_+<@!&.&4N(PFOY(T?14)ED42''YV3',/R[N3)!$U,:D#"Z6OFWB M`PO/8DX[>*=2>=& MF@$0LQ@4F"#?]R+.!TU!ZU@]&)B9'C:">=>]`#\MA(9Y$**^&8LU6A& M=Z(J*%29.3G2-2NB'#P$Q35"/)$1@*56`4B3K,+:?)MD:8.^;4"6,'W3QA+Q M@&`Y\=G82TA\O).9H=S>09@+04D$)I#Z#A_P\E87K@E\,_,:MQO=%EVC;U!Z?'N67*;I M?9\8^/O<=`^]Y?;*#M/4!$V6C]AY3 M[8SL+"\*8%\*]NGIYKWX#^S._BI02SZI*\^[:T>3!2:=YZ1*=BK(9>Y2:%$>ZE3YO9-CLE MB,?CGJN:L"TMR*5L\HS!)X>;B_/#_BCM"9V$0U=%^@XRX&41BGV#J>FQ\(CX M>3J8+X$3WC*31%]<'=#YX2_O]WM4IMBX7^KRX'W>NNV`1+ MI/4YFH)M*?1=T08E3\])GH;Z<-)[$?*D&/(D&#)URT&QI6)+Q9:-=11:.]`9 M['>@4]+Q/*B=4"8$_L.`[)0=VU;M\JL&/!4 M6EOW!Y=7W?,HFZ!M68^R=DV]@[Q*4$Y"4,;Z5>^46\`K3CL53NNRL:WX[?GQ M6[.M\UKKL=34U;G&(\]@)PS03MBQN]2;5M:9[M-=BT3M!/(8)Y'Z>#S0)[UF M0]6GNSP=!.DDZ-;BP>7E^`4S;ZF[I*WM,SOV>R60W0"R68&QQ+K.[,* MQP5IO\M1IP9TT^?Z@X'B;L7=SY.[Q_JHW^SIT!&XNPE/?E3.D]\4-2F`MRFK MJ0.MS$^W!7Q=Q[5;P#R][N.*)SL#Y`'AVQ?*DCNU^3X'N$J==V9]E>B\1&V^ MV8P&X#3+B^X=5ANV5.]]EU@)09*##HG!N`K-WQCZ@ABD/*5 M?Z!:MGDKQZFYHK7/M"=&I9"3$KVR!+.E6=3/2%1I]AG3%C#P')YPL66$K`:# M19E'Z5K,;Y/7`OO;EI=T45X_V%[G.0514E/;TY:1;\Z-@&F#Z4`?CGN;NNY0 M:6XOI++'GLF818]\U[L<:0O;<6S/S15EKT@4K'N\%<]A.P7*W\P-]X$%<9N% M7:68RQ6B]EE\-,^[QDO#9:@./CBZEN M(!Q8'#$+76%CD\M\MX^"&^^B#TZ9KC5Q:QQ1BH^*1M\"_IZE?:[8#I@F38W# MAXF;LJ[W]L'&OP/JD+-G"^"?;L?_$,ANF7=_'-=;7%?%D9I9$X[[MK5N&L?U MQKR5UQ$;M/-.1WNV:J^((XV?0DO[[<A_:!:OEC3;KRF!9"2P/A.`T@BZ]> M]`87@X$4U*T0'(KV!B:NAG8-?(RO7O3&%W$OOV;1WJ"?*J[VX2H*7Z75KHBV M**V;PEN4RI6E;\MSN.P[)Q[CX\AA&FFHO=8);S0I:H17"-!!%-C`[)4HL"^' M;Z9`#PD`_[EJ'/]:.&!/Q;8=__%X,&F!`3:(?34"["GK6PEPW0<&N*Z$/]=\ M27UX;#1#0.A:4FV7>I\,E39]+>3H9Z=?[)[YV^" M#%5VPQUDJ&5+'._>$C>0@;>G_,#[1PGW6AJZKO8NU4*MNM%+8_.A^V0.<)OD.[E`P87\I9`/Y2#O80QZ<"@&B-_?R7[8Q(8*SO^\ MBC_^E\U\PS?G*QJ3\Z+\[8.[C,*`3U;$D.N-G:^RE-D!<-)XVOXSLBULQ/C6 M#DS'"R*T&C>V=XX?3SW=5%_G?(.T%KH\#S)]A1/:?+&#/WBKND^&:SQ0L#+3 M8OC6,=RBGD3UQVM_8[PKH.V:D4]M4:-[;#A*+0AA19`;`YOW'Q4]%.-.A"BO M0\\"NKB%0+L`(HA5V0F M`/!_N3U%[6&9A8FBRP9`)38/W8%@&K^^&B`PHZ`;O`@=80%:)R(6N^*#IL(^Y)"W2S=NE(VWH17L&^[!C03(7#@ M6FPXS![P9<>Q1:M91"0*XIBU'6+\6W2)GMDN/$5-<.-AM+,W[]Z_QR:8`(`1 M7L#[%PO#_X.%VMG-UT_G\MVE[SWXQD)0V326V.>*?ESR1J-R[*"=4X7]W]K9 M?/N&+/O"&EGV2GZUY?#:E-@*V`8TP+EBOTN9==DY-^WC/DSFSF6 M]M$S7-&F?38#/@$N(_R2)_)*BB3D#3]]T;6/E[>7VEG\]+EVEH%Z%\`;N[8' MC.F51J*W-%*\5QG%F^G_GD8[=:)SKJ7%_V('N^9Z"[<=T(GOI")X/8!/T]=D;N]R[^.^Z$C(I='(:FNT70 M@:AV1O\O7I)0]:Y?__?Y>4DZ/_'FNZ:]1$TN6RP_@?CQ#2.(0*1,F]I@DRZ) MN\0#XKB;$%*I+81OG?>X,_F/U'L8]HN'W/["3WUMW]+^C`P_Y&W@T+6_7%N\ M`]7NYGS&@\9][VW:@_7TEH[DI';K2#HO"F?8D9>6EN]99$PDAD/68DA9"BE; M)+6S;:,ZK2#,N#1,QCMJX_KBZJ8[L#\PE]$//DP`AD>VK[J'Q_5F!#]G[`6Q MCX/B7,(07.VGUAA!*6*,+7:+'O.SN420';'[YL++'+-$,CQK,B,Q1PXV.B'SCD/B4$P/5@XP0LM:ZXJ!)P$O4T$7^;VP[F06ADG**EB%W`09YQ))_Q'N2( M.!KD'(BT(\Z3VUXK98>@TDV2E?(QX`3&=!,)@@B):D MT(1B))LV8U#G\$22<,QPSX?50:2_O+W+X,LE)D"F#A`D@7\I/9=>D8R&03FF MC>_=E\]WOWYY7R1IQ)VPC?VA&1F^7+=G.>7B!NC.*D?%C$OALX?(,2@(D*.& ML&=1B?@A.*?"W[`3KM5S)-Y(R!@OP3#O?J7)9,MYT7A\`VG35+M#\8KM=BU< M+;EK`=\%GO:403/9_F*NT"4`,]RK`+!H";*&-#96)#,ZVHS@BWE@Q2;?K?M4 MOKJ1%0_K<_+\/OVQALDM0FXR\O7C- M8@6N&5$X!RD3`(*("6^%3`$03AP#%!<@SI]`B3"HH[PP"5SP\"T_>L#E!;N) M/W7VR]N;\T3RQ3COW]YP94D$1Z/#1MM-^FN)QP1\;7H.[-2>".Y3O.-!V")I M"4]QJUS`%)HI)BS)MWOH.1$Q'AK]O4TPI#S"W87%<+Z`LJ(^`K*O= M`&Q`1[0B??`*;F;X%TV)`'RR+0MT\CLC"',<08XL$[L'QL\PAT[H.VXJ(;,O M'="QW%OGU.?25.`8"U\TY13O,+IUL3TGFP7NTH`J[##2()0[6+1$((A!OE&& M&CS]W6`8^UY"C?),L("G@NFX.3XQV&_@WQSLA&72>X#.]U-XBM/$*G*=TVZY M)\D0V```F*SIT=IQL3\#MK,HQ!64>U1Z5^8&AL66N/E&2P^Y$[PCC.IX:(+` MH@&[V@[MIAJ;`;UY@N29?1X;0A5X7_+Z:Q@`1I#:!K_>MMMPSEHL'28'Q3>6 M/$-3,QW;)>L0)`*8$1<(V=%-L@IAO3Q`<&XX,VE4$P0(0H#AR93++O9FSJ,D MWPXW%>YA+6/N2=FFSLI;@D$#2V%I__UQR]9[)7?>46:[A3E\)+B1<<1)]XFM M7L_(-SGU;SY])FW_`P`F[.E,.$ZR(:H#D.+0>T+)_S_:&?^LO1<_G[\F',[L MQW,IZ;C;H#&.KG)!>"KAZFVZ-+%W$+0B4WW-K#/2ALZ:=<>W>HQ,;%&A:1N3 M:??,L6'BK`-WC]^'Z%TMO8#,-T9F)]4\0=[U=ELT``GJ/3*"352)LPC97K"S MS.`M(Q*"!L38N&NB&7*/&R'^Q5Q0[K[Q@)]A'X^<,&6SQ^*R)@529I!/Q&:: M>+,6N0,;=<]&SU!\O'&P[?W#/&N\;R*T=(D3*CFK[>Y32G8I#$IJR\6Q7(^+ M:F)2HJ+:PBWQIB*)K<=P)2L#\#S:!"9M),7@IR%.]$16W!!H/?%MMRHS.7Z* M>;:L%2RYL6"<_4/D07TSG;D`ES#(4)_%,!K2+R6I/E"%R27`=;,H])/8N60T M)J:VD&*!#S%U*M06(Q<'5\#6I>/"5.2II0;C(+F8>\Z6(7\5 M5CBX1"52Q@.78Q*K!S1CXN.#U0`?@MEZ5$!/BS^+"9=W"4MNL[B"C:Q=XF&E M]>M[6!6R"S=8B#M(SFUUBJ89&AIJ/FVGUB,#IQT-#0P5>6Y&2^@I)PKW_%10]0#-(3!&N6W&Z6RNG'%"\; M?1%<#5HT;@0`,M=I#OI,-B?`+9'1B]&ZTG(PT74?FZ>^P(/)485-7B](#+$Q M674H0KDC'-KHXBM"'`4Z41I<3OO:$IT+G"=WS2@U2IS\@GQXSU*WC7`3X$%8 MG]0?_>'@=GQO!'9&?CZX&FSQ$4Z\-.AN#KU('H,K+2HL_ACIK;E8]DXXU2I])MI#7BA(44R"$DI5Z>5JR_ MD!P1%W*S6%2`,GNWK"27CZH>+6ZX@R;B%EQ5H/5P88%J)LR6,OE%1#<,ZU^P M/Q41C>M&PH@,J_0,>OHP&R:B2XTH.R0HV2<3ES=YY0PTY[_D:3Z\BW!B;A"E M'>"I-0`F;FF!)0E>/3\)8>X%^V8'9+T4+_%3P<)^S0AIRDCE>TVA*&&AR424 MQ*:[Q`T_M[:3]$QI6SAM`2=A/?*[XST`LR(PJ:U@MXFM>I9*A0.R.,P(D#CH M2*6V^2)NW&DNX_`BB!ICOJ8LR=J!30Y@$@E<9%3CXP[NAH*/^.Z],/[(0EPH M)8[]!\-L"WHQ=R>S0$N)(-[A M%WTZ?.`@IJ>D@P.I+418DNQ2D2C&LEG#&;;\!-XT'O:0/;41+N2^6#^+7I)Y(,QKW\-K]VOQ2%43I=($2IT.:"GUSC(GQA`0^)OT&=BIY%2+3\ M`*Z_OQ2AE7U2!<"/-O@\^V1;4"!ZBWTVO+HY!I+40"-<+ M^7[RA-*)AQD^^2';.&S+#=ZMB8EQMN,G`]".%MJM#+II_.:OQM.8;V)P\:", MWYFC=,R+FY!LKT_IU"OISA;FC(J9XHE2-XSC66`2FH.FV'"Y+$XN1L)AEB'E MB=Z$')*;<"&@V)TD.GGUTV#82]\MJPQCR/V.G'E:)V*"'OV,D4R MDWB9OYN?EKBED#`[+M$!'P_2J%:9,,;RQC1]-`/OZ/!>,NX71N0"]-]X`6CV MWV\]V"Y6VJ:463%*/,B-:\5#T`C\_::R:`_)F\WF-VW1M1'ITS+D(M&-6ML^ M;N*R!#S2SQ9+QULQ)A(R))!^#.0].0=KIL3`OPDD=0I&]*"`- M,,N/SJUUX2^15WJ/Y\:VI4N3EI]L6S(7,`4`/Z+C9\P`S/`&S(;=_$FD3'-R(`^)'500'<`KLM$#T_,)E.1VA3=#!OUS/O0`.\-PT%EDQ M]-PH8#)W3(I;SN#Y8P^G#*.2;'-%T<:8H@25$BB$3 MT6,B%7J])*1Y0O`",CR3D,L3Y%*N>Y?] M"%+KV_(MGP^>%H?YB2W*>Y)TY,XUB002?(?*&T>\-_ M$,K9>`#FH>7@?,W3/V#%);"BT'M]>TAX]X%+.ED7QG72< M3T_M)HSG&1;'K\1Y)!E*=O#'Q0Q5..;E@K8,>:HTP,.!C$]SO_H$^DI;41@/ M`*=;9S*:)...*4*@];DC$K^+W*Y'$GH/-HH>1Y2+Z2X.(D(,5?+D#I/'RW#+ M3MA>$(5L77ON>3PZ$]H+D8B'/WHF#R;ST"F:88]T&)$$1/DQI#RVH%C[@B6Q MN7S(G4ZQ;8EY:GX,NML/>!C@8>+$$R;6%2_2/@8X/Z@7 M91=YRZ)7HI(DWKX&OG`<468Q_CM8&J;\>ZM/6_JZJ6P4T/L^T3&95@1U=(D0 MDXS3DQQPG37=WRF],Z35MT;ZNXI=46'29%N@#5%>JXXWA[4[LMG:FS62=#"J MGZ29_;T]3"0BN:3^*O.!H16R"Q02P)M7-CT^.=&TAZ:9^(.6:R&;DJQKA MBM'?<=EJGQF.!>'AE&VD51TODPOFSH/M7N`?/VI7EX/X*=O%6ST_:A?\2QH^ MN0.N_3VVHFI9FU$+_?C&@U(NQ_?IF[+9=*])__N:.+$2LIVEZ&20(99V-=E& MG^;DH&JEZD/EX)WT"KZB5W`&IAM=.SQO6A0.PC.]<*4$(:?<$M?]JISKGKEP MGCD#O=S1$O-@,2HD5'=7(R8T1%]22NN+\:1]$NG5X,=ZKDB(RX3PXL?A MZ?CAY-DR9^MKI:9&Z8/U'1.T!?>P/QCV2Y8[JPQR,61[P=#O#PIHM_>4999K M.AINFQ*78Q$OAX?GM'A>++)LJ=)=^^X"$Z9>N(D>,*[H-_Q$E+^5%WP2CREQJ`D8^\7F5^"XQWYIQ9D2/2 MVB2/[CI4$"]]GL6O=/W$`*.]]FPE3\HDHC:E?X!\4.1\)N[[X^5ENJ4ISDNY ML&"**0OHF/_'YQL1K=+.3YIYD_T#*Q4[\R0M=W:V<`(+`\@'0P]*]_]!I)J* M-VXGPX$-B[;U)JJ[U]6>2[!'<+/&I3NE-Z8]2$?FZEJ*/R<:-G:5!T9#M1-*K(SG*:N9#<_@1DY57M3-Y4X%,Z.U25 M4<1'UOR7#O.'F*5K+*+(5(,DC6J3I+:.&?J37><,Z6!/0V)6'MGZN'>?]K=5 MB4_/U-N\>*^VQ'O!W1]='-*'MS*OL\-\*HFQV?[K+0!=6MZKLA^/ M&%SOR'AI.V!PC#51O/TL>7O2>VZL77^\K*KQT$I,[70MPV;@:=;D&XV:C1EW MC;+=6=O?(MCN!&5(KU8GZ'A:.\Q+).N64HU&4%;`#J",#5)L.XL M5Q>H\<+9Y\AQGF=T.+"GY]ND0=*8Y]LIH!LVZ7LGXOHVN2:*MY\E;^?OP#XC M'F]H7QL=Z?QB,-ZQKWVE&FEVQO]@:_4I:E4"HRZ'=@$XS?*B>X?594&U?E)9 M';EF8\#3AH-;A?S5-7=!"<'+%H*F(V]'$(*--W!+7*G*7]+==2TMOO66ZV02 M5Q[\?=.-M_@%?%X^WM1UM_R=K?V+/V].-L_9B]-9"N4)WTB1RX]Q M\S9JQ46]2K$X-QBF6.T4J[J)VLE6Q$3Q24/[;I@4^W=P,<^RH)_SHFG&;`9K M)DLK)X]\2FI!O_$62VIA^/'R]C(US/F+O`=8JU%]T!6CQBX4'8JBO%O6S(VX MRMY:OOI*->W0QKW'ZM>4CK!$BBOVXHK=FNVNLR/-H1I".G0RBTN,+X`;+I-?PV4K7PO^*(Q5'GN"A MQ[$N;>S:.7YUC066IL+64K+/8Z,G'BJ9O26@FXWAGO5[^M7P9"]KE,"PU3HN M)\%12@P*Q*"O3T8O50R.G"#0MI>5#>W']QM;V39+GI$>)_'FT#/2#EC(#9Z1 M[G<[X5H?3-JMAK7W,6F;67-*#EZ8'$SUX?C9R<$AZ0+5CZ2IDZ9ONZ:]-!S9 M_E-V(\/#9FSIR8.'O&\7UI=G?T;XL.M&E!,7A(;C\&9GHC7;S(O\<*YK,WN& M_Q)]./&0VG5MH'5@8`J=G">7JY"T7[QGL`%32T:8^CV[]R/#7V$/GBM=-FZU MDAZ_`G@);0:4U,0K[`7/&P%;;,9\7S0<]%Q&'2BP9R.SL8ND=F:?QRD#@][K M7V!/OS,<%L3?]5_')^?V8L$LF[DH[R(P1#\+;&<>$F2'BS-=W4@@7*4.@L]![ M8$0!GEG@KN2K,<4V4O>\@+SPINV(SGK?]XKZT=Y0'ST``?N] MBIZ?\!@+0N`JV0QZ;K-'WJ:1P1_$:[KL%"I%84T43=EPM!0QL;=A6GKU1&JP MDS-(SG63O:8S*3=?,X6F96*+K$5=)/AQVXI\-]_GEY5R?6AUZES(>S1XEA5N M]SF'G.Q=4*ZFO)"OM$=^\JCG]#OL.5U%GE3A[1-;[CO[FUKL-HY&\CJN`!Y5 M65M5UG[QJWE29;75:BK9?$&K>5*R66].7(O;]\M+7^P:C?*VMB*38J5G1*/Z M-6-7SK'?&,%\+1#7D')629H=3-*<-'RBUK5#9,6.G6;'07^JV%&Q8U?8L:\/ M>Z=<&E0QY#-CR.&P?\+LV)X=W?;=B5^P."W:TN(*A1%B^0;,",7*#S(MM.WV M2:KP:!.)WJ.K[EUJ4@5NGQ^?]3MH"RL^>WY\=MV[5GRF^*QY?7;5O7Z"G:KL MW:7`\$V1'6MZ0;9C:#.ZOK/-D&S'T&">BJI$_VQNE^\7G=#[@V;C8*HA@Q*#SHO! M<-3L`;,2`B4$G1>"@3X8*#%08O#"Q6#<;[>:W9&;\TAP38<9/D$Y3VA57PF> MPI1[S6>BVD60_&;`_UQ9=\<7M3ZFEU?C[V4]%B\*@]!PJ1K*6BV1;#D-/:X# M\V=D^#"#L\+:))BTE"YM4BZ1*0VNJ#23>3CT#3+T4TW-=QE^F@C3KM4/2$'\MF#\YK4I#ZK`'H`[_&F@5 M47V5DO.M+WL!GZT_\*%X=%ZLY8E)I$,O-6%,$?AV&?GFW`#^N+I,N@(%<\/G MY92\R,<2*PO\,L2^39QEV#?FFUAU!7C")$I_-[B<]I$3^,N\1A#PGNU37:"" MLC%9`A=`A\.`NK(?@>J/+.!#8J4H>[8BWN.`+):<"WQOH3FV<<_[4ADF\1'G M6U'`"%;BYNZ--NV/B5UP?-,Q@L"&B>'/`.M0P;MIT)#2*';;KVO2CW']$Q+" M.\:C!_@[_JUK5#?_6D^7",KR@)ZN$@1+@^N(+9TPF`6R:6DSVS5``H'%0"9# MMA#"3(N$=T&U]YZ_`+@N_GN-G7)]O[8WYXJ;?O&HR`>I+MYQ5:+#8MV'F69? M]*!\3CSV5K2DRK3Y&L9MOH;4YDN+7)O_^FNO-W@%ZVW:"\,)_OKJ8OCJ)]@? M>KV>@'G3'`U".^J-,DW)MD/;!__^J.`.8W#+$!</_T7B'J:@9F9-^;3%BRW6B^V=:K<(,TT_.?9;V+P#S3V5^]6C'S'S>%B MBKT!&]\.I0U%U(@A2``0\Q<1J)\AT/C53U=9B2P%7`&IJ`3BAU0QU4*<\:GT M0\589B&>I"'^\,M[T"(Y8/.CQN#)AK.\I2A8!?B4']$:Y8T+[7?J1:NA75K4 M839I7HLC)0/E[()L0]N:&\]*!Z!BJUE5Y%(5N51%+E612U7D\D4OMBIR><*E MUU0AO>>TFB=52$^MII+-%[2:)R6;JLCE1OYYUMZ^5"DCJ?'SU8=2#D0AXKN8&-E2<#S\&B5T`B63_$BI@&J\U\S="^&R9U M'K%*I':6+2ARSHM(&K.9[6!AIX#3>G--'5W[>'E[F1KF_!F7()EN+$%2:WAC M/#F@,DEC=4@.15%?19,K6Y-JZNNIW+5%=FY M*QE-5,7ZEA=Z;TB0U)69+EZ9@3VSU[V,?76)2W'DJ7)D"[FPVW:.MB]W_>J* M6UW,BJ]RUZ:='"?0>F#:2:>`;C9^>M;OZ5?#=F.H>R>?[(5AO>5?E1@\ M4S'HZY/12Q6#%E*UNN1E94/[NN8R.O)H9=LL>3YYG,3'0\\G.V`A-W@^N5_& M\K4^F+1;,'/O(\HVLY:5'+PP.9CJPX;+>!U!#JH?U5`L``00E#@``!#D!``#M75ESX[@1 M?D]5_@-7^RS+Q^QD9VJ<+8UE3[G*.W)9GFS>MB@2DI"%"`4@;6M_?0"*I'D` M8(.2AU"2%Q]D=P/=_:'1./GIEYA/,`T)YPI`WHR2)A03NW3],;V[OKKWS MD_GWA7=;!E>KF+O[,.'G[RA=WYZ=N$]KNB:T\A[0$DLRO;&08!(PD^\ M,2%>2LX]ACAB3R@\&0YEZ01'?WR4/^8^1YZH=<0_OG!\.5C%\>;C:/3\_'SR M?'%"V7)T?GIZ-OKGKW>S8(76_A!'//:C``T\0?^1IP_O:.#'JD)13-EVCTHU9>Q1H5FR7OML.UW,\#+""QSX42Q`39,H%BWIGA(<8,3W MJ*UE`7NHK1"*#U=[G=1RI0.?!`E)];H3_U=*1"\QBL+7 M>LAJ'T"KM/2\?$*#2IE$!F_*JFIF1:8Q<.'S>1H(10>V]/W-2*H_0B3F^9/4 M(,/3LRQ:_Y@]_OT.^W-,<"S:TC@2KJ7!'RM*0M%'7?\[P?$V+U,HA,CE`$H> MXUB:I9U\Y(#B>AWUZKA1\ZN$,=$0]0K4")IZ%`2]J9,%=7[O;_TY06J5S$29 M6CJBJFJEQCUF52U]%N0BQ9^5EMU,-S**$9<=E90V%`UYG?,O&%T;/4&!2I6J M^]%KRO-BZNGD4"9:VN7@)YGC/B.99&8);W_0I='R$;'U!,UC$1"N_`V.?7*' M1$(XG1.\W'4E&E1WXLO MW'']!"V0J%SX@,1P-]'D$V:BHN&KB5SU.$@I4&-7R\E\_:[%UST9I-)1=@5] MV@T>!=LDQ+W<%99\=QH3=1H,.8B*3MI"XX%)(#"_[W40;0*[I>TRBM:7TX`V;( MQS4`AOY`;H:UM;(5M*OQ#9'I7B[XR$3(2M@VK>`_?)*@&B[T!)EI5`2N^KU5 M&8"?53)4.<&P7\>6<*=RJ^YU9H?F:U==VJ((P*%-">XE]0]RL3I"X;7/(APM M^3@(DK74"X5BR(T#7$_NX0R9H2`,KF+`6ED`*B`RWP&8/>VRL=(-8 MO+TG[#550+RT M!`>2YUZ_K6Z6X_C*9VPK$G#E(-:&)Q_9PG@RH,+7W&IU%=PSOQ M_WR MHN5.H6P\HHJ+K<3E4&D@=DUEF*XP)?N$.=!)%*IB!?%FX46_HA*J`K]CV`>B M'HAW#=*/!`MJ)?<%0R$5N@;O1`=A%??,/42;*`?3Y&I-%=F.@2)O&RJ*'N?U MT^WN-\+I7U39CO9],4O?>-]C$S<8G[;K4FW035F[V?B&#/$+"]W*V;R)L3VBZ2J;NG4"TK\M+)EH'0-QP#K734`WG7&JVM&22 MYAZP9X@(F^ MHEP,/[]0&O(9)6$-(IJWQ9;"VEM'G6[6HMV[#7[@=+Q#77Q;SP;IXA4R'-PE M._,)XEDVDKJLN:!D(LG#G)+$6?<"-()X6"W&0;3K1V&MPXR6H9>*W\'^ON0H M,[[-T.X9U;J*=D!T350KFMNFF!PQ@]703&$#_;!,EX,XLXZCN!/-K9TL]XAA M&HI`(8^/H`G:_09M:#&S&O>UZ%A[BT5RG5I4\9[1)RQ<_WG[C2-1OR*2C@.1 M`JNNUK)G?%T=`S/VN*&EZJ';J'EQ1F.C"YREV``#8>FUH[;U,>UDB'JW#BQU MM]4&4EH>-AW:@_,FJ\ONH\.DVAXPJ(EU;ZC>Q&FZ4%"H8Q-86CFU\<7`>6Q` MZFZ6@T8;0Z$Y"!VZM4\9+KTA\_SLPF.'1?5BTJQY1#P]EF MK;,M[_GE4\JM[ZU`LQ&B11],R/%#LH.Q#HI36/DY>`\SX]B\'%H^^3W507X2 MX(:RZY<`<5[LQJYA#D#Y>H9/3WELZ(&KO0=$C(6X=YOM_^)6R0[0V6&J0Z&>),4JUQ:WE&YM(]WO*8LQG^F M6D\7-SCRHT"H)Y.!MD#<_`2,]R]=SFR M50>\P&3>Q`2W#*[J6\QZJ,&7-EQG7@N_8,-;5 M)'O@S:)(]P[M-QM+[7;_UO"EH=>&L`;]L4',U@0'#66-HC)(?7!H\U*G#2YT MC]T?%0O;E)XM\H)+=:_]:FI?C`=MM]H8&,U;;92,?=ZZ%R`4G+8',KS.WKZ?J1+S"]`D,:^F,&$L0$ M!T*3IBCWEKJ5O3F3IP^F"^6'5N`,IGRKQG#,J`(9X=#Y5JTLX$K1$8\EVXWE["GO2RH9^XMM69[X2,>!``%#V@O)ZS'.FC&/ M=1:,SL4\D]?I'D:!Q#Y%V6GLLRC3Q1N&#AP$V]OE6P1!9:FNW2`YDUY@V^EB MAI<17N!`XF.WET?4_)X2'(AZ3^1G8PAWXP[)\9.HB]QA]$A+'SG*/N$QP22) M&PE]9W[5:2$8__]/1!WD8+N5LRP/1MF5HC\?Y=!T75I7_(2TDW)Z@GQ;AX+@ M2+'0JNO^@%`5X5Z>^UM:"Q2.1?SWE^AKLIXC-EUD>J1KMWR:Q#SVHU!$_1ID M.G)G-K;F[G=E6.9$Q>1)G:/`)R>8G1(J@V=M^`$GEU>2NDOIK MMETA0P]INTKKMJQ1L1;=M29'$P0:JG_V.0Y@(<#,:PX`.MZC!.T^]MD7II9E MM^0LWWT`4AQHZC[&T!QATQU8TYW3TAY&.^I/P/11^0?_^5<_%N-EGS2[1@-- M79TJ37^106EZ"E.FTKS+@BI?N*D*<&]<453T1E[IN$)A?IG4="$O"F5/BFV_ M8(ZZVTT<#H,`K"@,$B9QP.RB%_,H;=-R1L`/B^27*BDUY M;629V?5DCIRKE)7)#^3=BT$43M8U3<'TRI.42OK^6E*KVQH')ML5KC0M70'- MX=(#(=YC0B14T*.&Y[7/@PJMD1&G69[NWM5JAQ_1*01`Y?#8<7;=F* MKAG*YC9R.JH/1A%JI MQ!D```/'`0`5`!P`9'-C;RTR,#$T,#8S,%]D968N>&UL550)``,?[^-3'^_C M4W5X"P`!!"4.```$.0$``.U=6W/;.+)^/U7G/^AXGQW'SLSL3&JR6XXOLZZR M8Y?L[-E]FJ(IR&*%(C0`J=CSZQ>@2(H77$E`A+1XR<5N-+K1']"X=#=__?OK M,IZL`<(13#X=G;Y[?S0!20AG4?+RZ2C#QP$.H^CH[W_[W__Y]?^.CW\#"4!! M"F:3Y[?)983#&.(,@3LW4_OSMZ]GUS`U1N*7A;I MY/277WZ<'$_.WI]^F#PMX!+#9#(%64KZGIR'(8@S_&YR'L>3G!Q/$,``K<'L MW?$Q[3V.DF\?Z1_/`083(G6"/[[BZ-/1(DU7'T].OG___N[[AW<0O9RO*ON]O'<`&6P7&4X#1(0G`T(?0?G9\8?3=Z]X=E2(2'^MT$E)_MJA+W0BH_?+2?[;BI0PB@2L:VKG M].EI15PG_#'_WRP](H,\F6R&&<$83,%\0O_^.KVIVLV(Q2$!RUL M4(J3QQ2&W^Y7.0#.DUG^7ZK4[&JYBN$;`!=PN0()SD?\$J1!%&,B5=Y5^K8" MGXYP1"A!^;,%`O-/1S/2%QG4TQ_>__3A/1W2O_3KYZ2_8I<`H'D$XMDM#(8( MSN8S0#"BZ!(F^0#\?X!0D*2W4?`@Q/V* MWB#2==N*%DSVAM3X',3T0NUQ`4"Z9?\0(-+U`J1D)N5&"Z#2,'8?00N M6)N0-V=UO`3+9X!,"MOD:T#2!1$*A=DS.*X&PJ"\3.YUJ0E(HB2B\^V6_+?1 M,7A-03+;KD-4W&$+A,6.=1>^G7N,9KAOSL'5.+H5S^RF5UC^)89I&/6_V1D%T#L!=O];R-W.L!U( M(+SWWMULVT'OTG>2,6?>#N11?JK+12B%B&'8Z#FFD3X0,7>R^2YV'N#G?"N; MX>.7(%B=T+/B"8A37/XD/ST>OS\M0GO^4OSX]XLXP&1G44#C'DUIX!)1'=R0 M74=UFT24`O&G(S5BLGFE`R,C/G%*Y?LLI:%&-&9,16D&N4CM!GE3\2W@SE%S M",@YI^1=''EZGM[F""Z5C0>U-=YJ\'$B[F220C9%@SE$,X"*.#ZW0'+U2HZ$ M$08/*`I!]4M<_!:?JB!'E8<(3G(>^XDQS;$Q`#QYCP4:SWJBL7MS1W_R>]$O M=4`/`$5PMNV[!2(%RF(XA)3.`T)=3SVS"_D6QOU@UKA?,CH053^/BP`!?(-Q M1H5HF5>)ME!<0NN\B75TU3.RA'-AYA_&]2C;C?A&OO,L74`4_;G=499^0TY9 M>@<1I?-X4-=3Z>@O`:HAR/FV!VCK65 MFW;-K]!TG_"@.Q*]`:+048&8G]S;CSXQ'(J<4+2S?++O2FH/BT8VC2S=#.P, MGQJNXZ_4^.GI1YHL!&:?CE*4@*'_<`TIYZ^1TF&^ M3B?"R8;.)DP$KWL"V#3!P(,,0TLI8G+.7+1L.+I['`*:64@Q0UEP(E"P/!P2_GSD(@V;8AQD<=!0U@03*U,[E MP76T!O\&`2IZ_7#7V'45=A43%7KRB%S:*K:F*E1436K"#5]J1!X_-V8R`K,H MO0["_,F&Y<>Y!.6L91#L@^>6Z:7ALAFL!DY-&\9EK\\"$J:!'7#+?,MU["IW MQ!UF78NZY7K[V;3K;,>T*M/+:IM5[%>5#6O/DU;/T]MG6?I`'"1O3)^J2EYH M*RW4 M72F'FYV'E+*?^WG>[1-AP%Q/I72%F@*Z\;REV#Y07;NZ$9E,J?T$S.Q,P,$V M[#B1\:W(\H[]S2CTDOJ&M.4D15:\LE&\HKR M>0:5E:N;D,N7FI'/SZ(_7,"8\,97?V3$1]]R@KT4*.N^D4=I3O2[X#5:9LL' MF)+-0Q3$M5><]L,-R.,[6PKU;E^HV:/]2$A6,1T3]1I4AA5 MKEV!L/AW.[15MQEK,(3-1O*<6@:&O<>A/M-5NJ23 M7;TK)ZY!FVHM`O0"Q+.I2<*HN$9?2* M9!^-SM9OL-$KMG;CE\N<*?P$IR`$T1H\`N+L\\U&\-:H0M2*9M9HV8IM5FJY M)U#H/QI]$*+5FQ,1T=L]KL"W8?&I3+EEYWRFT'*G)S5==/4?@S[HTNJM'F.] M'T&3#:4XST1"&I;KY*JMC;Y,I-?+L.$ M=LQ\F5*D+K<*,FH7MJ&,V0EU%16:=OM4)67JWI1N;FAD/IU/+;_+.Q`_+QT" M4QZ?U9$35QCT>;:E$-,I2.F*`1/0.;(#$-@*@H/86`K1/+R&`8=!SH M^$"0[@]Z(D%]KZ")!0/[!C-H*.]4*A?(W%Y(J,HR#3RJD;83\@D.556KVYW+ M-B_*P&,W^M.EXE=NQ@)B)=XYQB"E!:7*:EX1P'<@H%^RF]TG4Q!FJ/#%7V"" MRO]^#G"$.[=)9<:0#=YEHI%9WJ,M!";T.'\F<`K"U,+PMUD;'/TMZY'6*3OP MA%8'OKX@&I4_3ULS*K<3NZZ-)I5BVZ]S`EI?@.:VD;>-11%/" MCTUS<&A3&`J[X&(+X,0S?%TVH@75(7^,Y8*I2\1`4YWHD.'$'8R=X:DNP<#J M9KOPGEI>4\M;'B#0=`9G1._H2)$T[O92]=B@>EPX/*2I#LDXQX-F';:]OOUA MA;,9YVOPWF>,4#BGKWID$75.WO,T`_-^WI_`O$KYSV^%JE2@:P3^R$`2LNHA M:;1H3Q-1BU&?]LWC%O89*-,PKT(#E$1QXH:RDI0E)_.%6*-%&X^B%N,%#^C@ M!O;1GPDS?F<-`(DZ.5P`=5[@78(0*^S`/(:$00CF4.1,2`)+5ERMMNR2D!I- M!#CJ-AG[,*2PLG!`)%&?B2%^;SP,=7MQ8RGJ!CBP]E-BJJJ2*(?J`/=-2@-B M;Z_$Z]Z)9>D)!0F>`T25?`1H'85$`H+X;D[J/N&?N)W<+?/%F@IIRH*W;)JQPF)MK)-0;20:<;0&Y<@+[++[=V(9O0`HS))3EJ@241X:MI1'Q2K"1%(XL6(5M6V9R&+^KABUUN\.##TBS6WB MI=6O$_%5TR!Y8>8+MG]>9@9N?WYX!UZ>TM:.N+4.W4$#<[5@_*:.B)VL%.), MOX[MH$CJ1N96V;0RB5.;!26C='/T1S`+,^].8A=Q3AW',LX<">Z(J,N,71Z: M^;NRQ&[S=V,EV#.F!Q0+WK'.ABHO?=MLYL3<*"#0J-N[(.PT>'M:GH-URXB((32.!$Q MSGSCZHJM_)HM;2MZC>2W=2)$0@5;O,=)Q6'AO'0+>N8^5/)[=,)O[0QX2@$5 MXT-/$EIA`WNJ<18FT>?,OK82\"9992G.-3H5QUKP*=O(8E$Z%%DA7XV@CMJR MT`IN=PWTL+IQ:Z6J27BFC)0S9:2<'1)2V&H;1\J9FWO]FH2<3_K**05(&?OC MOD:1(O_FKQ&DM#\%_,'5NC0;::J\85J=/3(!?^:P&=:F8L> M2O-90'X-$_HISR!?(,P4KNG354_KZ'4U]L(X=K;3`,,XE0"EIX>=[XPQW<_] MO/;=L^+9$W_%1.3:AY(Z@M<6]^O-XJYRLC7=E^@<;*ZO@YV".S#-;N:@'46< MV(E?`A2MR>I`/WU0#=8%LQR&"FGU%7`1Z:$!7F-@K.)5+(>=[^8\(!@",,/7 M9(@W&"_FQ-4K0&&$.Q_`4F]0#)E*@T-#E/8@6<65BC1.O-%4D5FEPF_GV\I# M#V1VP-E-$B(R!.`2;/YNH7,`AZJ"?@\.AX;?X<-H%="]Q'.BS)#Q5V%?C<-7 MXQBA&L=/OAH'OQN&K<>P=@'PU#E^-PU?C\-4X?#6.7>R;?#6. MO:]+T#+67E8E\-4XG-G4[0GJ?34.7XW#//CO8`+>[@+T#:3763)CE^,0$Y7) M7ARB`TM[5QH+F_GO/`&<6$M]20Y?DF,7./,E.7Q)#E^2PY?D\"4Y?$D.7Y+# MQKG`E^3P)3EV;A]?DD,G%]N7Y.@Q7+XDAR_)X4MR'#[P?$D.Y9'Q)3E\28XN ME'Q)#D$I""E2?$D.FTCQ)3GV'BF^)$?S-KV3`HMK.;#D?)(M5U04?#_?Z$59 MY:GIV-?N\+4[2CU*E%R]KD"8@MD_84Q`0M.TID$JREQ2:\@8.5G#L=ZRSUWVNZR,YNZ/4&]SUWVN]SEWWNLL]==@9=/G?9YR[[W&6?NVSXU.MSEWWN MLL]=-GMJ\;G+/G?9YR[[W&6?N^Q`#(3Z61\[K+/ M7>Y"R>ZRFMH^=]GG+JNI?<"YRS?)FB@`T=O8N<:5(+>!J7C5I;IIF-L!J^!+I3S8>:J2Y[)>`9RW1S]!]_6-[!OHSFX MGT^#[W=!"E`4Q.WUG$]0*,$B<-(*4DWDYF"Q&'@EQ[%+O8_[Y!]!,GO(R(8E MP&#V@"*(GN`4K"!*H^1E\]'?SB-8S_;50YEV>R>-/G0@-EO$,XP M.6^1[8=DF9:W:%M6W*ZK&(N[%^VAW^,LBJ*PRXK<"(9^&:ID=/3_:DULJ_QOAS+*0;M-ENS M(V_W(,B391L?>>LC;WWD;=,Z/O)V_+GC(V\U(F]W_,9Z`9=+F#RF,/Q6Y"25 M`9VCO[I>Q`'&]_-"K'LTC5X6:6),-UJ;.Y! MJU[;"BA0%M(+*4>:)(K##W7TK,\B,7\ZL81\!RZ#/./B-%H&*9A5813;/L_# M$&8)_1U$Y_B22+0.TF@-:N'2G"=:PUQ+T)CBZC[`K(R?)AA-R6#GJ9FIP`W& M&;CL5AY6(Q:MK#5BY]&CI:T>*&2L[;QU?\GH<%3=/BX"!##ME7&7HT1;Z"ZA M==[0.KKJV5G"V8EL%J86A0L%#R@*:PM6\5M\JK(PJ/(0K1=R'LZCR\38&%A= MY#T.?)77<3!7KZL(Y:_$JEZ&W4(,G6:+?06*0&\CL&CR'_A6;[1`"?X"TT>0 M$E4WWR&Z"/"BVD5=DD-L#&EH5(-&0P]?NET-C![@K#?Y M_46^E9I=9J@*.KI/R@60>^SNT;(8)ZV6SD.F_SCHX46K'R>"$AX0#`&8X6LR MHH5HI:QM,*F0%J,F)G4>+AJ:ZN%#S-B)2`2F$JRG<3FA:"LSQI/YP'V+["F] MYW:E]<3^?G^>V)GJ,)[/ MZV@-_@T"5/3**8P@)*H^*<`FO):!'K6,U5T0,UZG`("0B*V]<8N&]#/>O+Z`'K6'8+@V3LL!1Z7KF?7R`PB]+K(,Q#93I'I"J/5(&V2BD5THZV?6')540Q?88( MP>]1\G(1K,AOTG;J.3RV?/^E< MI;6O@SC.ZY!PWIIY9*UGYBZ9ZS975%#+OGR>3@3B7H+G=%ON_"%XHW_1;V^W MC2\G+$9'1.@Z`)25U(*`B*NE"!*0/@8QP-<0W2R71+`@!?';`P(A^7?R\O0= MQ&MP!Y-TL;G+9Q%-P6HC*>/IUQK_<@DQS]]UZ-D>4KU%R[PP=LI/7/V1$=DW MY6U3$6+EA&74I8#0=0PI*ZD%!A%7)RI$--?7FR0%".!T2@1\3&E$)\%H2'X1 MO+1!H=^0Z>/$#5T'3>]!&.`#Q;W8J4/1BO'#FQ?M)UA60=D$_7&VO&J-V'&6 MW$:N(Z.7\KTVQ[(>G"A@X0,PK:+-=/RE%'S#PB_'C7"YA#IT#O.FQT5=;" MBP+S$BCCWC$W!2V^LIF\7$#<>6)0(67"HTVZ7\@0*CH`%&V^)1X,7S<_P91^ M-+6S?+6,*R,K/_G.)7/=J(H*:AF4S[,TYKAIBNV5U1PP*59G6=I>Y,J*C8X]*>5.//S'B7.-/1@9^")'C)5_P+N%P%R1LS?EZ5O-IER\C'BJD734&HK2??JMMX M>CE+.Q&XYTD2K0'"`7JCX?R8X3Y%).65&)/$?1>JH)JR$V7SLC,OVWTQ5U$Q M$<=RXWM'H4T8-I-Z2!9#EL$,>4GS)NNXB9&-QG)^_:PF=(!Z=K.8M@DSE"YJ MO;)SQ\149?(8CVHD3R>93%!5+Y'=:DEC/%YVIMQC]"JWFYBHK-_#(7+6:DI: MJ1F-Q\J)+)+IGGZ70FEWPE-">4LR[7RMHN_[F_]:A?]:Q>AF\5^KJ%O'?ZVB M-7=VG&B>5Z>[7U%^^#R9Y?]]IA\UO5JN8O@&`#V_$^AN:F>.G(A>RO0(T#H* M-^'MGZFP=2'/XUR"/(!C"D+XDM`GO4VB51['<PY7?=DQ+%M^8E64R8G]P&.X`+,L)KM* M,R/!>JZUVD=Y9K/3QTZ?B2W.DUV8P/*TLJ1"?>>W'R_@-PG9E6SR&:DDMX6: MC'.Q`F450B^@'/7L;!>Y4&>0Z@"W(M8F/%\@CA,N@R,A\XI;B5:,P?'?*%00 MP@>2],5"P%X`"*=>^8U!HG.`=P,4K+L($Z@0WE<,P84S=QKT6^%D0!?DS'P) MUB"&*RILL0=FWT.IMRAOIU1:C/:%;Y5%`?916P$KVWM])?9.K"6_@02@(":" MGL^61$&:V4BS7468T6I3#)]B&]=QTT=U+>0H=J#^O=+BY_0/>H-&?O(?4$L# M!!0````(`%R+!T6SGE'3XV,``.5=!0`5`!P`9'-C;RTR,#$T,#8S,%]L86(N M>&UL550)``,?[^-3'^_C4W5X"P`!!"4.```$.0$``.V]ZW+056%E*4?]A-`>N2A?R^E2OO__&_OFP3](BS/";I7[Y;?O_Z.X33-=G$Z?U? MOMOGKZ)\'K5+SC%653@#;I]0J=QODY(OL\PNB;)OJ`6 M2#;G*3H M"N\+ZAN=K-??HY,D05P\1QG.L6\)W'ZV\_L_VZC'"-:ZC3_ M^4L>_^6[AZ+8_?S##Y\_?_[^\_'W)+O_X>CUZ^4/_^^'\^OU`]Y&K^(T+Z)T MC;]#5/[GG#\\)^NHX#^YH_[E-DMJ`\<_-+Z4$NQ?KVJQ5^S1J^71J^/E]U_R MS7=5$=EK"R>U^)>!?/6;Z-?[Z0?^MA&EAF*-Z>9GTZ^'4/G],I+@*WR'V']_ MO3I3:O_T`Y/X(<7%>72+$^J2JQ=/._R7[_)XNTMP_>PAPW=R.TF6-6;8U_F) M?9WEC^SK_(_6\@]3BG?/L'A#BBB!*2>W-RSKP,WT0G^$^K2Z(G^$_,J4I_@` M7[GC9GJA+W$6D\V[=.._X*(KJ,)?%U%V`*@,G4W_`?Y++2EJPAZ=T[]Z?O&7 M`J<;O*D],]N:V,E=\V#++3>VR;IG-6&M",FD/X<;S/'Z^WOR^,,&Q]3P\@_L MCU?LCU>OEU5#\3_HH_\ZV=+2T?\5[Y/HOC;'?\E?OI.^*^*"_0#AW0_]TC+] M7GEIDTKVV1H+'@8E^*_D-G'Z4KV*+HNF,KI-J%N67.#TU:_7WZ%XHY)=-8\0 M>_8?/[1E'O[.DZQ?-5&VK@M$_S3\B$KBAS6A[>6N>-7[/7<9V:IJ@1@^7O4M MN+V?44\,%00I='\X#.C>[K.,^:5I7)3\`T<9#5ZGE%4".DQBU6]4BTU`IH?(W8>T0%$).8%\3&JB3VG[T/;95&C7*]Q0,!_I2L]XQI M35,M0;M6IOK-"ID).)=:A`*YSK@*X6J=5?T*E>\"@;:^WHCE9^Z#6BI>(UIC MZT!P?I?2XC[]'2?)?Z;DE"&(RKWYC0JB60J78O#RPJVCB6!]]7FC5:GY8V#XH3_Y&DGU*NS=/ M[^.$]C&E_%#(]'@QD)G,!\$B+`_DQO7XE^G4N&_>H?)E"&A751NQ_,HR=`OB M?51+;1T4S54^=85W)"OB])YVW(N]'-1ZT1ZV5:*3(2XW#(MTK0\]X#6J->[K MI+Z10:50"/@WU#!QJPD9&^1:?5+H+!^4&YR4;VDV=D^R)RDEI!(])@@2DPG0 MLP>+>YEI/=R'&C7*^1M4OPH!V_*J(E;?5H;DGG`?P!([!\7M%;Z/\R*+TN)C MM!6AI!/I(5<4F0S=OD%8[$IMZ\$K4:G1V[Y"[%T(\%54&+'[P#(`]Z7[")99 M.FQ:0AN`+$K.T@W^\I]8'GP5,OU$1)29GH'T+0*G'E+CAIQ#HM,D&^4[Q%\B M^C8$**OJC5A^9FE>T1<7$@J9K(8NQB7[!)=;8Z0HYM M"X4^T+4*TU&O,0],`;,G`Q],!AIR<$'$)1>HE$4=X2"X8H,#,J:FI"S2Z`J4 M,GHY\%!\.R'PGCX1.[`&*6$X?B`%,"`OV(0>DI>;-PW*R[3:8?GNM!-_'\;` MO*H.B?4'EP_."PKB\+S4WBP@+R<*S#"7R$F!WI,#@WK'JA^P#QW8P5W4&P"^ MFHX*#O*R^I2"7O'I=;#OJ,B!/[!Y8.C?4+,*M'=?"0`O7P%@FAF"AG''I@FY MC6@+5O8H#'3VOC_1?S/_.EFOR3YE0Y"7)(G7,%T(2#$+ULNL-((C46HN+`1NK;W(D&RI MO+K>;[=L0HCOX/HWOXC4;@FG54*V'/M6:_]_,J[G,-4](+*$CJ-S%.'0L M._"HWB[J2?NO'R=+>*`LYXV3V1YOSN/H-D[B@J8]RE"IEVNCI4IN.AODEOW$ M3*TO`S$TNJOJ-<)?=CC-\'.6OHUV<1$EG;D?,M(2R,[)JY6@B&V]>Q2E:EZ(ST\H>!F1L10D\,^KV"&?I:4;B M_?<^+]@H:'Y#:/>4?NJ8]T[/TC79XG.2T^=OH_SA,B./\09OWCS]FF/Z2RYV M[%2%.+T_61?Q(X\EJB%+CRX:&_]6.OKU\P7 MG1-N'&_XRI#UAWIF8.,&TS(E$H4`H&5?H_:#AX/ MAE"X+K&32QAXLLYR+5PN2*P`VI5'E<+S!ZJJ4^T1J;-VM[=LO]._>)$N[M[' M:43;RO3^+U.I!,4T'1R4=#/4F(YR$E4U[Y1^`N%>/RZ8`^"TN?HXP=XI"C%S%5YQMU7\XM_V3D14D4-:DVJ.CG9]#P`TN9[;U-AEKRQIL"\0D$1?MWNOR_#&H2HG!03AK M$LP+*(WJTM`-1!CG(#R\R$7&#.M(6X93?F\+BOB3$%"LAJHI)@XQ!QC=/(0P M^SC5"T;A5Y(V:,AK:7[Z2^*3;9YGF]_Y:VA!^Y0&)Z.:U3+6M*UH""#6U:1- M.SDB1[-J%H/H_E2;-;1='H5,CP8#&1`*"%;AX2]W8(:^3*^Y\:04F7O!K[;J M!KC7?&D9Y@7Q(=ZE]F;&NA;D6G0#PWHLGFUV3\H`7S-P M;1&KAJJ'/K+'#K%[[U?:U0VL3^M6S]K$TZZBYT]$%7N]9>]D+2UL"^NIC^JP M=EW++#M5<6?<+8P-U<[5JPU$ M-O4[9QAZ$^5Q?G$G'+[U5/[_#?Y2O$F&FZ3=E*K/8JLT$>MV;B`[$4X>==QP M,+3BLFS&])+=#9X6`6S\<40%F5)G?:K9Z7W@\OLM#+55U+(3"2:U"HDKW0.=#12ZZW>\E6VZ:;ZV(7M2J,Z]F.S2Z%;VE0\%[SKZ6O*PGQ=LHRYYH M#LJGAJQ:,H6.M@D;Z'CAN>`%.A^T=>C.:YD==;X8(F=5H#"255-G-B05U,WL ME/H[%!J=FIM=?:&Y>QZE<`T"S*6N)_,*8?J8W*&R\,\=J4[M"014ARV(-ZP> MN6/UNHBR`@2M1U!H/=*C]1;?QRE;&/[M8/;HT)@]FC/KP5G![\$H<,[VYNY( M'A?RL2RS9)WAZ"2GLE-M&S2;,;K1DL^@O>H(,%Y5$J$, MA4RVY^--$N6T2'\O]S]=9%?Q_4.AOG335KQFD%%\*HT,#L!WI5@ZU++*QL3J MXYZ#B+*JVIM6;4M#I'/59#"[U:QQ0<;5G<`Z@V:/>E9>#@!#N!$H2V=3,EG`^",OQ0OH^PBNR[8U2M\.45]>J%(''N- MFD$V&E.I9/8!RBEK=UIR65I9O>V<*;I`NRA#CWR%3)#=,@=\D-$5*)#0K-QC MHZVO$&@I72NM>#TD'-`*:,&@)RI9KVN6J0@D^=WK[U^_7K9<^3,Z^N/KQ>O7 M_']\A=ZR\^]J74.T+QY(%O\+;U!4H/^]IUG@\>L%8I54GAR.U^6ZFN,E?WJ\ M0%1MA]FMASAY^C/ZTQ\71T?_<_''UW_B\G_ZP^+'/_ZT6"Z7M0=V(/`DZZ]_ M7/RX_+&Q?ORGQ='R)]FZC#$N@HD M)C7D?E\*+@1T[7J*!!(7E@%AH"G$A3X/PUF\9*A<.054-:%D0E=!08BAS7!X M<=+$9Q,WAI(J?G0EH3G2VO;*DX$;)ZX(VG*^=%K&<#DCJ70=;^2U8^!.JZ3E MCV@['`YI%M9:B*I8!+J@5F/<*X\3U+\R+;;W'*BB:_ MHLXD5GT'M=A$V*L,@^^`,SC2<4"KNOI("HPNHRY\#*HTN M#_16/4(%;)>:R=(W[F&=OH4[>])(U%?G[.KH&W9U].GL5T=;U;&2+>JZT!&F MKZ4FC3N'$89INL?^P MH"`.2Y@%I3&X+PA*FZYISVFMQ)4]:P;*E#)1BN[J#MZN?(\8AX(BCK22E;11 M58>.,UT=-6.&EKWBR%/PE;D9#R)9WEO)H)OG!22KZ#L.2>%$WE_3:$NR@LU2 MLGO:C&FP1EX:AZ7RH#22>(`<9[-U9D\IE8U.1K/A&AL2I73UKV26H8IT M_)*HJFFF]',(P-F%[Y]*Q*7XGJTWM<\$-$XG(X_&],Z;9P\[J[@.@;MPHOQ9 M2L,*SHLK"KIRI?,EIG!/B^A>Q+R[HC3NZQ5!^:ASY:\EL/!J3TRCL?)0T;@2 M0QD[Z7"?;G"&DEY.SU:3/-`7&=X4#W.O*!D!)267;2M9QVF=#36YS9YG)/D= MSFA57^%'G.ZQ_'X]O5!#7KG09*+*S,*24N-!3T"EXJI^A[+RY=PTTE8@Y6&$C8JDPEB=@)+ M%VM_>O)8FEEU)?GVDZ@C,C>O'#!!QM>9R#FS=I^!MMYFY&,6/T9L^U#;:N:T MB'_%FWLVX,QV%L5%C//V)GC%Q=0`EAKV3K`TF=2C?<-R?6HQ]"%@FO5Z931? MXMML'3^/H]MZ?5T8MS5#0)*`8T.,*:.-]D/-Q+(%$(%J`-%2JM)AL^@@ALA$ MP8+$T+B'626C,SNN*]1[VQR:D\*3FLRA,%A3XU**ZFM&Q<&AEIQD*NN>@37B M3B#C/2LV/J<`;,GN`*;::\SV-`=WB0HTPI0CE#`0FWY$G,G#B+M\#/=.V7B< M@K"C'L("NE0*&EN*<]B@L#4\50T:6\?P^;':T11(';/>;RW29K8+5,D\+UP= M^\75\9S999SL6?XS MBM,UV6+$T(?6#]0&OP;Y+HKKDXPZ=\R$DCFJZY78UH1`AX%LCP0*2S,BO^[H M7=S1%'^'TYP/.%WAA$V$L!V..=^>^R;*\:9:Y9+?X"_%&UJJWP8T`;'6<&JB MMV1;?%ON\5730F!&'/-&13&#A7-I.YA M\WN`DH!$,K6#,8E".--&,+`=$[F,X!D9MZ1V1X4M30EG"UKOHHP-*>?UZ:\4 M9/'Z)-WP/AG>***3HU;UY:VU)L8;2S^0@<7-I2Z"N%A:?<0%HM`KCT!>5Y-1 M_,S?4`*"*U+(I&KL4]S20)?+3C[#(JT-16T(Z8=^WLDVEEHED?B?01XJKJ]' M$UT"OK8D>H=W\'A+,<*V% MJUXS76%[(CR1]Q#D; M$/X<99O\AA11TGW/YGP^DN(?N+C":W*?LB,R+OFJZOZ6RO9!*#0*[ M(`46@7MV_81*F0N[F#;47#4/T:?R\=R#!H9ZE,8!Y4=7$;:G(&>6Q&8`%-#P M_23A):!_7=R)C.8K;\[C%)\5>'#`KB?K+KF4B_5#)$OVY3EX-N1H-;[?ECGXNR_LOFR\^1M)Z$]@&]78Z7!"R'%7K&K(17%B M.+1W!3Y@Z^Q:%\DCXH M@L%&:=W=PL%W^=V**:#R3ON.R@+52EU4,[5O!\J*L=I#8'G.T=IN23$?5>[L MH_^`([8J?W.17K&=Q1D[S"G=?"1I5O^3K6E4[<#Q85K2TDTW#1A)IA8&LE_@ MH5RVL0C$W:HTQ&>2DM84VE:VV($KW6,`4A2AQARZ9?:"6=3@A0N*6`>)074P MG.I%%2YA2C]_/*V*S;^!H0L?+H./"M-K=B;5W?TE7`35?#S M)EK$&(::3;5I'F>663"-,JN]!L'@L:,[-]%MHJ,XB%W`P>7*;@`CR[PDH0TK M=POE>TRY]=6=_5(-];#!YJX)](GKAY)5@$$=>.QX@#+X@6/N`GK4N%/N`.+C MYK_W><$@>7%776RC['OH9`=Q3"H+%ILDUCTN^E![LPLD*OTR.)1325$CQ-:7 MK25WE,R\FMX.!E*.&VI+Q5N)FIR+2ON^\09]C[*5PTF86WZW>JLXT%R&N5!. M-X<'GW'MQ53T3=\L973A='6)77ZE\30)=T?]=4"]8/?W9QK?%->7P$%L>(%) M&$M-;W"V=5A@VA6W6%9:BGM(Y_EDLE\RU7N:GF&PFXY1LHU@\=,-!0[.J8Z#A8=9<\.&% M;D9WKC/F,BNJQ1S=J;M2/)3^O`4V#-/HFLHS3Z(+RJ8Y=*FO^2DYH?]_KMC< MYL4VX/CB.=C&-M#2A#;.*!;,]UACWU\O''46LW;LUE%J@_@E&\I1R#?E:M;S M4':T^>$'\*"D%);P`Y/GLKUL'LH_?Z!M#^HWKOG7B(IA4"H*%=4DQKT$*;4? MJYBC4N]VU&GO_'V<1NDZCA+4N6D[O$7NNLJ7<=Q020K*2K2D#%1:GY]0W5FH MX1(,ZVZ%45>W;%RMZV.!KLJ;[TZ'R;'S@EVM/H#?U*'S-`EA_5W7':F`+DR$AYAI2F\R MQH+8NV'9N>.]N5]3-M[EXG7*\)?[KPL\GG@Y,,970><,)LL)P^328O(PYWXYUI#\_0BTI9G@R2:B`.K3M96Q/Z<8JF"FT5_P) M.@IMN[VF9F5LUU>!@JM#)2G55+:#(LK2FBA+:Z(L/1)E>1BB+"<193DDRC)@ MHH@U:R"*I`K,1%G:$649+%&.K8ER;$V48X]$.3X,48XG$>5X2)3C@(DBUJR! M*)(J,!/EV(XHQV$197HV:9S1\>!"I":H"RA.`Q;*W_`=?"&M0@FTV]5;V0ZV MWCF*=92JANRHL#!.%TC8\D$76;SS!$]%H`3T)HVPX+\FT"@`/^CFH8!SA`!A MD`UR9*W3.97&BE,(VI?6:B8=02M7LK1KN20G>:EEZJ3*974U$@HMPO: MO]&ZT$8CC>9*ME`FC!.X#!5*G+Z^0$.Y0H]).INS<>$7G.(L2D[2S=ZCM9ZDQDC9472`ZY.-0QRM[.ZAHGM"3W"U3IH/\[ MVN[^C/IZ@8PJN"&%3*C(/AVMU+OD=/`W&U7/TC79XNLB*OCZ5<6Z((-4]9V4 M4A,)J+`+23F]"QW)=)JT*YSF)(DW[/0/U,CPM2L7.YSQ#"9'+WY-H_TFIC(O M@YD[-M4X<:J>/I$4"EWJ:&V&0I;SZFHP29YG(2DG35\2ECA=VQ[)(W'C0*"! M]JH4:.F#:I$@$D";FE:3154E6L)TE32D&=H.C3C2+4=6LGKR`&TITEH_`(&L MMPR9]74D"F(WD%VMFXEDVNVC5;,@4Q"[>6C9,ASE^!27_SU+3]9KLB^O'<#Q MH^3X4A>5EEP6*M,Y9G1B337[X]8OO"YIRCTNHR M7D9/3LV$(&]L(QIY;\2L/``G8E;.QA&R:Z-M$';ETU`I)]:[%=\D56/+M4K5 MCF@]/V&1+-OC[OIP&YXI5'14&ZCX8)O@Q#OAY/Z<.2(UR.P0!V>>X`%\X9FM M1S?BR6RLZH>T]\.?AL8Z5>5K*:>I'Q/?!%4]V:1^#H$VCWT=A;?)4%/W>6:SWZDABG;'JBI&$S[TY+6H.2-W%38,U-5Z#HBY9RE-#J@W MFU97(JOD9T\6G)(=ZP>9:!KZ<^.?J+^J'\Q\48]='6LYIJ@*$ZTZ:GHF#>S[ M!I/''I3$TR0H8ZCJ#47\26B\TV+"H0\TK#&W[D]U?I-#SZ?K\6!P]-@,Z%S"(%'= M,)0(;52JT[2>/U:M6PTXL(;5CEQF>!?%FWI0L-K/<))N>/$MVQ47(\IVQLX( M.-%MW!ZD'7(HB%LTL#:\JB2;&55^FA[AH8'MXV1K3<-LQ)P`J`T4KG`PQ0T; M>_HX8E^BV;CAL5%T*8(?6J@;S9HNE2IG2]F0AME\'IXEULWKX6@R>_/+EJ!' M27FRRO5#Q"Z7*8HLOMT7;/W3#7D;)8TE+;WB.G<`2]V&>*PEB(@SSC?X M*/ND8A@CSP3KJ],XV?,]N_7=WEP?,9:SYGB_Q9OFIF_\!6?KF#7=[.+84G+F MFV,AH"H&H^F8D02D<48'46E*V6:,3`6F)2VJL'F*;^F?ZV2_85V7+#J=7;*'^@:4FI4N?PPB]>0^*J<7#=*JED).'VNM.V9>TX3Y'KMU9E`KH"V^)LK64\MFSEP MI9*!0,',N#=`;\1;9K`\5!I9[=2$! MK_@-Y6AE4C)XMMHSXK&:[/^(AT%[^*K!8_?59#RVQF#Q.+"KQZ,@WBZ$6*`4 M%W,#4E(9Q/P114"V4GU`BMK`=>HT.%<0VG?1CUL/K;M4[3*@12YNU:H&Y(,,B!+I`(XB0>$F2>/VD.F[?)":& MQH$8%/@%P_Y"I-R1%0]DJL&U]JJ*E,%?\]$5#!`TI"R06O6($_A`J7`R%B3] M@%D*H$_5?X,Y(!P*0:8@.A)"0033]^QHU`>\^86034ZC_<7=%68G?DMV$5AK MB"%6IP'%(K4/+[UDHSLK9AFLK.KWZ)X)$XU.[TTJX0"89<%(&1$LZLQ!>74 MRE+VF7S-S\./]$.7O1)C=T\I.>CU223!4ON!;8]]0)4ONUQ?KMWO$:8D?15N MKU!=X](N@+9J5!V!@9*\/Z"P[1=6'CJ.2C\3,"5T(QN99XHH8]]R"J2"2(Y. MXWR=$'8SBK&WJ1$5P[)4%(I`$N.N@?D19[?$,C2KW5GQ2*4>7!]45[TRQABJ M0<$8B9:4,DKKGE$$'XA(.:*P/#]! MSN,4GQ5XJR3&0$`D1$<`B@B-22\$$*U;`;^OU`'$_8&\5>AM`_#*I.!7?J1 M%2!O9*7@%BS-#^JV13*-C*@EU2DX_,C(T+87X"O=..9-\D&1I_#ZK)K:U>=) M#J,@0R5#DA3,0LFJ9%?1YP]1@;,X2I2-@$Q&)$A?!HH:7:M>2"%Q8$6'@=Z* M/D';^E$@#)!6G`S[JN^L0'U77(KWH;W9D'Y.TGM:DBU;IV17#;+;J?<3N"RZ>T,E] MAO$VI/%0!VR0L;77YYQ9MTM`6T_SL;$]RO)M.88KLD\I4+--(C"570.3SE-3 MIC6U2A=:"LF55C?,6[,F,9@36#551VP_M@#^@6P/[`I+7M``-I*I-N\.A>5W MJ\Z+!:I>?;TP4`Q*CL'!G`.0G1*=I)OK@JQ_>R#)!F?YNW_N:HPKQ$> M!GFI,!R_).;!5V99N;.DE\K`BKU`_$TP?-+5LYQ-AMI04DFBIR"2TH-W2/D( MV!I7T_"TY*MIHW0=TXR!A>J/)+UK'O32[A9XG:4#SP^#YG@^&82!Q/*WVH6U M9D'E4`7<@*#2-.A`H,F+6Y=5&/BK>G(=N9DOH;"H6&T/UF(T3ZFC[]"&-WJG MYH2:!)"H]]D'=0.WHF<9#)0-V+4"JP*=T'F#KR3!,2,8]M6^ILHT-].:V@RD M`99V]LS-L96:Y2B:CZ9:Z\C#JFM'UU/&-_IM^_G9R9NS\[.;LW?7U0C;]X0)4>:A11K?EM85N9 M5QX&W//FE\.RGBMV7UG):AJI<[`]65KKL+FCV9$K6_OZ*G8&M(7+KMX-_)-6 MCYEOC9J)8(+]H`AUPZ[?L"!33TY#I$K.`XFX9=\$ZCIQ)4^KJR8.EPF0,_WJ M-?!E4!-FKG`5$T\Z=F?=^W)3;0<0:2%YU=G/TKX"V+E2&X.?LQL:-VU)Z8FO MV)-7;,,$VM!GS7EI&]H!#J#G(:LB8OZTPPTDM92X5:2O#5S3<)F]Q+!+-2^[ M]
?EW5JDJ:+>MUUJ2W4Y9F=$D3B`8RDHC4D0$$;&,5>A^=RH$M@/MZY1K' M9J=<0J(T'#`/:T^!:NG'5J.[$5?!7+`7!-Q/T@WM>L:L`6.75U[<)O$]/P)D MT-ES4I(00J<$R!"U&U^4,7JTY9#!T(K-1.WX/E-&*.%PQQV[$(P$1#,+D"AX M9U>%:B*J]57,-'D,G*J*+:IC=)V("[:QU<4;_*S""._3*=W;*3M@]E?(:MTF MRK'U.X;CLIV7[OX/C6@OO1!KSZ!P'O1C^+:$2@]Q1=31#&4[\,%!;M%A\HOR M4+I<[4&YFA9L*"1IJKI"@`QNS?K*(0<>;!DI*`Y&BGYW_'KQ^O5K<<2(_?V[ MY>O%_SS^$44%^M_[%",JB5AM<;K^;KE<_/@'_O(4K_'V%F?H>,D%CL,AJ@04 M"D;*JU#-O,XAUPJ*B1:]X;(6Y(\]#,.-$<5:&["&_`(PRJ_J)3.?RHL!\ZA_GS@)"E^^A!E MO^'B_3[=Y'*4:H5JN"J$IN)6:A84P#H/6B2K%5?\'2I?YJ$`6U^-Q.6C"U"7 MROY.(\D?5?]:N'=1(3WK(&/&LNLZT`]E%^Q^W@3 M^J]YT2NO$&+Q'?M8[8EU(2K1AZY9V(OEI>:=ZG;Y]5:NHI=K7[O3^[0#DTY= M65V3)+7L5+-';/.UU;*BGVI?RW/V2FEAWD;YPV5&'N,-WKQY M^C7'F[.T.@8IO3]9%_%CN953OA]RO(&VH7(V,)T4CBXA<[G1W@WD&F-TQ930 M74(^YXCA']W5"BAJ-&8^HF<"P@A4G0^H[6A+X/^HDH21@IX\1G'"UCG?D+=D MNR5I=W_W:9SL:037I:DN^K)4UDX?LM6T\0B^S'EL":P;8&N;JX_[+JHJ[]`E85OE08V?9Z#\&#.%1F*)I[=E9,7 M$[)J"P/ZK%IKP$]6K7%Y@*S:['U$5FTR.LBJXUHA^*S:!F'FK-JRSJVR:HTM MBZS:6)*O($:,C@VC8\(!8X&/S-G--4P`:(>AUXS\>RI':2]E_M="_&F$AR#Z M.()#9<$.[B#37T>W>-4JZ/8)O?BU!/-+U"BBDV\0S>K4UCN<`TQF M+W9L5&!",FMA0-]P:0WXH;_&Y0&26;/W$<'`9+1-9LM>R-@`S!P/+ M*K>*"1I;%K'!6))`1HB+(HMO]T791[^,V.++JE^N#A"CU*7CPS;JH"-D9H?` MH6&,;_O1,4N3G6'A4,[@'`TCY9B76]7J1KS,EM0#7K:E""U#D,QHC9X\'CUI M?,#)XD-U9=6N86:(A:[LKM,5D$T/STYZ5PB-FA6&F`T>-POLLSNK<.>[.ZMQ M"P=AV40R].^L%S6[=65`X?QW=V='=V-'=UP-V6P_56*E=P_15%>.NLEYJ MD-36P6=4YQ2B4SJN,^JSH5*X\]U0:=S"P=?<4#6*H3=47M#LUE"!PGG>ANKS MR9J?,$"+1=U4_G9DMYHHDCM^\SPZE2I<5!KOAL,'$`A/ZX5$//I:A\N`$]1+B MY2715;,P<_ZFKBH=OAUPK<4SR/"`U"K8*(#2NG/%TSY]VVE_]Y77OJ(#[E[] MINDOF9`F$*=$R)F#7?9?93&_^('U;XE:4Z2>,/_ M<9)N+BD0<5KP?U[<57-T47)-GY1C(*H.#Z3-.J3"V)Q*/8A2@':Z``ND)3>8 MGU77%#_W]LT^CU. MU/R<$5!2H&""H;ILWN*BRJ4Z1'[%<5&'=:@0:<`78+24>`(+G,I?,5\,9;,7 M)WF.BT%?>/BFCES=-U.#3FL+-%X,S&JI+DA7`6._'B1<= M35DP+=>!!$8*H4YUG!A6@($1U;BOCA!=F_X`XR^,]GV,1(L\B)X]&[C81E`G MO`08/RU34ZFP/IIZ2U-[YN%G%FW>U_2`-+>P/0IJLP?Q\SBZC1.^HT-Y.:99 ML!N\%8(0E)*:]I,0ZUP9V:16KHB4M`(!T$9?M2)EC)4@88M49\`4C66OZ($- MQEHWXZ'3!.&.Q`*U,L\'1[JP.Q%(P:Y>9J=@'$[HK5AW-1G$@P>U<>!H2=G>M8Z&AL=4F_R@.[:)S>!:;EYFCD`/F5JO?>+:V^@2V=7S00$,UF*XNX7#+FU1:@7VX2L55.LL$-=: M<#"_^_;`K&B&#H'F69LI:@O3!G/##XZ_C+*+C,_1;_X6)7M\B;-K=HV%V$0Y M*=7-DZ725&9;N8&<8'?RJ.6SO:%5(XMR)KQ`NRA#CTP.O8A3M"%)$F7E?23\ M(I*9^^N.B"%3ZE,@L)5^C[P.'@/A+2^9EJ0]"2DC*PE0^G&;_KC6-6]/K%9K MR*+?O?[^]>ME2Z8_HS\N7K]^S?Y7\BA'T;YX(%G\+[SY,TI)_33.\STU0S)$ M]D5>T$8T3N]#XEP?`$J"#6I,QR8NK*9.QU8@/.',S<]X76GI(A.4LJ8O"$J> MKFE_'))XL:?20'G(J#X_6-M4/@FJ09)6MY(CJHK14:6KHV;,T')0Q#EI0I\% M>8;"&@)UA3V0J#7OFT@#3ZYD$@PH"=4V0V&32@(#`['DE64F5ZMG(ICH(2B2 M7;3Y@P7+)-(:FO6D/?"L8]\WT8:N7)DF6E!2K9/1A95F4%N^^X&P= M#\_6L1%M.*@3G4P^M7%8UAG]Z.EF4%_5$N55-KAZR6:VZBN,60Q'GTOEV=EF M4?O$O99$?JFU^L0R6?<,,J6>- MVK*QT8J(?M2+[#I*\,4=F]HJGC2Q6Z\@B>`J!4"*R5WXBN9:;[8LTQ@1J!97 MDHQJ.:8I5+6:B-U:3Q^%<1R;`T(4'#37H9J(PN+DW3E)[V]PMCW% MM\.NC:V"CI."@@].]EQXYZ3,FS,GAT8TG$RH[*N""J,-E?X:>"E'B8F7RGJT MX&5/U\A+B:<@>,D'12YV[%"$O&[,AV/IEO(25BKD`4DI]>"+DSIGMI14V[#M M_Y!2.1P:ZE&A8*&QXM0DE*JJ.*CQ,R<%Y:NO/F))HV@4;8FG$9W..:5Q8+J9 M_!B8IE=?74H7R0:P6-WA>_?+. M\XDD:"Q!(EXTJH-W7W;%_XD^L0\O<69 M#'+]-UW0U6\@8%?:`@=>SZP1>AWI&GRG9!O%:0CP$^I!!.#P`TH@6`H-0-C5 MG0^&>%UF)7]"HKGS_5$((M-K5N"H@Y4>B9V]'QC(8#MZQCB&Q/"R`^*8 MUL@#+=LI?L0)X6%0?KR+E6S3EFEE)W->8QTT<;-PI.>T27]5BW`F;EJAN2EH M4]=D1)6('-.H]4EEM!\FBP(52MX9-6I8^#D:OG;C3%.E:41`OC MZ$\71-C2;EAE#N0KE:TIV/45)A'EPPKV&C9$A!J&,/L`/PS'WN=H-O;&-+IL M[(BB3Z74W,,<#KBPI:-Q6,2L;$U'S3"*)S`"]JNL_0$@<:F!8IV&?`N05/:! M?&!RYAY/D<7K`M/.6/[`^V3Y`YMS>8P2UF=3'H[FKMBV&-:*T[EJZ0HXD7/S M:N"MB[%5*X_65')VCKIBA$RMO0%A+6T(O'7R/"][]^MBG\7I/2WG%4[84/-; MDO,HLZ[^7LJXZZ#69:Z5&@1O+1SYR/I<'!N):VNJN@^8,19%6[*ONF&5DU0K4XQVFE@)C4`M4Z_)_?!G+5":57Z,Z>6M;E?/L09??M[?6Z M!DDA*FN$!J*01!6,^VULY,ZL.2E37YVLUQD[9>.ZUV1&8KK[GB9]U23*NRV"M9QW"R^@CQ>K%P#1=QBKHD1WF*L]]@Z-J;J8NG7 MC0J'@&D#BV`")%NB7JY"U<7(H90L3':E(%'?V@4?XE2ZL$:^H"E@G[T-99FO MH4)5))!_?0T-6@4E$T2;87"!]25X7S3'V:-TDX2=M#2%D$B#M@P#^]ZXHG1E MWUK(+0C$C#&95Q=+121"1<:@1@21. M9=1O&MYW8LV3KEJ3AM?W#SU]#?FW6*LJBDAJ0<.+2EI)AIXU3V#QDW\+#L8@ M99!_5^^^;E38Y-\.L`@J_S9E&J*,*O>&SRIJJU[S[C$91$]/FG.'EC<,*E&7 M;SOD"+6X-M<.+1_H9ROG<8K/"KQU2+<'*N:Q]=/3!QQ^9`89D*(77HNK4'K'+W1MDS4!6\SLK.@G7&\>1=E*2UD M?K)>[[=[GG">XKMX'0]G.VT5&F::%2;STN0"EI66WO28]C`19N+/@@1N!#J2"U*@+&S" M)8!'GW+P"0Y^\PY(\=*I%S;*7_>#->0"QKY!7P'9;:&B1*4F2/YS$)`W+`A3 M?U0IJA7KOF16/-0W=*AT7"THTVEJ.Z!%@>/J71_.K"M^SI#%[R*ZC7*V3'S+ MEJ7QPV].V,'Z]YAM4'SSU(I4%SB??(ZRS?LHSOA5EB=YOM_6)YN6*\[9J2[B M-B/_CJI*\.EH(D']%0VRA^F]E+J0X=GYZN\XOG^@CUY%;,;W'G>V5E&A>FCK40T-Z!%8+M@>7EW?26[? M%LL-C,N]PM48;D`XMH"P-7HUP%5A%J"VP7I."MN.5=WVFQ;HX]RGQ(^K:45W MR:VJ9^TLK1_P9L_N-NIF"KC(3]+->;6:,,;Y!QSE^PQO+M(K=I@EFZQ^$^5Q M?A/=)IB-[_'A/3&Z^;!=QT98VU.Y!ED:T!S#0\&T+`?WMRKU^2*3I+6`MI4) M%!7HCOI"C\S9S#'$"^#)`7`FA"](-[W@!U_^`"(G[WF]$7M>W?MQV"\M>VQM M+\PR=$(:'\1.&.-@P1.B.'ZB)V#)[,(GF,/A\%#4RJ,X13@OXBTUE-YWXBB; MQ`OB.BQ/1)#&5&CXJ8(JA!]Y5(7[!0&$U5.9 M&81*5S-@0='-L9_P-ZH,=H%NA.G5NS)DT>2O'['JZZ51M%ZS0\9P>:38IG'1 MS2!#B6LC\2F-8..QHHI5;A;E46E,J0*(/_7RT$NS MYDY19C*4(#,.A=(8,QH2JA#C9%`>84:4*80`L]TEY`GC:YP]QFO<)F^].;Z$ MEX7^=7%7K1'[%TWO:$@E_!B\,GM3AQ]X'\/@!.D#+G3!E#F'-*/'U^!W$<>"ENRH`/ZN%S6@^]5$\QS-H)4!?%UQ^`S MB\J6";`_+'J.SH8DVL?O"B!*][98]\^3-B3/UIJ#2&JA"18;C;[\1#M;MW;Q MR\Y:+]7LGT0@GL(>7.9H#R9IU'&J954<,1J11P9+W_-Q'2?4YOTO.,59E-`" MGFRV<1JS[0ALU%%^OZF;4LUP2Z6IY+9R`\IK%X]:2ML;6E6R"W1?2G,21SWY MF=GKAA$RI08%SEKI]^CJX'%&IK+<@A:SG@EXZLP#E%G$6;K.V,75I[C\[X"V MHRTT'!YA83*AG7U:L_NGDMTIOF=!6;M`=W0I](P?9W7U]H'M7F!K$/K3>/4` M.NMTU'-Z[=&&$\?`C8'@08X6SL7[@&%F6>3@!MXAYO'\/=%BRYK#21(TJ M6]W(E!'77M1#H[4!]*(V\?);IH5J%?8LO)A]Z^NPSS[8)C98(B3;)E8O'#LI MUXW]C;!Y3_89KF@[([;*!W?;#&^*AWSN0'QX(HH;<`\.<FP(9*Z]Q7_U[WP>8?\JSG][GV%\EA:8!KO"=]C7^?,1]N7^0@K[LA(& M&_8UA3U8V%>68=A'R*CHJSLJB^)*&&4L6CS?QD#++U^-@0G"'AL#F6MOC8'Z M=SZ/QN`DW7S`Q0/9D(3W&".E3PD#WTU'&:@>VPZY,Z]-1ZZWSI?\Q'?I_%=O(YH MP98Y888,J4^A8AAI=\CO8/'@X$5;J;=R24,3ME\NAZ= MZ%,P!],?`JJJ27*/6)UU*KR@_236-E[[^,T2M=QE%R2G-]?8::9465(-XT*'.V43CS1S^3/DH9Z M,WTZOHD2?BOT]0-FQ^H%3D(S4.1DM*I()2F5V@IR&KS-2%+:$#^09(.S_-T_ M]VP%FXJ:)L&&D&K!R314F88EG\&+GG):Y57W_>]1*3'S_2\6-4MN`!_6+?*A1L!ND=VYSWX8_X^-/3;H=X%[7J4PW39I6;A MNN=*\^Y86,JC(#HIBBR^W1?U)L/+**--Y]>+#E5O>@0\9NTE[W>[A&TXU9_[FS$$3AD4JT*U+0ST..KB\_9.'R316E^1T/*2;II]JQT.B5G M*=N]S4=@;FA9S,XPU>4$[\HZL?WR"]=(,@?.EGC)3\8H$GGH?Q273Q*G*-1!.W M)!*3P\_`)FP449G7!P.YUJI^42U1>1$5:$WRXB5?X,A//9U[<:.N%HGU9Q?I M-1#NLT1A*PRP\W4A.JSW!&10KP0@DCCF0.G$&NZMDA+M?T9'KQ=_^NFH M0GQ`@.]7I0KO@X^O@3N75:*]8\D+.L#&.=3FW8&Q[""#OUF46_2_7APH1C3& M`&'.$0V6@P@G5LF[-B:Y.@BJY::B7649M.TW.-$B7ZO+<_OA.6R!I/3&VB6. M%2&P0J72(X?>[FP4^7MYI,X'O+W%F0!.Z;OJMPOO)L*_9PT2\C+#.I@/Y5=O MRQ.(>%1#U?O.H2R?2MF9,2ZO*F+QA?M8[HEU\2O1GQNS^4=27.."%I]-))RE M?%2N7O=\V@R`RD'MJ-Q'O;4R#"TLW7G@C9MG"V*Y&%RUAQVQIJ6V$`317.$S M9.*(2I52U=*.A,M.)9B/[/WS+S[N60"J;C?++_9%7D3IAAU%*I^>&JM>$]Y9 M?2KE'1V"DGZ<;RWMQYA*4;..402J8A6BC@41@*E<@OZ.E'OU'E2+X`%#= M[],&KK,";U7+O&&-.@8+D]$#A1!],>8(+%8E@@@W%HZ&6S93;JU[*&DY\DM: MNU]'B+($]8C`90^I<>%,;W],D+,IZ!XQ;TYKWW$ MF7[;Y!CO$"&HM;?B?X8S8S8..2.BQ:!"QP6%\O.-X'['_Z$A##:/,2WC'7%U,KAP#[GA(RBL%4C/"BS79-FTM8W:FIM/S%!Y>]0 M#9O!_XC0H+6XJMX&3WDCBLRDMZE:*]:K#%GP7E^&PT/:J:$S;E0960!@4"]; M5#^C-L\S`=S:/4\,&+9]!Z#`D>=T*YR MA^([5%!G=]&Z7#[Q&6>TT4Q(CC??SQL@QL"33,--/R@X&&$?>9SC`[)C\AC' M6*=0O*!YWD<)*;0`_V8PK,CG#@#B<0,8BN:L\<"O,BVH#QJ>+RE\I"OB+*6; MRP4-TE/(:#`.WCS9^5-2ST9]=8)V]`G:X:RHVA<*D99C[$;0K-:=N;6P10)Q MKR[QXC*M8D,B*P>>`0<3\2T=38$:OV"O"ZM&#C'!0!9U>L"8\G8\,)"-[V+; M>G#J3RN'25V\38':T;<*-477%Q!J7OJU50_ZKESVS5=]7Q+N/DJ2I[,\W[/5 MDN^^X&P=YYC*E8T5%[QH#EJNEU@JNL!^G`B]96@G$%T'V#)YZX-[*::Q6^+! MZ^H*[ZA-GFZW'?QZ=%JX7GG7.D-QY0WARAV7+AT*Y]&SH%;=S)RC3;GSA_7Q M=_Q:U$!Z]9X8)W:>_.%;WLV"]3?HD?GX.6&&$=C!"C_EFR&`](9`_(6-?\<( M&/`^DR`QL0_AKV"`70^_A9PA5!P=)E2$,X_^U8<-10_MJPT;H/W!W^!L M>XIOBU\RDHM=.>7[ZF-*WD^):0-SX'T?E0=E*)$KK,[2=;+?4/*GE#K[C!WM M27F?,;<+%-W?9_S0%K2F%??$IQ"W[-H(1OZ$&GQ%H^86W9(L(Y_I6\I]'D58 M?^*V.JT\9Z>5(W:".;K%=R3#:(,W^S6_SV.?4G/4U[_XU;OYNC2=(=H)VL;[ M+8L>=S2O?LJ:UR1P3I6.>C,8*==JAJ9YM`'U;UD+BK5#[53F8)D&P_@C8F#4R7J MK6WPY2LL<6!-0;OCG38-33Y9-2%,J'CZ?=[/2IO4,BJO,*(1F^G2EF>#L_@Q MXHM>DLHW#,!R8PO6N)!M.>:/O[#+^ZAXE,4YO]^1DJ74 M?6!7^;';'SM7/K)6`C.1!==FP:AHVKR@ M<>+`B:T;IV$0S=65SDXGH_+(A,IG#$1%=]\+$$&[XN]I^_L/VOFI/"ZE2[/T M0M5/5@E-(8W<)GA&I76CY(5&JSLU&*%U0O,)EB0TR1`;GZ-9Q>U3)W-"+_XN MO*9,>OW''Y;'_%36ES,G%08,$.L:ZS-$+M]P0F?.#[!@T@&]_1&0HDT^>XG8 MVR:R+@-9X3(9&XIV?#0X0#NK@ILCFQ!Y9!,BCSR$R*/#A,BC42'R:&*(_%X> M(X]^.&(Q>0Y1AZ-BY%'AAAY%&:,=,>& M78RT!P=HC*RFDMB8_B5?FG1QIUBF9R%9_4"MY!1@:PR#QTVS+R703:K="%JN M!T.?X^(A3JM9CW;H+6LF@IFQF8.D#0"(6TWU&:%1:FAA-.P17S#1T\+)6&31 M.-J10*4(N@CEF%A``"EB*@"")HX6&:P#KI6Q\#061T=]'%4QJI/D/1L<*89_ M`'`$.MCS+B_B+9LU;XXB;IV=U/,S[TEVDI\VDS/G[=R,XKQ/8*MUZP]E=1(- M80H!&/5A"Z1F-J2?56,-=8X=[[0GJ#&)J$UTDJ/6*NJ8#>;`8FC($X]X$T(2 MC(K#Q]>G9ZB\J[FN=>]V*&".->=,*FKU6NGT,H6*S\30,=6L_#A_S8C1!<9XH*(2R(F^LRPI5JZ`@6NJ%F3'+B`SK7"V\C8>9L==F%7-8KT!.W[N M,#OV"K-CCVOTCFW6Z!W;K-$[]K!&[_@P:_2.1ZW1._:V1N^(K=%;!K9&3P2! M8AV6I,JTR[".]-P:O6/#&KWC,-?HN6/#;HV>/3@FYGMJ MPZ"[C/1N1H"D&JYAT\'X-MM'V1,Z.EH@%CZ>"U(4*=QHI/B?BWGW91=GO.VQ MG9"1:^AF940-\!',OH/#S,](?;H-9DI,:&=J,)/'7\\DC0(IVA%0=55:C(+V ME?5#H3)'!P"FQ]D;N;.ID&SF<3H]T?@V8B[;_5A[(ZFM&`PB:1">V@ MXS$X(],`(!SL;F^D/>3=U?$!80YTF86[4RB`LTLN^"$753^UU&FVRJ3UTG_< M289FWNYP0!"K;L+PC^*I-V2X>0/-C4;XAD)SNU&G'X=OGYHYCP>2;'#&ZV5' MO]Y#E`MG2@2;552/`CJG+[FD;0J&`HRSE)[.R5?68JZ&X MUILY";*I>^)627W::)0:FA@->X063-)BX60LJ)9=5,D0]&P`I$@P`!`T,8$P M6`=-&"Q\C472T3>#)$43#H`DV&/:ZLTZ'W#$#F#E%W;VSG>OLX-?V1FHU_%] M&M_%:_K@UY3K6%7U^3 M)D]]%@UPAOX0Q53/X?KWONKL&>YZ83T5V7F3.>*N4,<7ZCI#I3?T@OM#QR_1 M)^8354[GGE@^"/G(P3$N3'/[]-O.EA_@UP4=80"7\QZDK/.%F:,JS)0[G;=" MF)&?:+[G82;OA)E]-\S$59A)_AUF#@?T9QEFH`=[UAAO\O<4!Z6WJG3U0),X MR6:OT`[]&!4F]K$,]GT,!-FYU'6X;"SPZQ;64?Y`P\==0CZSFPC(.N9',;## MW?B<6+5M*\-K'#^R(QC8A0?U`&TUH5;-G]&0)D2MS^S^`_$"@SA'MU%>S\E) MPMC\8T^V&"2C4#+H_1ETNYU`*S?^`0\V/&7I:R+4R\$J+E@"N$K'FZ5#C?0S MA9YZ#`L6>]-'M"R4.'3*I5H5KV6QMM->U.7KU0,[3YF:P M7'5_FY6L2$*Y+`CQ9*;!^PTVWLPT4RJOVC>L_7J(::Z?T9YETER,MF8=A_)K M\)&,I+:Y0-%C%"<\Q>?]#:;!_\!4@O8*RDU_F@M"R_O3MET>[SB/*2ZW49R6 M=PWO[VA7-V;WE'XFV6_\&LUH%Q>TB,5#1O;W#_SZ39*Q:S]Q[>R.]G_Y%:7\ MMLVFH#^CW?XVB=?<\8X?3D8+A-?U?9[D[@ZSI1/Y@O\(&F_NXI26FE\*%ZVK M$\P630F8T(X5G1OD%XEVQ=A#1IP"WS.?21*S+\!>L*.PDH3]-Z< MTFX4SV-W&6$WIM*/MZ-_/E9'Y&VC[#=<-#^)7;K\@--&9NZ[1*W(.0AS)@XI M(IM,;1C-U,:]\A^XL=6Y&<_\7J/:$0KHWC=@2)E:RVF8FMA',MH'G?>W\C8> M6T>V"=NSPI>B9'PQ(1^7%B`[6K_Z M-"/TIY#+V1UX%C>V!$H.CC/8W5/!KZTMK:!=;:8]I[BP1X9LOT#[= MX`Q%319%,[HP0"-OT@X&RJ"0PC"W%PNL`D/:-=PQ*% M)D>5'FH4^RM%&EU^W'QYQ"A7_R9!KTBM#HSZB2G8*)^`ZR-&^X?%_E&+_:8Q M:-L'4[/P3<)?D?D=&/ZP.VK7#WBS3_#%'?=:30V_XV,B-Y)C5JWEZ]VS9OE) MN[!,YN%WREIZ5&^XLC(@C->5!V;1[A0G)#NM8YWL-WQ1$6=HM4]VL!NV&3H; M9&\+]FB-4514=\!5.V[9#7`Y+=,";7!!(V:]'>F@L2+>3ON0&EUEI:G,K&--NP<1?HS^4D)O`$HLBC-HS5_N8TV6+@P MOL[;^,1,K31W>-96_F"?K:JN%!MJN^+#K;-#8U[P!'QX@N[.U6=&N=KJ7)+0'E]3=Y^KG'K0?^:T8\ES2@I$:*#./K.596S,-IM_ MCG<4XLA$)`@G43E8:8^DCI4SS M&P*SZDB_0Z!YZB%_CNX@+W4:X1H,TT<-IF6#G7?[8E]=9<`->AP9VVXZ@;?4`.GA"U!$QAAE*L^A$9N"A>59L%3)Y,G)+ZEC>U5']'#4'#E*61^B6;=MD9UG0;.XV3ODWG#DS,^.2N$"H M3V>E2L-=@U%OD(=)G8PNQH%]V;DQL!Z:7"`F@SZ54C/WJH%`H\AM)J(&M)=] M4GS@BV=/BNUEN3A%>KN+2:SZ@6JQ*4!7604/[09'2K!K]58G];(??N0?C^51 M6@\S9A'?!!07>;-R^FZ?;OCQ@.5J(G'%43T_16WP*:69XZL1&<2A%OL\46DT M--&;]`4YF-!J\C`*;#2PGA2(;7,N9="+DYL/+U$E%\CU'B"(483629"9V!W4 MF09=HVQR-`HZM%-'L?(WR[:+T2=H6VXI7 M/]\LTD>5QLQ-KS40R(C*ZI/%I-F0 MQLZ%;\3!--&VGB9AC3;9.H@%$HB]0$W1AH-B#7Z!1F\AR'F>\J7W7+0YO786#42 M5?#[U%DJS,]2KV384KU]7AX'O2F7"[(IQ!W)BNH\GG;!B'@XT*;LHF\YM'*T MP;0,I;=ZDRVC:_2E/-*!C9$5`=SI;@-$XH88R5(!N5)_P8#.L$><`RXHT3L9 MB_!Z<4DE\?MF<1X'/A<+88T)#(9TZTVF@0AV5&R]SO9XA3-67U2M]71&_RHV[@"J'NY8^P)J\>C]9H= M`\?F5'9PRBBI_I)V*=WQQ76?[ MK^(@:Q>5>CF%EU!/=UD96M2CO89?"J+M/.Y2#JIV@0<96 MG3#S;:'>SG[;^P+<#5)?PG@5??X0T?8HCI+$_V*^RRC+P0X6TK7.T-,TI,6 MR^N-P^\2L?*G7CYOH;YJ_XWN,Y+G]=TUY(ZVISMVG4#.&LZXGD:[Y3/A-#J7 MT];E,8?I_HX"I3P%A[:PU0'+C(F5A>_129*3>GH];VXHWZ!=E/'3$MF!.'&2 M,/N\I8[X_H\=27%UQ5?$YNOC_('IE/;GWA1B"4SBCAYAJ;]>L5WP;^/`,_Z! MMHS8.9J"?+9]I+DPEHJA1@ZU@L\.8*K-)'`(F]@ELO``V-NQ]#8%9[2/PM"U MK=\^.T@IN@J`D(+=BBK>0RVF&:J$`@C7_I($ZW2@;/C?1EGVQ!KLJL%_D9#/ M]2D:>8&:&Q%>:N^88&_J.\?9#0$V[@9)4EG](OEZ/RL#?:;R\MI1CEXT=V10P&28KYZC-A_X!1,1*V>*T1..,E9@OH9NA[.(K[E8 M/ZT3S"]S2$AZC[.7H>0+:I99Y`!#X@"VZQY:\!OVT2;*C7^4OQ=8)X%#7 MOBU_[935<:T2Z=4I/["`]SL[*ZQOR;XH5TI7)_.UK0AK)`I^76O5U#4G+A+`K'](RAEZK`P`6XQ[(XOE8EW>G1!G$KJ7+&FUL14LZ## M=-V$_"+]*R7393UJ[/^L$`4CLK5X?'?).H5+=^!83^Q7S;* M)^BI#J-+``M_<=!3!W\AZ'^3Z%?T00^,?N!KP>_PQ5VW'`)CU`+-'<-#@6EW M0(KVP#,XI0O-98]2C<["W_P!)^Q:X#O><S-![T+Q)8QQFOU0IA0[LDQ079X3XX%JE37Y"A4)=?D:)UX9P?TW4P&5]-X(=S- M)(Y]!K3=P`_HC)\U,RK,$FFHQ/"S0_)P& M>$XBY;IUG8QX[E]?!N3HM:Y)P*7H.O/F0]:&6IV3U=C+<-:6:ZMO<(2:\FLK MSDWKR@\/2Y-8\P3>]]$Z3MAM>8HDW$Y8!F>),!BN![;!6$2SU"I(S1UJ.&.0,] M.844YOW"T$.<5?J9`,!AY*W%:((;2FH+CBV;L#P%7!/36;,#P%S6SMD$B!V) M$'MF8%(DKF!@`DU93](T?J1XB+*G?[`Q;22+=G M""E-^8`*T.EN&NO.(%ERE-2O$'\7Q%VTDY"@.DQM#!1`NS1\??192ML[G!?O MONQPFN-3?"MVR4UBU<]2BTU!K\HJ>+`S.%)B6:NWNJK/=U0)+!`3>09(4436 M25"9V!?1F0;<%&-R,PHPG2TS%6!P*?`,H*+H=4R""FA/XR,NKJ,$Y^S&T^T6 M;]CY_,G398;7]._T_N8S3A[Q!Y(6#^7:*)D0;6VB)]92G-+G`CJ]V:\^J`?[ M4W@(7ASPA,-7"974]^.PLRB,92\I+OB2A)R/R?*;5ELS:%?;0>'7"W:EW#HN7I8[=?DQ''S3`(5#S,]7I4&#DI`^HW)49TMQ%R=1@2R MC=?M>A'I+U`;1?A+=690T3,N-5.6,N:'$5%`-\:BHOJ5#_&N.S*,\OUM'E/V M9$\#$RDI=,5ZP8XPHBRDZ$A8J*VM+M`V3DG&3-6/7K(/0RVVOP1O=R3K.&6? MG@KD9(N+>(O9C>X)._."!O=ME/*OP`5G[J%9\)DX,:\?4]4Z37`TF?47+&"Z M(V8?(\,$[2!4M_^5QYU0Q(?4^(,A1Y%T3X;.Q#18;QPPGS4[&@F@HP9`?WO6 M`%+D^9+?(S_)\CS\H3;D\B[&?*PT4=2%:PA#MTPW]=P73!K8OV/0F%WCY MS(&J6J+A"ZBPZ](KMZR[<=;ID"CR&)68D+D,Q2"H)5KUEITH'!GY(]5;\6I[^.L#$X$=;)!LR!A`XNX>>S)I3" MXN1"5Z.*$V;%S9FT[4^BZBY"OF,\;GQ45QOS>P>C_&&@NF#W'+[BKZ(MVYK^ MKZC>GLXM,G_"Q;=C'CW)-PDU`_/'9Q)`A5)S$ZF).CE'=T09 MX.EQQ.ZV$QJCLL4I3S.AN5+!)R<9>:HK<$DZ,Q_8>E!.>\M?Z%N<3 MOAM"+)5E`CO&R""#=3,"$Q]!3>.XRO(WW6YZ`#B],%=+=8++04=`=AI:Q0%*%%A=[DMCB7IQY^`2= MBH[Q[X%)0C):JZ.39LN9F)^&FX[.1!!C0GI@AH"EI*Z.O>2D8PKA@2F0Y.-=NOEG/Y%']:/Z/_=1CFF3_Y_4$L# M!!0````(`%R+!T4GI2W]&C$``#9Z`P`5`!P`9'-C;RTR,#$T,#8S,%]P&UL550)``,?[^-3'^_C4W5X"P`!!"4.```$.0$``.U]6W/C.)+N^XDX_\%; M^USWF=ZMCNFSH?*EQ[&NDD-V3^\\==`B+/,41:A)RF7-KU^`(BE><$F`H`"H M^%(7,9%`)CXD$D`B\;?_>EG'9\\HS2*<_/+J_9MWK\Y0LL1AE*Q^>;7-7@?9 M,HI>_=?_^[__YV__]OKUKRA!:9"C\.QA=W819)L3#MG9[6)^ M=7US>?;AS4]O/KQY=W:.-[LT6CWE9^\_??KKV>NS#^_>?SR[?\+K#"=G"[3- M2=UGL^42Q=OLS=DLCL\*\NPL11E*GU'XYO5K6GL<)=]^IG\\!!DZ(ZU.LI]? MLNB75T]YOOGY[=OOW[^_^?[Q#4Y7;S^\>_?^[?]\N;E;/J%U\#I*LCQ(ENC5 M&:'_.2M^O,'+("]$;A1_>4CCBL''MW5=7`KZO]<5V6OZT^OW'UY_?/_F)0M? ME4VDGP&55.0O/?I2)J*]3V^+KS4I810)6-=B$^V=G>WUE^(8+=#C&?W[M\4U MM_2GMY3B;8+RF^`!Q:3*HGB^VZ!?7F71>A.CZK>G%#VR^<1I6K.AVOE$M?/^ M)ZJ=?S]P?CND>2N*Q7N9`>`2K]RH8+,'ZK%9H:DMD*DXEN%PH.2K)@M+E`>1'$F%RDD=9$F MO__+NY\^OBL:K%?/`,$N$$H?(Q2'-S@8TG`VGP$-(X*N<5(HX/<@38,DOXF" MARB.\MV`9D*X#FCT=?*,DARG0YK8YS&@05=!E/XCB+=H_G@5)62>CX+XFLSX MZ79-*LGNHE42/49+HH??$OR0H2Q]#AYB=)ULMODLR[;K/13GCS?H&<4?*:L" M>MD``<=OTW@*VU>YP''\B-/O01J.IP=^5>.)-YXT)AI_MUVO@W0W?VQ`A"P) M\#;)R3KD%L?1,D)#9%"L8(`H-]&?VR@D5F<19=^HI?\2),$*457=W<;!H/$% MYWVL"?&>CM_QY\.J&E/3H7ZSF6S&F0SU&PE@:F(JU&]@C\5XAD^_D4#&HYN] M`6-,B?_H@E1_CR?*H89C&<#139\YHS?8W(UEZ`R;.#/&;9!9&].@C6#*CC#V MQQOSXWIKH[AI@YH\3U=!$OVK,`Z$]^=M%B4HTVHHE]6@<9YDI&="NCMSEY,_ M"X3-'\^#[.DJQM^SWY)@2Y2#0KUA#^<^@A#S#3W]H'9[%"F8[`V)\3F(Z6'` MW1-"^8'];9"2JI]03@878*=.+`JHBE'%&4>"85,P7A9&EHRO2V*W\MUU0E;] M:VWG0@O?XAJF3V0.2M8YA6CF&[__O)*I0CY3"6%%7FK+E6IPF(C.T/+-RO\_#9$ MT5LJ*/U'(?'K=^_+8\)_)S_]L6_!`JTB6G&2?PW6J".BB*04B4W2%J&)B5G: M%B=(EQ5'\L\6(/J'BR7%VTTQNE\OGZ*XQM)CBM>*G8)!$C9;__,9I(*S')^Q M&>,T1.DOK][1`V_"]Q&E:7F<()"Z$#ENGCD<"1OG1,Z4^FPA>OEOM&."@T/3 M0D>/QC-XB&4<@H\>YQ(@[UT'R/DVI3J^(C8[B/^)@O0R"2_(9-;!B(RL5"&? MS!ND`"75`PN?>8F7#Z[C92_>[RB._SO!WY,[%&0X0>%UEFU1RC0L$MJ6@>'2 M>@,?%9F'&!QN#260/OH!I'_@F*S'R3+]*HI1FC$!Q*%I`:='XQE@Q#(.`4J/ MY-9P*B@Q]%<_,%0@ M_YQ,LZO&SFP+.DR*%F(Z%)X!123?$'QT^):P^,D/6#0.`>Z>B,*S^3:G,:\T M>)EM8``%VF9&6,`S#"E(/\CD"*LI$?8?KB.LDOG@Z5^17[KSEH2JL]G4H_(& M0#`Y]5##Y5U"Y3_]@LH^D%8.%@8=$RXM.D\!PY?5!&1:W$O0?/(%-/>$+08<&AD3#`+!G6&W5.;^9.R-M#@O@QD'70V%^*Y74^>9-OXMDTNOX M#L>JYYW?I:WDJV^),+9HA30=`]"A\081$!F'F80.YPHA0_=E__:VI]H;\L.8 MYZV`D^EAX'T,LH="YFWV>A4$FSV"49QGU2]=*)<__U%'+30"BFYQ%@D.:56* ME$"`%1DX@O65,,LRTAD<<=D?*WO>^6A9A'*32"@)AZ8E4(_&FEPT'H@8#/K7 MY9_;Z#F(2;NR67X>I.F.K$.+8+CN"9E*F>JX#%;&FGD6]QW6$[IMGYE5%$=E M,-:V#^('#)Y]+&*V0$L4%3>9OJ*\5$1W#`%(JZ$D)'4720HB`@$DYFC[?%X? M-W68,!&G@Q/6IU)I[4_NXD`@`K#?VQQLGZOK]_-MBC9!%%Z^T&!^1$SA/']" M:4OL3O_OIFMRG>H#3?T?L6Q=8!\4`W="G9GW,AI+6U%9$Z MB`T%V600$;/RUQM;(")CM,Q1R%ZP?,7)DFEGU0N6FE8IZ""FM.66(4R%L;]> M8<,1Z0"*\:747.N+@Y#@MUS6YZV2OOMC3$>,Z8$YV8M:'=CI.U_=*Z7=:2S9 MWFWK#,+ZH$D3SM MS`6%B+?Z%=(FMF`M`Q&"A;VTCP&3=W M0KL,O3<11+!T2YK08&>4;+E M&!DQ4152P2%R'#`@V530PF/H[U+K`J5D[9A'STAJ8""D-5Y$I,ZC!BRG&G9$ M;/77=7DO&[`-MPTGJWN4KB_00U[L2FPBNF)!08;F#W&TVJ?L8.-*JVSEW*F5 M=1QY0S2A`D7%>@:L6YW`ILRP28>YAT;,J.D2&"R-VW%.;&8HKZ"9.@5M;D"K M8FOZ%$Z:FO:&>U8@)F+8>R?.`+1P!)%T`(8X[/T]?X+-5UINA98_X3'>P)HP M@S]1=?XNFHH3F89*N#9-3M@\O>(0>H4UL,3Z^!)5X?LRZB`5WT?E.Z>>884O MDQ$':IP#MZ/>(`$>!X$/@)P\\KFM>J9H'>O:@8#B$./9I[!X4@J!OURJ[B&I M"/A,;OXN&1H9$I@743B?JSLGO<^.8T$BCPH0^JS\=?QG85C$``3Q;1"%UTGI M2S9$[!Z"@0M4IV&``HYC1UEF%31!F/OKR"_H8S`)"B^#-(F2539;+K?K;4QO MDUZ@QV@9]0,:H07J0$9Y`;M/R:IWF^ZX\QB?H-0EB\!Q MO$AE4L$'BYF&6\]\=-$AQU[JT$L=>>=A(95)!18L9C_@B01XX:>_H!9583M# MXGAQE_S=%R$Y,,[2,Y0I2F]D\X93D7[R12?&N&H(M6:Q0CSWG/I7EB]FN*,]%19NL[X]2R_.[7!".1S\Q99,G9WSU1 M*L3A23IBJM8T8?6_R$J96KDM(V`32%]';4KIO8*5JOSZ,`/4Y.\F[`]Y#$7F M_WE:3(QAL>MPB](B4[/P9$I6B'E8Q2_D^()>2W;](RU^!?Y:]+:$^U3@LVW^ MA%-J/(18XQ$S,=8G]@I;$EGU,=5G[*^99DE6O)<#P5&;4("ABM!#_#!E'(J= MBJF_9V`LJ?B/1`"I!0ARXWD(?1A!7X10QQ+K$0@/#[T:9\-`+TJA1#_`PUO_ M25UJS3`0J>=D[9DL(R"3N$T`RCZHO'.8X%)J@HCK*GEX^M,3B^DG2:AXH/'$ M0X))-P@L'=_(VHM9!H'"=XP47HYR],4L3=R8\8?ZV7;/XXWZ!T M?Q?0_F,MUPEI+JI;QSG@D%#56>@Y5!;#G(MT-;QW6'B?ZQ#F[F=[1U%!C+*R M/;]B'&;]5,4BDNKXB4EBS4!QU8]!TK0-3Y=98=>93/P]-2E%N2+:^S4-DEY2 M4>[W-J";WYWL?)D<\IYGV9C#C8Q91VA^/^_AWS M:[T)T_EJ#>7R'L`R8=HPYS+<;[1T&/GL!V2(J)>FP;\@PS?&Q5L+I=`]GP!` M>WA\0$3K-E!4!%6`C82MQUX%B@G/U:\H(=+'1+Q9N(Z2B$I.6Z`I`@_+W-^"B)[YL1I;-Q*Y#1B:0`CH8K`:D_/'$QX6Z:&!G5\#0 M7T->"[47_*9_C4)`T1U:30HOH,$521T4359C+""/B(FK($J+D)=9^/^W6;[? MD/\]2%F[1B#:4JD26I<1HR(F&#L2IAHFVJT+^U]Q@MO#HWHUD[VH!M.7B@;0 MVTUVV&]@U[:*J9II#EE4UD8,O*CE#`P@D)K'8&/D.*I'(YDR3@76X+\LOU-LFZ)KHB1>/(19IF5?F6+JO*I9TZ%6647%V9X^ M#:,&#]-:VS28:1NU)(IM\GSSBB-MJ2;9?3#-TF+<\TN?/O*!FCLR]OFMTO=1 M^.AWRU$99:H$NS6F:C=TM]"ABS7G0?9T%>/O#MRK:=R#JELE3US))>TGK&20 MVMSRHLVY3?%S1+KR\^ZW#(7727VP/EOFT?/^KA?GV%";P6'S3)G!M$.HNTVO MWUM*FX?J]?#W%7WUQ0YQ!=D]7J`E3I91C%HRWN-A@V_,*NK'9L:HPF(^4H*D M953`E/P[1L6@2\+9/OME\7M'R2I%ZJRDD"+6K,"HL,%:&FN;CS$:N,]Y"FF8 MC>U<3I;E0KZ,M.H*IYIMG"NL-S'>(?09)>@QRHM$`>6!"0K/\9H>&;-LK7*YZNP!7NYD$:ZKN^/@ M7:%U`\(S7/#[?K0`WK%QK1_].Q:6S8<.NX3?IC-4IX))5O02)AVU57KX+I15 MBU7K"W"QDP6XIN:.@W5XXP:\7.T"[(F>:,8N=('V?SQ&J2]TX+@/71T2BI1V/EZE;D=%^^V7)O M7XA)0]%S\!!WXZ=5BG"QQRKB/02E>C"+1%9UWH?R]\6\3=$FB.A+OX4P5?AS M$A91Y[,L0SW7:!@3+FAA3+R'L8:NS`(;U@"-5:OK4*]&]&VP4S*\'7JIU:WI MO<>J6`/CV-NZ+G^?7V`*EVY)ZP^Y1B'HXQ01`;!7Y!0P*-:#<1CVJO/W"E!? MOLKLE]G6I##DT',QV*/W'H!B#9A%7Z^N`9>1'-V%H$[&89,&YE^*"O%W'YB% MO(YQ=>Y7F&7X3R9MHQB,$SYD(BARGF?[F3(-K43M263M"V=NQH*T;0V&_X,H] M3]T!NC"@U!^J3[OTJE7K`>./N[AC0>A)6C;DS@.`@=BB"!G8>VPWV)6SSVSY MYS9*$6DV`4:^NXV#))\E(7WVITBMW`U)52Y81:@J%'3-X$)`@`?H!F1P!8TH M8D\5*O?^2!FN(NU1KCVZO86OMFY,P%>E\@$W6D_`7X#/2$;\!6%U)[?BJ&/A M=/T%``.Q11$RL.TG=^YH_[%P*[?@*XP.$&B[2` M:X85TME80Q<@@RJHO+R+(JW47W>?*=WC#4Y6]RA=7Z"'GM\*+B#"8Z?`*>%1 MI(O1\-BIU-_II"E=\7KJ?%.\*'KY@M)EE/6RKX'I&6CDT)\`&"&:,(U%3IW^ M/NO2%*Z\OU+)U5T-04@9`.R3G@#V)/*;AEV_.G\CO19H4VX^M`WZ+`G+@ZD[ MM-RFK/6X3M'Z=325HIXB=(!^3"!6K7J-"#$OMI482M)>#&HO`KV%L+9N3`!8 MI?(Q4E[[LZT$W[@PLJTDK,Y?YXN*6AC'[(DNLI_)3?DP$:GA&>P1>)M9=^[OM9A,7J@CB M2A77R2-.U_L^Y^0"52M5I06%EK(8]ITC`I3\-HBZ.Y.L3W7@=O.3O0&DV"E8 M*%1GP,!X[\-QFSP-'Z4X:(_TQH*:/0+7H?]BA.UDR?-T%21E[A5B>C]OLRA! M668M,W*S/8=$SOO&W3:$K_/$!/$AQS/';!KE6;V29X:GO?<#A[3_D#3\GF#N M,VGF-Y,J%[`WH7TF>WM/Q1L%)QY=]6T+:J3UQ7N*QEMM:`JT8)-O(N+\AE&^ M6T39-YH!ZTN0!*M"U#L:/JECG3G)7Z55<4RJ.5A-\+8-`%='Q[FD&OU!R\I*:V'LWFW7ZR#=S1_OHE42/49+ M&NV\SZ)!%K"WQ*PMZ>Z^M<2+O:;PTKY+":ODB@)">\MKD?)Y0U^M4+6X!A:R M=TM5WI%84_;./5-N1<52"EB!]P:@3MS:\%2N$Z*(;>&J6!OY=;L:AILM5`&EQ>W@7JMX@Q="RI?5A:$+Z2RL)&@W=0>7_W[;6,37^V%[CM=K MG!1!M66(8Y5\Q-Y`OD!I]$Q$?$8-OX`LF_Z.PE4K`D4ZT`UPJE\3&L#)W$I= MT%T\"Z!2I#J2!16Q9A%,]"K64DS;<@QH1W&8"ZK?>PMS@5#Z&*$XO,%!8FYC MKL66._P%-/7`9M*8&[*M"JZ"I7"PPHA936<06QR@(KUC13&[@X[!>_^NF)BG MR9<,;>R;->Z]T'=[Z'\?@@R%U:,^K?=[K$W=M:6;/S8;M$`Q#1@O7JPHGAPJ MFE[E0.`-7R/,JL$RD)F]UQ*A#?_<;#C7P)CAIJI4'C=[)LH,MK!IC7:,W:!6 M%E9Q:.N\]S]@!P[3P<-QQ"0PB[+Y8Z=MN_V?/*.E5J@4'UK(\8,'+=E5#AZ@ M%?B;?*#>PA&C3$;6W2;S#4E`^52PPV'+D@DL:X2"M8/J&T M'ST]5(%+U-`"E'`>7ZI2JX$,P-W?1ULN@S0ADM/;F,5Z4CR?`JFKE\5EU(X# M2TU:%5!).1M.+'_4Y`[?&[*G."'_7.[#F2%K1MWB=:('U>*.8W"@/E1`J5Z5 MO]>#8+M+]_1QN&EO:>R@UN43"K=%PL2.6:1[',OBI>QXFZ.PZ`YNE.LP+E78 MJRX7Q\V(&>TH!<;JUNCO_19)B*QE:_)#!T%6HD+KTM#T$:KHVB6C53@_GHZ@6:,-,0FQ=+++N]/EPO MX5F5VB5I*U/NF$KH>\XFE][UZR.J(BO=(0$P]SPZ513+;G?83I=)S"^%#^UO M.&.SO)[.@,9%CTW/YJBR\?W>BB$%&KW+HM\F?W?I6A<.M*V<[]=;#CU?):&< MK>EN+D7"0WX`$]`FZ##I600U)NY>DS&B%N#U&=VZ3#HN9O'8;G>5_K$,N`!/ M4MKWJZ9[7>.YU[S[.['N0ADUXU'L] MAUT@Z%&32>8]4V>&^0E<"AM5WZ;OB)ENK+]'5HU8@]+FWJ'T.5JB@V*:*I[% M15LBFG6S#![^%U%=D4.]T#L@QF2<>OI1**;K.:E!.FXOC#=>C;?;T(N>+N:$ MO4!Y$,53:E@_GPWIZ,+U1T.T,LP.?\%&*=.LVF,B'L[F[<5C>UNCMY4F)ZUW MU$2D?B%.0>P!0!/7HC_EL!(,6(!9\Z'-KSBA@2BH!S`Q467A.41^@0HDZI`, MV1S^^G$.@X$DW8LLEE!/."8MS*BQ+8]%^:MT,7U_X)W@"Q[GXO8XEZ/9Q#96'H(2 M#38,!WA;G4RV1;('/CN/7],"FUP,,V\=9\.NE`X.C(Q-[15Z,NJ1M4W'[#` M`52EGY'$]J;,>1QDV?RQC!*=IXMH]92S%D-RPFHO4$#HEIB,%9.43B2D]LII M1!F92RT`I4A.\\NMJ^@9_1,%:5G/1^9B2TQ4W0_C$%FS;A!=8Z!P;2,FX%S< MT.)P]'ZA)1^C6`7B`*562RXA4W\770#3SM.H=,7%Y\U5J+WEEB$[3!H:Y57* M<]8DPR6HK"Z#P!%QV/.)@(0IDOD9I`Y>/'AR]-`]2';,N01*W@W;YI+;&[PB MW6-E23NCE\&\E=R?R]1C:\@?G1@$=9$*ZYF$R<9CI<&F$)GA4YH[&,S\703# M%*B^XRG6H7BK4^/HSOK) MW2)W:\@P=T@590:,H-:>J)R]M5LY(T+L\@6ERRA#MVE$#Z'*CUGY-7L/P1V4 MAPB,A[X*AZR&(I\ MB3ZK$U$N,W\/177L/DNM"M<:I!4Q5>U[Q$W;8R"R%I+3_,Q(-A7QJ9G>"(/: MFM3TQD^GQYD3E)2NE%1`9^\9NSJC1FEKF7.9A*K:U.=163,0\I[!4.':!H'+ MN-C"YS'TU])"AS2&CP;!M-6O@*I5P-A?Q9J8PJ0FUMQDQJK*<$R0&]-:;T]. M/K?QMO%@1=Q00AL$-._DLOQW-]Q`M1A+&<)B+MHZYHZZIB;`]J^UIPZOS/.0 M&-8F%6#+"[#5Y2NTV!(:@%'-V%KDR0B0*:460:9#PH),3>(G9-@2&H!,S=C5 MB)3*!\_N\0(M4?1\\,:K%(.<^!2%DIUH%5!);X"DKP\]?"G5Y^]QIGF'G^=W MCN7UW_1.E4W%L5L;#9SC,CSD:$DT"MKUM>_``^KQ=[D+>W19X2RSK67QR\IB MMI[[RY+'HCFGQHJEJHT^:"EKVOB*\NMDB=?H!F?9+,_3Z&&;%VF[\6T!3K%: M=(M7#H%R<3<4)=*"2$2+!D6[I[!8OK9=4:VE\&?:W/T]_"ED*]RP);&<]'FK M#D[X!/4;%7T"+Q$CE70X;%A5^+O#VM9`%?=YCQNAH66ZGU(50D.L4)YIB4'E MO03F4#T9-G>P%@S8.\!Y$-L.WU#UG7K=I.Q7M'L)6'^_Q/'AF3G.U54#G.HWS@=P\A+L MYG0W'/J#VN*OG\U153FM]S0&L^:RTF)[SB_M)Z;MK> MM7J]_J91@FW@ZVTKJ^SE@VNP8=,E9],E,!X;2^,ZW7>\JR[R5XE""!U*\R!* M.N_E]O91+U^6\39$X17I M<9I,<9N7CT1V;0GSQ32C/*L[IV9X.CYJQM"^T*93H:D!4PBD-9#5JV<\A*!01Z*!?Q-I\ MK=*I6$L![7D94%_QD`*H'G^#WE2L"4?MXJ''T3J_.I[6>]6<@-*-38A89U[@ M=,W01K4Z4-08?\]V&*XJ:Z864]6/UG"H[-TM)ROMC/0&Q<`=2I_)JB59L?US M>N\UX[CNS.OH(["N;K`;96TOP63["7CF["^DJ9(#LFGL77=^_$& M6U+D6F.WP%_K1G?@BNQJ.17^`FUP%N5L(,HI*SB**$\/E&"]C`Q-43L\/E'> M;P8S(%0?IN.1L]M2Y!LQVH9I)=5> M28'\]C%73[P&^&NR%T&R8N;CZOY>W70__&ZWSOG.MEL\ZSH MLO?B,TP^95=V%J5]"Z74FUA%#$9_\BB\#<:RWCB0L=F$'+(` M:X.L#6K?@0#N?>L9T>6\!\B@]-6=$#F]>[)#98;*:O-."[B_,%S0SG45617% MK14^ZQ_;`5#J!]!-4Y.M$G;=R22;;.@';@G5"I4]!2WDJ"J45*`DNM47694Z M$BO*W1Z2UBUUB( M:"H;P:8Y/9`"=#$R)MDM\/>\L2D0D9S*C7JWWL5$#!`VB4X:A5QM'`^&S2;H M[R:=S.36W_;!HVYHF._HF^9[&&9;_F.O&?F;QB-L,QYC;]E,LTM0_,5C4(@2 M01CJ9_GC'J+6F.HVLT]_N)>%9'_DN,!Q_(C3[T$:3FE)/#M2F-*23&E)IK0D M4UJ2*2V)CPNO*3?)J2QIIMPD4VZ2*3>)K[E)ON`$[;X$Z3>47VV3D)V<1$Q4 MW4?C$)WSHW;11T30EIJ2TQJ?X8=%3!8254` MU]14"^G\*VZ9OO.T(7QQ>)<'::Z?'X1C4VY3O$0HS.AKR7NA2B54;XIWITEX M@;(3(`5.'[7*:CLR=B'MTUCP?]HC.$&K("]I+1KD.I:B&I^[V>'*_VTQRJZ3 M94I4C"[0_N\.^@=P*/M5B\/ICX_ABCWR@-%JL,9^AELCR)!+\\>'R:D!.S4] M9;GHUFAL)NS=FLN$#6J'-X>TEIJ\';Z1UE3#MIE4).3N(YJ3[%2NXMG.@3)@ MC\2QG"AJDDSXF1*E3(E2ID0I;B=*Z6XAGO*J&)=_U6`]^7+!BUS%/X#QP34]&KI(LA%X<*P@@S-R0IZ;5WZ MT,$#U';$"U"R=HT11^D(Y.D+Z`I`;Y(#X+TG_[%`S5"112CO6W,"ZYR&;(LH M^W:5(N)ND^&%LAQHK$7%!%AF%_LQ,`U0F05LLUMU`@NMZ;KI=-UTNF[J[773 MZ^29\,/ISO;UT$-#ZM[BW`X%4)9X$%*:2X]65\.ZL.Y;LQ7E,N\ M,09)5Z06B7VA%L'W+V09GD9!S.TF%DU7K#:-_2')Z@D,DXDS2!L16A).+K[U9P4VR! MX1083!\PT9=`L?,+!OJ;H3G.@]AVY@_!S(Y!TR1'9ZVM938;S\_Z#D+A9+E/ M&2MU-KB4O2'$H!QAZZ1@AJ3&3#0,VF,+CI3[T#38MLP/&&%F\0N=^90[ING-ES2$?=1(^(^'#\ M)1:?H%0`B\#1/I3*`NE,%A,;,8.<#FTV;)[\/4C"VVVZ?`HR%-ZF$4[O\0)M M<)I'R6K_LD%O4UZS?+UUKUS>4;0,U00$3!IUZ)\[/Z/T`3OD1]9);V6+=RYA M=_9@$#H*+K!L2O,+@UD)E[^>TMZU='=6MHG-8N#OJ0?DI!US]2G46)]C2WW> MQU7T7[6HGP"R'6EQ>*JED;5FEH1_1^&*AKDLR:P;N?HMND8]G`TU!KN]-5HA6M#]^N6^GYU@^^>2)=EM+V,;1T0 M;:E@">TI`4]%+:/A3M((:W$-(_I/Y12);M-HV5!<^35[#S&<4!XB>RKG<4IH M-Z'&XUI?>>/T%[Z#CX)57(++ETV4%DJ#^@7L$F(PMTO\`-`5J.C80&TW13\: MQI$(A4HY7W%^AW*BT?W3O>=!]L2XK=X!M%[A]BLMX,*G!/-!BAL-\:JM,IP6 M8H@Q+HZU"Q\^O-BF=0C1/*EF%NY.B$;)LA^42IX2>O55-AITE9JD'R?DB-&^ M3?$2H3"[(CU-O]!CM5XIU_##Y:NCF%R$43D6D\SZQLJ2=^9;!G)IT.5./0V/XHQ.#H"Y281U6Q&3CK]+D M]KJG.VD<$9=G7X'VXH,W\7Q$+CB8%&2ZR^:JKFL3KQR1HP/2E,UVQN_B;" MZF6%G!(,3PF&3R3!\)2'UG'3S#,R"O9X<0HO3K,DO.%D4%6B#7]2ID=/O8#Q(%?(!=A.U,B"IU.1J MY#@].:#G/D$<%P<_'63)R#KQXGTR]Q$#%%$1'7RNG@=S7Z"'_'!0>!OLZ%_T M$;0N=.2$]?8[G]!]^(#%5`20B.^`]'GC&!.4WP4QRJYP>KU>$Y&"',6[VQ0M MR;^3U?UW%#^C+SC)G_:Q5RRB!=KL961$1X_&OS)?YOF[#]RQE:IJ,,TW1S\" M>Z2+EG]NB=3[5[QR$=[EA-5U2`&A^P@$BZD()1%?_I"2KT@0^Y#2$E]S-2&K0S\VV`GK-ET4'1FKYJ]_2J$[[%+G?WB*Y!NH*]?Q.0_21%DRPGWA!>H-NX`!1QQ4P@NT&Q-X^2%3DF?C.F"-,GLC3AX M=_6\#JZ_[.2ENPWY)@31.`_PN%-`Q=BB4!/1-43'HOT267 M?#C,F'5H[&M^VN,M02OJ$]M&'-7$?:D)AG7N?FK8X<,G3R`CD$<''6UVGC^- M!7:FE*=LU0,F`/]2U__IW_%NM2:^?-F@)$-42.X[6E+*^@4$`:5+DEZ^+.,M MW;&<[>UH`0FYV,)B?!UPBEG,U"_O4*RM@/8H$]2US^$/K:/5,1J MTKY-T3K:KCO``]-7T>%R>M>AIBJR$L8`S/T-E6P+=Q4E0;*D@0\XZ\420$B9 MD.J2^H4FH:`#@-3EZ]JA\#UUYA@2=5`A(RL5Q2=S'0U``960P.MU"QJ5V/YUHZ"E,^\KAJ!*VAI\-/&KB!M$=?8Y"(1D9&&QYBO0^U4*1 MGVF^H?QHVHGBOP_TZ;_+]2;&.X3HW6,R%/>I]6P_1U7GP"#]T&C7`L5T"ZN8 MBHO#N$*",FJ+ER+;#+-J/W,@,VL>9-7-=RA]CI;[H\S/M(U-*;[BY)D8913. MO@=IF!7S7_,[%>\KSO^)\@5:XE5"MR;W<4)7."U_HG3=TT([E5?1.T>NW)Z= M-`-T;+F_.E9ZD%!%G-*1A?%W"X.MFAD]-=[GI_B\.Y"4JB[T5:?LFF79=EU/ M,E]0_H1#'./5CF.;CUAC=8WY>1@_^CFB8`!D2Q)L(5N@?F(RXPAE:]&,I MCU_Q&/TIJ=B:93_F,,$6.[-M^H\@=7&Q_XC2>CXW/,BU]`#1$EWU+XF6Z&EF MUU<HQ`EX=C&0E3?&,:"7=]D+,;I.O^- M!5M(CP]ZC&U@'G]?R?2NY5$D\-@)73ZALHB>B<1:/R18A3*E.J'EC&?=3I"*^(.V`5_J;$ MA4Q*6,V>@U1<96"4,/8W)^.XOA2_2Z09'D=IF*`K[679/V(Z\3C@09K*FPMGDQW+KB?@*P M56/X?Z#NX1$V?HSO%X[39D,G3_R`]_(+_8/*1G[Y M7U!+`P04````"`!'-D550)``,?[^-3'^_C4W5X"P`!!"4.```$.0$``.U=6V_;.A)^7V#_`]D''M__0ZI&V7)NME)5*S> M9'%F.,-O2,[P(G_^=>TZ:$6XH!X[[QT/CGJ(,,NS*9N?]WS1Q\*BM/?KES__ MZ?-?^OW?"",<2V*CZ09=4F$YGO`Y08^>XTN0(-#]P^3ZYO8*G0P^#DX&1^C" M6VXXG2\D.CX]_8#ZZ.3H>(2>%IXK/(8>B"^A;C2V+.+X8H#&CH,TN4"<",)7 MQ![T^ZKVM3@3UH*X&$G,YT1^PRX12VR1\]Y"RN79<&B#/AZ8LG'P5`PLSQU" M7>^//HZ430YQ"9/7'G%CA\XHL7L(&H&)L[6(93T_/P^>1P./ MST'(T?'PWW>WC[KVB-:&NBK5')!#2\K-DB05S+"8:O%1B6;I'QWW1\<1DT/9 MCY1&ZREW(IU&0U4\Q8+$ZF?H0PN@Y4^'NC0F!4&T0#1E0F)F$9/>EC?QA M&!1&I)2MB-@B%<0:S+W5,"A3EH[2EC+?S=?&EGRHFF<(%(13*V;P6`4>C_6W M^&Q"\U6#`A,!\#B$E,]AQCR)E6_K5^'+Y9*RF1>^@7>J;<\B/![(#.G6/E-: MG/<$=9>.:DK];L')[+RGW*N6 M*Z2(:X_J3W#[<@2SP-$1S%^1!/,1,QL%XI`A[_-P6\BV?%\0>\*^Z.?M#AUR MAR1%G%M]ICICVBWS^<*W$1)[`G0!(8+G4%N%$%^QHZ:8QP4A4GQGV+>I5'.Q M@JD"72%8`)4&ZQ':DX1HF3)1*!0%4M&[6.[?.M0:H':/.;3"@D@*9E6%,,UD MV@R19E"('J#^LZK0Z4"QR"F.FSH%>I=2MG.28B>)6UA,9I.ERAA4;E#0Q\L8 M"G$]*>OLB73DS5`BO^OVC1"]P&)Q[7C/50'-H2_$:?D=GH5X3O@< M,_I?K2O$/U]]01D1(@!O5V$A4A^CF"A9">@C4Y*.C")9'2092&[I'SX%A]T\ M4/%#0+O?88;GVKZ1S1F<0#T`Z85F>#PD`F]_#*&5!5A,`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`+G_N)B&::Z"47OJFMBLD7 M_=A?&9_#$&!M:H.38HQ_[0T365N+VKK$3/II;QT8II:^5W]<1XF$*WCL)P*: MJ2&H55N)B$<]-%%@^\[N:3!+,3+'^K[.#AU2;`[G*:Z^DM,_/ND??]Q?#UE; M!]FD_G2CRB6OCT3$I)\.@87Y>84J;:!9U*]^Q*=:8J1:8@\MW@^YNK-=40%- MK:J%#OFI?WQ4#X#,IR(JUAHQJ(H_-+,T_V,05>HW.;\%C'OW@.SG+.IITER- MXN^--`\JM*PF(W5V9`@_'`"J6K)/UDL',ZS6"*[A=_71PI1RE0@I:+/PVS!: MQ_,>0#TE?#*+`ECQY#T0B]`5>200]JON=X\WQD41]2&%WVMQ!1]ET-]@.:-, MDCGA-Y*X*H8$._VID%3JS^G\QCU_&5,"20\QZCAJ&>R\)[D/Y)"$2`ZFGO=F MV-'?@M'$2_`3SW[2%=D^#T\H[[(YUA'RCP&0 MJ;"MY"Q@M/4_*##EIJR'A6*#$WFO&R2QG?"FD,GM95.';NMD5U.BJ M;,'8N8KT#4\I0)G'Q^(2Y*Y`VHI$78@2,0YU,!O@4!)3(ZKDE,W?%/X+!PL1 MFS+A#^JS=VJ>()=@K3GFE!"FG`#>O*T#1/-AJ&XP+4;37\Z\N8/N=:>_>/:H M..B,R@:=45L'G5QG@CB9!HQ57&^;NEW^I^=FW3OL2U]U\G#49$GHE3/*UN)J M6VAVS[T551_PA%'P:FT1(;8N36L3"ZE>.UQ+C-J*UVPR+0K7XCG@CF"U#Q%] M8B83EHGO`E#,G(\PCD<81W2N@_,N9G=^V7I:-A6!:UB$V.*:>VZ@;6A=Y/TB M[4>EQ#^+.Y6>!&N0UX?Y;L5GVSV/8=F+VT.0O/L0D75P!O>+')G`++:1OXLRW/ M%E#.+7^J`X.7\>QX^M8+;=`XXS7-G=[3YX+G6\;!A80-.V0'LL[S#_0>18NC!CSCEV M,SG#;I*V&1,?!$KF.G6N`[--QJARTK89EQWN;BG3@U5F"-E%U;*)?FQ9P&OG M+M9?>$(&GZG(7>"LS]K&<*`H'D^.17\7>N$H/A2M9[F\1CF,N#8V5-'WL'-B MWVKD+>L-<9K[@)_OL`1>:*]O'@O.NICFE5*V)>XK26ORTO\W3/;WM6([4MTN M:&U8:KK1A/T#,_O>Y]9"'9"\!SE<;1*K[?%XO5-!?GG+QOZ4EM?8VKFQ6T;81HC&C%'U MUTW0S=76@]A*>O.+6YOS/GE2W6V#7D^$VF.`^H@Z4&!8M)OD9UEP_$;D(W:( M4(FXZQ*;PBCG;.XYL8CZRZVG9^*LR)W'Y"(8U/.(8-P/CA)M;=:\@.RVS"AE MZUQ!0J87Y\9R5_L4$;V9H57[=F8I9!=!Z[)KNI8+0]GLD;(=!&TSY-KS>;$E M.RG:9LK6WKL(-CZ?O"C"#%8-=V_6[V1HV9)BI+::T]7M8NPXNPYN9DE,6U[A ME&:I,4D&UL550%``,?[^-3=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`7(L'13'Z'U11#0``5:L``!4`&````````0`` M`*2!AJH``&1S8V\M,C`Q-#`V,S!?8V%L+GAM;%54!0`#'^_C4W5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`%R+!T6^4>JIQ!D```/'`0`5`!@```````$` M``"D@2:X``!D`L``00E M#@``!#D!``!02P$"'@,4````"`!&UL550%``,?[^-3=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`7(L'12>E+?T:,0``-GH#`!4`&``````` M`0```*2!:S8!`&1S8V\M,C`Q-#`V,S!?<')E+GAM;%54!0`#'^_C4W5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`%R+!T5Q?>_XW@L``+US```1`!@````` M``$```"D@=1G`0!D XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments, Significant Unobsesrvable input assumptions of Level 3 valuations (Details) (Level 3 [Member])
6 Months Ended 12 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Minimum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Historical Volatility (in hundredths) 52.00% 62.00%

Expected Term (in years) 0 years 8 months 12 days 0 years 4 months 24 days

Risk-free interest rate (in hundredths) 0.08% 0.08%

Maximum [Member]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Historical Volatility (in hundredths) 61.00% 76.00%

Expected Term (in years) 1 year 7 months 6 days 2 years 1 month 6 days

Risk-free interest rate (in hundredths) 0.34% 0.44%

X

- Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedTerm

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 17 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments
6 Months Ended

Jun. 30, 2014

Fair Value of Financial Instruments [Abstract]

Fair Value of Financial Instruments
Note 4 – Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows:

· Level 1 – Quoted prices in active markets for identical assets and liabilities.

· Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

· Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Fair Value on a Recurring Basis

The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:

Fair Value

Fair value measurement using

June 30, 2014

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$
65,557

$
65,557

$
–

$
–

Certificate of Deposit

325

325

–

–

Total Assets

$
65,882

$
65,882

$
–

$
–

Liabilities:

Common stock warrant liability

$
3,224

$
–

$
–

$
3,224

Fair Value
Fair value measurement using

December 31, 2013

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$
86,283

$
86,283

$
–

$
–

Certificate of Deposit

325

325

–

–

Total Assets

$
86,608

$
86,608

$
–

$
–

Liabilities:

Common stock warrant liability

$
5,425

$
–

$
–

$
5,425

The table below summarizes the activity of Level 3 inputs measured on a recurring basis for the six months ended June 30, 2014 and 2013:

(in thousands)

Fair Value Measurements of
Common Stock Warrants Using
Significant Unobservable Inputs
(Level 3)

Balance at December 31, 2013

$
5,425

Exercise of warrants

(375
)
Change in fair value of common stock warrant liability

(1,826
)
Balance at June 30, 2014

$
3,224

(in thousands)

Fair Value Measurements of
Common Stock Warrants Using
Significant Unobservable Inputs
(Level 3)

Balance at December 31, 2012

$
6,305

Change in fair value of common stock warrant liability

(2,686
)
Balance at June 30, 2013

$
3,619

The significant unobservable inputs used in the fair value measurement of the common stock warrants measured on a recurring basis are the historical volatility of our common stock market price, expected term of the applicable warrants, and the risk-free interest rate based on the U.S. Treasury yield curve in effect at the measurement date. In addition to the significant unobservable inputs noted above, certain fair value measurements also take into account an assumption of the likelihood and timing of the occurrence of an event that would result in an adjustment to the exercise price in accordance with the anti-dilutive pricing provisions in the warrant. Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, may result in significantly higher or lower fair value measurements.

Significant Unobservable Input
Assumptions of Level 3 Valuations
June 30, 2014

December 31, 2013

Historical Volatility
52% – 61%
62% – 76%
Expected Term (in years)
0.7 – 1.6
0.4 – 2.1
Risk-free interest rate
0.08% – 0.34%
0.08% – 0.44%

Fair Value of Long-Term Debt

At June 30, 2014, the estimated fair value of the Deerfield Loan was $23.2 million compared to a carrying value, net of discounts, of $19.3 million. At December 31, 2013, the estimated fair value of the Deerfield Loan was $23.6 million compared to a carrying value, net of discounts, of $18.4 million. The estimated fair value of the Deerfield Loan was based on discounting the future contractual cash flows to the present value. This analysis utilizes certain Level 3 unobservable inputs, including current cost of capital. Considerable judgment is required to interpret market data and to develop estimates of fair value. The estimates presented are not necessarily indicative of amounts that could be realized in a current market exchange. The use of alternative market assumptions and estimation methodologies could have a material effect on these estimates of fair value.

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13504-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 18 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\T.#(R86,R-%\W9#@Y7S1E.3%?83'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A M#I.86UE/@T*("`@(#QX.E=O#I7;W)K M#I7;W)K#I7;W)K#I7;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K7T]P=&EO;G-? M86YD7U-T;V-K0F%S961?13PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/DEN=F5N M=&]R>5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DQI<75I9&ET>5]2:7-K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE/D9A:7)?5F%L=65?;V9?1FEN86YC:6%L7TEN#I7;W)K#I%>&-E;%=O#I7;W)K#I% M>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-T;V-K7T]P=&EO;G-?86YD7U-T;V-K M0F%S961?13(\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I3='EL M97-H965T($A2968],T0B5V]R:W-H965T3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#(R86,R-%\W9#@Y7S1E M.3%?83'0O:'1M M;#L@8VAA2!);F9O'0^)SQS M<&%N/CPO'0^)T1)4T-/5D5262!,04)/4D%43U))15,@24Y#("]$12\\"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS<&%N/CPO'0^)RTM,3(M M,S$\2!6;VQU;G1A M'0^)SQS<&%N/CPO'0^)S(P,30\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO2P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XT-#,\2!A;F0@97%U M:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3H\+W-TF5D(&%T($IU;F4@,S`L(#(P,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S+"!R M97-P96-T:79E;'D[(#@U+#(R-RPU,#@@86YD(#@T+#8U.2PQ,3$@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\T.#(R86,R-%\W9#@Y7S1E.3%?83'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO2!S=&]C:R`H870@8V]S="D@*&EN('-H87)E7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\T.#(R86,R-%\W9#@Y7S1E.3%?83'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO3PO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO6UE;G0@;V8@97%U:7!M96YT(&QO86YS M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S.2D\2!F:6YA;F-I;F<@86-T:79I=&EE'0O:F%V87-C3X-"B`@("`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`H04Q)*2P@8VAR;VYI8R!O8G-T M'0O:F%V87-C3X-"B`@("`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`R,#$Q('1O('!U&EM871E;'D@/"]F;VYT/C0N-B`\9F]N="!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0[)SYM:6QL:6]N('-H87)E&5R8VES92!P2`R,#$V M+B8C,38P.R!!;'1H;W5G:"!W92!B96QI979E('1H870L(&EN('1H92!F=71U M2!R96-E:79E(&%D9&ET:6]N86P@8V%P:71A;"!F&5R8VES92!O9B!A="!L96%S="!A('!O&5R8VES92!A;GD@;W(@86QL(&]F('1H96ER M('=A&5R8VES92X\+V9O;G0^/"]D:78^ M/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[)SX@86YD(&%P<')O>&EM871E;'D@/"]F;VYT/C$S-RXR M(#QF;VYT('-T>6QE/3-$)V9O;G0M7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N M/CPO2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T9#X- M"B`@("`@("`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`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`Q.'!T.R<^/"]T9#X\=&0@6QE/3-$)V9O;G0M2!F2!P=7)C:&%S92!T:&4@<')O9'5C="!A="!A(&1I2!T:&4@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\=&%B;&4@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!C;&%S6QE/3-$)W=I9'1H.B`Q-RXX<'0[)SX\+W1D/CQT9"!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B!3>6UB;VPL M('-E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B!A=71O.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M3LG M/CQF;VYT('-T>6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\=&%B;&4@8V5L;'!A9&1I;F<] M,T0P(&-E;&QS<&%C:6YG/3-$,"!C;&%S6QE/3-$)W=I9'1H.B`Q.'!T.R<^/"]T9#X\=&0@6QE/3-$)V9O;G0M3L@;6%R9VEN+6QE9G0Z(#,Q M+C5P=#LG/CQB6UB;VPL('-E'0M86QI9VXZ(&QE9G0[('=I9'1H.B!A=71O.R<^/&9O;G0@'!I'!I6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE M9G0[)SY4:&4@=&%B;&4@8F5L;W<@<')O=FED97,@:6YF;W)M871I;VX@<&5R M=&%I;FEN9R!T;R!T:&4@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@;&]S M6QE/3-$)V9O;G0MF4Z(#$P M<'0[(&9O;G0M6QE/3-$ M)W9E6QE/3-$)V9O;G0M M'0M86QI9VXZ(&-E M;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([)SXR,#$T/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SXR,#$S/"]D:78^/"]T9#X\=&0@ M;F]W#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\ M=&0@8V]L6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SXR,#$T/"]D:78^ M/"]T9#X\=&0@;F]W6QE M/3-$)W9EF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SXR M,#$S/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T M:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT@6QE/3-$ M)W9E'0M:6YD96YT.B`M-RXR<'0[)SY.=6UE6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0M6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXH."PV,C<\+V1I=CX\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQOF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQOF4Z M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA'0M:6YD96YT.B`M-RXR<'0[)SY,97-S.B!I;F-O;64@9G)O;2!C:&%N M9V4@:6X@9F%I3PO9&EV/CPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&)A M8VMG'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO M"!S;VQI9#L@=&5X="UA;&EG;CH@ M6QE M/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&)A8VMG6QE/3-$)V9O;G0M#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXH,2PX,C`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQO"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD M+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT M+7-I>F4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXH,C,L.3$Y/"]D:78^ M/"]T9#X\=&0@;F]W6QE/3-$)V9O;G0M M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T M+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9EF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXI/"]D:78^/"]T M9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$ M)W9E'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQO6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG M6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A M8VMG6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA'0M:6YD96YT.B`M-RXR<'0[)SY"87-I8R!W96EG M:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXX-2PP-C$\ M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXT M-BPT,3$\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA'0M:6YD96YT.B`M-RXR<'0[)SY$:6QU=&EV92!C;VUM;VX@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD M+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O M;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S M."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9EF4Z(#$P<'0[)SXQ+#,T-3PO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F M=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR M-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$)V9O;G0M M6QE/3-$)W9E"!D;W5B;&4[('1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\ M+W1R/CPO=&%B;&4^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O M;G0MF4Z(#$P<'0[(&9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SY);B!-87D@,C`Q-"P@ M=&AE($9!4T(@:7-S=65D($%352!.;RX@,C`Q-"TP.2P@/&9O;G0@&-H86YG92!F;W(@=')A;G-F97)R:6YG(&=O;V1S(&]R('-E65T('-E;&5C=&5D(&$@=')A;G-I M=&EO;B!M971H;V0@;F]R(&1E=&5R;6EN960@=&AE(&5F9F5C="!O9B!T:&4@ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T M.#(R86,R-%\W9#@Y7S1E.3%?83'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@ M5&EM97,L('-EF4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$ M)V9O;G0M'0M86QI M9VXZ(&QE9G0[)SY.;W1E(#0@)B,X,C$Q.R!&86ER(%9A;'5E(&]F($9I;F%N M8VEA;"!);G-T'0M86QI9VXZ(&QE9G0[)SY& M86ER('9A;'5E(&ES(&1E9FEN960@87,@=&AE(&5X8VAA;F=E('!R:6-E('1H M870@=V]U;&0@8F4@6QE/3-$)V9O;G0MF4@=&AE('5S92!O M9B!O8G-EF4@=&AE('5S92!O9B!U M;F]B6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SX\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!C M;&%S3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)W=I9'1H.B`Q.'!T M.R<^/"]T9#X\=&0@3H@4WEM8F]L+"!S97)I9CL@=F5R=&EC86PM86QI9VXZ('1O<#L@=VED M=&@Z(#$X<'0[(&%L:6=N.B!R:6=H=#LG/B8C,3@S.SPO=&0^/'1D('-T>6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B!A=71O.R<^3&5V96P@,B`F(S@R,3$[($EN<'5T6UB;VPL('-E2!L:71T;&4@;W(@;F\@;6%R:V5T(&%C=&EV:71Y(&%N9"!T:&%T(&%R92!S M:6=N:69I8V%N="!T;R!T:&4@9F%IF4Z(#$P<'0[(&9O;G0M M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI M9VXZ(&-E;G1E6QE M/3-$)V)O"!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^/&1I=B!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^1F%I6QE/3-$)V9O;G0M6QE/3-$)W9E'0M M86QI9VXZ(&-E;G1E6QE M/3-$)W9E'0M86QI9VXZ(&-E;G1E#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T M9#X\=&0@8V]L'0M86QI9VXZ(&-E;G1E#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@ M#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L'0M86QI M9VXZ(&-E;G1E#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q M-C`[/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q M-C`[/"]T9#X\=&0@8V]L'0M86QI9VXZ(&-E;G1E#L@=&5X="UA;&EG;CH@ M8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@8V]L'0M86QI9VXZ(&-E;G1E#L@ M=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$)W9E M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[(&UA M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX] M,T1B;W1T;VT@6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@6QE M/3-$)W9E6QE/3-$)V9O;G0M M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQOF4Z(#$P<'0[ M)SXV-2PU-3<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQOF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[(&UA M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H M,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A M8VMG6QE M/3-$)V9O;G0M6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z M(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXS,C4\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQO"!S;VQI M9#L@=&5X="UA;&EG;CH@6QE/3-$ M)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXF(S@R,3$[/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z(#4R)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E"!D;W5B;&4[('1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A M8VMG6QE M/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E M"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXF(S@R,3$[/"]D:78^ M/"]T9#X\=&0@;F]W6QE/3-$)W9E6QE/3-$)W9E M6QE/3-$)W9E6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE M/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E"!D;W5B;&4[('1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&)A8VMG6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H M,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXD/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$ M)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0M MF4Z(#$P<'0[)SXS+#(R-#PO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD M+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\+W1R/CPO M=&%B;&4^/&1I=CX\8G(@+SX\+V1I=CX\=&%B;&4@8V5L;'!A9&1I;F<],T0P M(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O M;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM97,L('-E'0M86QI9VXZ(&-E;G1E#L@ M=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@#L@ M=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)V)O"!S;VQI9#L@9F]N="UW96EG:'0Z(&)O;&0[('!A9&1I;F'0M86QI9VXZ(&-E;G1E#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^/&1I=CXF(S$V M,#L\+V1I=CX\+W1D/CQT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T M=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!T97AT+6%L:6=N.B!C96YT97([ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]W"!S;VQI9#L@=&5X="UA;&EG;CH@8V5N M=&5R.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R<^1&5C96UB97(@,S$L(#(P,3,\+V1I=CX\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^ M)B,Q-C`[/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^ M)B,Q-C`[/"]T9#X\=&0@8V]L'0M86QI9VXZ(&-E;G1E#L@=&5X="UA;&EG M;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@8V]L'0M86QI9VXZ(&-E;G1E#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@8V]L'0M86QI9VXZ(&-E M;G1E#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`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`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXX-BPR.#,\+V1I=CX\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXD/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A M8VMG6QE M/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD M+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U M+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9EF4Z(#$P<'0[)SXS,C4\+V1I=CX\+W1D M/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO M'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F M=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR M-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E#L@=VED=&@Z(#4R)3L@8F%C:V=R;W5N M9"UC;VQO6QE/3-$)W9E"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M M6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[ M)SXF(S@R,3$[/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE M/3-$)W9E6QE/3-$ M)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#$P M<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O M;G0M6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P M<'0[)SXU+#0R-3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z M(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q M-C`[/"]T9#X\+W1R/CPO=&%B;&4^/&1I=CXF(S$V,#L\+V1I=CX\9&EV/E1H M92!T86)L92!B96QO=R!S=6UM87)I>F5S('1H92!A8W1I=FET>2!O9B!,979E M;"`S(&EN<'5T"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,SH\ M+V1I=CX\=&%B;&4@86QI9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D M9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T M9#X\=&0@8V]L6QE/3-$)W9E M#L@=VED=&@Z(#8R)3LG/CQD:78@6QE.B!I=&%L:6,[('1E>'0M86QI9VXZ(&QE M9G0[(&UA6QE/3-$)W9E6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SY&86ER(%9A;'5E($UE87-U MF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N M.B!C96YT97([)SY3:6=N:69I8V%N="!5;F]BF4Z(#$P<'0[(&9O;G0M=V5I9VAT M.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SXH3&5V96P@,RD\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M/"]T6QE/3-$)W9E6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E M>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE M/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQOF4Z M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA3PO9&EV/CPO=&0^/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T M=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&)A8VMG'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^/&1I=B!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$)V9O;G0M M6QE/3-$ M)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@,34E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H M,C4U+#(U-2PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M)SXS+#(R-#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[ M/"]T9#X\+W1R/CPO=&%B;&4^/&1I=CXF(S$V,#L\+V1I=CX\=&%B;&4@86QI M9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P M86-I;F<],T0P('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&9O;G0MF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SY& M86ER(%9A;'5E($UE87-UF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B M;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SY3:6=N:69I8V%N="!5;F]BF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SXH M3&5V96P@,RD\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B8C,38P.SPO=&0^/"]T6QE M/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQO6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA3PO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&)A8VMG M'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^/&1I=B!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$)V9O M;G0M6QE M/3-$)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C`T+#(S."PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[)SXS+#8Q.3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z M(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q M-C`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`R,#$T+"!T:&4@ M97-T:6UA=&5D(&9A:7(@=F%L=64@;V8@=&AE($1E97)F:65L9"!,;V%N('=A MF4Z(#$P<'0[)SYM:6QL:6]N+B8C,38P.R!!="!$96-E M;6)E2!I;F1I M8V%T:79E(&]F(&%M;W5N=',@=&AA="!C;W5L9"!B92!R96%L:7IE9"!I;B!A M(&-U7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO3H@)U1I;65S M($YE=R!2;VUA;B<[(&9O;G0M3PO9&EV/CQD:78^ M/&)R("\^/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E M>'0M86QI9VXZ(&IU6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M M.R!W:&ET92US<&%C93H@;F]WF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT M97([('1E>'0M:6YD96YT.B`X+CEP=#LG/D1E8V5M8F5R(#,Q+#PO9&EV/CPO M=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0M M'0M:6YD96YT.B`M-RXR<'0[ M)SXH:6X@=&AO=7-A;F1S*3PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O M='1O;3H@,G!X.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P M861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^/"]T6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA'0M:6YD96YT.B`M-RXR<'0[)SY287<@;6%T M97)I86QS/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQOF4Z(#$P<'0[)SXU,CPO M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W9E6QE/3-$)V9O;G0M#L@ M=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED M=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P M<'0[)SXV,#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX] M,T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[ M/"]T9#X\+W1R/CQT6QE/3-$)W9E M6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T M+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG M6QE/3-$ M)V9O;G0M6QE M/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXF(S@R,3$[/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z(#4V)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0M MF4Z(#$P<'0[)SXX-#,\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXQ,3(\+V1I=CX\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI M9VXZ(&QE9G0[)SY287<@;6%T97)I86QS(&EN=F5N=&]R>2!T:&%T(&ES(&YO M="!E>'!E8W1E9"!T;R!B92!U6EN9R!V86QU M92!O9B!Z97)O+"!A2!AF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0[)SY);G9E;G1O6QE/3-$)V9O;G0M&-E960@;F5T(')E86QI>F%B;&4@=F%L M=64N/"]F;VYT/CPO9&EV/CPO9&EV/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@=V%R2!A;F0@F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SY4:&4@9F]R;2!O9B!W87)R M86YT(&%G2`R,#$Q('=A6QE M/3-$)W9E#LG/CQD:78^/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@8V]L M6QE/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)W9EF4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E M;G1E6QE M/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[ M)SY.=6UB97(@;V8@/"]D:78^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[)SY787)R86YT(%-H87)E6QE/3-$)V9O;G0M M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D(')O=W-P86X],T0R('-T>6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M/'1D(&-O;'-P86X],T0R(')O=W-P86X],T0R('-T>6QE/3-$)W9EF4Z(#$P<'0[)SY%>&5R8VES92`\+V1I=CX\9&EV('-T>6QE/3-$)V9O M;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D(')O=W-P86X],T0R('-T>6QE M/3-$)W9EF4Z(#$P<'0[)SY787)R86YT(#PO9&EV/CQD:78@6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^/'1D(&-O;'-P86X],T0R(')O=W-P86X],T0R('-T>6QE/3-$ M)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[)SY)6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\ M=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q M-C`[/"]T9#X\=&0@8V]L6QE M/3-$)W9E"!S;VQI9#LG/CQD:78@ M#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)W9EF4Z(#$P<'0[('1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,34E.R<^/&1I=CXF(S$V,#L\+V1I M=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$ M,B!V86QI9VX],T1B;W1T;VT@F4Z(#$P<'0[ M('1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@,38E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^ M/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQOF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQOF4Z M(#$P<'0[)SXS+#,V,#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXQ,BXW-3PO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0M6QE/3-$)W9E#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M#L@=VED M=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXQ+C4P/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z(#$U)3L@8F%C:V=R;W5N9"UC;VQO#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXX+#`P M-#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXS+#(R-#PO M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H M,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXU+#0Q.3PO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD M+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE/3-$)W9E6QE/3-$)W9E#L@=&5X="UA;&EG;CH@6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U M+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9EF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)V9O;G0MF4Z(#$P<'0[)SXU+#0R M-3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T M;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\ M+W1R/CPO=&%B;&4^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O M;G0M2`R,#$Q('=A&5R8VES960@9'5R:6YG('1H92!T:')E92!A;F0@F4Z(#$P<'0[('1E>'0M86QI M9VXZ(&QE9G0[)SY#:&%N9V5S(&EN('1H92!E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQD M:78@3LG/DYO=&4@-R`F(S@R,3$[($1E97)F:65L9"!,;V%N/"]D M:78^/&1I=CX\8G(@+SX\+V1I=CX\9&EV('-T>6QE/3-$)V9O;G0M2!O9B!A;6]U;G1S(&1U92!U;F1E2P@3"Y0+B`H1&5EF4Z M(#$P<'0[(&9O;G0M6QE/3-$)W9E6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E M'0M86QI9VXZ(&-E;G1E'0M86QI M9VXZ(&-E;G1E3H@)U1I;65S($YE=R!2;VUA;B#L@=&5X="UA;&EG;CH@8V5N=&5R.R!W:61T:#H@ M,24[)SXF(S$V,#L\+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E M>'0M86QI9VXZ(&QE9G0[(&UAF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M M6QE/3-$)W9E6QE/3-$)V9O;G0M'0M:6YD96YT.B`M-RXR<'0[)SY5 M;F%M;W)T:7IE9"!D:7-C;W5N=#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG M+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&)A8VMG'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C4U+#(U-2PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXH,3$L-C0V/"]D:78^/"]T9#X\=&0@;F]W6QE/3-$)V9O;G0M#L@=VED M=&@Z(#4V)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E"!D;W5B;&4[('1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&)A8VMG6QE/3-$)V9O;G0M#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M6%B;&4@:6X@=&AR964@97%U86P@86YN=6%L(&EN'1H(&%N;FEV97)S87)I97,@ M;V8@=&AE($1E97)F:65L9"!,;V%N(&%G6%B M;&4@;VX@=&AE(&9O=7)T:"!A;FYI=F5R2!S:&%L;"!B92!D969E2`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`[/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#LG/CQD:78@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#LG/CQD:78@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9E"!S;VQI9#LG/CQD:78@6QE/3-$)W9E"!S;VQI9#LG M/CQD:78@#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\+W1R/CQT M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$ M,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXR,3@\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQOF4Z(#$P<'0[)SXD/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG M6QE/3-$ M)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXS,S$\+V1I=CX\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG M6QE/3-$ M)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[ M)SXY,#D\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O M;G0M6QE/3-$)W9E6QE/3-$)V9O;G0MF%T:6]N(&]F(&1E8G0@8V]S=',\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$ M)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXQ,#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED M=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P M<'0[)SXX/"]D:78^/"]T9#X\=&0@;F]W#L@=VED M=&@Z(#0R)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXQ+#$R.3PO9&EV/CPO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E M>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z M(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD M+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[ M)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M6QE/3-$)V-L96%R.B!B;W1H.R<^/&)R("\^/"]D:78^/&1I=B!S='EL93TS M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SY#87-H(&EN M=&5R97-T(&5X<&5NF%T:6]N(&]F(&1E8G0@9&ES M8V]U;G0@F%T:6]N(&]F('1R86YS86-T M:6]N(&9E97,@86YD('1H92!F86ER('9A;'5E(&]F('1H92!W87)R86YT2`Q,RP@ M,C`Q.2XF(S$V,#L@5&AE($1E97)F:65L9"!W87)R86YT&5M<'1I;VX@9G)O;2!L:6%B M:6QI='D@86-C;W5N=&EN9R!P6QE/3-$)V9O M;G0M'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA65E($-O;7!E;G-A=&EO;CPO=&0^#0H@ M("`@("`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`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O M='1O;3H@,G!X.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E6QE/3-$ M)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQOF4Z(#$P M<'0[)SXR,#`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M#L@=VED=&@Z(#,R)3L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U M-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9EF4Z(#$P<'0[)SXT.#(\+V1I=CX\+W1D/CQT M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U M+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG M6QE/3-$ M)V9O;G0M6QE M/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXV,C(\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E M>'0M86QI9VXZ(&QE9G0[(&UA'0M:6YD M96YT.B`M-RXR<'0[)SY4;W1A;#PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG M+6)O='1O;3H@-'!X.R!W:61T:#H@,24[(&)A8VMG6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXW.#$\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE M/3-$)V9O;G0MF4Z(#$P<'0[)SXV M,#<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXQ+#0X-3PO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`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`R,#$T+B8C,38P.R!4:&5R92!H879E(&)E96X@;F\@ M8VAA;F=E6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)SL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[(&9O;G0M3LG/CQU/DEN=F5N=&]R>3PO=3X\+V1I=CX\9&EV/CQB2!A<'!R;W9A;"!A;F0@=&AE(')E;&%T960@8V]S=',@=VEL;"!B92!R96-O M=F5R86)L92!T:')O=6=H('1H92!C;VUM97)C:6%L('-A;&4@;V8@=&AE('!R M;V1U8W0N)B,Q-C`[($-OF%B;&4@=F%L=64L(&QO=V5R(&]F(&-O'!I2!R:7-K(&)Y M(&5V86QU871I;F<@8W5R2!C;VYS:61E3H@)U1I M;65S($YE=R!2;VUA;B<[(&9O;G0MF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SY!(&QI M86)I;&ET>2!F;W(@96UP;&]Y964@F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SY);B!397!T96UB97(@,C`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`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`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`Q)3LG/B8C,38P.SPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@ M,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T M;VT@6QE/3-$)V9O;G0M M'0M86QI9VXZ(&-E M;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@6QE M/3-$)V9O;G0M'0M M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T6QE/3-$)W9E6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\ M+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M86QI9VXZ M(&QE9G0[(&UA6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA'0M:6YD96YT.B`M-RXR<'0[)SY.970@;&]SF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9E'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`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`[ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXH,2PT-#<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQO"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O M;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O M;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z M(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q M-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXH,BPU.#0\+V1I=CX\+W1D/CQT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI M9VXZ(&QE9G0[(&UA'0M:6YD96YT.B`M M-RXR<'0[)SY.=6UE6QE/3-$)V9O;G0MF4Z(#$P M<'0[)SXH,3(L,#
6QE/3-$)V9O;G0M6QE/3-$)W9EF4Z(#$P M<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C`T+#(S."PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$ M)W9E6QE/3-$)W9E6QE M/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXX M-"PW-C8\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O M;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$ M)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXX,C$\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQO"!S;VQI9#L@=&5X M="UA;&EG;CH@6QE/3-$)W9E'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@ M=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M6QE/3-$)W9E#L@ M=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M6QE/3-$)W9E#L@ M=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M6QE/3-$)W9E#L@ M=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M6QE/3-$)W9E2!I&5R8VES92!O9B!C97)T M86EN('-T;V-K(&]P=&EO;G,@86YD('=AF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[ M)SY792!D;R!N;W0@:&%V92!A;GD@8V]M<&]N96YT'0^)SQD:78@F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$ M)V9O;G0M6QE/3-$)V9O M;G0M2`R,#$T M+"!T:&4@1D%30B!IF4Z(#$P<'0[(&9O;G0M2!E>'!E8W1S('1O(&)E(&5N=&ET;&5D(&EN M(&5X8VAA;F=E(&9OF4Z(#$P<'0[)SYG96YE65A2!A<'!L:6-A=&EO;B!I'1087)T M7S0X,C)A8S(T7S=D.#E?-&4Y,5]A-S!A7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N M:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A486)L97,I/&)R/CPO2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T'0^)SQD:78@F4Z(#$P<'0[)SX\9&EV('-T>6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O M;G0M'0M:6YD96YT.B`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`Q)3LG/B8C,38P.SPO=&0^/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG M;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[)SXF M(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T M:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B M;W1T;VT@6QE/3-$)V9O M;G0M'0M86QI9VXZ M(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[ M(&UA6QE/3-$ M)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS M<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE M/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA'0M:6YD96YT.B`M-RXR<'0[)SY.970@;&]SF4Z M(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[ M)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&)A8VMG6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXI/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXI/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$ M)V9O;G0M6QE/3-$)W9E M"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z M(#$P<'0[)SXH,2PT-#<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$ M)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C4U+#(U-2PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXH,BPU.#0\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE M9G0[(&UA'0M:6YD96YT.B`M-RXR<'0[ M)SY.=6UE6QE M/3-$)V9O;G0MF4Z(#$P<'0[)SXH M,3(L,#
6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O M;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[ M)SXI/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXH,C,L.#0W/"]D:78^/"]T9#X\=&0@;F]W M6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$ M)W9E6QE/3-$)W9E6QE M/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXX-"PW-C8\ M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE M/3-$)V9O;G0M6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P M<'0[)SXX,C$\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQO"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'1087)T7S0X,C)A8S(T7S=D.#E?-&4Y,5]A M-S!A7S'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@ M9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SY4:&4@=&%B;&5S(&)E;&]W(&-A=&5G M;W)I>F4@87-S971S(&%N9"!L:6%B:6QI=&EE'0M86QI9VXZ(&-E;G1E#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@ M#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`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`M M-RXR<'0[)SY!6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXF(S@R,3$[/"]D:78^/"]T9#X\=&0@;F]W M6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO#L@=VED=&@Z(#4R)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E"!S;VQI9#L@=&5X="UA M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H M,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXS,C4\+V1I=CX\ M+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQO'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$)V9O;G0M M6QE/3-$)V9O;G0M MF4Z(#$P<'0[)SXV-2PX.#(\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXV-2PX.#(\+V1I=CX\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXF(S@R,3$[/"]D:78^/"]T9#X\=&0@;F]W#L@ M=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E MF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E M.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[ M/"]T9#X\+W1R/CQT6QE/3-$)W9E M6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG M6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A M8VMG6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&)A8VMG6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E M>'0M86QI9VXZ(&QE9G0[(&UA3PO M9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@-'!X.R!W:61T:#H@ M,24[(&)A8VMG6QE/3-$)V9O M;G0MF4Z(#$P<'0[)SXS+#(R-#PO M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXF(S@R,3$[/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR M-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E M'0M86QI9VXZ(&-E;G1E#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E M'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI M9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI M9VXZ(&-E;G1E6QE M/3-$)W9E6QE/3-$)V9O;G0M6QE M/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE M/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/CPO='(^/'1R/CQT9"!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M-RXR<'0[)SY!6QE/3-$)W9E6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)W9E M6QE/3-$)W9E6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXD/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXF(S@R,3$[/"]D M:78^/"]T9#X\=&0@;F]W6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQOF4Z(#$P<'0[)SXF(S@R M,3$[/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z(#4R)3L@8F%C:V=R;W5N9"UC;VQO M6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P M<'0[)SXS,C4\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQO"!S;VQI9#L@=&5X="UA;&EG M;CH@6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K M9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\ M+W1R/CQT6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P M<'0[)SXX-BPV,#@\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O M;G0MF4Z(#$P<'0[)SXX-BPV,#@\ M+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXD/"]D:78^ M/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$ M)W9E'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE M9G0[(&UA6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@ M8F%C:V=R;W5N9"UC;VQO6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA3PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O M;3H@-'!X.R!W:61T:#H@,24[(&)A8VMG6QE/3-$)V9O;G0MF4Z M(#$P<'0[)SXU+#0R-3PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V M86QI9VX],T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED M=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^ M)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXF(S@R,3$[/"]D:78^/"]T M9#X\=&0@;F]W#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXD/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0^)SQD:78@F4Z(#$P<'0[)SX\9&EV/E1H92!T86)L92!B96QO M=R!S=6UM87)I>F5S('1H92!A8W1I=FET>2!O9B!,979E;"`S(&EN<'5T"!M;VYT M:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,SH\+V1I=CX\=&%B;&4@ M86QI9VX],T1C96YT97(@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L M;'-P86-I;F<],T0P('-T>6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)W9E#L@ M=VED=&@Z(#8R)3LG/CQD:78@6QE.B!I=&%L:6,[('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E M6QE/3-$ M)W9EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([)SY&86ER(%9A;'5E($UE87-UF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SY3 M:6=N:69I8V%N="!5;F]BF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT M+6%L:6=N.B!C96YT97([)SXH3&5V96P@,RD\+V1I=CX\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T6QE/3-$)W9E6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE M9G0[(&UA6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQOF4Z M(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M M86QI9VXZ(&QE9G0[(&UA3PO9&EV/CPO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG M+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&)A8VMG'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C`T+#(S."PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[)SXI/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E"!D;W5B M;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC M;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@,34E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I M.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXS+#(R-#PO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD M+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\+W1R/CPO M=&%B;&4^/&1I=CXF(S$V,#L\+V1I=CX\=&%B;&4@86QI9VX],T1C96YT97(@ M8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('-T M>6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T M9#X\=&0@8V]LF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SY&86ER(%9A;'5E($UE M87-UF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L M:6=N.B!C96YT97([)SY3:6=N:69I8V%N="!5;F]BF4Z(#$P<'0[(&9O;G0M=V5I M9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SXH3&5V96P@,RD\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^/"]T6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[ M('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E M>'0M86QI9VXZ(&QE9G0[(&UA3PO9&EV/CPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D M:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[(&)A8VMG'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@6QE/3-$)V9O;G0M#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z M(#$P<'0[)SXI/"]D:78^/"]T9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E"!D M;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@,34E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR M-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXS+#8Q.3PO M9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@ M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\+W1R M/CPO=&%B;&4^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)V9O;G0M9F%M:6QY M.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.B`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`\+V9O;G0^,2XV/"]D:78^/"]T M9#X\=&0@F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[ M(&UA3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#(R86,R-%\W9#@Y7S1E.3%?83
'0O:'1M;#L@8VAA M2`H5&%B;&5S*3QB2!;06)S=')A M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=F M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&IU6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@ M,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:&ET92US<&%C93H@;F]WF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`X+CEP=#LG/D1E M8V5M8F5R(#,Q+#PO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0M'0M:6YD96YT.B`M-RXR<'0[)SXH:6X@=&AO=7-A;F1S*3PO9&EV/CPO=&0^ M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@ M8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[)SXF(S$V M,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@ M,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T M;VT@6QE/3-$)V9O M;G0M'0M86QI9VXZ M(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0M M6QE/3-$)W9E M6QE/3-$)W9E6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M M86QI9VXZ(&QE9G0[(&UA'0M:6YD96YT M.B`M-RXR<'0[)SY287<@;6%T97)I86QS/"]D:78^/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXU,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A M<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE M/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R M9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9E6QE/3-$)W9E MF4Z(#$P<'0[)SXV,#PO9&EV/CPO=&0^/'1D(&YO=W)A M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M:6YD96YT.B`M-RXR<'0[)SY);G9E;G1O6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD M+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG M;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T M+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9EF4Z(#$P<'0[)SXF(S@R,3$[/"]D:78^ M/"]T9#X\=&0@;F]W6QE/3-$)V9O;G0MF4Z M(#$P<'0[)SXX-#,\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O M;G0MF4Z(#$P<'0[)SXQ,3(\+V1I M=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQO3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#(R86,R-%\W9#@Y7S1E.3%? M83'0O:'1M;#L@ M8VAA2`H5&%B M;&5S*3QB2!;06)S=')A M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM M97,@3F5W(%)O;6%N)SL@9F]N="US:7IE.B`Q,'!T.R<^/&1I=CY396QE8W1E M9"!T97)M#L@=VED=&@Z(#@E.R<^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA M;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@,24[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M#LG/CQD:78^/"]D:78^/"]T9#X\=&0@;F]W#L@ M=VED=&@Z(#$U)3LG/CQD:78^)B,Q-C`[)B,Q-C`[)B,Q-C`[/"]D:78^/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M'0M86QI9VXZ(&QE9G0[('=I9'1H.B`X)3LG/CQD:78@F4Z(#$P<'0[)SY$871E/"]D:78^/"]T9#X\=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q M-C`[/"]T9#X\=&0@8V]L'0M86QI9VXZ(&QE9G0[)SX\9&EV('-T>6QE M/3-$)V9O;G0M6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\ M=&0@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED M=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@8V]L'0M86QI9VXZ(&QE9G0[ M)SX\9&EV('-T>6QE/3-$)V9O;G0M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\ M=&0@'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q-24[ M)SX\9&EV('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[)SY%>'!IF4Z(#$P<'0[)SY$871E/"]D M:78^/"]T9#X\=&0@'0M86QI M9VXZ(&QE9G0[)SX\9&EV/CPO9&EV/CQD:78@6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXF(S$V,#L\+V1I=CX\+W1D/CPO='(^/'1R/CQT9"!V M86QI9VX],T1B;W1T;VT@#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T M9#X\=&0@8V]L6QE/3-$)W9E MF4Z(#$P<'0[ M('1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@ M,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T M;VT@6QE/3-$)V9O M;G0MF4Z(#$P<'0[('1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE M/3-$)W9E6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^/"]T6QE M/3-$)V9O;G0M6QE/3-$ M)W9E6QE/3-$)W9E6QE/3-$)V9O;G0M6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@ M.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXF(S@R,3$[/"]D:78^ M/"]T9#X\=&0@;F]W6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO MF4Z(#$P<'0[)SXF(S@R,3$[ M/"]D:78^/"]T9#X\=&0@;F]W'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,38E.R!B86-K9W)O=6YD+6-O M;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W9E'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQOF4Z(#$P<'0[)SXU+#6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO M#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I M9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O M;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR M-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M M#L@ M=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I M.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@=VED=&@Z(#@E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR M-34I.R<^/&1I=CXF(S$V,#L\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H M,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQO#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T M9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E#L@ M=&5X="UA;&EG;CH@6QE M/3-$)W9E#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O M=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[(&)A8VMG6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXS+#(R-#PO9&EV/CPO=&0^ M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O M;G0M'1087)T7S0X,C)A8S(T7S=D M.#E?-&4Y,5]A-S!A7S'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA3H@)U1I;65S($YE=R!2 M;VUA;B<[(&9O;G0M6QE/3-$)V9O;G0M6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`U-B4[)SX\9&EV('-T>6QE/3-$)V9O;G0M M'0M:6YD96YT.B`M-RXR<'0[)SXH:6X@=&AO=7-A;F1S*3PO M9&EV/CPO=&0^/'1D('-T>6QE/3-$)W9E'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI M9VXZ(&-E;G1E#L@=&5X="UA;&EG;CH@8V5N=&5R.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D M/CQT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T M=&]M.R!B;W)D97(M8F]T=&]M.B!R9V(H,"PP+#`I(#)P>"!S;VQI9#L@=&5X M="UA;&EG;CH@8V5N=&5R.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I M>F4Z(#$P<'0[(&9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RP@5&EM M97,L(%-E6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXS,"PP,#`\+V1I=CX\+W1D/CQT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ M(&QE9G0[(&UAF5D(&1I6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@ M;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U M-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9EF4Z(#$P<'0[)SXH,3`L-S,V/"]D:78^/"]T M9#X\=&0@;F]W6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U M-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O M;G0M6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI M9VXZ(&QE9G0[(&UA6QE/3-$)W9EF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$)W9E#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O M;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)SL@9F]N M="US:7IE.B`Q,'!T.R<^/&1I=B!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[ M('1E>'0M86QI9VXZ(&IU6QE/3-$)W9E6QE/3-$)V9O;G0M'0M:6YD96YT.B`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`Q)3LG/B8C M,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T:6-A M;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X.R!W:61T:#H@ M,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T M;VT@6QE/3-$)V9O;G0M M'0M86QI9VXZ(&-E M;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O='1O;3H@,G!X M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI M9VX],T1B;W1T;VT@6QE M/3-$)V9O;G0M'0M M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!P861D:6YG+6)O M='1O;3H@,G!X.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N M/3-$,B!V86QI9VX],T1B;W1T;VT@6QE/3-$)V9O;G0M'0M86QI9VXZ(&-E;G1E6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[ M)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,B!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)W9E M6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]TF4Z(#$P<'0[('1E>'0M86QI9VXZ M(&QE9G0[(&UAF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$ M)W9E'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXQ+#,P,CPO9&EV/CPO=&0^/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E6QE/3-$)V9O;G0M'0M:6YD96YT.B`M-RXR<'0[)SY.;VXM8V%S:"!A;6]R=&EZ871I;VX@ M;V8@9&5B="!D:7-C;W5N=',\+V1I=CX\+W1D/CQT9"!V86QI9VX],T1B;W1T M;VT@6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXT-S`\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQO6QE/3-$)W9E M'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R M;W5N9"UC;VQOF4Z(#$P<'0[)SXQ-S<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQOF4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[(&UA6QE/3-$)W9E6QE/3-$)W9E MF4Z(#$P<'0[)SXU/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S M."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O M;G0M6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C M:V=R;W5N9"UC;VQO"!S;VQI9#L@ M=&5X="UA;&EG;CH@6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQO"!S;VQI9#L@=&5X="UA M;&EG;CH@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B M86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T M9#X\+W1R/CQT6QE/3-$)W9E6QE/3-$)V9O;G0M#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXD/"]D M:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P M<'0[)SXS-#$\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3L@8F%C:V=R;W5N9"UC;VQO6QE/3-$)V9O;G0M MF4Z(#$P<'0[)SXR+#(R,3PO9&EV M/CPO=&0^/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@#L@=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD M+6-O;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E"!D;W5B;&4[('1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A M8VMG6QE M/3-$)V9O;G0M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#(R86,R M-%\W9#@Y7S1E.3%?83'0O:'1M;#L@8VAA65E($-O;7!E;G-A=&EO;B`H5&%B;&5S*3QB65E($-O;7!E;G-A=&EO M;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`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`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`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T M:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B M;W1T;VT@6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=V97)T M:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT M9"!C;VQS<&%N/3-$-B!V86QI9VX],T1B;W1T;VT@6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^/"]T#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD M.R!T97AT+6%L:6=N.B!C96YT97([)SXR,#$T/"]D:78^/"]T9#X\=&0@;F]W M#L@=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@ M8V]L6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SXR,#$S/"]D:78^ M/"]T9#X\=&0@;F]W6QE M/3-$)W9EF4Z(#$P M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C96YT97([)SXR M,#$T/"]D:78^/"]T9#X\=&0@;F]W#L@=VED=&@Z M(#$E.R<^)B,Q-C`[/"]T9#X\=&0@8V]L6QE/3-$)W9EF4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R!T97AT+6%L:6=N.B!C M96YT97([)SXR,#$S/"]D:78^/"]T9#X\=&0@;F]WF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L M:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M6QE/3-$)W9E M'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3L@8F%C:V=R;W5N9"UC;VQOF4Z(#$P<'0[)SXU-#<\+V1I=CX\+W1D/CQT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQOF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[(&)A8VMG6QE/3-$)V9O M;G0M6QE/3-$)W9E6QE/3-$)V9O;G0M'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O M;&]R.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[(&)A8VMG6QE/3-$)V9O;G0M#L@ M=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R M.B!R9V(H,C4U+#(U-2PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$ M8F]T=&]M('-T>6QE/3-$)W9E"!S;VQI9#L@=&5X="UA;&EG;CH@;&5F M=#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C4U+#(U-2PR M-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W9E6QE/3-$)W9E'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO"!S;VQI9#L@=&5X="UA;&EG;CH@#L@=VED=&@Z(#,R)3L@8F%C:V=R;W5N9"UC;VQO#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O M;&]R.B!R9V(H,C`T+#(S."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)W9EF4Z(#$P<'0[)SXD M/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E#L@=VED=&@Z(#$E.R!B86-K9W)O=6YD+6-O;&]R.B!R9V(H,C`T+#(S M."PR-34I.R<^)B,Q-C`[/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE M/3-$)W9EF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E6QE/3-$)W9EF4Z(#$P<'0[)SXD/"]D:78^/"]T9#X\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)W9E6QE/3-$)W9E'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N M9"UC;VQO6QE/3-$)V9O;G0MF4Z(#$P<'0[)SXY-C,\+V1I=CX\+W1D/CQT9"!N;W=R M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@8F%C:V=R;W5N9"UC;VQO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!2:7-K'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D("AI;B!S:&%R97,I M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L,#`P+#`P,#QS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES97,@*&EN('-H87)E'0^)SQS M<&%N/CPO&5R8VES M92!O9B!S=&]C:R!O<'1I;VYS(&%N9"!W87)R86YT'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO2P@6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO M3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^)SQS<&%N/CPO'0^)S`@>65A7,\'0^)SQS<&%N/CPO'0^)S$@>65A7,\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#(R86,R M-%\W9#@Y7S1E.3%?83'0O:'1M;#L@8VAA&EM=6T@6TUE;6)E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)S(@>65A'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\T.#(R86,R-%\W9#@Y7S1E.3%?83'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2`Q,RP@,C`P.3QB'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S4@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M1F5B(#(R+`T*"0DR,#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^1F5B(#(R+`T* M"0DR,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@=&5R;7,\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)U1H92!P6%B;&4@:6X@97%U86P@86YN=6%L M(&EN65A M2!P2`H=&]G971H97(@=VET:"!A;GD@86UO=6YT(&1E9F5R2!I9B!E:71H97(@*&DI(&]U M2!P'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-30L,#`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO2!;365M8F5R72!\($UI;FEM M=6T@6TUE;6)E'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO6UE;G0@9&%T93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N/CPO M2!686QU92!A="!R97!A>6UE;G0@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\T.#(R86,R-%\W9#@Y M7S1E.3%?83'0O M:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M2`H:6X@:'5N9')E9'1H M'0^)SQS<&%N/CPO'0^)S0@>65A'0^)SQS<&%N/CPO65E(%-E'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF5D(%!E'0^)SQS<&%N/CPO65E M('-T;V-K+6)A&UL/@T*+2TM+2TM M/5].97AT4&%R=%\T.#(R86,R-%\W9#@Y7S1E.3%?83 XML 19 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Options and Stock-Based Employee Compensation (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Stock Options and Stock-Based Employee Compensation [Abstract]

Weighted-average vesting period of stock options 3 years

Weighted-average assumptions used in estimating fair value of stock options [Abstract]

Weighted-average expected volatility (in hundredths) 100.00% 110.00%

Weighted-average expected term 5 years 4 months 24 days 4 years 8 months 12 days

Weighted-average risk-free interest rate (in hundredths) 1.60% 0.74%

Expected dividends (in hundredths) 0.00% 0.00%

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Employee stock-based compensation $ 781 $ 607 $ 1,485 $ 963

Research and Development [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Employee stock-based compensation 299 200 547 341

Selling, General & Administrative [Member]

Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]

Employee stock-based compensation $ 482 $ 407 $ 938 $ 622

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average expected volatility rate of share-based compensation awards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 20 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Deerfield Loan (Details) (USD $)
Share data in Millions, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2014

Installment

Jun. 30, 2013

Jun. 30, 2014

Installment

Jun. 30, 2013

Dec. 31, 2013

Line of Credit Facility [Line Items]

Loan facility, maximum amount $ 30,000,000 $ 30,000,000

Number of loan installments 3 3

Loan facility payment terms The principal amount of the loan is payable in equal annual installments on the fourth, fifth and sixth anniversaries of the Deerfield Loan agreement, provided that the amount payable on the fourth anniversary shall be deferred for one year if either (i) our “Net Sales” for the immediately preceding 12-month period are at least $20 million, or (ii) our “Equity Value” is at least $200 million; and provided further, that the amount payable on the fifth anniversary (together with any amount deferred on the fourth anniversary) shall be deferred until the sixth anniversary if either (i) our “Net Sales” for the immediately preceding 12-month period are at least $30 million, or (ii) our “Equity Value” is at least $250 million.

Cash interest rate under loan facility (in hundredths) 8.75% 8.75%

Carrying value of Facility Agreement [Abstract]

Note Payable 30,000,000 30,000,000 30,000,000

Unamortized discount (10,736,000) (10,736,000) (11,646,000)

Long-term debt, net of discount 19,264,000 19,264,000 18,354,000

Interest expense [Abstract]

Cash interest expense 654,000 218,000 1,302,000 331,000

Non-cash amortization of debt discounts 470,000 118,000 909,000 177,000

Amortization of debt costs 5,000 5,000 10,000 8,000

Total interest expense 1,129,000 341,000 2,221,000 516,000

Fourth anniversary [Member] | Minimum [Member]

Line of Credit Facility [Line Items]

Net sales for 12-month period immediately preceding repayment date 20,000,000 20,000,000

Equity Value at repayment date 200,000,000 200,000,000

Sixth anniversary [Member] | Minimum [Member]

Line of Credit Facility [Line Items]

Net sales for 12-month period immediately preceding repayment date 30,000,000 30,000,000

Equity Value at repayment date $ 250,000,000 $ 250,000,000

Deerfield Management Company [Member]

Line of Credit Facility [Line Items]

Number of shares under issued warrants (in shares) 7.0 7.0

Exercise price of warrants (in dollars per share) $ 2.81 $ 2.81

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

No definition available.

+ Details

Name: dsco_EquityValueAtRepaymentDate

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition

Refers to the net sales for the immediately preceding 12-month period immediately preceding repayment date.

+ References

No definition available.

+ Details

Name: dsco_NetSalesForImmediatelyPrecedingTwelveMonthPeriodImmediatelyPrecedingRepaymentDate

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

This line item represents the number of installments in which loan repaid.

+ References

No definition available.

+ Details

Name: dsco_NumberOfLoanInstallments

Namespace Prefix: dsco_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of warrants issued to purchase common stock shares.

+ References

No definition available.

+ Details

Name: dsco_NumberOfWarrantsIssuedToPurchaseShares

Namespace Prefix: dsco_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings.

+ References

No definition available.

+ Details

Name: dsco_TotalInterestExpenseDebt

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentPaymentTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InterestExpenseDebtAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_InterestExpenseDebtExcludingAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_LineOfCreditFacilityLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 22

-Article 5

+ Details

Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 22

-Article 5

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtNetAlternativeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies
6 Months Ended

Jun. 30, 2014

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies
Note 3 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying interim unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information in accordance with the instructions to Form10‑Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. There have been no changes to our critical accounting policies since December 31, 2013. For a discussion of our accounting policies, see, Note 3, “Accounting Policies and Recent Accounting Pronouncements,” to the consolidated financial statements in our 2013 Form 10-K. Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.

Inventory

Inventories, which are recorded at the lower of cost or market, include materials, labor, and other direct and indirect costs and are valued at cost using the first-in, first-out method. We capitalize inventories produced in preparation for commercial launch when the related product candidates receive regulatory approval and the related costs will be recoverable through the commercial sale of the product. Costs incurred prior to FDA approval of drug products and registration of medical devices are recorded in our statement of operations as research and development expense. Inventories are evaluated for impairment through consideration of factors such as the net realizable value, lower of cost or market, obsolescence, and expiry. Inventories do not have carrying values that exceed either cost or net realizable value.

We evaluate our expiry risk by evaluating current and future product demand relative to product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and hospital ordering practices.

Accrued Severance and Retention Costs

A liability for employee severance and retention benefits is recognized when (1) management has committed to a plan of termination; (2) the plan provides sufficient details, such as the employees affected, amounts to be paid, and expected dates of termination and payment; (3) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn; and (4) the plan has been communicated to employees. The cost of such benefits are accrued over the remaining service period.

In September 2013, we implemented an employee severance and retention plan for employees at our Totowa Facility to minimize employee turnover and encourage employees to remain with us through any potential plant closing. The plan provides for severance for non-union employees and retention bonuses for management. If we succeed in our efforts to secure longer-term utilization of the Totowa Facility, the severance plan and retention bonuses will remain in effect. The total cash amount expected to be paid for severance and retention under this plan through June 2016, assuming a June 2015 plant closing, is approximately $1.1 million. The plan-related expense for the three and six months ended June 30, 2014 was $0.1 million and $0.3 million, respectively, and is included in research and development expense. The related accrued liability is $0.4 million as of June 30, 2014.

In addition, at the Totowa Facility, there are 13 employees who are subject to a collective bargaining agreement under which they would be eligible to receive severance payments if the Totowa Facility were closed. The related accrued liability is $0.4 million as of June 30, 2014.

Product Sales

Revenues from product sales are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured.

Our products are distributed in the U.S. using a specialty distributor. Under this model, the specialty distributor purchases and takes physical delivery and title of product, and then sells to hospitals. We began the commercial introduction of SURFAXIN in the fourth quarter of 2013 and we currently cannot make a reasonable estimate of future product returns when product is delivered to the specialty distributor. Therefore, we currently do not recognize revenue upon product shipment to the specialty distributor, even though the distributor is invoiced upon product shipment. Instead, we recognize revenue once product has been sold through to the hospital and all revenue recognition criteria have been met. Once product has been delivered to a hospital, the risk of material returns is significantly mitigated. We will begin to recognize revenue at the time of shipment of product to our specialty distributor when we can reasonably estimate expected distributor sales deductions and returns. In developing estimates for sales returns, we consider the shelf life of the product, expected demand based on market data and return rates of other surfactant products.

Product sales are recorded net of accruals for estimated chargebacks, discounts, specialty distributor deductions and returns.

· Chargebacks. Chargebacks are discounts that occur when contracted customers purchase directly from our specialty distributor. Contracted customers, which currently consist primarily of Group Purchasing Organizations member hospitals, generally purchase the product at a discounted price. Our specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for specialty distributor chargebacks is based on known sales to contracted customers.

·
Sales discounts. Sales discounts are offered to certain contracted customers based upon a customer’s historical volume of surfactant product purchases. Customers must enter into a Letter of Participation (LOP) with us to receive sales discounts. Sales discounts are periodically adjusted on a prospective basis based upon the customer’s purchases of SURFAXIN, as provided in the LOP. The allowance for sales discounts is based on known sales to contracted customers.

· Specialty distributor deductions. Our specialty distributor is offered various forms of consideration including allowances, service fees and prompt payment discounts. Specialty distributor allowances and service fees are provided in our contractual agreement and are generally a percentage of the purchase price paid by the specialty distributor. The specialty distributor is offered a prompt pay discount for payment within a specified period.

· Returns. Sales of our products are not subject to a general right of return; however, we will accept product that is damaged or defective when shipped or for expired product up to six months subsequent to its expiry date. Product that has been administered to patients is no longer subject to any right of return.

Research and development expense

We track research and development expense by activity, as follows: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs.   Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred.

Net loss per common share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the quarters ended June 30, 2014 and 2013, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants was 20.9 million and 15.8 million shares, respectively.

In accordance with Accounting Standards Codification (ASC) Topic 260, “Earnings per Share,” when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of certain warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of the warrants results in an adjustment to the weighted average common shares outstanding. We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of the warrants. For the three and six months ended June 30, 2014 and 2013, the effect of the adjustments for warrants issued in February 2011 was dilutive.

The table below provides information pertaining to the calculation of diluted net loss per common share for the periods presented:

(in thousands)

Three Months Ended
June 30,

Six Months Ended
June 30,

2014

2013

2014

2013

Numerator:

Net loss as reported

$
(10,623
)

$
(8,627
)

$
(22,099
)

$
(21,263
)
Less: income from change in fair value of warrant liability

(1,447
)

(2,494
)

(1,820
)

(2,584
)
Numerator for diluted net loss per common share

$
(12,070
)

$
(11,121
)

$
(23,919
)

$
(23,847
)

Denominator:

Basic weighted average common shares outstanding

85,061

49,135

84,766

46,411

Dilutive common shares from assumed warrant exercises

821

731

1,345

1,362

Diluted weighted average common shares outstanding

85,882

49,866

86,111

47,773

As of June 30, 2014 and 2013, 16.4 million and 10.8 million shares of common stock potentially issuable upon the exercise of certain stock options and warrants were excluded from the computation of diluted net loss per common share because their impact would have been anti-dilutive.

We do not have any components of other comprehensive income (loss).

Recent accounting pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. generally accepted accounting principles (GAAP) when it becomes effective. The new standard is effective for us in our fiscal year 2017. Early application is not permitted. We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. The standard permits the use of either the retrospective or cumulative effect transition method. We have not yet selected a transition method nor determined the effect of the standard on our financial reporting.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (Unaudited) (USD $)
In Thousands, unless otherwise specified

Jun. 30, 2014

Dec. 31, 2013

Current Assets:

Cash and cash equivalents $ 65,557 $ 86,283

Accounts receivable 41 67

Inventory, net 443 112

Prepaid expenses and other current assets 443 777

Total current assets 66,484 87,239

Property and equipment, net 2,178 1,656

Restricted cash 325 325

Other assets 487 97

Total assets 69,474 89,317

Current Liabilities:

Accounts payable 1,507 1,433

Accrued expenses 5,951 4,785

Deferred revenue 105 139

Common stock warrant liability 3,224 5,425

Equipment loans, current portion 75 73

Total current liabilities 10,862 11,855

Long-term debt, $30,000 net of discount of $10,736 at June 30, 2014 and $11,646 at December 31, 2013 19,264 18,354

Equipment loans, non-current portion 28 69

Other liabilities 114 538

Total liabilities 30,268 30,816

Stockholders' Equity:

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding 0 0

Common stock, $0.001 par value; 250,000,000 and 150,000,000 shares authorized at June 30, 2014 and December 31, 2013, respectively; 85,227,508 and 84,659,111 shares issued at June 30, 2014 and December 31, 2013, respectively; 85,206,616 and 84,638,219 shares outstanding at June 30, 2014 and December 31, 2013, respectively 85 85

Additional paid-in capital 544,224 541,420

Accumulated deficit (502,049) (479,950)

Treasury stock (at cost); 20,892 shares (3,054) (3,054)

Total stockholders' equity 39,206 58,501

Total liabilities & stockholders' equity $ 69,474 $ 89,317

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=34720828&loc=SL20225862-175312

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section H

+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of long-term debt and capital leases due within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 7

+ Details

Name: us-gaap_OtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 23 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Organization and Business
6 Months Ended

Jun. 30, 2014

Organization and Business [Abstract]

Organization and Business
Note 1 – Organization and Business

Discovery Laboratories, Inc. (referred to as “we,” “us,” or the “Company”) is a specialty biotechnology company focused on creating life-saving products for critical-care patients with respiratory disease and improving the standard of care in pulmonary medicine. Our proprietary drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. We are developing our KL4 surfactant in liquid, lyophilized and aerosolized dosage forms. We are also developing novel drug delivery technologies and devices potentially to enable efficient delivery of our aerosolized KL4 surfactant. We believe that our proprietary technologies may make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies.

We are initially focused on improving the management of respiratory distress syndrome (RDS) in premature infants. RDS is a serious respiratory condition caused by insufficient surfactant production in underdeveloped lungs of premature infants. RDS is the most prevalent respiratory disease in the Neonatal Intensive Care Unit (NICU) and can result in long-term respiratory problems, developmental delay and death. Our first KL4 surfactant drug product, SURFAXIN® (lucinactant) Intratracheal Suspension for the prevention of RDS in premature infants at high risk for RDS, was approved by the United States Food and Drug Administration (FDA) in 2012. SURFAXIN is our KL4 surfactant in liquid form, and is the first synthetic, peptide-containing surfactant approved by the FDA and the only alternative to animal-derived surfactants currently used in the United States (U.S.). SURFAXIN has been commercially available in the U.S. since November 2013.

Premature infants with severe RDS currently are treated with surfactants that can only be administered by endotracheal intubation supported with mechanical ventilation, both invasive procedures that may result in serious respiratory conditions and other complications. To avoid such complications, many neonatologists initially treat infants with less severe RDS by less invasive means, typically nasal continuous positive airway pressure (nCPAP). Unfortunately, a significant number of premature infants on nCPAP will not respond well (an outcome referred to as nCPAP failure) and thereafter may require endotracheal intubation, mechanical ventilation, and delayed surfactant therapy. Since neonatologists currently cannot predict which infants will experience nCPAP failure, neonatologists are faced with difficult choices in treating infants with less severe RDS. This is because the medical outcomes for those infants who experience nCPAP failure and receive delayed surfactant therapy may be less favorable than the outcomes for infants who receive surfactant therapy in the first hours of life.

AEROSURF® is our investigational combination drug/device product that combines our KL4 surfactant with our proprietary capillary aerosol generator (CAG). AEROSURF potentially will enable administration of aerosolized KL4 surfactant to premature infants supported with nCPAP, without invasive intubation and mechanical ventilation. By enabling delivery of our KL4 surfactant using less invasive procedures, we believe that AEROSURF may address a serious unmet medical need and potentially enable the treatment of a significantly greater number of premature infants with RDS who could benefit from surfactant therapy but are currently not treated. We are currently conducting a phase 2a clinical trial for AEROSURF for the treatment of RDS in premature infants, for which results are expected in the fourth quarter of 2014, and are initiating activities to prepare for a phase 2b clinical trial, with results expected in the second half of 2015.

We are also developing a lyophilized (freeze-dried) dosage form of our KL4 surfactant that is stored as a powder and reconstituted to liquid form prior to use with the objective of improving ease of use for healthcare practitioners, as well as potentially to prolong shelf life and eliminate the need for cold-chain storage. We are initially developing this dosage form for use in our AEROSURF development program. We are also planning to seek regulatory advice to determine if we could gain marketing authorization for a lyophilized dosage form of our KL4 surfactant under a development plan that would be both capital efficient and capable of implementation within a reasonable time. If feasible, we would likely implement such a development plan and would plan to introduce it commercially as a life-cycle extension of SURFAXIN under the name SURFAXIN LS™, in the U.S. and potentially in other markets.

To support the commercial introduction of SURFAXIN in the U.S. and our other KL4 surfactant pipeline products, if approved, we have our own specialty respiratory critical care commercial and medical affairs team. This team includes medical professionals with experience in neonatal/pediatric respiratory critical care, and has focused on products that address neonatal indications, beginning with SURFAXIN. We believe that this team will be positioned to efficiently introduce our other KL4 surfactant products under development, if approved, including AEROSURF and potentially SURFAXIN LS and future applications of our aerosolized KL4 surfactant. In addition, we recognize that our commercial and medical affairs team could potentially support introductions of other synergistic pipeline products, including products owned or developed by third parties for the NICU/PICU. To that end, we would consider potential transactions focused on securing commercial rights to such synergistic products, including in the form of product acquisitions, in-licensing agreements or distribution, marketing or co-marketing arrangements.

In the future, we expect that we may be able to leverage the information, data and know-how that we gain from our development efforts with SURFAXIN and AEROSURF to support development of a product pipeline to address serious critical care respiratory conditions in larger children and adults in pediatric and adult intensive care units (PICUs and ICUs), including potentially acute lung injury (ALI), chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). At the present time, however, we are focusing our resources primarily on the commercial introduction of SURFAXIN and development of AEROSURF through phase 2 clinical trials. Once we have advanced these objectives, we expect to be in a better position to assess the potential of other development programs to address the critical care needs of patients in the PICU and ICU.

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=35735333&loc=d3e288-107754

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Details) (USD $)
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Numerator [Abstract]

Net loss as reported $ (10,623,000) $ (8,627,000) $ (22,099,000) $ (21,263,000)

Less: income from change in fair value of warrant liability (1,447,000) (2,494,000) (1,820,000) (2,584,000)

Numerator for diluted net loss per common share (12,070,000) (11,121,000) (23,919,000) (23,847,000)

Denominator [Abstract]

Basic weighted average common shares outstanding (in shares) 85,061,000 49,135,000 84,766,000 46,411,000

Dilutive common shares from assumed warrant exercises (in shares) 821,000 731,000 1,345,000 1,362,000

Diluted weighted average common shares outstanding (in shares) 85,882,000 49,866,000 86,111,000 47,773,000

Number of shares of common stock potentially issuable exercise of certain stock options and warrants (in shares) 20,900,000 15,800,000

Potential common stock issuable upon exercise of stock options and warrants (in shares) 16,400,000 10,800,000

Severance and Retention Plan [Member]

Restructuring Cost and Reserve [Line Items]

Total cash amount expected to be paid for severance and retention 1,100,000 1,100,000

Related expense incurred, severance and retention 100,000 300,000

Related liability, severance and retention 400,000 400,000

Severance and Retention Plan [Member] | Severance [Member]

Restructuring Cost and Reserve [Line Items]

Related liability, severance and retention $ 400,000 $ 400,000

Number of employees to receive severance payments 13

X

- Definition

The number of employees subject to collective bargaining agreement eligible to receive severance payments if the facility were closed.

+ References

No definition available.

+ Details

Name: dsco_NumberOfEmployeesToReceiveSeverancePayments

Namespace Prefix: dsco_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents number of shares of common stock potentially issuable exercise of certain stock options and warrants during the period.

+ References

No definition available.

+ Details

Name: dsco_NumberOfSharesOfCommonStockPotentiallyIssuableExerciseOfCertainStockOptionsAndWarrants

Namespace Prefix: dsco_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_DilutiveSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 23

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1757-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Treasury Stock Method

-URI http://asc.fasb.org/extlink&oid=6527216

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Call Option

-URI http://asc.fasb.org/extlink&oid=6506649

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NetIncomeLossAttributableToParentDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount expected to be recognized in earnings for the specified restructuring cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB Topic 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

+ Details

Name: us-gaap_RestructuringAndRelatedCostExpectedCost1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 5.P.3)

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140864-122747

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 420

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.P.4(b))

-URI http://asc.fasb.org/extlink&oid=27011515&loc=d3e140904-122747

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section P

-Subsection 3, 4

+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 25 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments, Level 3 Rollforward (Details) (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Level 3 [Member]

Jun. 30, 2013

Level 3 [Member]

Fair value measurements of common stock warrants using significant unobservable inputs (level 3) [Roll Forward]

Balance at beginning of period $ 3,224 $ 5,425 $ 5,425 $ 6,305

Exercise of warrants (375)

Change in fair value of common stock warrant liability (1,826) (2,686)

Balance at end of period $ 3,224 $ 5,425 $ 3,224 $ 3,619

X

- Details

Name: dsco_FairValueMeasurementsOfCommonStockWarrantsUsingSignificantUnobservableInputsLevel3RollForward

Namespace Prefix: dsco_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants where the fair value is based upon unobservable inputs.

+ References

No definition available.

+ Details

Name: dsco_ProceedsFromLevel3WarrantExercises

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13495-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=34720828&loc=SL20225862-175312

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The net increase (decrease) in the fair value of servicing liabilities subsequently measured at fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 860

-SubTopic 50

-Section 50

-Paragraph 3

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7882072&loc=d3e122625-111746

+ Details

Name: us-gaap_ServicingLiabilityAtFairValuePeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

XML 26 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 27 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Liquidity Risks and Management's Plans
6 Months Ended

Jun. 30, 2014

Liquidity Risks and Management's Plans [Abstract]

Liquidity Risks and Management's Plans
Note 2 – Liquidity Risks and Management’s Plans

We have incurred substantial losses since inception, due to investments in research and development, manufacturing, and, more recently, commercialization and medical affairs activities, and we expect to continue to incur substantial losses over the next several years. Historically, we have funded our business operations through various sources, including public and private securities offerings, debt facilities, strategic alliances, the use of committed equity financing facilities (CEFFs) and at-the-market (ATM) equity programs, and capital equipment financings.

As of June 30, 2014, we had cash and cash equivalents of $65.6 million and long-term debt of $30 million ($19.3 million net of discount) under our Deerfield Loan with affiliates of Deerfield Management Company, L.P. (Deerfield) (see, Note 7 – “Deerfield Loan”) . Before any additional financings, including under our ATM Program (see, Note 11 - “At-the-Market Program (ATM Program),” to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2013 (2013 Form 10‑K)), we anticipate that we will have sufficient cash available to fund our operations and debt service obligations through the third quarter of 2015.

For the next several years, we expect that our cash outflows for marketing, commercial and medical activities, development programs, operations and debt service will outpace the rate at which we may generate revenues. To execute our business strategy, pay debt obligations and fund our operations over the next several years, we will require significant additional infusions of capital until such time as the net revenues from the sale of approved products and from other sources are sufficient to offset our cash flow requirements. While we currently intend to retain all rights and commercialize our approved products in the U.S. by ourselves, an important priority for us is to identify strategic transactions that could provide additional capital and strategic resources to support the continued development and commercial introduction of our RDS products in markets outside the U.S. For our AEROSURF development program, we seek a significant strategic alliance that potentially could provide development, regulatory and commercial market expertise, and, if approved, support the commercial introduction of AEROSURF in the EU and other selected markets outside the U.S. Such alliances typically also would provide financial resources, in the form of upfront payments, milestone payments, commercialization royalties and a sharing of research and development expenses. To advance SURFAXIN in markets outside the U.S. where regulatory marketing authorization is facilitated by the information contained in our new drug application (NDA) approved by the FDA, we would consider various financing or collaboration arrangements that could potentially provide regulatory expertise, support the commercial introduction of SURFAXIN in markets outside the U.S., and a sharing of revenues. Such countries could potentially include those in Latin America, North Africa and the Middle East. To secure the necessary capital, we also plan to consider other public and private equity offerings, including under our ATM Program, which currently may allow for the sale of up to approximately $23 million of our commons stock, as well as other financing transactions, such as secured equipment financing facilities or other similar transactions.

Our future capital requirements will depend upon many factors, primarily our efforts to (i) execute the commercial introduction of SURFAXIN in the U.S.; (ii) advance the AEROSURF development program to completion of the phase 2 clinical trials as planned in the second half of 2015; (iii) assure long-term continuity of supply for both our commercial and lyophilized KL4 surfactant drug product, potentially with CMOs and/or at our manufacturing facility in Totowa, NJ (Totowa Facility); and (iv) secure one or more strategic alliances or other collaboration arrangements to support our development programs and commercialization of our approved products, if any, in markets outside the U.S. We believe that we will be better positioned to enter into a significant strategic alliance if we are successful in advancing the commercial introduction of SURFAXIN and completing and obtaining encouraging results from the AEROSURF phase 2 clinical program within our anticipated time.

Although we currently believe that we will be able to successfully execute our business strategy as planned, there can be no assurance that any of our approved products, including SURFAXIN, will be commercially viable or that we will be able to execute our long-term manufacturing plan, that our AEROSURF development program will be successful within our anticipated time frame, if at all, that we will be able to secure regulatory marketing authorization for AEROSURF and our other KL4 surfactant product candidates, in the U.S. and other markets, that the ATM Program will be available when needed, if at all, or that we will be able to obtain additional capital when needed and on acceptable terms. We will require significant additional capital to sustain operations, satisfy debt obligations, and complete product development and execute the commercial introduction of our KL4 surfactant product candidates, if approved. Failure to secure the necessary additional capital when needed would have a material adverse effect on our business, financial condition and results of operations. Even if we succeed in raising additional capital and developing and subsequently commercializing our product candidates, we may never achieve sufficient sales revenue to achieve or maintain profitability.

As of June 30, 2014, we had outstanding warrants to purchase approximately 14.0 million shares of our common stock at various prices, exercisable on different dates into 2019. Of these warrants, warrants to purchase 7 million shares were issued to Deerfield in connection with the Deerfield Loan at an exercise price of $2.81 per share. The Deerfield Warrants may be exercised for cash or on a cashless basis. In lieu of paying cash upon exercise, the holders also may elect to reduce the principal amount of the Deerfield Loan in an amount sufficient to satisfy the exercise price of the Deerfield Warrants. In addition to the Deerfield Warrants, we have outstanding warrants issued in February 2011 to purchase approximately 4.6 million shares of common stock that contain anti-dilution provisions that adjust the exercise price if we issue any common stock, securities convertible into common stock, or other securities (subject to certain exceptions) at a value below the then-existing exercise price of the warrants. These warrants currently have an exercise price of $1.50 per share and expire in February 2016. Although we believe that, in the future, we may receive additional capital from the exercise of at least a portion of our outstanding warrants, there can be no assurance that the market price of our common stock will equal or exceed price levels that would make exercise of outstanding warrants likely, that holders of the Deerfield Warrants would choose to exercise their warrants for cash, or that holders of any of our outstanding warrants would choose to exercise any or all of their warrants prior to the applicable warrant expiration dates. Moreover, if our outstanding warrants are exercised, such exercises likely will be at a discount to the then-market value of our common stock and have a dilutive effect on the value of our shares of common stock at the time of exercise.

As of June 30, 2014, 250 million shares of common stock were authorized under our Amended and Restated Certificate of Incorporation, as amended, and approximately 137.2 million shares of common stock were available for issuance and not otherwise reserved.

X

- Definition

Disclosure of historical and expected sources of liquidity, available cash and cash equivalents as of the balance sheet date, and management's plans to maintain sufficient working capital through one or more of the following, if available: public and private securities offerings, equity financing facilities, capital equipment and debt facilities, and strategic alliances, as well as sales revenue from products approved for marketing, if and when approved.

+ References

No definition available.

+ Details

Name: dsco_LiquidityDisclosuresTextBlock

Namespace Prefix: dsco_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dsco_LiquidityRisksAndManagementSPlansAbstract

Namespace Prefix: dsco_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)
In Thousands, except Share data, unless otherwise specified

Jun. 30, 2014

Dec. 31, 2013

LIABILITIES & STOCKHOLDERS' EQUITY

Long term debt, gross $ 30,000 $ 30,000

Long-term debt, discount $ 10,736 $ 11,646

Stockholders' Equity:

Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001

Preferred stock, shares authorized (in shares) 5,000,000 5,000,000

Preferred stock, shares issued (in shares) 0 0

Preferred stock, shares outstanding (in shares) 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized (in shares) 250,000,000 150,000,000

Common stock, shares issued (in shares) 85,227,508 84,659,111

Common stock, shares outstanding (in shares) 85,206,616 84,638,219

Treasury stock (at cost) (in shares) 20,892 20,892

X

- Definition

Includes noncurrent portion, aggregate carrying amount of long-term borrowings as of the balance sheet date before deducting unamortized discount or premiums (if any). May include notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, which had initial maturities beyond one year or beyond the normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name: dsco_LongTermDebtGross

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 29 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventory (Tables)
6 Months Ended

Jun. 30, 2014

Inventory [Abstract]

Schedule of inventory
Inventory is comprised of the following for the periods presented:

June 30,

December 31,

(in thousands)

2014

2013

Inventories, current:

Raw materials

$
147

$
52

Finished goods, net of reserves

296

60

443

112

Inventories, non-current:

Raw materials

400

–

Total inventories, net

$
843

$
112

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

No definition available.

+ Details

Name: dsco_ScheduleOfInventoryTableTextBlock

Namespace Prefix: dsco_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
6 Months Ended

Jun. 30, 2014

Jul. 31, 2014

Document and Entity Information [Abstract]

Entity Registrant Name DISCOVERY LABORATORIES INC /DE/

Entity Central Index Key 0000946486

Current Fiscal Year End Date --12-31

Entity Well-known Seasoned Issuer No

Entity Voluntary Filers No

Entity Current Reporting Status Yes

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 85,206,616

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q2

Document Type 10-Q

Amendment Flag false

Document Period End Date Jun. 30, 2014

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dsco_DocumentAndEntityInformationAbstract

Namespace Prefix: dsco_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Common Stock Warrant Liability (Tables)
6 Months Ended

Jun. 30, 2014

Common Stock Warrant Liability [Abstract]

Estimated fair value of warrants accounted for derivative liabilities
Selected terms and estimated fair value of warrants accounted for as derivative are as follows:



Fair Value of Warrants
(in thousands)
Issuance
Date

Number of
Warrant Shares
Issuable

Exercise
Price

Warrant
Expiration
Date

Value at
Issuance
Date

June 30,
2014

December 31,
2013

5/13/2009

466,667

$
17.25

5/13/2014

$
3,360

$
–

$
–

2/23/2010

916,669

12.75

2/23/2015

5,701

–

6

2/22/2011

4,552,600

1.50

2/22/2016

8,004

3,224

5,419

$
3,224

$
5,425

X

- Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of derivative liabilities at fair value.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Operations (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Revenues:

Product sales $ 42 $ 0 $ 70 $ 0

Grant revenue 1,051 182 1,054 254

Total revenues 1,093 182 1,124 254

Expenses:

Cost of product sales 731 0 1,512 0

Research and development 6,858 6,863 12,448 15,335

Selling, general and administrative 4,446 4,129 8,869 8,349

Total expenses 12,035 10,992 22,829 23,684

Operating loss (10,942) (10,810) (21,705) (23,430)

Change in fair value of common stock warrant liability 1,448 2,525 1,826 2,686

Other income / (expense):

Interest and other income 2 1 4 1

Interest and other expense (1,131) (343) (2,224) (520)

Other income / (expense), net (1,129) (342) (2,220) (519)

Net loss $ (10,623) $ (8,627) $ (22,099) $ (21,263)

Net loss per common share

Basic (in dollars per share) $ (0.12) $ (0.18) $ (0.26) $ (0.46)

Diluted (in dollars per share) $ (0.14) $ (0.22) $ (0.28) $ (0.50)

Weighted-average number of common shares outstanding

Basic (in shares) 85,061 49,135 84,766 46,411

Diluted (in shares) 85,882 49,866 86,111 47,773

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_OtherNonoperatingIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RevenueFromGrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 4

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 30

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34747878&loc=d3e3636-108311

+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Deerfield Loan
6 Months Ended

Jun. 30, 2014

Deerfield Loan [Abstract]

Deerfield Loan
Note 7 – Deerfield Loan

Long-term debt consists solely of amounts due under a $30 million loan (Deerfield Loan) with affiliates of Deerfield Management Company, L.P. (Deerfield) for the periods presented:

(in thousands)

June 30,
2014

December 31,
2013

Note Payable

$
30,000

$
30,000

Unamortized discount

(10,736
)

(11,646
)
Long-term debt, net of discount

$
19,264

$
18,354

The principal amount of the loan is payable in three equal annual installments on the fourth, fifth, and sixth anniversaries of the Deerfield Loan agreement beginning in February 2017, provided that the amount payable on the fourth anniversary shall be deferred for one year if either (i) “Net Sales” for the immediately preceding 12-month period are at least $20 million, or (ii) “Equity Value” is at least $200 million; and provided further, that the amount payable on the fifth anniversary (together with any amount deferred on the fourth anniversary) shall be deferred until the sixth anniversary if either (i) “Net Sales” for the immediately preceding 12-month period are at least $30 million, or (ii) “Equity Value” is at least $250 million. Accordingly, if the milestones are achieved in each year, payment of the principal amount could be deferred until the sixth anniversary date of the loan, February 13, 2019.

The following amounts comprise the Deerfield Loan interest expense for the periods presented:

(in thousands)

Three Months Ended
June 30,

Six Months Ended
June 30,

2014

2013

2014

2013

Cash interest expense

$
654

$
218

$
1,302

$
331

Non-cash amortization of debt discounts

470

118

909

177

Amortization of debt costs

5

5

10

8

Total interest expense

$
1,129

$
341

$
2,221

$
516

Cash interest expense represents interest at an annual rate of 8.75% on the outstanding principal amount for the period, payable quarterly in cash. Non-cash amortization of debt discount represents the amortization of transaction fees and the fair value of the warrants issued in connection with the Deerfield Loan. The amortization of debt costs represents legal costs incurred in connection with the Deerfield Loan.

In connection with the loan, we issued to Deerfield warrants to purchase 7.0 million shares of our common stock at an exercise price of $2.81 per share that expire on February 13, 2019. The Deerfield warrants are derivatives that qualify for an exemption from liability accounting provided in ASC 815 and are classified as equity. See, Note 9, “Deerfield Loan,” to the consolidated financial statements in our 2013 Form 10-K.

X

- Details

Name: dsco_DeerfieldLoanAbstract

Namespace Prefix: dsco_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for certain of the entity's deerfield loan facility.

+ References

No definition available.

+ Details

Name: dsco_DeerfieldLoanFacilityTextBlock

Namespace Prefix: dsco_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Common Stock Warrant Liability
6 Months Ended

Jun. 30, 2014

Common Stock Warrant Liability [Abstract]

Common Stock Warrant Liability
Note 6 – Common Stock Warrant Liability

We account for common stock warrants in accordance with applicable accounting guidance provided in ASC Topic 815 “Derivatives and Hedging – Contracts in Entity’s Own Equity” (ASC 815), either as derivative liabilities or as equity instruments depending on the specific terms of the warrant agreement.

The form of warrant agreement for the registered warrants that we issued in our February 2010 public offering generally provide that, in the event a related registration statement or an exemption from registration is not available for the issuance or resale of the warrant shares upon exercise of the warrant, the holder may exercise the warrant on a cashless basis. Notwithstanding the availability of cashless exercise, under GAAP, these registered warrants are deemed to be subject to potential net cash settlement and must be classified as derivative liabilities because (i) under federal securities laws, issuing freely-tradable registered shares upon exercise of the warrants may not be within our control in all circumstances, and (ii) the warrant agreements do not expressly provide that there is no circumstance in which we may be required to effect a net cash settlement of the warrants. The accounting guidance expressly precludes an evaluation of the likelihood that cash settlement could occur. Accordingly, the February 2010 warrants have been classified as a derivative liability and reported, at each balance sheet date, at estimated fair value determined using the Black-Scholes option-pricing model.

The form of warrant agreement for the registered warrants that we issued in the February 2011 public offering (February 2011 warrants) contain anti-dilutive provisions that adjust the exercise price if we issue any common stock, securities convertible into common stock, or other securities (subject to certain exceptions) at a value below the then-existing exercise price of the February 2011 warrants. Although by their express terms, these warrants are not subject to potential cash settlement, due to the nature of the anti-dilution provisions, these warrants have been classified as derivative liabilities and reported, at each balance sheet date, at estimated fair value determined using a trinomial pricing model.

Selected terms and estimated fair value of warrants accounted for as derivative are as follows:



Fair Value of Warrants
(in thousands)
Issuance
Date

Number of
Warrant Shares
Issuable

Exercise
Price

Warrant
Expiration
Date

Value at
Issuance
Date

June 30,
2014

December 31,
2013

5/13/2009

466,667

$
17.25

5/13/2014

$
3,360

$
–

$
–

2/23/2010

916,669

12.75

2/23/2015

5,701

–

6

2/22/2011

4,552,600

1.50

2/22/2016

8,004

3,224

5,419

$
3,224

$
5,425

There were no warrants exercised during the three months ended June 30, 2014. During the six months ended June 30, 2014, holders of the February 2011 warrants exercised warrants to purchase 282,350 shares of common stock for total proceeds of $0.4 million. There were no warrants exercised during the three and six months ended June 30, 2013.

Changes in the estimated fair value of warrants classified as derivative liabilities are reported in the accompanying Consolidated Statement of Operations as the “Change in fair value of common stock warrants.”

X

- Definition

The entire disclosure for certain of the entity's common stock warrants accounted for as derivative liabilities. Describes the common stock warrants, income and expenses arising from the change in fair value therefrom, and the methodologies and assumptions used in determining the fair value of such warrants.

+ References

No definition available.

+ Details

Name: dsco_CommonStockWarrantLiabilityTextBlock

Namespace Prefix: dsco_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Liabilities [Abstract]

Fair value of loan $ 23,200,000 $ 23,600,000

Long-Term Debt 19,264,000 18,354,000

Recurring [Member]

Assets [Abstract]

Fair Value 65,882,000 86,608,000

Recurring [Member] | Level 1 [Member]

Assets [Abstract]

Fair Value 65,882,000 86,608,000

Recurring [Member] | Level 2 [Member]

Assets [Abstract]

Fair Value 0 0

Recurring [Member] | Level 3 [Member]

Assets [Abstract]

Fair Value 0 0

Recurring [Member] | Cash and cash equivalents [Member]

Assets [Abstract]

Fair Value 65,557,000 86,283,000

Recurring [Member] | Cash and cash equivalents [Member] | Level 1 [Member]

Assets [Abstract]

Fair Value 65,557,000 86,283,000

Recurring [Member] | Cash and cash equivalents [Member] | Level 2 [Member]

Assets [Abstract]

Fair Value 0 0

Recurring [Member] | Cash and cash equivalents [Member] | Level 3 [Member]

Assets [Abstract]

Fair Value 0 0

Recurring [Member] | Certificate of Deposit [Member]

Assets [Abstract]

Fair Value 325,000 325,000

Recurring [Member] | Certificate of Deposit [Member] | Level 1 [Member]

Assets [Abstract]

Fair Value 325,000 325,000

Recurring [Member] | Certificate of Deposit [Member] | Level 2 [Member]

Assets [Abstract]

Fair Value 0 0

Recurring [Member] | Certificate of Deposit [Member] | Level 3 [Member]

Assets [Abstract]

Fair Value 0 0

Recurring [Member] | Common Stock Warrant Liability [Member]

Liabilities [Abstract]

Fair Value 3,224,000 5,425,000

Recurring [Member] | Common Stock Warrant Liability [Member] | Level 1 [Member]

Liabilities [Abstract]

Fair Value 0 0

Recurring [Member] | Common Stock Warrant Liability [Member] | Level 2 [Member]

Liabilities [Abstract]

Fair Value 0 0

Recurring [Member] | Common Stock Warrant Liability [Member] | Level 3 [Member]

Liabilities [Abstract]

Fair Value $ 3,224,000 $ 5,425,000

X

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Fair value of financial and nonfinancial obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_LiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesFairValueDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.

+ References

No definition available.

+ Details

Name: us-gaap_LongTermDebtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 36 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Deerfield Loan (Tables)
6 Months Ended

Jun. 30, 2014

Deerfield Loan [Abstract]

Long term debt included in balance sheet
Long-term debt consists solely of amounts due under a $30 million loan (Deerfield Loan) with affiliates of Deerfield Management Company, L.P. (Deerfield) for the periods presented:

(in thousands)

June 30,
2014

December 31,
2013

Note Payable

$
30,000

$
30,000

Unamortized discount

(10,736
)

(11,646
)
Long-term debt, net of discount

$
19,264

$
18,354

Interest expense included in statement of operations
The following amounts comprise the Deerfield Loan interest expense for the periods presented:

(in thousands)

Three Months Ended
June 30,

Six Months Ended
June 30,

2014

2013

2014

2013

Cash interest expense

$
654

$
218

$
1,302

$
331

Non-cash amortization of debt discounts

470

118

909

177

Amortization of debt costs

5

5

10

8

Total interest expense

$
1,129

$
341

$
2,221

$
516

X

- Details

Name: dsco_DeerfieldLoanAbstract

Namespace Prefix: dsco_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of principal amount, unamortized discount premium and carrying value of debt instrument.

+ References

No definition available.

+ Details

Name: dsco_ScheduleOfCarryingAmountOfDebtInstrumentTableTextBlock

Namespace Prefix: dsco_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of interest expense related to debt instrument including cash interest expense, non-cash amortization of debt discount and amortization of finance cost.

+ References

No definition available.

+ Details

Name: dsco_ScheduleOfDebtInstrumentInterestExpenseTableTextBlock

Namespace Prefix: dsco_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Tables)
6 Months Ended

Jun. 30, 2014

Summary of Significant Accounting Policies [Abstract]

Calculation of diluted net loss per common share
The table below provides information pertaining to the calculation of diluted net loss per common share for the periods presented:

(in thousands)

Three Months Ended
June 30,

Six Months Ended
June 30,

2014

2013

2014

2013

Numerator:

Net loss as reported

$
(10,623
)

$
(8,627
)

$
(22,099
)

$
(21,263
)
Less: income from change in fair value of warrant liability

(1,447
)

(2,494
)

(1,820
)

(2,584
)
Numerator for diluted net loss per common share

$
(12,070
)

$
(11,121
)

$
(23,919
)

$
(23,847
)

Denominator:

Basic weighted average common shares outstanding

85,061

49,135

84,766

46,411

Dilutive common shares from assumed warrant exercises

821

731

1,345

1,362

Diluted weighted average common shares outstanding

85,882

49,866

86,111

47,773

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Options and Stock-Based Employee Compensation
6 Months Ended

Jun. 30, 2014

Stock Options and Stock-Based Employee Compensation [Abstract]

Stock Options and Stock-Based Employee Compensation
Note 8 – Stock Options and Stock-Based Employee Compensation

We recognize in our consolidated financial statements all stock-based awards to employees and non-employee directors based on their fair value on the date of grant, calculated using the Black-Scholes option-pricing model. Compensation expense related to stock-based awards is recognized ratably over the vesting period, which for employees is typically three years.

The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions:

June 30,

2014
2013

Weighted average expected volatility
100%

110%
Weighted average expected term
5.4 years

4.7 years
Weighted average risk-free interest rate
1.6%

0.74%
Expected dividends
–

–

The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented:

(in thousands)

Three Months Ended

Six Months Ended

June 30,

June 30,

2014

2013

2014

2013

Research & Development

$
299

$
200

$
547

$
341

Selling, General & Administrative

482

407

938

622

Total

$
781

$
607

$
1,485

$
963

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Policies)
6 Months Ended

Jun. 30, 2014

Summary of Significant Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation

The accompanying interim unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information in accordance with the instructions to Form10‑Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete consolidated financial statements. In the opinion of management, all adjustments (consisting of normally recurring accruals) considered for fair presentation have been included. Operating results for the three and six months ended June 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014. There have been no changes to our critical accounting policies since December 31, 2013. For a discussion of our accounting policies, see, Note 3, “Accounting Policies and Recent Accounting Pronouncements,” to the consolidated financial statements in our 2013 Form 10-K. Readers are encouraged to review those disclosures in conjunction with this Quarterly Report on Form 10-Q.

Inventory
Inventory

Inventories, which are recorded at the lower of cost or market, include materials, labor, and other direct and indirect costs and are valued at cost using the first-in, first-out method. We capitalize inventories produced in preparation for commercial launch when the related product candidates receive regulatory approval and the related costs will be recoverable through the commercial sale of the product. Costs incurred prior to FDA approval of drug products and registration of medical devices are recorded in our statement of operations as research and development expense. Inventories are evaluated for impairment through consideration of factors such as the net realizable value, lower of cost or market, obsolescence, and expiry. Inventories do not have carrying values that exceed either cost or net realizable value.

We evaluate our expiry risk by evaluating current and future product demand relative to product shelf life. We build demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and hospital ordering practices.

Accrued Severance and Retention Costs
Accrued Severance and Retention Costs

A liability for employee severance and retention benefits is recognized when (1) management has committed to a plan of termination; (2) the plan provides sufficient details, such as the employees affected, amounts to be paid, and expected dates of termination and payment; (3) it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn; and (4) the plan has been communicated to employees. The cost of such benefits are accrued over the remaining service period.

In September 2013, we implemented an employee severance and retention plan for employees at our Totowa Facility to minimize employee turnover and encourage employees to remain with us through any potential plant closing. The plan provides for severance for non-union employees and retention bonuses for management. If we succeed in our efforts to secure longer-term utilization of the Totowa Facility, the severance plan and retention bonuses will remain in effect. The total cash amount expected to be paid for severance and retention under this plan through June 2016, assuming a June 2015 plant closing, is approximately $1.1 million. The plan-related expense for the three and six months ended June 30, 2014 was $0.1 million and $0.3 million, respectively, and is included in research and development expense. The related accrued liability is $0.4 million as of June 30, 2014.

In addition, at the Totowa Facility, there are 13 employees who are subject to a collective bargaining agreement under which they would be eligible to receive severance payments if the Totowa Facility were closed. The related accrued liability is $0.4 million as of June 30, 2014.

Product Sales
Product Sales

Revenues from product sales are recognized when (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable and (4) collectability is reasonably assured.

Our products are distributed in the U.S. using a specialty distributor. Under this model, the specialty distributor purchases and takes physical delivery and title of product, and then sells to hospitals. We began the commercial introduction of SURFAXIN in the fourth quarter of 2013 and we currently cannot make a reasonable estimate of future product returns when product is delivered to the specialty distributor. Therefore, we currently do not recognize revenue upon product shipment to the specialty distributor, even though the distributor is invoiced upon product shipment. Instead, we recognize revenue once product has been sold through to the hospital and all revenue recognition criteria have been met. Once product has been delivered to a hospital, the risk of material returns is significantly mitigated. We will begin to recognize revenue at the time of shipment of product to our specialty distributor when we can reasonably estimate expected distributor sales deductions and returns. In developing estimates for sales returns, we consider the shelf life of the product, expected demand based on market data and return rates of other surfactant products.

Product sales are recorded net of accruals for estimated chargebacks, discounts, specialty distributor deductions and returns.

· Chargebacks. Chargebacks are discounts that occur when contracted customers purchase directly from our specialty distributor. Contracted customers, which currently consist primarily of Group Purchasing Organizations member hospitals, generally purchase the product at a discounted price. Our specialty distributor, in turn, charges back the difference between the price initially paid by the specialty distributor and the discounted price paid to the specialty distributor by the customer. The allowance for specialty distributor chargebacks is based on known sales to contracted customers.

·
Sales discounts. Sales discounts are offered to certain contracted customers based upon a customer’s historical volume of surfactant product purchases. Customers must enter into a Letter of Participation (LOP) with us to receive sales discounts. Sales discounts are periodically adjusted on a prospective basis based upon the customer’s purchases of SURFAXIN, as provided in the LOP. The allowance for sales discounts is based on known sales to contracted customers.

· Specialty distributor deductions. Our specialty distributor is offered various forms of consideration including allowances, service fees and prompt payment discounts. Specialty distributor allowances and service fees are provided in our contractual agreement and are generally a percentage of the purchase price paid by the specialty distributor. The specialty distributor is offered a prompt pay discount for payment within a specified period.

· Returns. Sales of our products are not subject to a general right of return; however, we will accept product that is damaged or defective when shipped or for expired product up to six months subsequent to its expiry date. Product that has been administered to patients is no longer subject to any right of return.

Research and development expense
Research and development expense

We track research and development expense by activity, as follows: (a) product development and manufacturing, (b) medical and regulatory operations, and (c) direct preclinical and clinical programs.   Research and development expense includes personnel, facilities, manufacturing and quality operations, pharmaceutical and device development, research, clinical, regulatory, other preclinical and clinical activities and medical affairs. Research and development costs are charged to operations as incurred.

Net loss per common share
Net loss per common share

Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding for the period. Diluted net loss per common share is computed by giving effect to all potentially dilutive securities outstanding for the period. For the quarters ended June 30, 2014 and 2013, the number of shares of common stock potentially issuable upon the exercise of certain stock options and warrants was 20.9 million and 15.8 million shares, respectively.

In accordance with Accounting Standards Codification (ASC) Topic 260, “Earnings per Share,” when calculating diluted net loss per common share, a gain associated with the decrease in the fair value of certain warrants classified as derivative liabilities results in an adjustment to the net loss; and the dilutive impact of the assumed exercise of the warrants results in an adjustment to the weighted average common shares outstanding. We utilize the treasury stock method to calculate the dilutive impact of the assumed exercise of the warrants. For the three and six months ended June 30, 2014 and 2013, the effect of the adjustments for warrants issued in February 2011 was dilutive.

The table below provides information pertaining to the calculation of diluted net loss per common share for the periods presented:

(in thousands)

Three Months Ended
June 30,

Six Months Ended
June 30,

2014

2013

2014

2013

Numerator:

Net loss as reported

$
(10,623
)

$
(8,627
)

$
(22,099
)

$
(21,263
)
Less: income from change in fair value of warrant liability

(1,447
)

(2,494
)

(1,820
)

(2,584
)
Numerator for diluted net loss per common share

$
(12,070
)

$
(11,121
)

$
(23,919
)

$
(23,847
)

Denominator:

Basic weighted average common shares outstanding

85,061

49,135

84,766

46,411

Dilutive common shares from assumed warrant exercises

821

731

1,345

1,362

Diluted weighted average common shares outstanding

85,882

49,866

86,111

47,773

As of June 30, 2014 and 2013, 16.4 million and 10.8 million shares of common stock potentially issuable upon the exercise of certain stock options and warrants were excluded from the computation of diluted net loss per common share because their impact would have been anti-dilutive.

We do not have any components of other comprehensive income (loss).

Recent accounting pronouncements
Recent accounting pronouncements

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which requires an entity to recognize revenue at an amount that reflects the consideration to which the entity expects to be entitled in exchange for transferring goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. generally accepted accounting principles (GAAP) when it becomes effective. The new standard is effective for us in our fiscal year 2017. Early application is not permitted. We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. The standard permits the use of either the retrospective or cumulative effect transition method. We have not yet selected a transition method nor determined the effect of the standard on our financial reporting.

X

- Definition

Disclosure of accounting policy related to accrued severance and retention costs.

+ References

No definition available.

+ Details

Name: dsco_AccruedSeveranceAndRetentionCostsPolicyTextBlock

Namespace Prefix: dsco_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Research and Development

-URI http://asc.fasb.org/extlink&oid=6523717

+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition for the sale of goods, which is a transaction between an entity delivering a tangible good to a purchaser. The entity also may disclose its treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2197222

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 15

-Section 25

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6406683&loc=d3e47119-111625

+ Details

Name: us-gaap_RevenueRecognitionSalesOfGoods

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Fair Value of Financial Instruments (Tables)
6 Months Ended

Jun. 30, 2014

Fair Value of Financial Instruments [Abstract]

Assets and liabilities measured at fair value
The tables below categorize assets and liabilities measured at fair value on a recurring basis for the periods presented:

Fair Value

Fair value measurement using

June 30, 2014

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$
65,557

$
65,557

$
–

$
–

Certificate of Deposit

325

325

–

–

Total Assets

$
65,882

$
65,882

$
–

$
–

Liabilities:

Common stock warrant liability

$
3,224

$
–

$
–

$
3,224

Fair Value
Fair value measurement using

December 31, 2013

Level 1

Level 2

Level 3

Assets:

Cash and cash equivalents

$
86,283

$
86,283

$
–

$
–

Certificate of Deposit

325

325

–

–

Total Assets

$
86,608

$
86,608

$
–

$
–

Liabilities:

Common stock warrant liability

$
5,425

$
–

$
–

$
5,425

Common stock warrants measured at Level 3 inputs on recurring basis
The table below summarizes the activity of Level 3 inputs measured on a recurring basis for the six months ended June 30, 2014 and 2013:

(in thousands)

Fair Value Measurements of
Common Stock Warrants Using
Significant Unobservable Inputs
(Level 3)

Balance at December 31, 2013

$
5,425

Exercise of warrants

(375
)
Change in fair value of common stock warrant liability

(1,826
)
Balance at June 30, 2014

$
3,224

(in thousands)

Fair Value Measurements of
Common Stock Warrants Using
Significant Unobservable Inputs
(Level 3)

Balance at December 31, 2012

$
6,305

Change in fair value of common stock warrant liability

(2,686
)
Balance at June 30, 2013

$
3,619

Significant unobservable input assumption used for valuation
The significant unobservable inputs used in the fair value measurement of the common stock warrants measured on a recurring basis are the historical volatility of our common stock market price, expected term of the applicable warrants, and the risk-free interest rate based on the U.S. Treasury yield curve in effect at the measurement date. In addition to the significant unobservable inputs noted above, certain fair value measurements also take into account an assumption of the likelihood and timing of the occurrence of an event that would result in an adjustment to the exercise price in accordance with the anti-dilutive pricing provisions in the warrant. Any significant increases or decreases in the unobservable inputs, with the exception of the risk-free interest rate, may result in significantly higher or lower fair value measurements.

Significant Unobservable Input
Assumptions of Level 3 Valuations
June 30, 2014

December 31, 2013

Historical Volatility
52% – 61%
62% – 76%
Expected Term (in years)
0.7 – 1.6
0.4 – 2.1
Risk-free interest rate
0.08% – 0.34%
0.08% – 0.44%

X

- Definition

Refers to Significant unobservable input assumption used for valuation.

+ References

No definition available.

+ Details

Name: dsco_SignificantUnobservableInputAssumptionUsedForValuationTableTextBlock

Namespace Prefix: dsco_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Liquidity Risks and Management's Plans (Details) (USD $)
0 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2013

Dec. 31, 2012

Jun. 30, 2014

Deerfield Management Company [Member]

Feb. 22, 2011

Issued February 22, 2011 [Member]

Jun. 30, 2014

Issued February 22, 2011 [Member]

Jun. 30, 2014

ATM Program [Member]

Liquidity Risks and Management's Plans [Abstract]

Cash and cash equivalents $ 65,557,000 $ 86,283,000 $ 31,253,000 $ 26,892,000

Long-Term Debt 30,000,000

Long-term debt, carrying amount 19,264,000 18,354,000

Stockholders' Equity [Line Items]

Maximum value of potential common stock available for issue $ 23,000,000

Class of Warrant or Right [Line Items]

Number of warrant shares outstanding (in shares) 14,000,000 7,000,000

Exercise price of warrants (in dollars per share) $ 2.81 $ 1.50 $ 1.50

Exercisable period of warrants 5 years

Number of warrant shares issuable (in shares) 4,552,600 4,600,000

Common stock, shares authorized (in shares) 250,000,000 150,000,000

Common stock available for future issuance (in shares) 137,200,000

X

- Definition

Aggregate number of common shares available for issuance and not otherwise reserved.

+ References

No definition available.

+ Details

Name: dsco_CommonStockCapitalSharesAvailableForIssuance

Namespace Prefix: dsco_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents period within which warrants are exercisable.

+ References

No definition available.

+ Details

Name: dsco_ExercisablePeriodOfWarrants

Namespace Prefix: dsco_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dsco_LiquidityRisksAndManagementSPlansAbstract

Namespace Prefix: dsco_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the maximum potential value of common stock available for issue under a private placement program.

+ References

No definition available.

+ Details

Name: dsco_MaximumPotentialCommonStockAvailableForIssueValue

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate amount of each class of warrants or rights issuable.

+ References

No definition available.

+ Details

Name: dsco_NumberOfWarrantSharesIssuable

Namespace Prefix: dsco_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: dsco_StockholdersEquityLineItems

Namespace Prefix: dsco_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 16

-Article 9

+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 42 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventory (Details) (USD $)
6 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Oct. 04, 2013

Jun. 30, 2014

Minimum [Member]

Jun. 30, 2014

Maximum [Member]

Inventories, current [Abstract]

Raw materials $ 147,000 $ 52,000

Finished goods, net of reserves 296,000 60,000

Inventory 443,000 112,000

Inventories, non-current [Abstract]

Raw materials 400,000 0

Total inventories, net 843,000 112,000

Life of raw materials 2 years 5 years

Raw materials on hand purchased prior to October 4, 2013 700,000

Inventory reserves $ 2,000,000 $ 500,000

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Includes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

No definition available.

+ Details

Name: dsco_Inventory

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Noncurrent gross amount of unprocessed items to be consumed in the manufacturing or production process. Also includes purchased parts that will be used as components of a finished product.

+ References

No definition available.

+ Details

Name: dsco_InventoryRawMaterialsNoncurrent

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Refers to shelf life of raw materials in years.

+ References

No definition available.

+ Details

Name: dsco_LifeOfRawMaterials

Namespace Prefix: dsco_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross amount of unprocessed items to be consumed in the manufacturing or production process that were purchased prior to October 4, 2013.

+ References

No definition available.

+ Details

Name: dsco_RawMaterialsOnHandPurchasedPriorToReportingPeriod

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 5

-Section BB

+ Details

Name: us-gaap_InventoryFinishedGoodsNetOfReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_InventoryNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of valuation reserve for inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-09)

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 5.BB)

-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 09

-Article 12

+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 43 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Cash Flows (Unaudited) (USD $)
In Thousands, unless otherwise specified
6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Cash flow from operating activities:

Net loss $ (22,099) $ (21,263)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization 371 364

Provision for excess inventory 1,465 0

Stock-based compensation and 401(k) Plan employer match 1,975 1,489

Fair value adjustment of common stock warrants (1,826) (2,686)

Amortization of discount on long-term debt 909 177

Changes in:

Inventory (2,196) 159

Accounts receivable 26 0

Prepaid expenses and other current assets 334 101

Accounts payable 74 753

Accrued expenses 1,166 580

Deferred revenue (34) 0

Other assets 0 (107)

Other liabilities (423) (10)

Net cash used in operating activities (20,258) (20,443)

Cash flows from investing activities:

Purchase of property and equipment (883) (120)

Net cash used in investing activities (883) (120)

Cash flows from financing activities:

Proceeds from issuance of securities, net of expenses 0 15,110

Proceeds from issuance of long-term debt, net of expenses 0 9,850

Proceeds from exercise of common stock options 31 1

Proceeds from exercise of common stock warrants 423 0

Repayment of equipment loans (39) (37)

Net cash provided by financing activities 415 24,924

Net decrease in cash and cash equivalents (20,726) 4,361

Cash and cash equivalents - beginning of period 86,283 26,892

Cash and cash equivalents - end of period 65,557 31,253

Supplementary disclosure of cash flows information:

Interest paid $ 1,305 $ 336

X

- Definition

Provision charged to earnings for excess inventory.

+ References

No definition available.

+ Details

Name: dsco_ProvisionForExcessInventory

Namespace Prefix: dsco_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of noncash expense included in interest expense to allocate debt discount and premium, and the costs to issue debt and obtain financing over the related debt instruments. Alternate captions include noncash interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Costs and payments related to employee benefits and equity-based compensation, such as pension expense and contributions, other postretirement benefits expense and payments, stock or unit options expense, and amortization of restricted stock or unit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of expense (income) related to adjustment to fair value of warrant liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section 25

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6939902&loc=d3e20148-110875

+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other liabilities used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current liabilities, other noncurrent liabilities, or a combination of other current and noncurrent liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOrSaleOfEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow associated with security instruments that either represent a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes repayments of (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventory
6 Months Ended

Jun. 30, 2014

Inventory [Abstract]

Inventory
Note 5 – Inventory

Inventory is comprised of the following for the periods presented:

June 30,

December 31,

(in thousands)

2014

2013

Inventories, current:

Raw materials

$
147

$
52

Finished goods, net of reserves

296

60

443

112

Inventories, non-current:

Raw materials

400

–

Total inventories, net

$
843

$
112

Raw materials inventory that is not expected to be used in commercial production until more than 12 months from the balance sheet date is classified as a non-current other asset on the balance sheet. The shelf life of our raw materials is 2‑5 years.

In addition, as of June 30, 2014, we had $0.7 million of raw materials that were purchased prior to October 4, 2013, the date the FDA approved updated SURFAXIN product specifications, which enabled the commercial introduction of SURFAXIN. These raw materials have a carrying value of zero, as the costs to purchase this material were expensed in the period of purchase as research and development expense, and accordingly are not reflected in the inventory balances shown above. These raw materials are anticipated to be used in manufacturing development, research and development activities and in the manufacture of commercial product.

Inventory reserves as of June 30, 2014 and December 31, 2013 were $2.0 million and $0.5 million, respectively. Inventory reserves reflect costs of SURFAXIN finished goods inventories that are not anticipated to be recoverable through the commercial sale of the product during the initial launch period due to product expiration. These reserves ensure that the inventory carrying values do not exceed net realizable value.

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Common Stock Warrant Liability (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
6 Months Ended 0 Months Ended 0 Months Ended 0 Months Ended 3 Months Ended 6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

May 13, 2009

Five Year Warrant 1 [Member]

Jun. 30, 2014

Five Year Warrant 1 [Member]

Dec. 31, 2013

Five Year Warrant 1 [Member]

Feb. 23, 2010

Five Year Warrant 2 [Member]

Jun. 30, 2014

Five Year Warrant 2 [Member]

Dec. 31, 2013

Five Year Warrant 2 [Member]

Feb. 22, 2011

Five Year Warrant 3 [Member]

Jun. 30, 2014

Five Year Warrant 3 [Member]

Jun. 30, 2014

Five Year Warrant 3 [Member]

Jun. 30, 2013

Five Year Warrant 3 [Member]

Dec. 31, 2013

Five Year Warrant 3 [Member]

Class of Warrant or Right [Line Items]

Exercisable period of warrants 5 years 5 years 5 years

Estimated fair value of warrants accounted for as derivative liabilities [Abstract]

Issuance Date May 13, 2009 Feb. 23, 2010 Feb. 22, 2011

Number of Warrant Shares Issuable (in shares) 466,667 916,669 4,552,600 4,600,000 4,600,000

Exercise Price (in dollars per share) $ 17.25 $ 12.75 $ 1.50 $ 1.50 $ 1.50

Warrant Expiration Date May 13, 2014 Feb. 23, 2015 Feb. 22, 2016

Fair Value of Warrants $ 3,224 $ 5,425 $ 3,360 $ 0 $ 0 $ 5,701 $ 0 $ 6 $ 8,004 $ 3,224 $ 3,224 $ 5,419

Exercise of warrants by warrant holders to purchase common stock (in shares) 0 282,350 0

Proceeds from exercise of warrants $ 423 $ 0 $ 400

X

- Definition

Date the warrants or rights expire, in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name: dsco_ClassOfWarrantOrRightExpirationDate

Namespace Prefix: dsco_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

Date the warrants or rights were issued, in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name: dsco_ClassOfWarrantOrRightIssueDate

Namespace Prefix: dsco_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dsco_EstimatedFairValueOfWarrantsAccountedForAsDerivativeLiabilitiesAbstract

Namespace Prefix: dsco_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents period within which warrants are exercisable.

+ References

No definition available.

+ Details

Name: dsco_ExercisablePeriodOfWarrants

Namespace Prefix: dsco_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate amount of each class of warrants or rights issuable.

+ References

No definition available.

+ Details

Name: dsco_NumberOfWarrantSharesIssuable

Namespace Prefix: dsco_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Represents number of shares issued upon exercise of warrants during the period.

+ References

No definition available.

+ Details

Name: dsco_StockIssuedDuringPeriodOnExerciseOfWarrants

Namespace Prefix: dsco_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Exercise price per share or per unit of warrants or rights outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Fair value portion of warrants not settleable in cash classified as equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_WarrantsNotSettleableInCashFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 86 169 1 false 20 0 false 6 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://discoverylabs.com/role/DocumentAndEntityInformation Document and Entity Information true false R2.htm 010000 - Statement - Consolidated Balance Sheets (Unaudited) Sheet http://discoverylabs.com/role/ConsolidatedBalanceSheetsUnaudited Consolidated Balance Sheets (Unaudited) false false R3.htm 010100 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://discoverylabs.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical Consolidated Balance Sheets (Unaudited) (Parenthetical) false false R4.htm 020000 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://discoverylabs.com/role/ConsolidatedStatementsOfOperationsUnaudited Consolidated Statements of Operations (Unaudited) false false R5.htm 030000 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://discoverylabs.com/role/ConsolidatedStatementsOfCashFlowsUnaudited Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 060100 - Disclosure - Organization and Business Sheet http://discoverylabs.com/role/OrganizationAndBusiness Organization and Business false false R7.htm 060200 - Disclosure - Liquidity Risks and Management's Plans Sheet http://discoverylabs.com/role/LiquidityRisksAndManagementSPlans Liquidity Risks and Management's Plans false false R8.htm 060300 - Disclosure - Summary of Significant Accounting Policies Sheet http://discoverylabs.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 060400 - Disclosure - Fair Value of Financial Instruments Sheet http://discoverylabs.com/role/FairValueOfFinancialInstruments Fair Value of Financial Instruments false false R10.htm 060500 - Disclosure - Inventory Sheet http://discoverylabs.com/role/Inventory Inventory false false R11.htm 060600 - Disclosure - Common Stock Warrant Liability Sheet http://discoverylabs.com/role/CommonStockWarrantLiability Common Stock Warrant Liability false false R12.htm 060700 - Disclosure - Deerfield Loan Sheet http://discoverylabs.com/role/DeerfieldLoan Deerfield Loan false false R13.htm 060800 - Disclosure - Stock Options and Stock-Based Employee Compensation Sheet http://discoverylabs.com/role/StockOptionsAndStockbasedEmployeeCompensation Stock Options and Stock-Based Employee Compensation false false R14.htm 070300 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://discoverylabs.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R15.htm 080300 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://discoverylabs.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R16.htm 080400 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://discoverylabs.com/role/FairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) false false R17.htm 080500 - Disclosure - Inventory (Tables) Sheet http://discoverylabs.com/role/InventoryTables Inventory (Tables) false false R18.htm 080600 - Disclosure - Common Stock Warrant Liability (Tables) Sheet http://discoverylabs.com/role/CommonStockWarrantLiabilityTables Common Stock Warrant Liability (Tables) false false R19.htm 080700 - Disclosure - Deerfield Loan (Tables) Sheet http://discoverylabs.com/role/DeerfieldLoanTables Deerfield Loan (Tables) false false R20.htm 080800 - Disclosure - Stock Options and Stock-Based Employee Compensation (Tables) Sheet http://discoverylabs.com/role/StockOptionsAndStockbasedEmployeeCompensationTables Stock Options and Stock-Based Employee Compensation (Tables) false false R21.htm 090200 - Disclosure - Liquidity Risks and Management's Plans (Details) Sheet http://discoverylabs.com/role/LiquidityRisksAndManagementSPlansDetails Liquidity Risks and Management's Plans (Details) false false R22.htm 090300 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://discoverylabs.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R23.htm 090400 - Disclosure - Fair Value of Financial Instruments (Details) Sheet http://discoverylabs.com/role/FairValueOfFinancialInstrumentsDetails Fair Value of Financial Instruments (Details) false false R24.htm 090402 - Disclosure - Fair Value of Financial Instruments, Level 3 Rollforward (Details) Sheet http://discoverylabs.com/role/FairValueOfFinancialInstrumentsLevel3RollforwardDetails Fair Value of Financial Instruments, Level 3 Rollforward (Details) false false R25.htm 090404 - Disclosure - Fair Value of Financial Instruments, Significant Unobsesrvable input assumptions of Level 3 valuations (Details) Sheet http://discoverylabs.com/role/FairValueOfFinancialInstrumentsSignificantUnobsesrvableInputAssumptionsOfLevel3ValuationsDetails Fair Value of Financial Instruments, Significant Unobsesrvable input assumptions of Level 3 valuations (Details) false false R26.htm 090500 - Disclosure - Inventory (Details) Sheet http://discoverylabs.com/role/InventoryDetails Inventory (Details) false false R27.htm 090600 - Disclosure - Common Stock Warrant Liability (Details) Sheet http://discoverylabs.com/role/CommonStockWarrantLiabilityDetails Common Stock Warrant Liability (Details) false false R28.htm 090700 - Disclosure - Deerfield Loan (Details) Sheet http://discoverylabs.com/role/DeerfieldLoanDetails Deerfield Loan (Details) false false R29.htm 090800 - Disclosure - Stock Options and Stock-Based Employee Compensation (Details) Sheet http://discoverylabs.com/role/StockOptionsAndStockbasedEmployeeCompensationDetails Stock Options and Stock-Based Employee Compensation (Details) false false All Reports Book All Reports Element us-gaap_ClassOfWarrantOrRightOutstanding had a mix of decimals attribute values: -6 -5. Element us-gaap_ProceedsFromWarrantExercises had a mix of decimals attribute values: -5 -3. 'Shares' elements on report '090200 - Disclosure - Liquidity Risks and Management's Plans (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090200 - Disclosure - Liquidity Risks and Management's Plans (Details)' had a mix of different decimal attribute values. 'Shares' elements on report '090300 - Disclosure - Summary of Significant Accounting Policies (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090300 - Disclosure - Summary of Significant Accounting Policies (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090400 - Disclosure - Fair Value of Financial Instruments (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090500 - Disclosure - Inventory (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '090700 - Disclosure - Deerfield Loan (Details)' had a mix of different decimal attribute values. Process Flow-Through: 010000 - Statement - Consolidated Balance Sheets (Unaudited) Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 010100 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) Process Flow-Through: 020000 - Statement - Consolidated Statements of Operations (Unaudited) Process Flow-Through: 030000 - Statement - Consolidated Statements of Cash Flows (Unaudited) dsco-20140630.xml dsco-20140630.xsd dsco-20140630_cal.xml dsco-20140630_def.xml dsco-20140630_lab.xml dsco-20140630_pre.xml true true XML 47 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stock Options and Stock-Based Employee Compensation (Tables)
6 Months Ended

Jun. 30, 2014

Stock Options and Stock-Based Employee Compensation [Abstract]

Weighted-average assumptions in estimating fair value of options
The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing formula based on the following weighted average assumptions:

June 30,

2014
2013

Weighted average expected volatility
100%

110%
Weighted average expected term
5.4 years

4.7 years
Weighted average risk-free interest rate
1.6%

0.74%
Expected dividends
–

–

Employee stock-based compensation
The table below summarizes the total stock-based compensation expense included in the statements of operations for the periods presented:

(in thousands)

Three Months Ended

Six Months Ended

June 30,

June 30,

2014

2013

2014

2013

Research & Development

$
299

$
200

$
547

$
341

Selling, General & Administrative

482

407

938

622

Total

$
781

$
607

$
1,485

$
963

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Fair Value of Financial Instruments, Significant Unobsesrvable input assumptions of Level 3 valuations (Details) (Level 3 [Member])	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Historical Volatility (in hundredths)	52.00%	62.00%
Expected Term (in years)	0 years 8 months 12 days	0 years 4 months 24 days
Risk-free interest rate (in hundredths)	0.08%	0.08%
Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Historical Volatility (in hundredths)	61.00%	76.00%
Expected Term (in years)	1 year 7 months 6 days	2 years 1 month 6 days
Risk-free interest rate (in hundredths)	0.34%	0.44%

Stock Options and Stock-Based Employee Compensation (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock Options and Stock-Based Employee Compensation [Abstract]
Weighted-average vesting period of stock options			3 years
Weighted-average assumptions used in estimating fair value of stock options [Abstract]
Weighted-average expected volatility (in hundredths)			100.00%	110.00%
Weighted-average expected term			5 years 4 months 24 days	4 years 8 months 12 days
Weighted-average risk-free interest rate (in hundredths)			1.60%	0.74%
Expected dividends (in hundredths)			0.00%	0.00%
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee stock-based compensation	$ 781	$ 607	$ 1,485	$ 963
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee stock-based compensation	299	200	547	341
Selling, General & Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Employee stock-based compensation	$ 482	$ 407	$ 938	$ 622

Deerfield Loan (Details) (USD $) Share data in Millions, except Per Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014 Installment	Jun. 30, 2013	Jun. 30, 2014 Installment	Jun. 30, 2013	Dec. 31, 2013
Line of Credit Facility [Line Items]
Loan facility, maximum amount	$ 30,000,000		$ 30,000,000
Number of loan installments	3		3
Loan facility payment terms			The principal amount of the loan is payable in equal annual installments on the fourth, fifth and sixth anniversaries of the Deerfield Loan agreement, provided that the amount payable on the fourth anniversary shall be deferred for one year if either (i) our “Net Sales” for the immediately preceding 12-month period are at least $20 million, or (ii) our “Equity Value” is at least $200 million; and provided further, that the amount payable on the fifth anniversary (together with any amount deferred on the fourth anniversary) shall be deferred until the sixth anniversary if either (i) our “Net Sales” for the immediately preceding 12-month period are at least $30 million, or (ii) our “Equity Value” is at least $250 million.
Cash interest rate under loan facility (in hundredths)	8.75%		8.75%
Carrying value of Facility Agreement [Abstract]
Note Payable	30,000,000		30,000,000		30,000,000
Unamortized discount	(10,736,000)		(10,736,000)		(11,646,000)
Long-term debt, net of discount	19,264,000		19,264,000		18,354,000
Interest expense [Abstract]
Cash interest expense	654,000	218,000	1,302,000	331,000
Non-cash amortization of debt discounts	470,000	118,000	909,000	177,000
Amortization of debt costs	5,000	5,000	10,000	8,000
Total interest expense	1,129,000	341,000	2,221,000	516,000
Fourth anniversary [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Net sales for 12-month period immediately preceding repayment date	20,000,000		20,000,000
Equity Value at repayment date	200,000,000		200,000,000
Sixth anniversary [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Net sales for 12-month period immediately preceding repayment date	30,000,000		30,000,000
Equity Value at repayment date	$ 250,000,000		$ 250,000,000
Deerfield Management Company [Member]
Line of Credit Facility [Line Items]
Number of shares under issued warrants (in shares)	7.0		7.0
Exercise price of warrants (in dollars per share)	$ 2.81		$ 2.81

Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$ 65,557	$ 86,283
Accounts receivable	41	67
Inventory, net	443	112
Prepaid expenses and other current assets	443	777
Total current assets	66,484	87,239
Property and equipment, net	2,178	1,656
Restricted cash	325	325
Other assets	487	97
Total assets	69,474	89,317
Current Liabilities:
Accounts payable	1,507	1,433
Accrued expenses	5,951	4,785
Deferred revenue	105	139
Common stock warrant liability	3,224	5,425
Equipment loans, current portion	75	73
Total current liabilities	10,862	11,855
Long-term debt, $30,000 net of discount of $10,736 at June 30, 2014 and $11,646 at December 31, 2013	19,264	18,354
Equipment loans, non-current portion	28	69
Other liabilities	114	538
Total liabilities	30,268	30,816
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 250,000,000 and 150,000,000 shares authorized at June 30, 2014 and December 31, 2013, respectively; 85,227,508 and 84,659,111 shares issued at June 30, 2014 and December 31, 2013, respectively; 85,206,616 and 84,638,219 shares outstanding at June 30, 2014 and December 31, 2013, respectively	85	85
Additional paid-in capital	544,224	541,420
Accumulated deficit	(502,049)	(479,950)
Treasury stock (at cost); 20,892 shares	(3,054)	(3,054)
Total stockholders' equity	39,206	58,501
Total liabilities & stockholders' equity	$ 69,474	$ 89,317

Organization and Business	6 Months Ended
Organization and Business	Jun. 30, 2014
Organization and Business [Abstract]
Organization and Business	Note 1 – Organization and Business Discovery Laboratories, Inc. (referred to as “we,” “us,” or the “Company”) is a specialty biotechnology company focused on creating life-saving products for critical-care patients with respiratory disease and improving the standard of care in pulmonary medicine. Our proprietary drug technology produces a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to pulmonary surfactant, a substance produced naturally in the lung and essential for normal respiratory function and survival. We are developing our KL4 surfactant in liquid, lyophilized and aerosolized dosage forms. We are also developing novel drug delivery technologies and devices potentially to enable efficient delivery of our aerosolized KL4 surfactant. We believe that our proprietary technologies may make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. We are initially focused on improving the management of respiratory distress syndrome (RDS) in premature infants. RDS is a serious respiratory condition caused by insufficient surfactant production in underdeveloped lungs of premature infants. RDS is the most prevalent respiratory disease in the Neonatal Intensive Care Unit (NICU) and can result in long-term respiratory problems, developmental delay and death. Our first KL4 surfactant drug product, SURFAXIN® (lucinactant) Intratracheal Suspension for the prevention of RDS in premature infants at high risk for RDS, was approved by the United States Food and Drug Administration (FDA) in 2012. SURFAXIN is our KL4 surfactant in liquid form, and is the first synthetic, peptide-containing surfactant approved by the FDA and the only alternative to animal-derived surfactants currently used in the United States (U.S.). SURFAXIN has been commercially available in the U.S. since November 2013. Premature infants with severe RDS currently are treated with surfactants that can only be administered by endotracheal intubation supported with mechanical ventilation, both invasive procedures that may result in serious respiratory conditions and other complications. To avoid such complications, many neonatologists initially treat infants with less severe RDS by less invasive means, typically nasal continuous positive airway pressure (nCPAP). Unfortunately, a significant number of premature infants on nCPAP will not respond well (an outcome referred to as nCPAP failure) and thereafter may require endotracheal intubation, mechanical ventilation, and delayed surfactant therapy. Since neonatologists currently cannot predict which infants will experience nCPAP failure, neonatologists are faced with difficult choices in treating infants with less severe RDS. This is because the medical outcomes for those infants who experience nCPAP failure and receive delayed surfactant therapy may be less favorable than the outcomes for infants who receive surfactant therapy in the first hours of life. AEROSURF® is our investigational combination drug/device product that combines our KL4 surfactant with our proprietary capillary aerosol generator (CAG). AEROSURF potentially will enable administration of aerosolized KL4 surfactant to premature infants supported with nCPAP, without invasive intubation and mechanical ventilation. By enabling delivery of our KL4 surfactant using less invasive procedures, we believe that AEROSURF may address a serious unmet medical need and potentially enable the treatment of a significantly greater number of premature infants with RDS who could benefit from surfactant therapy but are currently not treated. We are currently conducting a phase 2a clinical trial for AEROSURF for the treatment of RDS in premature infants, for which results are expected in the fourth quarter of 2014, and are initiating activities to prepare for a phase 2b clinical trial, with results expected in the second half of 2015. We are also developing a lyophilized (freeze-dried) dosage form of our KL4 surfactant that is stored as a powder and reconstituted to liquid form prior to use with the objective of improving ease of use for healthcare practitioners, as well as potentially to prolong shelf life and eliminate the need for cold-chain storage. We are initially developing this dosage form for use in our AEROSURF development program. We are also planning to seek regulatory advice to determine if we could gain marketing authorization for a lyophilized dosage form of our KL4 surfactant under a development plan that would be both capital efficient and capable of implementation within a reasonable time. If feasible, we would likely implement such a development plan and would plan to introduce it commercially as a life-cycle extension of SURFAXIN under the name SURFAXIN LS™, in the U.S. and potentially in other markets. To support the commercial introduction of SURFAXIN in the U.S. and our other KL4 surfactant pipeline products, if approved, we have our own specialty respiratory critical care commercial and medical affairs team. This team includes medical professionals with experience in neonatal/pediatric respiratory critical care, and has focused on products that address neonatal indications, beginning with SURFAXIN. We believe that this team will be positioned to efficiently introduce our other KL4 surfactant products under development, if approved, including AEROSURF and potentially SURFAXIN LS and future applications of our aerosolized KL4 surfactant. In addition, we recognize that our commercial and medical affairs team could potentially support introductions of other synergistic pipeline products, including products owned or developed by third parties for the NICU/PICU. To that end, we would consider potential transactions focused on securing commercial rights to such synergistic products, including in the form of product acquisitions, in-licensing agreements or distribution, marketing or co-marketing arrangements. In the future, we expect that we may be able to leverage the information, data and know-how that we gain from our development efforts with SURFAXIN and AEROSURF to support development of a product pipeline to address serious critical care respiratory conditions in larger children and adults in pediatric and adult intensive care units (PICUs and ICUs), including potentially acute lung injury (ALI), chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). At the present time, however, we are focusing our resources primarily on the commercial introduction of SURFAXIN and development of AEROSURF through phase 2 clinical trials. Once we have advanced these objectives, we expect to be in a better position to assess the potential of other development programs to address the critical care needs of patients in the PICU and ICU.

Fair Value of Financial Instruments, Level 3 Rollforward (Details) (USD $) In Thousands, unless otherwise specified			6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014 Level 3 [Member]	Jun. 30, 2013 Level 3 [Member]
Fair value measurements of common stock warrants using significant unobservable inputs (level 3) [Roll Forward]
Balance at beginning of period	$ 3,224	$ 5,425	$ 5,425	$ 6,305
Exercise of warrants			(375)
Change in fair value of common stock warrant liability			(1,826)	(2,686)
Balance at end of period	$ 3,224	$ 5,425	$ 3,224	$ 3,619

Liquidity Risks and Management's Plans	6 Months Ended
Liquidity Risks and Management's Plans	Jun. 30, 2014
Liquidity Risks and Management's Plans [Abstract]
Liquidity Risks and Management's Plans	Note 2 – Liquidity Risks and Management’s Plans We have incurred substantial losses since inception, due to investments in research and development, manufacturing, and, more recently, commercialization and medical affairs activities, and we expect to continue to incur substantial losses over the next several years. Historically, we have funded our business operations through various sources, including public and private securities offerings, debt facilities, strategic alliances, the use of committed equity financing facilities (CEFFs) and at-the-market (ATM) equity programs, and capital equipment financings. As of June 30, 2014, we had cash and cash equivalents of $65.6 million and long-term debt of $30 million ($19.3 million net of discount) under our Deerfield Loan with affiliates of Deerfield Management Company, L.P. (Deerfield) (see, Note 7 – “Deerfield Loan”) . Before any additional financings, including under our ATM Program (see, Note 11 - “At-the-Market Program (ATM Program),” to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2013 (2013 Form 10‑K)), we anticipate that we will have sufficient cash available to fund our operations and debt service obligations through the third quarter of 2015. For the next several years, we expect that our cash outflows for marketing, commercial and medical activities, development programs, operations and debt service will outpace the rate at which we may generate revenues. To execute our business strategy, pay debt obligations and fund our operations over the next several years, we will require significant additional infusions of capital until such time as the net revenues from the sale of approved products and from other sources are sufficient to offset our cash flow requirements. While we currently intend to retain all rights and commercialize our approved products in the U.S. by ourselves, an important priority for us is to identify strategic transactions that could provide additional capital and strategic resources to support the continued development and commercial introduction of our RDS products in markets outside the U.S. For our AEROSURF development program, we seek a significant strategic alliance that potentially could provide development, regulatory and commercial market expertise, and, if approved, support the commercial introduction of AEROSURF in the EU and other selected markets outside the U.S. Such alliances typically also would provide financial resources, in the form of upfront payments, milestone payments, commercialization royalties and a sharing of research and development expenses. To advance SURFAXIN in markets outside the U.S. where regulatory marketing authorization is facilitated by the information contained in our new drug application (NDA) approved by the FDA, we would consider various financing or collaboration arrangements that could potentially provide regulatory expertise, support the commercial introduction of SURFAXIN in markets outside the U.S., and a sharing of revenues. Such countries could potentially include those in Latin America, North Africa and the Middle East. To secure the necessary capital, we also plan to consider other public and private equity offerings, including under our ATM Program, which currently may allow for the sale of up to approximately $23 million of our commons stock, as well as other financing transactions, such as secured equipment financing facilities or other similar transactions. Our future capital requirements will depend upon many factors, primarily our efforts to (i) execute the commercial introduction of SURFAXIN in the U.S.; (ii) advance the AEROSURF development program to completion of the phase 2 clinical trials as planned in the second half of 2015; (iii) assure long-term continuity of supply for both our commercial and lyophilized KL4 surfactant drug product, potentially with CMOs and/or at our manufacturing facility in Totowa, NJ (Totowa Facility); and (iv) secure one or more strategic alliances or other collaboration arrangements to support our development programs and commercialization of our approved products, if any, in markets outside the U.S. We believe that we will be better positioned to enter into a significant strategic alliance if we are successful in advancing the commercial introduction of SURFAXIN and completing and obtaining encouraging results from the AEROSURF phase 2 clinical program within our anticipated time. Although we currently believe that we will be able to successfully execute our business strategy as planned, there can be no assurance that any of our approved products, including SURFAXIN, will be commercially viable or that we will be able to execute our long-term manufacturing plan, that our AEROSURF development program will be successful within our anticipated time frame, if at all, that we will be able to secure regulatory marketing authorization for AEROSURF and our other KL4 surfactant product candidates, in the U.S. and other markets, that the ATM Program will be available when needed, if at all, or that we will be able to obtain additional capital when needed and on acceptable terms. We will require significant additional capital to sustain operations, satisfy debt obligations, and complete product development and execute the commercial introduction of our KL4 surfactant product candidates, if approved. Failure to secure the necessary additional capital when needed would have a material adverse effect on our business, financial condition and results of operations. Even if we succeed in raising additional capital and developing and subsequently commercializing our product candidates, we may never achieve sufficient sales revenue to achieve or maintain profitability. As of June 30, 2014, we had outstanding warrants to purchase approximately 14.0 million shares of our common stock at various prices, exercisable on different dates into 2019. Of these warrants, warrants to purchase 7 million shares were issued to Deerfield in connection with the Deerfield Loan at an exercise price of $2.81 per share. The Deerfield Warrants may be exercised for cash or on a cashless basis. In lieu of paying cash upon exercise, the holders also may elect to reduce the principal amount of the Deerfield Loan in an amount sufficient to satisfy the exercise price of the Deerfield Warrants. In addition to the Deerfield Warrants, we have outstanding warrants issued in February 2011 to purchase approximately 4.6 million shares of common stock that contain anti-dilution provisions that adjust the exercise price if we issue any common stock, securities convertible into common stock, or other securities (subject to certain exceptions) at a value below the then-existing exercise price of the warrants. These warrants currently have an exercise price of $1.50 per share and expire in February 2016. Although we believe that, in the future, we may receive additional capital from the exercise of at least a portion of our outstanding warrants, there can be no assurance that the market price of our common stock will equal or exceed price levels that would make exercise of outstanding warrants likely, that holders of the Deerfield Warrants would choose to exercise their warrants for cash, or that holders of any of our outstanding warrants would choose to exercise any or all of their warrants prior to the applicable warrant expiration dates. Moreover, if our outstanding warrants are exercised, such exercises likely will be at a discount to the then-market value of our common stock and have a dilutive effect on the value of our shares of common stock at the time of exercise. As of June 30, 2014, 250 million shares of common stock were authorized under our Amended and Restated Certificate of Incorporation, as amended, and approximately 137.2 million shares of common stock were available for issuance and not otherwise reserved.

Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
LIABILITIES & STOCKHOLDERS' EQUITY
Long term debt, gross	$ 30,000	$ 30,000
Long-term debt, discount	$ 10,736	$ 11,646
Stockholders' Equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	250,000,000	150,000,000
Common stock, shares issued (in shares)	85,227,508	84,659,111
Common stock, shares outstanding (in shares)	85,206,616	84,638,219
Treasury stock (at cost) (in shares)	20,892	20,892

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2014	Jul. 31, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	DISCOVERY LABORATORIES INC /DE/
Entity Central Index Key	0000946486
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		85,206,616
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2014

Fair Value of Financial Instruments (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Liabilities [Abstract]
Fair value of loan	$ 23,200,000	$ 23,600,000
Long-Term Debt	19,264,000	18,354,000
Recurring [Member]
Assets [Abstract]
Fair Value	65,882,000	86,608,000
Recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Fair Value	65,882,000	86,608,000
Recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Cash and cash equivalents [Member]
Assets [Abstract]
Fair Value	65,557,000	86,283,000
Recurring [Member] \| Cash and cash equivalents [Member] \| Level 1 [Member]
Assets [Abstract]
Fair Value	65,557,000	86,283,000
Recurring [Member] \| Cash and cash equivalents [Member] \| Level 2 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Cash and cash equivalents [Member] \| Level 3 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Certificate of Deposit [Member]
Assets [Abstract]
Fair Value	325,000	325,000
Recurring [Member] \| Certificate of Deposit [Member] \| Level 1 [Member]
Assets [Abstract]
Fair Value	325,000	325,000
Recurring [Member] \| Certificate of Deposit [Member] \| Level 2 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Certificate of Deposit [Member] \| Level 3 [Member]
Assets [Abstract]
Fair Value	0	0
Recurring [Member] \| Common Stock Warrant Liability [Member]
Liabilities [Abstract]
Fair Value	3,224,000	5,425,000
Recurring [Member] \| Common Stock Warrant Liability [Member] \| Level 1 [Member]
Liabilities [Abstract]
Fair Value	0	0
Recurring [Member] \| Common Stock Warrant Liability [Member] \| Level 2 [Member]
Liabilities [Abstract]
Fair Value	0	0
Recurring [Member] \| Common Stock Warrant Liability [Member] \| Level 3 [Member]
Liabilities [Abstract]
Fair Value	$ 3,224,000	$ 5,425,000

Inventory (Details) (USD $)				6 Months Ended
Inventory (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Oct. 04, 2013	Jun. 30, 2014 Minimum [Member]	Jun. 30, 2014 Maximum [Member]
Inventories, current [Abstract]
Raw materials	$ 147,000	$ 52,000
Finished goods, net of reserves	296,000	60,000
Inventory	443,000	112,000
Inventories, non-current [Abstract]
Raw materials	400,000	0
Total inventories, net	843,000	112,000
Life of raw materials				2 years	5 years
Raw materials on hand purchased prior to October 4, 2013			700,000
Inventory reserves	$ 2,000,000	$ 500,000

Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flow from operating activities:
Net loss	$ (22,099)	$ (21,263)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	371	364
Provision for excess inventory	1,465	0
Stock-based compensation and 401(k) Plan employer match	1,975	1,489
Fair value adjustment of common stock warrants	(1,826)	(2,686)
Amortization of discount on long-term debt	909	177
Changes in:
Inventory	(2,196)	159
Accounts receivable	26	0
Prepaid expenses and other current assets	334	101
Accounts payable	74	753
Accrued expenses	1,166	580
Deferred revenue	(34)	0
Other assets	0	(107)
Other liabilities	(423)	(10)
Net cash used in operating activities	(20,258)	(20,443)
Cash flows from investing activities:
Purchase of property and equipment	(883)	(120)
Net cash used in investing activities	(883)	(120)
Cash flows from financing activities:
Proceeds from issuance of securities, net of expenses	0	15,110
Proceeds from issuance of long-term debt, net of expenses	0	9,850
Proceeds from exercise of common stock options	31	1
Proceeds from exercise of common stock warrants	423	0
Repayment of equipment loans	(39)	(37)
Net cash provided by financing activities	415	24,924
Net decrease in cash and cash equivalents	(20,726)	4,361
Cash and cash equivalents - beginning of period	86,283	26,892
Cash and cash equivalents - end of period	65,557	31,253
Supplementary disclosure of cash flows information:
Interest paid	$ 1,305	$ 336